Warning message:
package 'XML' was built under R version 3.3.2 
Warning message:
package 'ggplot2' was built under R version 3.3.2 
Warning message:
package 'data.table' was built under R version 3.3.2 
Warning message:
package 'caret' was built under R version 3.3.2 
Warning message:
package 'coda' was built under R version 3.3.2 
Warning message:
package 'ggbeeswarm' was built under R version 3.3.2 
Registering 3 cores.
mkdir: output/: File exists
Logging in
Please upgrade to the latest version of the Synapse Client, 1.14-3, by running the following commands:
	source('http://depot.sagebase.org/CRAN.R')
	pkgInstall("synapseClient")

Here are this version's release notes:
https://sagebionetworks.jira.com/issues/?jql=project%20%3D%20SYNR%20AND%20fixVersion%20in%20(R-1.14-0%2C%20R-1.14-1%2C%20R-1.14-2%2C%20R-1.14-3)%20ORDER%20BY%20key%20DESC



Welcome brian.white!
Logged in
Reading clinical data
Reading CMS results
Read 83 records
Read 5691 items
12345678910111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182831
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Reading bindea
Reading CIRC signature
Read 217 records
Read 4964 items
1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606162636465666768697071727374757677787980818283848586878889909192939495969798991001011021031041051061071081091101111121131141151161171181191201211221231241251261271281291301311321331341351361371381391401411421431441451461471481491501511521531541551561571581591601611621631641651661671681691701711721731741751761771781791801811821831841851861871881891901911921931941951961971981992002012022032042052062072082092102112122132142152162171
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
Read 186 records
Read 13247 items
1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606162636465666768697071727374757677787980818283848586878889909192939495969798991001011021031041051061071081091101111121131141151161171181191201211221231241251261271281291301311321331341351361371381391401411421431441451461471481491501511521531541551561571581591601611621631641651661671681691701711721731741751761771781791801811821831841851861
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
Read 674 records
Read 38949 items
1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606162636465666768697071727374757677787980818283848586878889909192939495969798991001011021031041051061071081091101111121131141151161171181191201211221231241251261271281291301311321331341351361371381391401411421431441451461471481491501511521531541551561571581591601611621631641651661671681691701711721731741751761771781791801811821831841851861871881891901911921931941951961971981992002012022032042052062072082092102112122132142152162172182192202212222232242252262272282292302312322332342352362372382392402412422432442452462472482492502512522532542552562572582592602612622632642652662672682692702712722732742752762772782792802812822832842852862872882892902912922932942952962972982993003013023033043053063073083093103113123133143153163173183193203213223233243253263273283293303313323333343353363373383393403413423433443453463473483493503513523533543553563573583593603613623633643653663673683693703713723733743753763773783793803813823833843853863873883893903913923933943953963973983994004014024034044054064074084094104114124134144154164174184194204214224234244254264274284294304314324334344354364374384394404414424434444454464474484494504514524534544554564574584594604614624634644654664674684694704714724734744754764774784794804814824834844854864874884894904914924934944954964974984995005015025035045055065075085095105115125135145155165175185195205215225235245255265275285295305315325335345355365375385395405415425435445455465475485495505515525535545555565575585595605615625635645655665675685695705715725735745755765775785795805815825835845855865875885895905915925935945955965975985996006016026036046056066076086096106116126136146156166176186196206216226236246256266276286296306316326336346356366376386396406416426436446456466476486496506516526536546556566576586596606616626636646656666676686696706716726736741
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
Read 50 records
Read 7424 items
12345678910111213141516171819202122232425262728293031323334353637383940414243444546474849501
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Reading TCIA Neoantigens
Reading TCGA data
Reading KFS data
doaffy reading file: /Users/Brian/work/sage/middleton/input/KFSYSCC_frma_expression.tsv
Head of data set
          COLON001.CEL COLON002.CEL COLON003.CEL COLON004.CEL COLON005.CEL
1007_s_at     9.645729     9.413360    10.221282     9.377074     9.512167
1053_at       6.751939     7.810647     6.681705     6.135659     6.560988
117_at        5.858411     7.921070     6.682436     6.708764     7.474377
121_at        7.987047     8.407711     7.203580     7.489876     7.579698
1255_g_at     3.429960     3.787172     3.529689     3.551455     3.563567
1294_at       7.903483     7.638184     8.374211     7.998328     7.583686
          COLON317.CEL COLON318.CEL COLON319.CEL COLON320.CEL COLON321.CEL
1007_s_at    10.105556    10.068166     8.408196     9.590564     9.473769
1053_at       7.393007     7.421711     5.835812     7.482128     7.315747
117_at        5.750133     5.505114     6.967844     5.791408     6.185478
121_at        8.076047     8.129237     8.102351     7.846494     7.736630
1255_g_at     3.630935     3.459033     3.572719     3.509263     3.456586
1294_at       7.140371     7.531761     8.307762     7.067356     8.029720
          COLON322.CEL
1007_s_at    10.263674
1053_at       6.127273
117_at        5.710394
121_at        8.251955
1255_g_at     3.412572
1294_at       7.643918
doaffy reading file: /Users/Brian/work/sage/middleton/input/KFSYSCC_frma_expression.tsv
Head of data set
          COLON001.CEL COLON002.CEL COLON003.CEL COLON004.CEL COLON005.CEL
1007_s_at     9.645729     9.413360    10.221282     9.377074     9.512167
1053_at       6.751939     7.810647     6.681705     6.135659     6.560988
117_at        5.858411     7.921070     6.682436     6.708764     7.474377
121_at        7.987047     8.407711     7.203580     7.489876     7.579698
1255_g_at     3.429960     3.787172     3.529689     3.551455     3.563567
1294_at       7.903483     7.638184     8.374211     7.998328     7.583686
          COLON317.CEL COLON318.CEL COLON319.CEL COLON320.CEL COLON321.CEL
1007_s_at    10.105556    10.068166     8.408196     9.590564     9.473769
1053_at       7.393007     7.421711     5.835812     7.482128     7.315747
117_at        5.750133     5.505114     6.967844     5.791408     6.185478
121_at        8.076047     8.129237     8.102351     7.846494     7.736630
1255_g_at     3.630935     3.459033     3.572719     3.509263     3.456586
1294_at       7.140371     7.531761     8.307762     7.067356     8.029720
          COLON322.CEL
1007_s_at    10.263674
1053_at       6.127273
117_at        5.710394
121_at        8.251955
1255_g_at     3.412572
1294_at       7.643918
Combining probes using mean
Number of rows analyzed: 20294
Number of columns analyzed: 344
tcga-gene-sets: 28 of 34 genes from data set analyzed in set B cells: MS4A1 TCL1A HLA-DOB PNOC KIAA0125 CD19 CR2 FCRL2 BLK COCH OSBPL10 TNFRSF17 ABCB4 BLNK GLDC MEF2C SPIB BCL11A GNG7 CD72 MICAL3 BACH2 CCR9 QRSL1 DTNB HLA-DQA1 SCN3A SLC15A2
tcga-gene-sets: 6 of 34 genes missing from data set analyzed in set B cells: IGHG1 IGHA1 IGHM FAM30A IGKC IGL@
tcga-gene-sets: 16 of 18 genes from data set analyzed in set T cells: PRKCQ CD3D CD3G CD28 LCK TRAT1 BCL11B CD2 ITM2A SH2D1A CD6 CD96 NCALD GIMAP5 CD3E SKAP1
tcga-gene-sets: 2 of 18 genes missing from data set analyzed in set T cells: TRBC1 TRA@
tcga-gene-sets: 27 of 27 genes from data set analyzed in set Th1 cells: IFNG LTA APBB2 DOK5 IL12RB2 APOD ZBTB32 CD38 CSF2 CTLA4 CD70 DPP4 EGFL6 BST2 DUSP5 LRP8 IL22 DGKI CCL4 GGT1 LRRN3 SYNGR3 ATP9A BTG3 CMAH HBEGF SGCB
tcga-gene-sets: 26 of 27 genes from data set analyzed in set Th2 cells: PMCH AHI1 PTGIS CXCR6 EVI5 IL26 MB NEIL3 GSTA4 PHEX SMAD2 CENPF ANK1 ADCY1 LAIR2 SNRPD1 MICAL2 DHFR WDHD1 BIRC5 SLC39A14 HELLS LIMA1 CDC25C CDC7 GATA3
tcga-gene-sets: 1 of 27 genes missing from data set analyzed in set Th2 cells: AI582773
tcga-gene-sets: 16 of 17 genes from data set analyzed in set Cytotoxic cells: KLRD1 KLRF1 GNLY CTSW KLRB1 KLRK1 NKG7 GZMH SIGIRR ZBTB16 RUNX3 APOL3 RORA APBA2 DUSP2 GZMA
tcga-gene-sets: 1 of 17 genes missing from data set analyzed in set Cytotoxic cells: WHDC1L1
tcga-gene-sets: 30 of 31 genes from data set analyzed in set iDC: CD1B VASH1 F13A1 CD1E MMP12 FABP4 CLEC10A SYT17 MS4A6A CTNS GUCA1A CARD9 ABCG2 CD1A PPARG RAP1GAP SLC7A8 GSTT1 FZD2 CSF1R HS3ST2 CH25H LMAN2L SLC26A6 BLVRB NUDT9 PREP TM7SF4 TACSTD2 CD1C
tcga-gene-sets: 1 of 31 genes missing from data set analyzed in set iDC: NM_021941
tcga-gene-sets: 26 of 31 genes from data set analyzed in set Neutrophils: CSF3R CYP4F3 VNN3 KCNJ15 MME FCGR3B DYSF FCAR CEACAM3 HIST1H2BC HPSE CREB5 S100A12 TNFRSF10C SLC22A4 SLC25A37 BST1 CRISPLD2 G0S2 SIGLEC5 CD93 MGAM ALPL FPR1 PDE4B LILRB2
tcga-gene-sets: 5 of 31 genes missing from data set analyzed in set Neutrophils: FPRL1 IL8RA IL8RB FLJ11151 KIAA0329
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
tcga-gene-sets wnt vs CIRC: t = -7.66668942196379 df = 342 nrow = 344 cor = -0.3829621607261 pval = 1.84617074915233e-13
tcga-gene-sets tak1 vs CIRC: t = -1.90764957903146 df = 342 nrow = 344 cor = -0.102609400758207 pval = 0.0572738736909823
tcga-gene-sets wnt vs myc.sig: t = 29.5867669875905 df = 342 nrow = 344 cor = 0.847978818740452 pval = 2.60927229013165e-96

tcga-gene-sets: Analyzing B cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 14142, n_WT = 219, n_MT = 125, p = 0.608824327411549
tcga-gene-sets: Analyzing T cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 14788, n_WT = 219, n_MT = 125, p = 0.215001784047338
tcga-gene-sets: Analyzing Th1 cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15200, n_WT = 219, n_MT = 125, p = 0.0883179042343788
tcga-gene-sets: Analyzing Th2 cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 13675, n_WT = 219, n_MT = 125, p = 0.989207748046283
tcga-gene-sets: Analyzing Cytotoxic cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15515, n_WT = 219, n_MT = 125, p = 0.0394550958525481
tcga-gene-sets: Analyzing iDC vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15012, n_WT = 219, n_MT = 125, p = 0.135588232256003
tcga-gene-sets: Analyzing Neutrophils vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15981, n_WT = 219, n_MT = 125, p = 0.00974672529331536

Computing B cells ~ KRAS
Computing T cells ~ KRAS
Computing Th1 cells ~ KRAS
Computing Th2 cells ~ KRAS
Computing Cytotoxic cells ~ KRAS
Computing iDC ~ KRAS
Computing Neutrophils ~ KRAS
Number of rows analyzed: 20534
Number of columns analyzed: 290
kfs-gene-sets: 31 of 34 genes from data set analyzed in set B cells: MS4A1 TCL1A HLA-DOB PNOC KIAA0125 CD19 CR2 IGHG1 FCRL2 BLK COCH OSBPL10 TNFRSF17 ABCB4 BLNK GLDC MEF2C IGHM SPIB BCL11A GNG7 IGKC CD72 MICAL3 BACH2 CCR9 QRSL1 DTNB HLA-DQA1 SCN3A SLC15A2
kfs-gene-sets: 3 of 34 genes missing from data set analyzed in set B cells: IGHA1 FAM30A IGL@
kfs-gene-sets: 16 of 18 genes from data set analyzed in set T cells: PRKCQ CD3D CD3G CD28 LCK TRAT1 BCL11B CD2 TRBC1 ITM2A SH2D1A CD6 CD96 NCALD CD3E SKAP1
kfs-gene-sets: 2 of 18 genes missing from data set analyzed in set T cells: TRA@ GIMAP5
kfs-gene-sets: 26 of 27 genes from data set analyzed in set Th1 cells: IFNG LTA APBB2 DOK5 IL12RB2 APOD ZBTB32 CD38 CSF2 CTLA4 CD70 DPP4 EGFL6 BST2 DUSP5 LRP8 IL22 DGKI CCL4 GGT1 LRRN3 SYNGR3 ATP9A BTG3 HBEGF SGCB
kfs-gene-sets: 1 of 27 genes missing from data set analyzed in set Th1 cells: CMAH
kfs-gene-sets: 26 of 27 genes from data set analyzed in set Th2 cells: PMCH AHI1 PTGIS CXCR6 EVI5 IL26 MB NEIL3 GSTA4 PHEX SMAD2 CENPF ANK1 ADCY1 LAIR2 SNRPD1 MICAL2 DHFR WDHD1 BIRC5 SLC39A14 HELLS LIMA1 CDC25C CDC7 GATA3
kfs-gene-sets: 1 of 27 genes missing from data set analyzed in set Th2 cells: AI582773
kfs-gene-sets: 15 of 17 genes from data set analyzed in set Cytotoxic cells: KLRD1 KLRF1 GNLY CTSW KLRB1 NKG7 GZMH SIGIRR ZBTB16 RUNX3 APOL3 RORA APBA2 DUSP2 GZMA
kfs-gene-sets: 2 of 17 genes missing from data set analyzed in set Cytotoxic cells: KLRK1 WHDC1L1
kfs-gene-sets: 28 of 31 genes from data set analyzed in set iDC: CD1B VASH1 F13A1 CD1E MMP12 FABP4 CLEC10A SYT17 MS4A6A CTNS GUCA1A ABCG2 CD1A PPARG RAP1GAP SLC7A8 GSTT1 FZD2 CSF1R HS3ST2 CH25H LMAN2L SLC26A6 BLVRB NUDT9 PREP TACSTD2 CD1C
kfs-gene-sets: 3 of 31 genes missing from data set analyzed in set iDC: CARD9 NM_021941 TM7SF4
kfs-gene-sets: 26 of 31 genes from data set analyzed in set Neutrophils: CSF3R CYP4F3 VNN3 KCNJ15 MME FCGR3B DYSF FCAR CEACAM3 HIST1H2BC HPSE CREB5 S100A12 TNFRSF10C SLC22A4 SLC25A37 BST1 CRISPLD2 G0S2 SIGLEC5 CD93 MGAM ALPL FPR1 PDE4B LILRB2
kfs-gene-sets: 5 of 31 genes missing from data set analyzed in set Neutrophils: FPRL1 IL8RA IL8RB FLJ11151 KIAA0329
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
kfs-gene-sets wnt vs CIRC: t = -4.09851997685246 df = 288 nrow = 290 cor = -0.234758375311116 pval = 5.41194167783526e-05
kfs-gene-sets tak1 vs CIRC: t = -0.274339048635223 df = 288 nrow = 290 cor = -0.0161634716390661 pval = 0.784020752365827
kfs-gene-sets wnt vs myc.sig: t = 36.8247724188401 df = 288 nrow = 290 cor = 0.908198394193576 pval = 5.93740129656503e-111

kfs-gene-sets: Analyzing B cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11068, n_WT = 175, n_MT = 115, p = 0.150261830011206
kfs-gene-sets: Analyzing T cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 9787, n_WT = 175, n_MT = 115, p = 0.693840383174566
kfs-gene-sets: Analyzing Th1 cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11113, n_WT = 175, n_MT = 115, p = 0.132833240987183
kfs-gene-sets: Analyzing Th2 cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 9304, n_WT = 175, n_MT = 115, p = 0.277904336868388
kfs-gene-sets: Analyzing Cytotoxic cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11653, n_WT = 175, n_MT = 115, p = 0.0228456800761803
kfs-gene-sets: Analyzing iDC vs KRAS using Wilcoxon rank sum test with continuity correction: W = 9570, n_WT = 175, n_MT = 115, p = 0.481262527172169
kfs-gene-sets: Analyzing Neutrophils vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12009, n_WT = 175, n_MT = 115, p = 0.00534284757937905

Computing B cells ~ KRAS
Computing T cells ~ KRAS
Computing Th1 cells ~ KRAS
Computing Th2 cells ~ KRAS
Computing Cytotoxic cells ~ KRAS
Computing iDC ~ KRAS
Computing Neutrophils ~ KRAS
Number of rows analyzed: 20294
Number of columns analyzed: 344
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
tcga-circ wnt vs CIRC: t = -7.66668942196379 df = 342 nrow = 344 cor = -0.3829621607261 pval = 1.84617074915233e-13
tcga-circ tak1 vs CIRC: t = -1.90764957903146 df = 342 nrow = 344 cor = -0.102609400758207 pval = 0.0572738736909823
tcga-circ wnt vs myc.sig: t = 29.5867669875905 df = 342 nrow = 344 cor = 0.847978818740452 pval = 2.60927229013165e-96

tcga-circ: Analyzing HLA-DQA1 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15808, n_WT = 219, n_MT = 125, p = 0.0168630270833641
tcga-circ: Analyzing HLA-DQA2 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15558, n_WT = 219, n_MT = 125, p = 0.035041481937021
tcga-circ: Analyzing HLA-DRB5 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16044, n_WT = 219, n_MT = 125, p = 0.00791435794906807
tcga-circ: Analyzing CTLA4 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15960, n_WT = 219, n_MT = 125, p = 0.0104366466521535
tcga-circ: Analyzing PDCD1LG2 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16366, n_WT = 219, n_MT = 125, p = 0.00253892683604747
tcga-circ: Analyzing ICAM1 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16853, n_WT = 219, n_MT = 125, p = 0.000360248172285815
tcga-circ: Analyzing CD274 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16180, n_WT = 219, n_MT = 125, p = 0.00496953367325217
tcga-circ: Analyzing STAT1 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16069, n_WT = 219, n_MT = 125, p = 0.0072772800538876
tcga-circ: Analyzing IRF1 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15380, n_WT = 219, n_MT = 125, p = 0.0564900708047821
tcga-circ: Analyzing IFNG vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15329, n_WT = 219, n_MT = 125, p = 0.0642763496059861
tcga-circ: Analyzing GNLY vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15711, n_WT = 219, n_MT = 125, p = 0.0225874412608977
tcga-circ: Analyzing TBX21 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16514, n_WT = 219, n_MT = 125, p = 0.00144502345464943
tcga-circ: Analyzing CCL5 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15276, n_WT = 219, n_MT = 125, p = 0.0734529316408623
tcga-circ: Analyzing LAG3 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15535, n_WT = 219, n_MT = 125, p = 0.0373467551282688
tcga-circ: Analyzing CD247 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15908, n_WT = 219, n_MT = 125, p = 0.0123353892395922
tcga-circ: Analyzing ICOS vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16749.5, n_WT = 219, n_MT = 125, p = 0.000558622963071092
tcga-circ: Analyzing IL18RAP vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15826, n_WT = 219, n_MT = 125, p = 0.0159537672587926
tcga-circ: Analyzing CXCL9 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16432, n_WT = 219, n_MT = 125, p = 0.00198105152839399
tcga-circ: Analyzing CXCL10 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16218, n_WT = 219, n_MT = 125, p = 0.0043467533177559
tcga-circ: Analyzing HLA-DPB1 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16098, n_WT = 219, n_MT = 125, p = 0.00659620530713424
tcga-circ: Analyzing HLA-DPA1 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16643, n_WT = 219, n_MT = 125, p = 0.000865659270663289
tcga-circ: Analyzing HLA-DMB vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16365, n_WT = 219, n_MT = 125, p = 0.00254839221670098
tcga-circ: Analyzing HLA-DRA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16404, n_WT = 219, n_MT = 125, p = 0.00220233515414556
tcga-circ: Analyzing HLA-DMA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15994, n_WT = 219, n_MT = 125, p = 0.00934028438812116
tcga-circ: Analyzing CD80 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16345.5, n_WT = 219, n_MT = 125, p = 0.00273944982772266
tcga-circ: Analyzing HLA-DOA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15934, n_WT = 219, n_MT = 125, p = 0.0113508130289826
tcga-circ: Analyzing CD4 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16386, n_WT = 219, n_MT = 125, p = 0.00235631909214539
tcga-circ: Analyzing HAVCR2 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16371, n_WT = 219, n_MT = 125, p = 0.00249210246307242
tcga-circ: Analyzing CIITA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15715, n_WT = 219, n_MT = 125, p = 0.0223216042395995

Computing HLA-DQA1 ~ KRAS
Computing HLA-DQA2 ~ KRAS
Computing HLA-DRB5 ~ KRAS
Computing CTLA4 ~ KRAS
Computing PDCD1LG2 ~ KRAS
Computing ICAM1 ~ KRAS
Computing CD274 ~ KRAS
Computing STAT1 ~ KRAS
Computing IRF1 ~ KRAS
Computing IFNG ~ KRAS
Computing GNLY ~ KRAS
Computing TBX21 ~ KRAS
Computing CCL5 ~ KRAS
Computing LAG3 ~ KRAS
Computing CD247 ~ KRAS
Computing ICOS ~ KRAS
Computing IL18RAP ~ KRAS
Computing CXCL9 ~ KRAS
Computing CXCL10 ~ KRAS
Computing HLA-DPB1 ~ KRAS
Computing HLA-DPA1 ~ KRAS
Computing HLA-DMB ~ KRAS
Computing HLA-DRA ~ KRAS
Computing HLA-DMA ~ KRAS
Computing CD80 ~ KRAS
Computing HLA-DOA ~ KRAS
Computing CD4 ~ KRAS
Computing HAVCR2 ~ KRAS
Computing CIITA ~ KRAS
Number of rows analyzed: 20534
Number of columns analyzed: 290
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
kfs-circ wnt vs CIRC: t = -4.09851997685246 df = 288 nrow = 290 cor = -0.234758375311116 pval = 5.41194167783526e-05
kfs-circ tak1 vs CIRC: t = -0.274339048635223 df = 288 nrow = 290 cor = -0.0161634716390661 pval = 0.784020752365827
kfs-circ wnt vs myc.sig: t = 36.8247724188401 df = 288 nrow = 290 cor = 0.908198394193576 pval = 5.93740129656503e-111

kfs-circ: Analyzing HLA-DQA1 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10466, n_WT = 175, n_MT = 115, p = 0.564024338088676
kfs-circ: Analyzing CTLA4 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11071, n_WT = 175, n_MT = 115, p = 0.149048191332231
kfs-circ: Analyzing PDCD1LG2 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11353, n_WT = 175, n_MT = 115, p = 0.0648094122558285
kfs-circ: Analyzing ICAM1 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12223, n_WT = 175, n_MT = 115, p = 0.00198858391453122
kfs-circ: Analyzing CD274 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11396, n_WT = 175, n_MT = 115, p = 0.0563753393980843
kfs-circ: Analyzing STAT1 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 13044, n_WT = 175, n_MT = 115, p = 1.9798386029578e-05
kfs-circ: Analyzing IRF1 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11192, n_WT = 175, n_MT = 115, p = 0.106071169338738
kfs-circ: Analyzing IFNG vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11389, n_WT = 175, n_MT = 115, p = 0.0576825539239636
kfs-circ: Analyzing GNLY vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12364, n_WT = 175, n_MT = 115, p = 0.000988545957617425
kfs-circ: Analyzing TBX21 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10623, n_WT = 175, n_MT = 115, p = 0.422777432762042
kfs-circ: Analyzing CCL5 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11659, n_WT = 175, n_MT = 115, p = 0.0223366329966404
kfs-circ: Analyzing LAG3 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12286, n_WT = 175, n_MT = 115, p = 0.00146204582090518
kfs-circ: Analyzing CD247 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11319, n_WT = 175, n_MT = 115, p = 0.0721926652054417
kfs-circ: Analyzing ICOS vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11741, n_WT = 175, n_MT = 115, p = 0.0163069072460512
kfs-circ: Analyzing IL18RAP vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10523, n_WT = 175, n_MT = 115, p = 0.510238094127099
kfs-circ: Analyzing CXCL9 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12185, n_WT = 175, n_MT = 115, p = 0.00238520193680007
kfs-circ: Analyzing CXCL10 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12348, n_WT = 175, n_MT = 115, p = 0.00107219740701228
kfs-circ: Analyzing HLA-DPB1 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11540, n_WT = 175, n_MT = 115, p = 0.0344937790815394
kfs-circ: Analyzing HLA-DPA1 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12047, n_WT = 175, n_MT = 115, p = 0.00451139853402407
kfs-circ: Analyzing HLA-DMB vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11630, n_WT = 175, n_MT = 115, p = 0.0248915171379084
kfs-circ: Analyzing HLA-DRA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11461, n_WT = 175, n_MT = 115, p = 0.0453743846210762
kfs-circ: Analyzing HLA-DMA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11847, n_WT = 175, n_MT = 115, p = 0.0106582962972748
kfs-circ: Analyzing CD80 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11287, n_WT = 175, n_MT = 115, p = 0.0797575074966993
kfs-circ: Analyzing HLA-DOA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10826, n_WT = 175, n_MT = 115, p = 0.274746805229835
kfs-circ: Analyzing CD4 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11852, n_WT = 175, n_MT = 115, p = 0.010441220368938
kfs-circ: Analyzing HAVCR2 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11857, n_WT = 175, n_MT = 115, p = 0.0102280869123119
kfs-circ: Analyzing CIITA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 9670, n_WT = 175, n_MT = 115, p = 0.574710007860122

Computing HLA-DQA1 ~ KRAS
Computing CTLA4 ~ KRAS
Computing PDCD1LG2 ~ KRAS
Computing ICAM1 ~ KRAS
Computing CD274 ~ KRAS
Computing STAT1 ~ KRAS
Computing IRF1 ~ KRAS
Computing IFNG ~ KRAS
Computing GNLY ~ KRAS
Computing TBX21 ~ KRAS
Computing CCL5 ~ KRAS
Computing LAG3 ~ KRAS
Computing CD247 ~ KRAS
Computing ICOS ~ KRAS
Computing IL18RAP ~ KRAS
Computing CXCL9 ~ KRAS
Computing CXCL10 ~ KRAS
Computing HLA-DPB1 ~ KRAS
Computing HLA-DPA1 ~ KRAS
Computing HLA-DMB ~ KRAS
Computing HLA-DRA ~ KRAS
Computing HLA-DMA ~ KRAS
Computing CD80 ~ KRAS
Computing HLA-DOA ~ KRAS
Computing CD4 ~ KRAS
Computing HAVCR2 ~ KRAS
Computing CIITA ~ KRAS
The following circ components are in the direction opposite the circ metagene
variable	pval.tcga	apval.tcga	mutUp.tcga	pval.kfs	apval.kfs	mutUp.kfs	val.tcga	val.kfs
Th2 cells	0.989207748046283	0.989207748046283	TRUE	0.277904336868388	0.389066071615743	TRUE	0.989207748046283	0.277904336868388
The following circ components are in the direction opposite the circ metagene
variable	pval.tcga	apval.tcga	mutUp.tcga	pval.kfs	apval.kfs	mutUp.kfs	val.tcga	val.kfs
T cells	0.215001784047338	0.301002497666273	FALSE	0.693840383174566	0.693840383174566	TRUE	0.215001784047338	0.693840383174566
Th2 cells	0.989207748046283	0.989207748046283	TRUE	0.277904336868388	0.389066071615743	TRUE	0.989207748046283	0.277904336868388
iDC	0.135588232256003	0.237279406448005	FALSE	0.481262527172169	0.561472948367531	TRUE	0.135588232256003	0.481262527172169
Using GeneSet as id variables
[1] -3 -2 -1  0  1  2  3
           GeneSet Dataset value
1          B cells    TCGA  0.61
2  Cytotoxic cells    TCGA  0.04
3      Neutrophils    TCGA  0.01
4          T cells    TCGA  0.22
5        Th1 cells    TCGA  0.09
6        Th2 cells    TCGA  0.99
7              iDC    TCGA  0.14
8          B cells KFSYSCC  0.15
9  Cytotoxic cells KFSYSCC  0.02
10     Neutrophils KFSYSCC  0.01
11         T cells KFSYSCC  0.69
12       Th1 cells KFSYSCC  0.13
13       Th2 cells KFSYSCC  0.28
14             iDC KFSYSCC  0.48
Scale for 'fill' is already present. Adding another scale for 'fill', which
will replace the existing scale.
[1] 3 2 1 0
[1] 3 2 1 0
Using Gene as id variables
 [1] -5 -4 -3 -2 -1  0  1  2  3  4  5
       Gene Dataset value
1      CCL5    TCGA  0.07
2     CD247    TCGA  0.01
3     CD274    TCGA  0.00
4       CD4    TCGA  0.00
5      CD80    TCGA  0.00
6     CTLA4    TCGA  0.01
7    CXCL10    TCGA  0.00
8     CXCL9    TCGA  0.00
9      GNLY    TCGA  0.02
10   HAVCR2    TCGA  0.00
11  HLA-DMA    TCGA  0.01
12  HLA-DMB    TCGA  0.00
13  HLA-DOA    TCGA  0.01
14 HLA-DPA1    TCGA  0.00
15 HLA-DPB1    TCGA  0.01
16 HLA-DQA1    TCGA  0.02
17 HLA-DQA2    TCGA  0.04
18  HLA-DRA    TCGA  0.00
19 HLA-DRB5    TCGA  0.01
20    ICAM1    TCGA  0.00
21     ICOS    TCGA  0.00
22     IFNG    TCGA  0.06
23  IL18RAP    TCGA  0.02
24     IRF1    TCGA  0.06
25     LAG3    TCGA  0.04
26 PDCD1LG2    TCGA  0.00
27    STAT1    TCGA  0.01
28    TBX21    TCGA  0.00
29     CCL5 KFSYSCC  0.02
30    CD247 KFSYSCC  0.07
31    CD274 KFSYSCC  0.06
32      CD4 KFSYSCC  0.01
33     CD80 KFSYSCC  0.08
34    CTLA4 KFSYSCC  0.15
35   CXCL10 KFSYSCC  0.00
36    CXCL9 KFSYSCC  0.00
37     GNLY KFSYSCC  0.00
38   HAVCR2 KFSYSCC  0.01
39  HLA-DMA KFSYSCC  0.01
40  HLA-DMB KFSYSCC  0.02
41  HLA-DOA KFSYSCC  0.27
42 HLA-DPA1 KFSYSCC  0.00
43 HLA-DPB1 KFSYSCC  0.03
44 HLA-DQA1 KFSYSCC  0.56
46  HLA-DRA KFSYSCC  0.05
48    ICAM1 KFSYSCC  0.00
49     ICOS KFSYSCC  0.02
50     IFNG KFSYSCC  0.06
51  IL18RAP KFSYSCC  0.51
52     IRF1 KFSYSCC  0.11
53     LAG3 KFSYSCC  0.00
54 PDCD1LG2 KFSYSCC  0.06
55    STAT1 KFSYSCC  0.00
56    TBX21 KFSYSCC  0.42
Scale for 'fill' is already present. Adding another scale for 'fill', which
will replace the existing scale.
[1] 5 4 3 2 1 0
[1] 5 4 3 2 1 0
null device 
          1 
Warning messages:
1: package 'Matrix.utils' was built under R version 3.3.2 
2: In .local(expr, gset.idx.list, ...) :
  1genes with constant expression values throuhgout the samples.
3: In .local(expr, gset.idx.list, ...) :
  Since argument method!="ssgsea", genes with constant expression values are discarded.
4: In .local(expr, gset.idx.list, ...) :
  1genes with constant expression values throuhgout the samples.
5: In .local(expr, gset.idx.list, ...) :
  Since argument method!="ssgsea", genes with constant expression values are discarded.
Doing TCGA analysis
Number of rows analyzed: 20294
Number of columns analyzed: 344
tcga-all: 28 of 28 genes from data set analyzed in set CIRC: HLA-DQA1 HLA-DQA2 HLA-DRB5 CTLA4 PDCD1LG2 ICAM1 CD274 STAT1 IRF1 IFNG GNLY TBX21 CCL5 LAG3 CD247 ICOS IL18RAP CXCL9 CXCL10 HLA-DPB1 HLA-DPA1 HLA-DMB HLA-DRA HLA-DMA CD80 HLA-DOA CD4 HAVCR2
tcga-all: 85 of 88 genes from data set analyzed in set myc.sig: AKAP1 APEX1 BAX CAD CCKBR CCNB1 CCND2 CCT5 CDC25C CEBPZ CKS2 CSDA CTSC DDX10 DDX18 DDX5 DKC1 E2F1 EIF4A1 EIF4B ENO1 EXOSC8 FASN FOSL1 H2AFZ HSPA8 HSPD1 HSPE1 ID2 IMPA2 LTA4H MAT2A METTL1 MINA MSH2 MTHFD1 NAP1L1 NCL NME1 NPM1 NRAS NUP155 PA2G4 PCNA PHB POLD2 PPAT PPIA PPID PRDX3 PREP PRPS2 PSMB1 PTEN PYCR1 RPL10 RPL19 RPL22 RPL27 RPL27A RPL32 RPL5 RPL9 RPS13 RPS16 RPS19 RPS5 RPS6KA2 SFRS1 SFRS2 SFRS7 SHMT1 SLC25A3 SLC39A6 SNRPB SNRPD3 SRM TERT TFRC TOP1 TXN TYMS UBE2C UCHL1 UXT
tcga-all: 3 of 88 genes missing from data set analyzed in set myc.sig: DSCR2 HNRPA2B1 HSPA9B
tcga-all: 50 of 78 genes from data set analyzed in set wnt: PHLDA1 SLC7A5 CTPS BYSL SCD SOX4 WDR77 NLE1 PPIL1 CIRH1A ZNF511 ZNF593 DKC1 ODC1 AURKB WDR12 CDT1 NOC3L CAD XPOT YAP1 SRM NXT1 MRPS12 RHEB WDR3 CRTAP SF3A2 GEMIN5 HNRPDL TREX2 IMP4 HEATR1 SLC19A1 PDCD11 ASCL2 TDGF1 TBX3 EPHB3 ZNRF3 IL20RA RHOBTB3 GEMIN4 ID3 FUT4 PIGW APEX1 SRPRB ZNRD1 TFB2M
tcga-all: 28 of 78 genes missing from data set analyzed in set wnt: FLJ20315 NOB1P PSF1 PMSCL1 RNU3IP2 HIG2 C1orf33 LOC389362 HSPC111 MGC40397 LOC56902 SDCCAG16 FLJ10774 RAB9P40 RFP RRP41 C16orf35 CGI-96 C20orf64 C12orf14 NOL1 SKB1 C11orf5 MGC16824 ZNF278 RPC62 JTV1 ZNF339
tcga-all: 87 of 87 genes from data set analyzed in set HALLMARK_IL6_JAK_STAT3_SIGNALING: IL4R IL6ST STAT1 IL1R1 CSF2RB SOCS3 STAT3 OSMR IL2RG IFNGR1 TYK2 IL13RA1 TLR2 IFNGR2 IL10RB IL6 IL1R2 IL3RA IFNAR1 TNFRSF1A MYD88 ACVR1B CSF3R ITGB3 REG1A CXCL1 A2M CSF2RA IL15RA IRF9 PDGFC HAX1 BAK1 EBI3 INHBE CRLF2 TNFRSF1B CD14 PTPN1 PTPN2 IL1B CSF1 IL18R1 TNF PF4 CXCL13 LTBR FAS IL17RA CXCL10 IL9R STAM2 TNFRSF12A STAT2 HMOX1 LEPR CBL CD9 CXCL3 TGFB1 MAP3K8 ITGA4 CD38 JUN SOCS1 ACVRL1 PIM1 TNFRSF21 PIK3R5 GRB2 IRF1 DNTT CSF2 IL2RA PTPN11 IL12RB1 CCR1 CNTFR PLA2G2A CXCL9 CD44 IL7 CXCL11 CCL7 LTB IL17RB CD36
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: STAT1 ISG15 IFIT1 MX1 IFIT3 IFI35 IRF7 IFIT2 OAS2 TAP1 EIF2AK2 RSAD2 MX2 IRF1 OAS3 TNFSF10 IRF9 CXCL10 IFI44 BST2 XAF1 SP110 OASL PSMB8 IFI44L IFITM3 DDX60 LGALS3BP GBP4 IRF8 PSMB9 PML IFIH1 UBE2L6 IFI27 ADAR LY6E STAT2 CXCL9 IL10RA PLA2G4A TRIM21 USP18 PTGS2 EPSTI1 C1S DDX58 IL15 NLRC5 NMI IDO1 PSMB10 CXCL11 ITGB7 SAMHD1 HERC6 CMPK2 SAMD9L RTP4 PTPN2 PARP14 TNFAIP2 IFITM2 PLSCR1 SOCS1 CASP1 ICAM1 WARS PSME1 ISG20 IRF2 TRIM14 FCGR1A MARCH1 SOCS3 JAK2 HLA-DMA PARP12 TNFAIP6 TRIM26 VCAM1 CD274 CIITA NAMPT SELP GPR18 FPR1 PRIC285 PSME2 SERPING1 CCL5 RNF31 SOD2 TRIM25 LAP3 PSMA3 RNF213 PELI1 CFB CD86 TXNIP HLA-DQA1 GCH1 PNP CCL7 PTPN6 SPPL2A IL4R PNPT1 DHX58 BTG1 CASP8 IFI30 CCL2 FGL2 CASP7 SECTM1 IL15RA CD40 TRAFD1 HLA-DRB1 GBP6 LCP2 HLA-G MT2A RIPK1 KLRK1 UPP1 PSMB2 TDRD7 HIF1A EIF4E3 VAMP8 PFKP CD38 ZBP1 BANK1 TOR1B RBCK1 PDE4B MVP IL7 BPGM FTSJD2 AUTS2 B2M RIPK2 CD69 MYD88 PSMA2 PIM1 NOD1 CFH TAPBP SLC25A28 PTPN1 TNFAIP3 SSPN NUP93 MTHFD2 CDKN1A IRF4 NFKB1 BATF2 HLA-B LATS2 IRF5 SLAMF7 ISOC1 P2RY14 STAT3 NCOA3 HLA-A IL6 GZMA IFNAR2 CD74 RAPGEF6 CASP4 FAS OGFR ARL4A SRI LYSMD2 CSF2RB ST3GAL5 C1R CASP3 CMKLR1 NFKBIA METTL7B ST8SIA4 XCL1 IL2RB VAMP5 IL18BP ZNFX1 ARID5B APOL6 STAT4
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_COMPLEMENT: C2 C1S CFB C1R SERPINE1 MMP14 SERPING1 CTSL1 F5 MMP13 F7 CTSS LGMN PLG C1QA CASP1 GZMA ADAM9 CALM3 C1QC TIMP1 DPP4 KLK1 KLKB1 CD59 CR2 MMP15 LAP3 SPOCK2 F10 CTSB SERPINA1 CTSO CD40LG CBLB PDP1 C4BPB PLEK GP9 PLAUR C3 F2 CASP4 STX4 CTSC USP15 CR1 DUSP6 SERPINB2 GPD2 CFH FN1 CD36 CA2 PSMB9 APOBEC3G FCN1 GZMK PDGFB CLU CASP10 LRP1 CTSD S100A9 WAS BRPF3 PLAT CDA MT3 CASP7 PRSS36 PFN1 GZMB RNF4 ZEB1 CASP5 IRF1 PGCP CDK5R1 ATOX1 PIK3CA TMPRSS6 CPM RCE1 CALM1 DOCK9 KYNU RASGRP1 USP14 LCP2 GP1BA KIF2A GNB4 LCK OLR1 PREP SEPX1 LTA4H ZFPM2 LYN ACTN2 SIRT6 APOC1 PRKCD ITGAM DGKH LTF MAFF KCNIP2 PCLO DOCK10 SH2B3 RABIF SRC HPCAL4 CD46 PRDM4 GNAI3 C9 PPP2CB IRF2 FYN JAK2 PLA2G4A PRCP USP8 RHOG L3MBTL4 LAMP2 PIM1 CXCL1 F3 GNAI2 CASP9 XPNPEP1 PLSCR1 IRF7 CD55 HSPA5 GNB2 DYRK2 PLA2G7 S100A12 GRB2 PHEX GNGT2 DOCK4 MMP12 KCNIP3 FDX1 TIMP2 MMP8 FCER1G ZFYVE20 ANXA5 CTSL2 GCA EHD1 PRSS3 COL4A2 CSRP1 PIK3R5 SERPINC1 ANG APOBEC3F GATA3 DUSP5 CASP3 USP16 CP PSEN1 LIPA PCSK9 DGKG GNG2 ME1 GMFB SCG3 PPP4C CCL5 CTSH F8 APOA4 IL6 AKAP10 ERAP2 VCPIP1 HSPA1A RAF1 NOTCH4 ADRA2B CEBPB HNF4A LGALS3 TNFAIP3 CDH13 ITIH1 TFPI2 PIK3CG S100A13
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: CXCL10 CCL2 CCL5 FPR1 CCL20 IL1A IL8 CCL7 CCL22 CXCL11 CCR7 EDN1 CD40 CXCL9 IL6 IL1B TLR2 IL1R1 CD69 ICAM1 CCRL2 AQP9 EREG C3AR1 GNA15 CMKLR1 PTGER4 LIF IL15 NAMPT OPRK1 ITGB8 PTAFR ADM PLAUR NFKB1 INHBA OSM TNFSF10 TNFSF15 IFNGR2 EMR1 IL12B CSF1 CXCL6 TNFRSF9 LYN ACVR2A LDLR BDKRB1 HRH1 F3 BST2 PTGIR CD55 CALCRL CSF3 GPR132 IL4R NLRP3 IL15RA ADORA2B GCH1 OLR1 PTGER2 CSF3R MYC RELA TNFAIP6 IL7R IL18 GABBR1 CD82 TNFSF9 NMUR1 IL2RB TLR1 LPAR1 IRAK2 RIPK2 MMP14 P2RX7 SLC11A2 SELL P2RY2 ABCA1 FFAR2 PROK2 GNAI3 TACR1 SLC7A1 CDKN1A CYBB TIMP1 HBEGF SCARF1 EBI3 NFKBIA SRI SLC7A2 CCL17 TLR3 APLNR OSMR IL10RA PSEN1 GPR183 ATP2B1 TNFRSF1B BEST1 GPC3 SCN1B ACVR1B HPN SEMA4D KLF6 CD48 CXCR6 SLC1A2 GP1BA TAPBP RGS16 SLAMF1 LCK HIF1A AHR NMI RHOG TPBG NPFFR2 IFNAR1 ICOSLG RASGRP1 IFITM1 KCNJ2 LY6E IL18R1 IL10 KCNA3 HAS2 DCBLD2 LAMP3 VIP CD70 RGS1 SLC31A1 ADRM1 KCNMB2 SERPINE1 MXD1 AXL MEFV PVR CCL24 PDE4B LCP2 PDPN IRF7 MET ATP2A2 SLC31A2 FZD5 ITGA5 SGMS2 MARCO CD14 EIF2AK2 ROS1 ATP2C1 NDP BTG2 MSR1 PTPRE RNF144B PCDH7 SPHK1 IL18RAP RTP4 RAF1 CHST2 ITGB3 KIF1B SELE NOD2 C5AR1 EMP3 CLEC5A TACR3 SLC4A4 MEP1A SELS LTA PIK3R5 STAB1 IRF1 ICAM4 P2RX4 ABI1 CX3CL1 SLC28A2
tcga-all: 198 of 200 genes from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: SOCS2 CISH PIM1 IL2RA TNFRSF4 SOCS1 TNFRSF9 XBP1 RRAGD HK2 PHLDA1 IL2RB CTLA4 NFIL3 CD83 IKZF2 IL10 TNFRSF18 DHRS3 ECM1 ADAM19 SLC2A3 HIPK2 BATF3 BHLHE40 PTGER2 DENND5A ITIH5 PHTF2 GADD45B NRP1 NCOA3 CD79B AHR TNFRSF1B NDRG1 BCL2L1 GABARAPL1 LIF TIAM1 BMPR2 MAP3K8 RHOB MYC S100A1 CAPG ST3GAL4 PENK IRF4 CST7 WLS TLR7 IKZF4 GBP4 RGS16 SPP1 IL13 SLC29A2 NFKBIZ IL4R MXD1 CSF2 FAH CTSZ ITGAE MUC1 MAPKAPK2 TNFRSF21 NT5E FLT3LG CCND2 TRAF1 LCLAT1 IL3RA CYFIP1 BCL2 FGL2 PRNP N6AMT2 PUS1 ITGAV NCS1 DCPS AMACR FAM126B PTH1R ODC1 IGF1R PTCH1 ENO3 CD81 MAFF EMP1 CDKN1C CAPN3 IL1R2 SYT11 TTC39B ANXA4 BATF P4HA1 GPR65 SLC1A5 IGF2R CKAP4 CCR4 CD44 P2RX4 GATA1 KLF6 ARL4A HOPX GPR83 ITGA6 CD48 SELP GLIPR2 SMPDL3A PLSCR1 FURIN SERPINB6 TNFSF11 GPX4 LRRC8C CCNE1 CASP3 SH3BGRL2 SNX9 PLEC BMP2 ICOS ALCAM LTB ENPP1 IL1RL1 MYO1C IFNGR1 PLIN2 IL18R1 AHNAK PRKCH TNFRSF8 SYNGR2 GALM POU2F1 EOMES NOP2 PTRH2 RHOH CDC6 MYO1E CXCL10 SNX14 IRF6 IL10RA MAP6 TNFSF10 SPRED2 SELL SERPINC1 CDCP1 RORA COCH CSF1 F2RL2 UCK2 CA2 IFITM3 UMPS HUWE1 COL6A1 ABCB1 RNH1 IRF8 GUCY1B3 AHCY PRAF2 GSTO1 TWSG1 CDC42SE2 PLAGL1 APLP1 AKAP2 PPAP2A SPRY4 SCN9A SHE PDCD2L CCND3 LRIG1 SWAP70 SLC39A8 RABGAP1L TGM2 PNP AGER ETV4 CD86
tcga-all: 2 of 200 genes missing from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: METTL20 CCDC164
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: PTPRC IL12B TGFB1 IL12A CD3E CD3D CD28 LYN HCLS1 IL18 CRTAM IFNG CD3G CD86 IL10 UBE2N BCL10 CD4 LCK NCK1 C2 HLA-A ITGB2 HLA-DQA1 CD1D CD80 HLA-DRA THY1 TLR1 HLA-G HLA-DMB IL7 IL4 TNF CD247 IL2 HLA-DMA STAT1 IRF4 SRGN INHBA TLR3 ZAP70 CD74 CD40 TRAF2 B2M BCL3 LTB IFNGR1 CCR5 CD40LG HLA-DOA GLMN IL6 HLA-E CD2 CCL5 FAS FASLG TLR6 PF4 TGFB2 CD79A INHBB ELANE SPI1 MAP3K7 IL15 CTSS CD47 PRF1 IL12RB1 LCP2 SOCS1 CDKN2A STAT4 CD7 HLA-DOB CD8A ICAM1 CCL4 GZMB CSF1 IL11 STAB1 IL2RA NLRP3 CCND3 EIF3A SIT1 IFNAR2 HDAC9 CARTPT TRAT1 CCL22 APBB1 FYB IL1B TIMP1 RPS19 JAK2 KRT1 WARS IFNGR2 CCR2 EREG MMP9 EGFR IL16 CFP WAS ITGAL KLRD1 RARS TLR2 CCND2 IL2RG ETS1 ITK NCR1 MAP4K1 CCL19 PSMB10 RPL39 EIF3J ABCE1 CD8B F2 ELF4 LY86 FCGR2B GBP2 PRKCG RPS9 MTIF2 GZMA AARS CD96 CSK HIF1A CCL2 ICOSLG NPM1 IL4R CCL11 NME1 FLNA GPR65 ACHE EIF3D IGSF6 F2R IL13 TAP1 DARS IRF7 ACVR2A CXCR3 PRKCB CXCL9 PTPN6 NCF4 UBE2D1 LIF CCR1 MBL2 DEGS1 TPD52 AKT1 RIPK2 IKBKB GCNT1 SOCS5 IRF8 TAP2 EIF4G3 ABI1 CCL7 IL2RB BRCA1 FGR IL18RAP MRPL3 CXCL13 CAPG EIF5A RPS3A GALNT1 ST8SIA4 CCL13 RPL3L LY75 TAPBP NOS2 RPL9 BCAT1 IL9 IL27RA DYRK3
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
tcga-all wnt vs CIRC: t = -7.66668942196379 df = 342 nrow = 344 cor = -0.3829621607261 pval = 1.84617074915233e-13
tcga-all tak1 vs CIRC: t = -1.90764957903146 df = 342 nrow = 344 cor = -0.102609400758207 pval = 0.0572738736909823
tcga-all wnt vs myc.sig: t = 29.5867669875905 df = 342 nrow = 344 cor = 0.847978818740452 pval = 2.60927229013165e-96
tcga-all CIRC vs neoantigens: tcga-all: Analyzing CIRC vs neoantigens using Fisher's Exact Test for Count Data: p = 2.77695954746732e-11 n = 342

tcga-all: Analyzing CIRC vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16382, n_WT = 219, n_MT = 125, p = 0.00239184964757301
tcga-all: Analyzing CIITA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15715, n_WT = 219, n_MT = 125, p = 0.0223216042395995
tcga-all: Analyzing wnt vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12793, n_WT = 219, n_MT = 125, p = 0.31358705965474
tcga-all: Analyzing myc.sig vs KRAS using Wilcoxon rank sum test with continuity correction: W = 13241, n_WT = 219, n_MT = 125, p = 0.61515080317447
tcga-all: Analyzing neoantigens vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12947, n_WT = 217, n_MT = 125, p = 0.48487310568218
tcga-all: Analyzing BATF3 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16590, n_WT = 219, n_MT = 125, p = 0.00107108341658283
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15416, n_WT = 219, n_MT = 125, p = 0.0514370798293169
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15524, n_WT = 219, n_MT = 125, p = 0.0384941627253121
tcga-all: Analyzing HALLMARK_COMPLEMENT vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15574, n_WT = 219, n_MT = 125, p = 0.03351041769351
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15189, n_WT = 219, n_MT = 125, p = 0.0906576030400835
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15094, n_WT = 219, n_MT = 125, p = 0.112999450326277
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16010, n_WT = 219, n_MT = 125, p = 0.00886085021184704

Computing CIRC ~ KRAS
Computing CIITA ~ KRAS
Computing wnt ~ KRAS
Computing myc.sig ~ KRAS
Computing neoantigens ~ KRAS
Computing BATF3 ~ KRAS
Computing HALLMARK_IL6_JAK_STAT3_SIGNALING ~ KRAS
Computing HALLMARK_INTERFERON_GAMMA_RESPONSE ~ KRAS
Computing HALLMARK_COMPLEMENT ~ KRAS
Computing HALLMARK_INFLAMMATORY_RESPONSE ~ KRAS
Computing HALLMARK_IL2_STAT5_SIGNALING ~ KRAS
Computing HALLMARK_ALLOGRAFT_REJECTION ~ KRAS
tcga-all: Analyzing CIRC CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6373, n_CMS2 = 136, n_CMS1 = 51, p = 1.23959499498166e-18
tcga-all: Analyzing CIITA CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6354, n_CMS2 = 136, n_CMS1 = 51, p = 2.06965323810782e-18
tcga-all: Analyzing wnt CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1682, n_CMS2 = 136, n_CMS1 = 51, p = 6.07843507246058e-08
tcga-all: Analyzing myc.sig CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 3171, n_CMS2 = 136, n_CMS1 = 51, p = 0.368407693350513
tcga-all: Analyzing neoantigens CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6531.5, n_CMS2 = 136, n_CMS1 = 51, p = 4.11558761110611e-21
tcga-all: Analyzing BATF3 CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 5218, n_CMS2 = 136, n_CMS1 = 51, p = 1.11279876119261e-07
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 5944, n_CMS2 = 136, n_CMS1 = 51, p = 5.92825960733478e-14
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6354, n_CMS2 = 136, n_CMS1 = 51, p = 2.06965323810782e-18
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6283, n_CMS2 = 136, n_CMS1 = 51, p = 1.36512464223987e-17
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6153, n_CMS2 = 136, n_CMS1 = 51, p = 3.83449838870921e-16
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6061, n_CMS2 = 136, n_CMS1 = 51, p = 3.70317139786468e-15
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6119, n_CMS2 = 136, n_CMS1 = 51, p = 8.94468341238934e-16
tcga-all: Analyzing CIRC CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2261, n_CMS2 = 136, n_CMS3 = 42, p = 0.0416825581123066
tcga-all: Analyzing CIITA CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2169, n_CMS2 = 136, n_CMS3 = 42, p = 0.0186800531842814
tcga-all: Analyzing wnt CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 3902, n_CMS2 = 136, n_CMS3 = 42, p = 0.000341313512774918
tcga-all: Analyzing myc.sig CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 3320, n_CMS2 = 136, n_CMS3 = 42, p = 0.112311766739075
tcga-all: Analyzing neoantigens CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2002.5, n_CMS2 = 136, n_CMS3 = 42, p = 0.00411497321796958
tcga-all: Analyzing BATF3 CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 3154, n_CMS2 = 136, n_CMS3 = 42, p = 0.308110741016249
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2166, n_CMS2 = 136, n_CMS3 = 42, p = 0.0181701403762754
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1960, n_CMS2 = 136, n_CMS3 = 42, p = 0.00215597285366311
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2227, n_CMS2 = 136, n_CMS3 = 42, p = 0.0313065006910169
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1948, n_CMS2 = 136, n_CMS3 = 42, p = 0.00187740277326145
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1896, n_CMS2 = 136, n_CMS3 = 42, p = 0.00101219247066293
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2130, n_CMS2 = 136, n_CMS3 = 42, p = 0.0129382781216049
tcga-all: Analyzing CIRC CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2243, n_CMS2 = 136, n_CMS4 = 87, p = 5.51962791445972e-15
tcga-all: Analyzing CIITA CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2711, n_CMS2 = 136, n_CMS4 = 87, p = 9.19059090892192e-12
tcga-all: Analyzing wnt CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 10043, n_CMS2 = 136, n_CMS4 = 87, p = 1.62745548681933e-18
tcga-all: Analyzing myc.sig CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 9838, n_CMS2 = 136, n_CMS4 = 87, p = 7.16387570835703e-17
tcga-all: Analyzing neoantigens CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 5232.5, n_CMS2 = 136, n_CMS4 = 87, p = 0.217060840755576
tcga-all: Analyzing BATF3 CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2627, n_CMS2 = 136, n_CMS4 = 87, p = 2.60795652066801e-12
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2189, n_CMS2 = 136, n_CMS4 = 87, p = 2.20261185577197e-15
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2624, n_CMS2 = 136, n_CMS4 = 87, p = 2.49178889113305e-12
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1399, n_CMS2 = 136, n_CMS4 = 87, p = 7.22974585311007e-22
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1369, n_CMS2 = 136, n_CMS4 = 87, p = 3.88143263561137e-22
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1393, n_CMS2 = 136, n_CMS4 = 87, p = 6.38611857062415e-22
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2123, n_CMS2 = 136, n_CMS4 = 87, p = 7.04096492629695e-16


tcga-all: Analyzing CIRC CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 480, n_CMS2 = 41, n_CMS1 = 12, p = 2.03910940079564e-09
tcga-all: Analyzing CIITA CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 451, n_CMS2 = 41, n_CMS1 = 12, p = 1.32651563247495e-06
tcga-all: Analyzing wnt CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 149, n_CMS2 = 41, n_CMS1 = 12, p = 0.0391350009745337
tcga-all: Analyzing myc.sig CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 203, n_CMS2 = 41, n_CMS1 = 12, p = 0.371180469696714
tcga-all: Analyzing neoantigens CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 425.5, n_CMS2 = 41, n_CMS1 = 12, p = 0.000141818624469331
tcga-all: Analyzing BATF3 CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 419, n_CMS2 = 41, n_CMS1 = 12, p = 9.89261031427735e-05
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 461, n_CMS2 = 41, n_CMS1 = 12, p = 2.19848978999018e-07
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 483, n_CMS2 = 41, n_CMS1 = 12, p = 7.27182396607269e-10
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 465, n_CMS2 = 41, n_CMS1 = 12, p = 9.72475262761803e-08
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 456, n_CMS2 = 41, n_CMS1 = 12, p = 5.61069947699806e-07
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 460, n_CMS2 = 41, n_CMS1 = 12, p = 2.67003383892417e-07
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 464, n_CMS2 = 41, n_CMS1 = 12, p = 1.20007585617414e-07
tcga-all: Analyzing CIRC CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 334, n_CMS2 = 41, n_CMS3 = 28, p = 0.00300622689012917
tcga-all: Analyzing CIITA CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 335, n_CMS2 = 41, n_CMS3 = 28, p = 0.00313513226569386
tcga-all: Analyzing wnt CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 875, n_CMS2 = 41, n_CMS3 = 28, p = 0.000161601913359647
tcga-all: Analyzing myc.sig CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 783, n_CMS2 = 41, n_CMS3 = 28, p = 0.0101843523865015
tcga-all: Analyzing neoantigens CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 433, n_CMS2 = 41, n_CMS3 = 28, p = 0.0859444272951382
tcga-all: Analyzing BATF3 CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 551, n_CMS2 = 41, n_CMS3 = 28, p = 0.784775042456067
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 329, n_CMS2 = 41, n_CMS3 = 28, p = 0.00243037267700144
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 277, n_CMS2 = 41, n_CMS3 = 28, p = 0.000200346187722386
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 383, n_CMS2 = 41, n_CMS3 = 28, p = 0.0192080204955667
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 307, n_CMS2 = 41, n_CMS3 = 28, p = 0.000902323254047049
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 305, n_CMS2 = 41, n_CMS3 = 28, p = 0.000820821498299194
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 264, n_CMS2 = 41, n_CMS3 = 28, p = 9.83654240194228e-05
tcga-all: Analyzing CIRC CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 111, n_CMS2 = 41, n_CMS4 = 27, p = 1.35462358863744e-09
tcga-all: Analyzing CIITA CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 110, n_CMS2 = 41, n_CMS4 = 27, p = 1.2138464426316e-09
tcga-all: Analyzing wnt CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 986, n_CMS2 = 41, n_CMS4 = 27, p = 3.92922989387343e-09
tcga-all: Analyzing myc.sig CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 1010, n_CMS2 = 41, n_CMS4 = 27, p = 2.74920522125321e-10
tcga-all: Analyzing neoantigens CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 513, n_CMS2 = 41, n_CMS4 = 27, p = 0.616048341754066
tcga-all: Analyzing BATF3 CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 93, n_CMS2 = 41, n_CMS4 = 27, p = 1.70035530281561e-10
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 82, n_CMS2 = 41, n_CMS4 = 27, p = 4.25297854449279e-11
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 160, n_CMS2 = 41, n_CMS4 = 27, p = 1.5452160059747e-07
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 61, n_CMS2 = 41, n_CMS4 = 27, p = 2.1976880330611e-12
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 33, n_CMS2 = 41, n_CMS4 = 27, p = 1.58386288116536e-14
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 47, n_CMS2 = 41, n_CMS4 = 27, p = 2.24027384591496e-13
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 101, n_CMS2 = 41, n_CMS4 = 27, p = 4.39428203218074e-10

tcga-all: Analyzing CIRC CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1152, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.000163233994822283
tcga-all: Analyzing CIITA CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1323, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.00308528346316024
tcga-all: Analyzing wnt CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2204, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.224749979645318
tcga-all: Analyzing myc.sig CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2218, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.2004099792463
tcga-all: Analyzing neoantigens CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2098, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.414530115017996
tcga-all: Analyzing BATF3 CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1167, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.000216545907835857
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1212, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.000491235015163277
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1252, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.000981403618670544
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1208, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.000457535134080067
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1270, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.00132529481366919
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1281, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.00158702224260874
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1137, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.00012245766085928
tcga-all: Analyzing CIRC CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 12, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 2.03910940079564e-09
tcga-all: Analyzing CIITA CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 41, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 1.32651563247495e-06
tcga-all: Analyzing wnt CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 343, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 0.0391350009745337
tcga-all: Analyzing myc.sig CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 289, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 0.371180469696714
tcga-all: Analyzing neoantigens CMS2-MT vs CMS1-MT using Wilcoxon rank sum test with continuity correction: W = 66.5, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 0.000141818624469331
tcga-all: Analyzing BATF3 CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 73, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 9.89261031427735e-05
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 31, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 2.19848978999018e-07
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 9, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 7.27182396607269e-10
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 27, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 9.72475262761803e-08
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 36, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 5.61069947699806e-07
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 32, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 2.67003383892417e-07
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 28, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 1.20007585617414e-07
tcga-all: Analyzing CIRC CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 42, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 5.96952388180639e-18
tcga-all: Analyzing CIITA CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 44, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 8.6088124778279e-18
tcga-all: Analyzing wnt CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 1337, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 4.77918260103951e-08
tcga-all: Analyzing myc.sig CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 957, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 0.131266270713507
tcga-all: Analyzing neoantigens CMS2-MT vs CMS1-WT using Wilcoxon rank sum test with continuity correction: W = 44.5, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 3.78947701123408e-13
tcga-all: Analyzing BATF3 CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 233, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 6.48215939432032e-09
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 70, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 5.68806345364985e-16
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 46, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 1.23199980318091e-17
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 61, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 1.4755391091352e-16
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 65, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 2.7181270720629e-16
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 107, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 6.86776260633255e-14
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 67, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 3.66394337310941e-16
tcga-all: Analyzing CIRC CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 334, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.00300622689012917
tcga-all: Analyzing CIITA CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 335, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.00313513226569386
tcga-all: Analyzing wnt CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 875, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.000161601913359647
tcga-all: Analyzing myc.sig CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 783, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.0101843523865015
tcga-all: Analyzing neoantigens CMS2-MT vs CMS3-MT using Wilcoxon rank sum test with continuity correction: W = 433, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.0859444272951382
tcga-all: Analyzing BATF3 CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 551, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.784775042456067
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 329, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.00243037267700144
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 277, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.000200346187722386
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 383, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.0192080204955667
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 307, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.000902323254047049
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 305, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.000820821498299194
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 264, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 9.83654240194228e-05
tcga-all: Analyzing CIRC CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 91, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 6.54057234168641e-05
tcga-all: Analyzing CIITA CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 114, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.000539102055503825
tcga-all: Analyzing wnt CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 370, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.111601847559311
tcga-all: Analyzing myc.sig CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 316, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.585875820946205
tcga-all: Analyzing neoantigens CMS2-MT vs CMS3-WT using Wilcoxon rank sum test with continuity correction: W = 215.5, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.170032865744795
tcga-all: Analyzing BATF3 CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 161, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.0140975959932344
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 92, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 7.23203698783448e-05
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 77, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 1.45158091465387e-05
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 120, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.000877984229380965
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 82, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 2.54064834666581e-05
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 88, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 4.81245157242012e-05
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 91, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 6.54057234168641e-05
tcga-all: Analyzing CIRC CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 111, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 1.35462358863744e-09
tcga-all: Analyzing CIITA CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 110, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 1.2138464426316e-09
tcga-all: Analyzing wnt CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 986, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 3.92922989387343e-09
tcga-all: Analyzing myc.sig CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 1010, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 2.74920522125321e-10
tcga-all: Analyzing neoantigens CMS2-MT vs CMS4-MT using Wilcoxon rank sum test with continuity correction: W = 513, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 0.616048341754066
tcga-all: Analyzing BATF3 CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 93, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 1.70035530281561e-10
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 82, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 4.25297854449279e-11
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 160, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 1.5452160059747e-07
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 61, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 2.1976880330611e-12
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 33, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 1.58386288116536e-14
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 47, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 2.24027384591496e-13
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 101, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 4.39428203218074e-10
tcga-all: Analyzing CIRC CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 173, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 2.74771126793874e-13
tcga-all: Analyzing CIITA CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 354, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 1.40844101480104e-09
tcga-all: Analyzing wnt CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 2163, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 1.12817482025658e-10
tcga-all: Analyzing myc.sig CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 2128, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 5.41250472810469e-10
tcga-all: Analyzing neoantigens CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 1181, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 0.844393016945285
tcga-all: Analyzing BATF3 CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 277, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 4.48788328101215e-11
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 214, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 2.1765152244209e-12
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 210, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 1.78477960727702e-12
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 139, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 4.6515836668407e-14
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 123, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 1.97892412576722e-14
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 139, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 4.6515836668407e-14
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 131, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 3.03856935589037e-14

Computing linear model with interaction for CIRC
Computing linear model with interaction for CIITA
Computing linear model with interaction for wnt
Computing linear model with interaction for myc.sig
Computing linear model with interaction for neoantigens
Computing linear model with interaction for BATF3
Computing linear model with interaction for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model with interaction for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model with interaction for HALLMARK_COMPLEMENT
Computing linear model with interaction for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model with interaction for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model with interaction for HALLMARK_ALLOGRAFT_REJECTION
Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for neoantigens
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
tcga-all: Analyzing CIRC CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 838, n_MT = 27, n_WT = 60, p = 0.800805944956622
tcga-all: Analyzing CIITA CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 688, n_MT = 27, n_WT = 60, p = 0.264967936293836
tcga-all: Analyzing wnt CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 765, n_MT = 27, n_WT = 60, p = 0.683072479140494
tcga-all: Analyzing myc.sig CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 807, n_MT = 27, n_WT = 60, p = 0.981700729741838
tcga-all: Analyzing neoantigens CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 765, n_MT = 27, n_WT = 60, p = 0.772967967357958
tcga-all: Analyzing BATF3 CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 705, n_MT = 27, n_WT = 60, p = 0.337681707373123
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 681, n_MT = 27, n_WT = 60, p = 0.238418604488919
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 792, n_MT = 27, n_WT = 60, p = 0.872442154498887
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 768, n_MT = 27, n_WT = 60, p = 0.703388786884955
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 736, n_MT = 27, n_WT = 60, p = 0.500094984426675
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 720, n_MT = 27, n_WT = 60, p = 0.411569105348044
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 799, n_MT = 27, n_WT = 60, p = 0.923255046909828
tcga-all: Analyzing CIRC CMS1 MT vs WT using Wilcoxon rank sum test: W = 270, n_MT = 12, n_WT = 39, p = 0.435533110162582
tcga-all: Analyzing CIITA CMS1 MT vs WT using Wilcoxon rank sum test: W = 289, n_MT = 12, n_WT = 39, p = 0.229512386317868
tcga-all: Analyzing wnt CMS1 MT vs WT using Wilcoxon rank sum test: W = 152, n_MT = 12, n_WT = 39, p = 0.0699676294093422
tcga-all: Analyzing myc.sig CMS1 MT vs WT using Wilcoxon rank sum test: W = 222, n_MT = 12, n_WT = 39, p = 0.801054269531538
tcga-all: Analyzing neoantigens CMS1 MT vs WT using Wilcoxon rank sum test: W = 269, n_MT = 12, n_WT = 39, p = 0.448643825148328
tcga-all: Analyzing BATF3 CMS1 MT vs WT using Wilcoxon rank sum test: W = 265, n_MT = 12, n_WT = 39, p = 0.503206494389321
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS1 MT vs WT using Wilcoxon rank sum test: W = 231, n_MT = 12, n_WT = 39, p = 0.95632638100914
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS1 MT vs WT using Wilcoxon rank sum test: W = 255, n_MT = 12, n_WT = 39, p = 0.653096326215835
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS1 MT vs WT using Wilcoxon rank sum test: W = 239, n_MT = 12, n_WT = 39, p = 0.921473042233286
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS1 MT vs WT using Wilcoxon rank sum test: W = 212, n_MT = 12, n_WT = 39, p = 0.637331827671416
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS1 MT vs WT using Wilcoxon rank sum test: W = 226, n_MT = 12, n_WT = 39, p = 0.869487167240641
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS1 MT vs WT using Wilcoxon rank sum test: W = 237, n_MT = 12, n_WT = 39, p = 0.95632638100914
tcga-all: Analyzing CIRC CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2743, n_MT = 41, n_WT = 95, p = 0.000163233994822283
tcga-all: Analyzing CIITA CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2572, n_MT = 41, n_WT = 95, p = 0.00308528346316024
tcga-all: Analyzing wnt CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1691, n_MT = 41, n_WT = 95, p = 0.224749979645318
tcga-all: Analyzing myc.sig CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1677, n_MT = 41, n_WT = 95, p = 0.2004099792463
tcga-all: Analyzing neoantigens CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1756, n_MT = 41, n_WT = 95, p = 0.414530115017996
tcga-all: Analyzing BATF3 CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2728, n_MT = 41, n_WT = 95, p = 0.000216545907835857
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2683, n_MT = 41, n_WT = 95, p = 0.000491235015163277
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2643, n_MT = 41, n_WT = 95, p = 0.000981403618670544
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2687, n_MT = 41, n_WT = 95, p = 0.000457535134080067
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2625, n_MT = 41, n_WT = 95, p = 0.00132529481366919
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2614, n_MT = 41, n_WT = 95, p = 0.00158702224260874
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2758, n_MT = 41, n_WT = 95, p = 0.00012245766085928
tcga-all: Analyzing CIRC CMS3 MT vs WT using Wilcoxon rank sum test: W = 242, n_MT = 28, n_WT = 14, p = 0.227805142383617
tcga-all: Analyzing CIITA CMS3 MT vs WT using Wilcoxon rank sum test: W = 232, n_MT = 28, n_WT = 14, p = 0.347887457660636
tcga-all: Analyzing wnt CMS3 MT vs WT using Wilcoxon rank sum test: W = 230, n_MT = 28, n_WT = 14, p = 0.375914690341709
tcga-all: Analyzing myc.sig CMS3 MT vs WT using Wilcoxon rank sum test: W = 233, n_MT = 28, n_WT = 14, p = 0.334372944037949
tcga-all: Analyzing neoantigens CMS3 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 182, n_MT = 28, n_WT = 14, p = 0.718651791550678
tcga-all: Analyzing BATF3 CMS3 MT vs WT using Wilcoxon rank sum test: W = 264, n_MT = 28, n_WT = 14, p = 0.0713942204883082
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 226, n_MT = 28, n_WT = 14, p = 0.435894904638578
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 214, n_MT = 28, n_WT = 14, p = 0.644481834091968
tcga-all: Analyzing HALLMARK_COMPLEMENT CMS3 MT vs WT using Wilcoxon rank sum test: W = 233, n_MT = 28, n_WT = 14, p = 0.334372944037949
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 236, n_MT = 28, n_WT = 14, p = 0.295840217194912
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 241, n_MT = 28, n_WT = 14, p = 0.238315993730082
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS3 MT vs WT using Wilcoxon rank sum test: W = 219, n_MT = 28, n_WT = 14, p = 0.552760737865497

Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for neoantigens
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
Computing rectum vs left
tcga-all: Analyzing CIRC site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3359, n_rectum = 60, n_left = 133, p = 0.0791927710817998
tcga-all: Analyzing CIITA site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3200, n_rectum = 60, n_left = 133, p = 0.02794450463594
tcga-all: Analyzing wnt site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3544, n_rectum = 60, n_left = 133, p = 0.214854656548409
tcga-all: Analyzing myc.sig site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3620, n_rectum = 60, n_left = 133, p = 0.303605065236952
tcga-all: Analyzing neoantigens site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3806, n_rectum = 60, n_left = 133, p = 0.667089937000163
tcga-all: Analyzing BATF3 site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2938, n_rectum = 60, n_left = 133, p = 0.00341693982164618
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3595, n_rectum = 60, n_left = 133, p = 0.272057685726368
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3626, n_rectum = 60, n_left = 133, p = 0.311524443923762
tcga-all: Analyzing HALLMARK_COMPLEMENT site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3778, n_rectum = 60, n_left = 133, p = 0.555967354803256
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3921, n_rectum = 60, n_left = 133, p = 0.848750939600781
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 4296, n_rectum = 60, n_left = 133, p = 0.395019724743971
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3508, n_rectum = 60, n_left = 133, p = 0.180065008977664
Computing right vs left
tcga-all: Analyzing CIRC site: right vs leftWilcoxon rank sum test with continuity correction: W = 6860, n_right = 148, n_left = 133, p = 1.16662152475699e-05
tcga-all: Analyzing CIITA site: right vs leftWilcoxon rank sum test with continuity correction: W = 6378, n_right = 148, n_left = 133, p = 3.53513859137319e-07
tcga-all: Analyzing wnt site: right vs leftWilcoxon rank sum test with continuity correction: W = 10768, n_right = 148, n_left = 133, p = 0.173585307958795
tcga-all: Analyzing myc.sig site: right vs leftWilcoxon rank sum test with continuity correction: W = 9237, n_right = 148, n_left = 133, p = 0.374108760826281
tcga-all: Analyzing neoantigens site: right vs leftWilcoxon rank sum test with continuity correction: W = 5200, n_right = 148, n_left = 133, p = 2.2275540553044e-11
tcga-all: Analyzing BATF3 site: right vs leftWilcoxon rank sum test with continuity correction: W = 8156, n_right = 148, n_left = 133, p = 0.0132043313359446
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 7765, n_right = 148, n_left = 133, p = 0.00226488873616202
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 6860, n_right = 148, n_left = 133, p = 1.16662152475699e-05
tcga-all: Analyzing HALLMARK_COMPLEMENT site: right vs leftWilcoxon rank sum test with continuity correction: W = 7745, n_right = 148, n_left = 133, p = 0.0020526399262592
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 7789, n_right = 148, n_left = 133, p = 0.00254604610432205
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 8051, n_right = 148, n_left = 133, p = 0.00847358302147921
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: right vs leftWilcoxon rank sum test with continuity correction: W = 7063, n_right = 148, n_left = 133, p = 4.40273274341645e-05

Plotting CIRC ~ site
Plotting CIITA ~ site
Plotting wnt ~ site
Plotting myc.sig ~ site
Plotting neoantigens ~ site
Plotting BATF3 ~ site
Plotting HALLMARK_IL6_JAK_STAT3_SIGNALING ~ site
Plotting HALLMARK_INTERFERON_GAMMA_RESPONSE ~ site
Plotting HALLMARK_COMPLEMENT ~ site
Plotting HALLMARK_INFLAMMATORY_RESPONSE ~ site
Plotting HALLMARK_IL2_STAT5_SIGNALING ~ site
Plotting HALLMARK_ALLOGRAFT_REJECTION ~ site
Computing MSS vs MSI
tcga-all: Analyzing CIRC status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 12383, n_MSS = 289, n_MSI = 53, p = 9.36844862356913e-13
tcga-all: Analyzing CIITA status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 12846, n_MSS = 289, n_MSI = 53, p = 4.5334700231437e-15
tcga-all: Analyzing wnt status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 5071, n_MSS = 289, n_MSI = 53, p = 9.23774128755386e-05
tcga-all: Analyzing myc.sig status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 8321, n_MSS = 289, n_MSI = 53, p = 0.317071268322223
tcga-all: Analyzing neoantigens status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 14555, n_MSS = 289, n_MSI = 53, p = 8.99612691829524e-26
tcga-all: Analyzing BATF3 status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 10400, n_MSS = 289, n_MSI = 53, p = 3.43494274356654e-05
tcga-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 11367, n_MSS = 289, n_MSI = 53, p = 2.09487143277198e-08
tcga-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 12582, n_MSS = 289, n_MSI = 53, p = 1.00507782619955e-13
tcga-all: Analyzing HALLMARK_COMPLEMENT status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 11826, n_MSS = 289, n_MSI = 53, p = 3.02144217595456e-10
tcga-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 11661, n_MSS = 289, n_MSI = 53, p = 1.46376286060136e-09
tcga-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 11182, n_MSS = 289, n_MSI = 53, p = 1.01295853062467e-07
tcga-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 12011, n_MSS = 289, n_MSI = 53, p = 4.79167964512724e-11

Plotting CIRC ~ status
Plotting CIITA ~ status
Plotting wnt ~ status
Plotting myc.sig ~ status
Plotting neoantigens ~ status
Plotting BATF3 ~ status
Plotting HALLMARK_IL6_JAK_STAT3_SIGNALING ~ status
Plotting HALLMARK_INTERFERON_GAMMA_RESPONSE ~ status
Plotting HALLMARK_COMPLEMENT ~ status
Plotting HALLMARK_INFLAMMATORY_RESPONSE ~ status
Plotting HALLMARK_IL2_STAT5_SIGNALING ~ status
Plotting HALLMARK_ALLOGRAFT_REJECTION ~ status
MSI nrow =  559 
  clusters Freq
1        1  390
2        2  169
MSI clusters: 2
MSS clusters: 1
[1] -2.980897e-13
[1] -3.522599e-13
Has MSI
Has BRAF
Has CMS
Has TYMS
Has Genomic
[1] NA  2  4  6  8 10 12 NA
       [,1] [,2] [,3] [,4] [,5] [,6] [,7] [,8]
layout   NA    2    4    6    8   10   12   NA
row       1    3    5    7    9   11   13   15
[1] 1.00 5.00 0.25 0.25 0.25 0.25 1.00 2.00
[1] 1.0 2.5 2.5 2.5 2.5 0.5 1.0 0.5
     [,1] [,2] [,3] [,4] [,5] [,6] [,7] [,8]
[1,]   NA    2    4    6    8   10   12   NA
[2,]    1    3    5    7    9   11   13   15
[3,]    1    3    5    7    9   11   13   16
[4,]    1    3    5    7    9   11   13   17
[5,]    1    3    5    7    9   11   13   18
[6,]   NA   NA   NA   NA   NA   NA   NA   NA
[7,]   NA   14   NA   NA   NA   NA   NA   NA
[8,]   NA   NA   NA   NA   NA   NA   NA   NA
[1] 18
tcga-msi: Analyzing TYMS vs Imputed Status using Wilcoxon rank sum test with continuity correction: W = 54712 p = 2.44358357254431e-35 n_MSS = 390, n_MSI = 169
tcga-msi: Analyzing TYMS vs Annotated Status using Wilcoxon rank sum test with continuity correction: W = 35644 p = 8.82290348137337e-34 n_MSS = 478, n_MSI = 81
Overlap of MSI inferred and annotated in TCGA:
     
      msi mss
  msi  78   3
  mss  91 387
Number of rows analyzed: 20294
Number of columns analyzed: 344
tcga-all-msi-inferred: 28 of 28 genes from data set analyzed in set CIRC: HLA-DQA1 HLA-DQA2 HLA-DRB5 CTLA4 PDCD1LG2 ICAM1 CD274 STAT1 IRF1 IFNG GNLY TBX21 CCL5 LAG3 CD247 ICOS IL18RAP CXCL9 CXCL10 HLA-DPB1 HLA-DPA1 HLA-DMB HLA-DRA HLA-DMA CD80 HLA-DOA CD4 HAVCR2
tcga-all-msi-inferred: 85 of 88 genes from data set analyzed in set myc.sig: AKAP1 APEX1 BAX CAD CCKBR CCNB1 CCND2 CCT5 CDC25C CEBPZ CKS2 CSDA CTSC DDX10 DDX18 DDX5 DKC1 E2F1 EIF4A1 EIF4B ENO1 EXOSC8 FASN FOSL1 H2AFZ HSPA8 HSPD1 HSPE1 ID2 IMPA2 LTA4H MAT2A METTL1 MINA MSH2 MTHFD1 NAP1L1 NCL NME1 NPM1 NRAS NUP155 PA2G4 PCNA PHB POLD2 PPAT PPIA PPID PRDX3 PREP PRPS2 PSMB1 PTEN PYCR1 RPL10 RPL19 RPL22 RPL27 RPL27A RPL32 RPL5 RPL9 RPS13 RPS16 RPS19 RPS5 RPS6KA2 SFRS1 SFRS2 SFRS7 SHMT1 SLC25A3 SLC39A6 SNRPB SNRPD3 SRM TERT TFRC TOP1 TXN TYMS UBE2C UCHL1 UXT
tcga-all-msi-inferred: 3 of 88 genes missing from data set analyzed in set myc.sig: DSCR2 HNRPA2B1 HSPA9B
tcga-all-msi-inferred: 50 of 78 genes from data set analyzed in set wnt: PHLDA1 SLC7A5 CTPS BYSL SCD SOX4 WDR77 NLE1 PPIL1 CIRH1A ZNF511 ZNF593 DKC1 ODC1 AURKB WDR12 CDT1 NOC3L CAD XPOT YAP1 SRM NXT1 MRPS12 RHEB WDR3 CRTAP SF3A2 GEMIN5 HNRPDL TREX2 IMP4 HEATR1 SLC19A1 PDCD11 ASCL2 TDGF1 TBX3 EPHB3 ZNRF3 IL20RA RHOBTB3 GEMIN4 ID3 FUT4 PIGW APEX1 SRPRB ZNRD1 TFB2M
tcga-all-msi-inferred: 28 of 78 genes missing from data set analyzed in set wnt: FLJ20315 NOB1P PSF1 PMSCL1 RNU3IP2 HIG2 C1orf33 LOC389362 HSPC111 MGC40397 LOC56902 SDCCAG16 FLJ10774 RAB9P40 RFP RRP41 C16orf35 CGI-96 C20orf64 C12orf14 NOL1 SKB1 C11orf5 MGC16824 ZNF278 RPC62 JTV1 ZNF339
tcga-all-msi-inferred: 87 of 87 genes from data set analyzed in set HALLMARK_IL6_JAK_STAT3_SIGNALING: IL4R IL6ST STAT1 IL1R1 CSF2RB SOCS3 STAT3 OSMR IL2RG IFNGR1 TYK2 IL13RA1 TLR2 IFNGR2 IL10RB IL6 IL1R2 IL3RA IFNAR1 TNFRSF1A MYD88 ACVR1B CSF3R ITGB3 REG1A CXCL1 A2M CSF2RA IL15RA IRF9 PDGFC HAX1 BAK1 EBI3 INHBE CRLF2 TNFRSF1B CD14 PTPN1 PTPN2 IL1B CSF1 IL18R1 TNF PF4 CXCL13 LTBR FAS IL17RA CXCL10 IL9R STAM2 TNFRSF12A STAT2 HMOX1 LEPR CBL CD9 CXCL3 TGFB1 MAP3K8 ITGA4 CD38 JUN SOCS1 ACVRL1 PIM1 TNFRSF21 PIK3R5 GRB2 IRF1 DNTT CSF2 IL2RA PTPN11 IL12RB1 CCR1 CNTFR PLA2G2A CXCL9 CD44 IL7 CXCL11 CCL7 LTB IL17RB CD36
tcga-all-msi-inferred: 200 of 200 genes from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: STAT1 ISG15 IFIT1 MX1 IFIT3 IFI35 IRF7 IFIT2 OAS2 TAP1 EIF2AK2 RSAD2 MX2 IRF1 OAS3 TNFSF10 IRF9 CXCL10 IFI44 BST2 XAF1 SP110 OASL PSMB8 IFI44L IFITM3 DDX60 LGALS3BP GBP4 IRF8 PSMB9 PML IFIH1 UBE2L6 IFI27 ADAR LY6E STAT2 CXCL9 IL10RA PLA2G4A TRIM21 USP18 PTGS2 EPSTI1 C1S DDX58 IL15 NLRC5 NMI IDO1 PSMB10 CXCL11 ITGB7 SAMHD1 HERC6 CMPK2 SAMD9L RTP4 PTPN2 PARP14 TNFAIP2 IFITM2 PLSCR1 SOCS1 CASP1 ICAM1 WARS PSME1 ISG20 IRF2 TRIM14 FCGR1A MARCH1 SOCS3 JAK2 HLA-DMA PARP12 TNFAIP6 TRIM26 VCAM1 CD274 CIITA NAMPT SELP GPR18 FPR1 PRIC285 PSME2 SERPING1 CCL5 RNF31 SOD2 TRIM25 LAP3 PSMA3 RNF213 PELI1 CFB CD86 TXNIP HLA-DQA1 GCH1 PNP CCL7 PTPN6 SPPL2A IL4R PNPT1 DHX58 BTG1 CASP8 IFI30 CCL2 FGL2 CASP7 SECTM1 IL15RA CD40 TRAFD1 HLA-DRB1 GBP6 LCP2 HLA-G MT2A RIPK1 KLRK1 UPP1 PSMB2 TDRD7 HIF1A EIF4E3 VAMP8 PFKP CD38 ZBP1 BANK1 TOR1B RBCK1 PDE4B MVP IL7 BPGM FTSJD2 AUTS2 B2M RIPK2 CD69 MYD88 PSMA2 PIM1 NOD1 CFH TAPBP SLC25A28 PTPN1 TNFAIP3 SSPN NUP93 MTHFD2 CDKN1A IRF4 NFKB1 BATF2 HLA-B LATS2 IRF5 SLAMF7 ISOC1 P2RY14 STAT3 NCOA3 HLA-A IL6 GZMA IFNAR2 CD74 RAPGEF6 CASP4 FAS OGFR ARL4A SRI LYSMD2 CSF2RB ST3GAL5 C1R CASP3 CMKLR1 NFKBIA METTL7B ST8SIA4 XCL1 IL2RB VAMP5 IL18BP ZNFX1 ARID5B APOL6 STAT4
tcga-all-msi-inferred: 200 of 200 genes from data set analyzed in set HALLMARK_COMPLEMENT: C2 C1S CFB C1R SERPINE1 MMP14 SERPING1 CTSL1 F5 MMP13 F7 CTSS LGMN PLG C1QA CASP1 GZMA ADAM9 CALM3 C1QC TIMP1 DPP4 KLK1 KLKB1 CD59 CR2 MMP15 LAP3 SPOCK2 F10 CTSB SERPINA1 CTSO CD40LG CBLB PDP1 C4BPB PLEK GP9 PLAUR C3 F2 CASP4 STX4 CTSC USP15 CR1 DUSP6 SERPINB2 GPD2 CFH FN1 CD36 CA2 PSMB9 APOBEC3G FCN1 GZMK PDGFB CLU CASP10 LRP1 CTSD S100A9 WAS BRPF3 PLAT CDA MT3 CASP7 PRSS36 PFN1 GZMB RNF4 ZEB1 CASP5 IRF1 PGCP CDK5R1 ATOX1 PIK3CA TMPRSS6 CPM RCE1 CALM1 DOCK9 KYNU RASGRP1 USP14 LCP2 GP1BA KIF2A GNB4 LCK OLR1 PREP SEPX1 LTA4H ZFPM2 LYN ACTN2 SIRT6 APOC1 PRKCD ITGAM DGKH LTF MAFF KCNIP2 PCLO DOCK10 SH2B3 RABIF SRC HPCAL4 CD46 PRDM4 GNAI3 C9 PPP2CB IRF2 FYN JAK2 PLA2G4A PRCP USP8 RHOG L3MBTL4 LAMP2 PIM1 CXCL1 F3 GNAI2 CASP9 XPNPEP1 PLSCR1 IRF7 CD55 HSPA5 GNB2 DYRK2 PLA2G7 S100A12 GRB2 PHEX GNGT2 DOCK4 MMP12 KCNIP3 FDX1 TIMP2 MMP8 FCER1G ZFYVE20 ANXA5 CTSL2 GCA EHD1 PRSS3 COL4A2 CSRP1 PIK3R5 SERPINC1 ANG APOBEC3F GATA3 DUSP5 CASP3 USP16 CP PSEN1 LIPA PCSK9 DGKG GNG2 ME1 GMFB SCG3 PPP4C CCL5 CTSH F8 APOA4 IL6 AKAP10 ERAP2 VCPIP1 HSPA1A RAF1 NOTCH4 ADRA2B CEBPB HNF4A LGALS3 TNFAIP3 CDH13 ITIH1 TFPI2 PIK3CG S100A13
tcga-all-msi-inferred: 200 of 200 genes from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: CXCL10 CCL2 CCL5 FPR1 CCL20 IL1A IL8 CCL7 CCL22 CXCL11 CCR7 EDN1 CD40 CXCL9 IL6 IL1B TLR2 IL1R1 CD69 ICAM1 CCRL2 AQP9 EREG C3AR1 GNA15 CMKLR1 PTGER4 LIF IL15 NAMPT OPRK1 ITGB8 PTAFR ADM PLAUR NFKB1 INHBA OSM TNFSF10 TNFSF15 IFNGR2 EMR1 IL12B CSF1 CXCL6 TNFRSF9 LYN ACVR2A LDLR BDKRB1 HRH1 F3 BST2 PTGIR CD55 CALCRL CSF3 GPR132 IL4R NLRP3 IL15RA ADORA2B GCH1 OLR1 PTGER2 CSF3R MYC RELA TNFAIP6 IL7R IL18 GABBR1 CD82 TNFSF9 NMUR1 IL2RB TLR1 LPAR1 IRAK2 RIPK2 MMP14 P2RX7 SLC11A2 SELL P2RY2 ABCA1 FFAR2 PROK2 GNAI3 TACR1 SLC7A1 CDKN1A CYBB TIMP1 HBEGF SCARF1 EBI3 NFKBIA SRI SLC7A2 CCL17 TLR3 APLNR OSMR IL10RA PSEN1 GPR183 ATP2B1 TNFRSF1B BEST1 GPC3 SCN1B ACVR1B HPN SEMA4D KLF6 CD48 CXCR6 SLC1A2 GP1BA TAPBP RGS16 SLAMF1 LCK HIF1A AHR NMI RHOG TPBG NPFFR2 IFNAR1 ICOSLG RASGRP1 IFITM1 KCNJ2 LY6E IL18R1 IL10 KCNA3 HAS2 DCBLD2 LAMP3 VIP CD70 RGS1 SLC31A1 ADRM1 KCNMB2 SERPINE1 MXD1 AXL MEFV PVR CCL24 PDE4B LCP2 PDPN IRF7 MET ATP2A2 SLC31A2 FZD5 ITGA5 SGMS2 MARCO CD14 EIF2AK2 ROS1 ATP2C1 NDP BTG2 MSR1 PTPRE RNF144B PCDH7 SPHK1 IL18RAP RTP4 RAF1 CHST2 ITGB3 KIF1B SELE NOD2 C5AR1 EMP3 CLEC5A TACR3 SLC4A4 MEP1A SELS LTA PIK3R5 STAB1 IRF1 ICAM4 P2RX4 ABI1 CX3CL1 SLC28A2
tcga-all-msi-inferred: 198 of 200 genes from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: SOCS2 CISH PIM1 IL2RA TNFRSF4 SOCS1 TNFRSF9 XBP1 RRAGD HK2 PHLDA1 IL2RB CTLA4 NFIL3 CD83 IKZF2 IL10 TNFRSF18 DHRS3 ECM1 ADAM19 SLC2A3 HIPK2 BATF3 BHLHE40 PTGER2 DENND5A ITIH5 PHTF2 GADD45B NRP1 NCOA3 CD79B AHR TNFRSF1B NDRG1 BCL2L1 GABARAPL1 LIF TIAM1 BMPR2 MAP3K8 RHOB MYC S100A1 CAPG ST3GAL4 PENK IRF4 CST7 WLS TLR7 IKZF4 GBP4 RGS16 SPP1 IL13 SLC29A2 NFKBIZ IL4R MXD1 CSF2 FAH CTSZ ITGAE MUC1 MAPKAPK2 TNFRSF21 NT5E FLT3LG CCND2 TRAF1 LCLAT1 IL3RA CYFIP1 BCL2 FGL2 PRNP N6AMT2 PUS1 ITGAV NCS1 DCPS AMACR FAM126B PTH1R ODC1 IGF1R PTCH1 ENO3 CD81 MAFF EMP1 CDKN1C CAPN3 IL1R2 SYT11 TTC39B ANXA4 BATF P4HA1 GPR65 SLC1A5 IGF2R CKAP4 CCR4 CD44 P2RX4 GATA1 KLF6 ARL4A HOPX GPR83 ITGA6 CD48 SELP GLIPR2 SMPDL3A PLSCR1 FURIN SERPINB6 TNFSF11 GPX4 LRRC8C CCNE1 CASP3 SH3BGRL2 SNX9 PLEC BMP2 ICOS ALCAM LTB ENPP1 IL1RL1 MYO1C IFNGR1 PLIN2 IL18R1 AHNAK PRKCH TNFRSF8 SYNGR2 GALM POU2F1 EOMES NOP2 PTRH2 RHOH CDC6 MYO1E CXCL10 SNX14 IRF6 IL10RA MAP6 TNFSF10 SPRED2 SELL SERPINC1 CDCP1 RORA COCH CSF1 F2RL2 UCK2 CA2 IFITM3 UMPS HUWE1 COL6A1 ABCB1 RNH1 IRF8 GUCY1B3 AHCY PRAF2 GSTO1 TWSG1 CDC42SE2 PLAGL1 APLP1 AKAP2 PPAP2A SPRY4 SCN9A SHE PDCD2L CCND3 LRIG1 SWAP70 SLC39A8 RABGAP1L TGM2 PNP AGER ETV4 CD86
tcga-all-msi-inferred: 2 of 200 genes missing from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: METTL20 CCDC164
tcga-all-msi-inferred: 200 of 200 genes from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: PTPRC IL12B TGFB1 IL12A CD3E CD3D CD28 LYN HCLS1 IL18 CRTAM IFNG CD3G CD86 IL10 UBE2N BCL10 CD4 LCK NCK1 C2 HLA-A ITGB2 HLA-DQA1 CD1D CD80 HLA-DRA THY1 TLR1 HLA-G HLA-DMB IL7 IL4 TNF CD247 IL2 HLA-DMA STAT1 IRF4 SRGN INHBA TLR3 ZAP70 CD74 CD40 TRAF2 B2M BCL3 LTB IFNGR1 CCR5 CD40LG HLA-DOA GLMN IL6 HLA-E CD2 CCL5 FAS FASLG TLR6 PF4 TGFB2 CD79A INHBB ELANE SPI1 MAP3K7 IL15 CTSS CD47 PRF1 IL12RB1 LCP2 SOCS1 CDKN2A STAT4 CD7 HLA-DOB CD8A ICAM1 CCL4 GZMB CSF1 IL11 STAB1 IL2RA NLRP3 CCND3 EIF3A SIT1 IFNAR2 HDAC9 CARTPT TRAT1 CCL22 APBB1 FYB IL1B TIMP1 RPS19 JAK2 KRT1 WARS IFNGR2 CCR2 EREG MMP9 EGFR IL16 CFP WAS ITGAL KLRD1 RARS TLR2 CCND2 IL2RG ETS1 ITK NCR1 MAP4K1 CCL19 PSMB10 RPL39 EIF3J ABCE1 CD8B F2 ELF4 LY86 FCGR2B GBP2 PRKCG RPS9 MTIF2 GZMA AARS CD96 CSK HIF1A CCL2 ICOSLG NPM1 IL4R CCL11 NME1 FLNA GPR65 ACHE EIF3D IGSF6 F2R IL13 TAP1 DARS IRF7 ACVR2A CXCR3 PRKCB CXCL9 PTPN6 NCF4 UBE2D1 LIF CCR1 MBL2 DEGS1 TPD52 AKT1 RIPK2 IKBKB GCNT1 SOCS5 IRF8 TAP2 EIF4G3 ABI1 CCL7 IL2RB BRCA1 FGR IL18RAP MRPL3 CXCL13 CAPG EIF5A RPS3A GALNT1 ST8SIA4 CCL13 RPL3L LY75 TAPBP NOS2 RPL9 BCAT1 IL9 IL27RA DYRK3
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
tcga-all-msi-inferred wnt vs CIRC: t = -7.66668942196379 df = 342 nrow = 344 cor = -0.3829621607261 pval = 1.84617074915233e-13
tcga-all-msi-inferred tak1 vs CIRC: t = -1.90764957903146 df = 342 nrow = 344 cor = -0.102609400758207 pval = 0.0572738736909823
tcga-all-msi-inferred wnt vs myc.sig: t = 29.5867669875905 df = 342 nrow = 344 cor = 0.847978818740452 pval = 2.60927229013165e-96
tcga-all-msi-inferred CIRC vs neoantigens: tcga-all-msi-inferred: Analyzing CIRC vs neoantigens using Fisher's Exact Test for Count Data: p = 2.77695954746732e-11 n = 342

tcga-all-msi-inferred: Analyzing CIRC vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16382, n_WT = 219, n_MT = 125, p = 0.00239184964757301
tcga-all-msi-inferred: Analyzing CIITA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15715, n_WT = 219, n_MT = 125, p = 0.0223216042395995
tcga-all-msi-inferred: Analyzing wnt vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12793, n_WT = 219, n_MT = 125, p = 0.31358705965474
tcga-all-msi-inferred: Analyzing myc.sig vs KRAS using Wilcoxon rank sum test with continuity correction: W = 13241, n_WT = 219, n_MT = 125, p = 0.61515080317447
tcga-all-msi-inferred: Analyzing neoantigens vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12947, n_WT = 217, n_MT = 125, p = 0.48487310568218
tcga-all-msi-inferred: Analyzing BATF3 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16590, n_WT = 219, n_MT = 125, p = 0.00107108341658283
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15416, n_WT = 219, n_MT = 125, p = 0.0514370798293169
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15524, n_WT = 219, n_MT = 125, p = 0.0384941627253121
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15574, n_WT = 219, n_MT = 125, p = 0.03351041769351
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15189, n_WT = 219, n_MT = 125, p = 0.0906576030400835
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15094, n_WT = 219, n_MT = 125, p = 0.112999450326277
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION vs KRAS using Wilcoxon rank sum test with continuity correction: W = 16010, n_WT = 219, n_MT = 125, p = 0.00886085021184704

Computing CIRC ~ KRAS
Computing CIITA ~ KRAS
Computing wnt ~ KRAS
Computing myc.sig ~ KRAS
Computing neoantigens ~ KRAS
Computing BATF3 ~ KRAS
Computing HALLMARK_IL6_JAK_STAT3_SIGNALING ~ KRAS
Computing HALLMARK_INTERFERON_GAMMA_RESPONSE ~ KRAS
Computing HALLMARK_COMPLEMENT ~ KRAS
Computing HALLMARK_INFLAMMATORY_RESPONSE ~ KRAS
Computing HALLMARK_IL2_STAT5_SIGNALING ~ KRAS
Computing HALLMARK_ALLOGRAFT_REJECTION ~ KRAS
tcga-all-msi-inferred: Analyzing CIRC CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6373, n_CMS2 = 136, n_CMS1 = 51, p = 1.23959499498166e-18
tcga-all-msi-inferred: Analyzing CIITA CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6354, n_CMS2 = 136, n_CMS1 = 51, p = 2.06965323810782e-18
tcga-all-msi-inferred: Analyzing wnt CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1682, n_CMS2 = 136, n_CMS1 = 51, p = 6.07843507246058e-08
tcga-all-msi-inferred: Analyzing myc.sig CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 3171, n_CMS2 = 136, n_CMS1 = 51, p = 0.368407693350513
tcga-all-msi-inferred: Analyzing neoantigens CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6531.5, n_CMS2 = 136, n_CMS1 = 51, p = 4.11558761110611e-21
tcga-all-msi-inferred: Analyzing BATF3 CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 5218, n_CMS2 = 136, n_CMS1 = 51, p = 1.11279876119261e-07
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 5944, n_CMS2 = 136, n_CMS1 = 51, p = 5.92825960733478e-14
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6354, n_CMS2 = 136, n_CMS1 = 51, p = 2.06965323810782e-18
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6283, n_CMS2 = 136, n_CMS1 = 51, p = 1.36512464223987e-17
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6153, n_CMS2 = 136, n_CMS1 = 51, p = 3.83449838870921e-16
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6061, n_CMS2 = 136, n_CMS1 = 51, p = 3.70317139786468e-15
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6119, n_CMS2 = 136, n_CMS1 = 51, p = 8.94468341238934e-16
tcga-all-msi-inferred: Analyzing CIRC CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2261, n_CMS2 = 136, n_CMS3 = 42, p = 0.0416825581123066
tcga-all-msi-inferred: Analyzing CIITA CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2169, n_CMS2 = 136, n_CMS3 = 42, p = 0.0186800531842814
tcga-all-msi-inferred: Analyzing wnt CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 3902, n_CMS2 = 136, n_CMS3 = 42, p = 0.000341313512774918
tcga-all-msi-inferred: Analyzing myc.sig CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 3320, n_CMS2 = 136, n_CMS3 = 42, p = 0.112311766739075
tcga-all-msi-inferred: Analyzing neoantigens CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2002.5, n_CMS2 = 136, n_CMS3 = 42, p = 0.00411497321796958
tcga-all-msi-inferred: Analyzing BATF3 CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 3154, n_CMS2 = 136, n_CMS3 = 42, p = 0.308110741016249
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2166, n_CMS2 = 136, n_CMS3 = 42, p = 0.0181701403762754
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1960, n_CMS2 = 136, n_CMS3 = 42, p = 0.00215597285366311
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2227, n_CMS2 = 136, n_CMS3 = 42, p = 0.0313065006910169
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1948, n_CMS2 = 136, n_CMS3 = 42, p = 0.00187740277326145
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1896, n_CMS2 = 136, n_CMS3 = 42, p = 0.00101219247066293
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2130, n_CMS2 = 136, n_CMS3 = 42, p = 0.0129382781216049
tcga-all-msi-inferred: Analyzing CIRC CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2243, n_CMS2 = 136, n_CMS4 = 87, p = 5.51962791445972e-15
tcga-all-msi-inferred: Analyzing CIITA CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2711, n_CMS2 = 136, n_CMS4 = 87, p = 9.19059090892192e-12
tcga-all-msi-inferred: Analyzing wnt CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 10043, n_CMS2 = 136, n_CMS4 = 87, p = 1.62745548681933e-18
tcga-all-msi-inferred: Analyzing myc.sig CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 9838, n_CMS2 = 136, n_CMS4 = 87, p = 7.16387570835703e-17
tcga-all-msi-inferred: Analyzing neoantigens CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 5232.5, n_CMS2 = 136, n_CMS4 = 87, p = 0.217060840755576
tcga-all-msi-inferred: Analyzing BATF3 CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2627, n_CMS2 = 136, n_CMS4 = 87, p = 2.60795652066801e-12
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2189, n_CMS2 = 136, n_CMS4 = 87, p = 2.20261185577197e-15
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2624, n_CMS2 = 136, n_CMS4 = 87, p = 2.49178889113305e-12
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1399, n_CMS2 = 136, n_CMS4 = 87, p = 7.22974585311007e-22
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1369, n_CMS2 = 136, n_CMS4 = 87, p = 3.88143263561137e-22
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1393, n_CMS2 = 136, n_CMS4 = 87, p = 6.38611857062415e-22
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2123, n_CMS2 = 136, n_CMS4 = 87, p = 7.04096492629695e-16


tcga-all-msi-inferred: Analyzing CIRC CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 480, n_CMS2 = 41, n_CMS1 = 12, p = 2.03910940079564e-09
tcga-all-msi-inferred: Analyzing CIITA CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 451, n_CMS2 = 41, n_CMS1 = 12, p = 1.32651563247495e-06
tcga-all-msi-inferred: Analyzing wnt CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 149, n_CMS2 = 41, n_CMS1 = 12, p = 0.0391350009745337
tcga-all-msi-inferred: Analyzing myc.sig CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 203, n_CMS2 = 41, n_CMS1 = 12, p = 0.371180469696714
tcga-all-msi-inferred: Analyzing neoantigens CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 425.5, n_CMS2 = 41, n_CMS1 = 12, p = 0.000141818624469331
tcga-all-msi-inferred: Analyzing BATF3 CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 419, n_CMS2 = 41, n_CMS1 = 12, p = 9.89261031427735e-05
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 461, n_CMS2 = 41, n_CMS1 = 12, p = 2.19848978999018e-07
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 483, n_CMS2 = 41, n_CMS1 = 12, p = 7.27182396607269e-10
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 465, n_CMS2 = 41, n_CMS1 = 12, p = 9.72475262761803e-08
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 456, n_CMS2 = 41, n_CMS1 = 12, p = 5.61069947699806e-07
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 460, n_CMS2 = 41, n_CMS1 = 12, p = 2.67003383892417e-07
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 464, n_CMS2 = 41, n_CMS1 = 12, p = 1.20007585617414e-07
tcga-all-msi-inferred: Analyzing CIRC CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 334, n_CMS2 = 41, n_CMS3 = 28, p = 0.00300622689012917
tcga-all-msi-inferred: Analyzing CIITA CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 335, n_CMS2 = 41, n_CMS3 = 28, p = 0.00313513226569386
tcga-all-msi-inferred: Analyzing wnt CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 875, n_CMS2 = 41, n_CMS3 = 28, p = 0.000161601913359647
tcga-all-msi-inferred: Analyzing myc.sig CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 783, n_CMS2 = 41, n_CMS3 = 28, p = 0.0101843523865015
tcga-all-msi-inferred: Analyzing neoantigens CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 433, n_CMS2 = 41, n_CMS3 = 28, p = 0.0859444272951382
tcga-all-msi-inferred: Analyzing BATF3 CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 551, n_CMS2 = 41, n_CMS3 = 28, p = 0.784775042456067
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 329, n_CMS2 = 41, n_CMS3 = 28, p = 0.00243037267700144
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 277, n_CMS2 = 41, n_CMS3 = 28, p = 0.000200346187722386
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 383, n_CMS2 = 41, n_CMS3 = 28, p = 0.0192080204955667
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 307, n_CMS2 = 41, n_CMS3 = 28, p = 0.000902323254047049
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 305, n_CMS2 = 41, n_CMS3 = 28, p = 0.000820821498299194
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 264, n_CMS2 = 41, n_CMS3 = 28, p = 9.83654240194228e-05
tcga-all-msi-inferred: Analyzing CIRC CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 111, n_CMS2 = 41, n_CMS4 = 27, p = 1.35462358863744e-09
tcga-all-msi-inferred: Analyzing CIITA CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 110, n_CMS2 = 41, n_CMS4 = 27, p = 1.2138464426316e-09
tcga-all-msi-inferred: Analyzing wnt CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 986, n_CMS2 = 41, n_CMS4 = 27, p = 3.92922989387343e-09
tcga-all-msi-inferred: Analyzing myc.sig CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 1010, n_CMS2 = 41, n_CMS4 = 27, p = 2.74920522125321e-10
tcga-all-msi-inferred: Analyzing neoantigens CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 513, n_CMS2 = 41, n_CMS4 = 27, p = 0.616048341754066
tcga-all-msi-inferred: Analyzing BATF3 CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 93, n_CMS2 = 41, n_CMS4 = 27, p = 1.70035530281561e-10
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 82, n_CMS2 = 41, n_CMS4 = 27, p = 4.25297854449279e-11
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 160, n_CMS2 = 41, n_CMS4 = 27, p = 1.5452160059747e-07
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 61, n_CMS2 = 41, n_CMS4 = 27, p = 2.1976880330611e-12
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 33, n_CMS2 = 41, n_CMS4 = 27, p = 1.58386288116536e-14
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 47, n_CMS2 = 41, n_CMS4 = 27, p = 2.24027384591496e-13
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 101, n_CMS2 = 41, n_CMS4 = 27, p = 4.39428203218074e-10

tcga-all-msi-inferred: Analyzing CIRC CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1152, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.000163233994822283
tcga-all-msi-inferred: Analyzing CIITA CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1323, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.00308528346316024
tcga-all-msi-inferred: Analyzing wnt CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2204, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.224749979645318
tcga-all-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2218, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.2004099792463
tcga-all-msi-inferred: Analyzing neoantigens CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2098, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.414530115017996
tcga-all-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1167, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.000216545907835857
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1212, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.000491235015163277
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1252, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.000981403618670544
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1208, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.000457535134080067
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1270, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.00132529481366919
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1281, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.00158702224260874
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1137, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.00012245766085928
tcga-all-msi-inferred: Analyzing CIRC CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 12, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 2.03910940079564e-09
tcga-all-msi-inferred: Analyzing CIITA CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 41, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 1.32651563247495e-06
tcga-all-msi-inferred: Analyzing wnt CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 343, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 0.0391350009745337
tcga-all-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 289, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 0.371180469696714
tcga-all-msi-inferred: Analyzing neoantigens CMS2-MT vs CMS1-MT using Wilcoxon rank sum test with continuity correction: W = 66.5, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 0.000141818624469331
tcga-all-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 73, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 9.89261031427735e-05
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 31, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 2.19848978999018e-07
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 9, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 7.27182396607269e-10
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 27, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 9.72475262761803e-08
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 36, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 5.61069947699806e-07
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 32, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 2.67003383892417e-07
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 28, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 1.20007585617414e-07
tcga-all-msi-inferred: Analyzing CIRC CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 42, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 5.96952388180639e-18
tcga-all-msi-inferred: Analyzing CIITA CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 44, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 8.6088124778279e-18
tcga-all-msi-inferred: Analyzing wnt CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 1337, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 4.77918260103951e-08
tcga-all-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 957, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 0.131266270713507
tcga-all-msi-inferred: Analyzing neoantigens CMS2-MT vs CMS1-WT using Wilcoxon rank sum test with continuity correction: W = 44.5, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 3.78947701123408e-13
tcga-all-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 233, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 6.48215939432032e-09
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 70, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 5.68806345364985e-16
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 46, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 1.23199980318091e-17
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 61, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 1.4755391091352e-16
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 65, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 2.7181270720629e-16
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 107, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 6.86776260633255e-14
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 67, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 3.66394337310941e-16
tcga-all-msi-inferred: Analyzing CIRC CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 334, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.00300622689012917
tcga-all-msi-inferred: Analyzing CIITA CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 335, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.00313513226569386
tcga-all-msi-inferred: Analyzing wnt CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 875, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.000161601913359647
tcga-all-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 783, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.0101843523865015
tcga-all-msi-inferred: Analyzing neoantigens CMS2-MT vs CMS3-MT using Wilcoxon rank sum test with continuity correction: W = 433, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.0859444272951382
tcga-all-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 551, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.784775042456067
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 329, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.00243037267700144
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 277, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.000200346187722386
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 383, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.0192080204955667
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 307, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.000902323254047049
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 305, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.000820821498299194
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 264, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 9.83654240194228e-05
tcga-all-msi-inferred: Analyzing CIRC CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 91, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 6.54057234168641e-05
tcga-all-msi-inferred: Analyzing CIITA CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 114, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.000539102055503825
tcga-all-msi-inferred: Analyzing wnt CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 370, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.111601847559311
tcga-all-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 316, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.585875820946205
tcga-all-msi-inferred: Analyzing neoantigens CMS2-MT vs CMS3-WT using Wilcoxon rank sum test with continuity correction: W = 215.5, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.170032865744795
tcga-all-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 161, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.0140975959932344
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 92, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 7.23203698783448e-05
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 77, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 1.45158091465387e-05
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 120, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.000877984229380965
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 82, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 2.54064834666581e-05
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 88, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 4.81245157242012e-05
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 91, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 6.54057234168641e-05
tcga-all-msi-inferred: Analyzing CIRC CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 111, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 1.35462358863744e-09
tcga-all-msi-inferred: Analyzing CIITA CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 110, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 1.2138464426316e-09
tcga-all-msi-inferred: Analyzing wnt CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 986, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 3.92922989387343e-09
tcga-all-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 1010, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 2.74920522125321e-10
tcga-all-msi-inferred: Analyzing neoantigens CMS2-MT vs CMS4-MT using Wilcoxon rank sum test with continuity correction: W = 513, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 0.616048341754066
tcga-all-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 93, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 1.70035530281561e-10
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 82, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 4.25297854449279e-11
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 160, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 1.5452160059747e-07
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 61, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 2.1976880330611e-12
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 33, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 1.58386288116536e-14
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 47, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 2.24027384591496e-13
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 101, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 4.39428203218074e-10
tcga-all-msi-inferred: Analyzing CIRC CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 173, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 2.74771126793874e-13
tcga-all-msi-inferred: Analyzing CIITA CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 354, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 1.40844101480104e-09
tcga-all-msi-inferred: Analyzing wnt CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 2163, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 1.12817482025658e-10
tcga-all-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 2128, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 5.41250472810469e-10
tcga-all-msi-inferred: Analyzing neoantigens CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 1181, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 0.844393016945285
tcga-all-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 277, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 4.48788328101215e-11
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 214, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 2.1765152244209e-12
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 210, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 1.78477960727702e-12
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 139, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 4.6515836668407e-14
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 123, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 1.97892412576722e-14
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 139, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 4.6515836668407e-14
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 131, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 3.03856935589037e-14

Computing linear model with interaction for CIRC
Computing linear model with interaction for CIITA
Computing linear model with interaction for wnt
Computing linear model with interaction for myc.sig
Computing linear model with interaction for neoantigens
Computing linear model with interaction for BATF3
Computing linear model with interaction for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model with interaction for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model with interaction for HALLMARK_COMPLEMENT
Computing linear model with interaction for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model with interaction for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model with interaction for HALLMARK_ALLOGRAFT_REJECTION
Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for neoantigens
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
tcga-all-msi-inferred: Analyzing CIRC CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 838, n_MT = 27, n_WT = 60, p = 0.800805944956622
tcga-all-msi-inferred: Analyzing CIITA CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 688, n_MT = 27, n_WT = 60, p = 0.264967936293836
tcga-all-msi-inferred: Analyzing wnt CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 765, n_MT = 27, n_WT = 60, p = 0.683072479140494
tcga-all-msi-inferred: Analyzing myc.sig CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 807, n_MT = 27, n_WT = 60, p = 0.981700729741838
tcga-all-msi-inferred: Analyzing neoantigens CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 765, n_MT = 27, n_WT = 60, p = 0.772967967357958
tcga-all-msi-inferred: Analyzing BATF3 CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 705, n_MT = 27, n_WT = 60, p = 0.337681707373123
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 681, n_MT = 27, n_WT = 60, p = 0.238418604488919
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 792, n_MT = 27, n_WT = 60, p = 0.872442154498887
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 768, n_MT = 27, n_WT = 60, p = 0.703388786884955
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 736, n_MT = 27, n_WT = 60, p = 0.500094984426675
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 720, n_MT = 27, n_WT = 60, p = 0.411569105348044
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 799, n_MT = 27, n_WT = 60, p = 0.923255046909828
tcga-all-msi-inferred: Analyzing CIRC CMS1 MT vs WT using Wilcoxon rank sum test: W = 270, n_MT = 12, n_WT = 39, p = 0.435533110162582
tcga-all-msi-inferred: Analyzing CIITA CMS1 MT vs WT using Wilcoxon rank sum test: W = 289, n_MT = 12, n_WT = 39, p = 0.229512386317868
tcga-all-msi-inferred: Analyzing wnt CMS1 MT vs WT using Wilcoxon rank sum test: W = 152, n_MT = 12, n_WT = 39, p = 0.0699676294093422
tcga-all-msi-inferred: Analyzing myc.sig CMS1 MT vs WT using Wilcoxon rank sum test: W = 222, n_MT = 12, n_WT = 39, p = 0.801054269531538
tcga-all-msi-inferred: Analyzing neoantigens CMS1 MT vs WT using Wilcoxon rank sum test: W = 269, n_MT = 12, n_WT = 39, p = 0.448643825148328
tcga-all-msi-inferred: Analyzing BATF3 CMS1 MT vs WT using Wilcoxon rank sum test: W = 265, n_MT = 12, n_WT = 39, p = 0.503206494389321
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS1 MT vs WT using Wilcoxon rank sum test: W = 231, n_MT = 12, n_WT = 39, p = 0.95632638100914
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS1 MT vs WT using Wilcoxon rank sum test: W = 255, n_MT = 12, n_WT = 39, p = 0.653096326215835
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS1 MT vs WT using Wilcoxon rank sum test: W = 239, n_MT = 12, n_WT = 39, p = 0.921473042233286
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS1 MT vs WT using Wilcoxon rank sum test: W = 212, n_MT = 12, n_WT = 39, p = 0.637331827671416
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS1 MT vs WT using Wilcoxon rank sum test: W = 226, n_MT = 12, n_WT = 39, p = 0.869487167240641
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS1 MT vs WT using Wilcoxon rank sum test: W = 237, n_MT = 12, n_WT = 39, p = 0.95632638100914
tcga-all-msi-inferred: Analyzing CIRC CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2743, n_MT = 41, n_WT = 95, p = 0.000163233994822283
tcga-all-msi-inferred: Analyzing CIITA CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2572, n_MT = 41, n_WT = 95, p = 0.00308528346316024
tcga-all-msi-inferred: Analyzing wnt CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1691, n_MT = 41, n_WT = 95, p = 0.224749979645318
tcga-all-msi-inferred: Analyzing myc.sig CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1677, n_MT = 41, n_WT = 95, p = 0.2004099792463
tcga-all-msi-inferred: Analyzing neoantigens CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1756, n_MT = 41, n_WT = 95, p = 0.414530115017996
tcga-all-msi-inferred: Analyzing BATF3 CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2728, n_MT = 41, n_WT = 95, p = 0.000216545907835857
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2683, n_MT = 41, n_WT = 95, p = 0.000491235015163277
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2643, n_MT = 41, n_WT = 95, p = 0.000981403618670544
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2687, n_MT = 41, n_WT = 95, p = 0.000457535134080067
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2625, n_MT = 41, n_WT = 95, p = 0.00132529481366919
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2614, n_MT = 41, n_WT = 95, p = 0.00158702224260874
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2758, n_MT = 41, n_WT = 95, p = 0.00012245766085928
tcga-all-msi-inferred: Analyzing CIRC CMS3 MT vs WT using Wilcoxon rank sum test: W = 242, n_MT = 28, n_WT = 14, p = 0.227805142383617
tcga-all-msi-inferred: Analyzing CIITA CMS3 MT vs WT using Wilcoxon rank sum test: W = 232, n_MT = 28, n_WT = 14, p = 0.347887457660636
tcga-all-msi-inferred: Analyzing wnt CMS3 MT vs WT using Wilcoxon rank sum test: W = 230, n_MT = 28, n_WT = 14, p = 0.375914690341709
tcga-all-msi-inferred: Analyzing myc.sig CMS3 MT vs WT using Wilcoxon rank sum test: W = 233, n_MT = 28, n_WT = 14, p = 0.334372944037949
tcga-all-msi-inferred: Analyzing neoantigens CMS3 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 182, n_MT = 28, n_WT = 14, p = 0.718651791550678
tcga-all-msi-inferred: Analyzing BATF3 CMS3 MT vs WT using Wilcoxon rank sum test: W = 264, n_MT = 28, n_WT = 14, p = 0.0713942204883082
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 226, n_MT = 28, n_WT = 14, p = 0.435894904638578
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 214, n_MT = 28, n_WT = 14, p = 0.644481834091968
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS3 MT vs WT using Wilcoxon rank sum test: W = 233, n_MT = 28, n_WT = 14, p = 0.334372944037949
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 236, n_MT = 28, n_WT = 14, p = 0.295840217194912
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 241, n_MT = 28, n_WT = 14, p = 0.238315993730082
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS3 MT vs WT using Wilcoxon rank sum test: W = 219, n_MT = 28, n_WT = 14, p = 0.552760737865497

Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for neoantigens
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
Computing rectum vs left
tcga-all-msi-inferred: Analyzing CIRC site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3359, n_rectum = 60, n_left = 133, p = 0.0791927710817998
tcga-all-msi-inferred: Analyzing CIITA site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3200, n_rectum = 60, n_left = 133, p = 0.02794450463594
tcga-all-msi-inferred: Analyzing wnt site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3544, n_rectum = 60, n_left = 133, p = 0.214854656548409
tcga-all-msi-inferred: Analyzing myc.sig site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3620, n_rectum = 60, n_left = 133, p = 0.303605065236952
tcga-all-msi-inferred: Analyzing neoantigens site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3806, n_rectum = 60, n_left = 133, p = 0.667089937000163
tcga-all-msi-inferred: Analyzing BATF3 site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2938, n_rectum = 60, n_left = 133, p = 0.00341693982164618
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3595, n_rectum = 60, n_left = 133, p = 0.272057685726368
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3626, n_rectum = 60, n_left = 133, p = 0.311524443923762
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3778, n_rectum = 60, n_left = 133, p = 0.555967354803256
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3921, n_rectum = 60, n_left = 133, p = 0.848750939600781
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 4296, n_rectum = 60, n_left = 133, p = 0.395019724743971
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3508, n_rectum = 60, n_left = 133, p = 0.180065008977664
Computing right vs left
tcga-all-msi-inferred: Analyzing CIRC site: right vs leftWilcoxon rank sum test with continuity correction: W = 6860, n_right = 148, n_left = 133, p = 1.16662152475699e-05
tcga-all-msi-inferred: Analyzing CIITA site: right vs leftWilcoxon rank sum test with continuity correction: W = 6378, n_right = 148, n_left = 133, p = 3.53513859137319e-07
tcga-all-msi-inferred: Analyzing wnt site: right vs leftWilcoxon rank sum test with continuity correction: W = 10768, n_right = 148, n_left = 133, p = 0.173585307958795
tcga-all-msi-inferred: Analyzing myc.sig site: right vs leftWilcoxon rank sum test with continuity correction: W = 9237, n_right = 148, n_left = 133, p = 0.374108760826281
tcga-all-msi-inferred: Analyzing neoantigens site: right vs leftWilcoxon rank sum test with continuity correction: W = 5200, n_right = 148, n_left = 133, p = 2.2275540553044e-11
tcga-all-msi-inferred: Analyzing BATF3 site: right vs leftWilcoxon rank sum test with continuity correction: W = 8156, n_right = 148, n_left = 133, p = 0.0132043313359446
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 7765, n_right = 148, n_left = 133, p = 0.00226488873616202
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 6860, n_right = 148, n_left = 133, p = 1.16662152475699e-05
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT site: right vs leftWilcoxon rank sum test with continuity correction: W = 7745, n_right = 148, n_left = 133, p = 0.0020526399262592
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 7789, n_right = 148, n_left = 133, p = 0.00254604610432205
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 8051, n_right = 148, n_left = 133, p = 0.00847358302147921
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: right vs leftWilcoxon rank sum test with continuity correction: W = 7063, n_right = 148, n_left = 133, p = 4.40273274341645e-05

Plotting CIRC ~ site
Plotting CIITA ~ site
Plotting wnt ~ site
Plotting myc.sig ~ site
Plotting neoantigens ~ site
Plotting BATF3 ~ site
Plotting HALLMARK_IL6_JAK_STAT3_SIGNALING ~ site
Plotting HALLMARK_INTERFERON_GAMMA_RESPONSE ~ site
Plotting HALLMARK_COMPLEMENT ~ site
Plotting HALLMARK_INFLAMMATORY_RESPONSE ~ site
Plotting HALLMARK_IL2_STAT5_SIGNALING ~ site
Plotting HALLMARK_ALLOGRAFT_REJECTION ~ site
Computing MSS vs MSI
tcga-all-msi-inferred: Analyzing CIRC status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 19155, n_MSS = 238, n_MSI = 104, p = 7.70278898812392e-16
tcga-all-msi-inferred: Analyzing CIITA status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 19340, n_MSS = 238, n_MSI = 104, p = 1.24450510973477e-16
tcga-all-msi-inferred: Analyzing wnt status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 7206, n_MSS = 238, n_MSI = 104, p = 7.95009822824259e-10
tcga-all-msi-inferred: Analyzing myc.sig status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 10537, n_MSS = 238, n_MSI = 104, p = 0.028833325194037
tcga-all-msi-inferred: Analyzing neoantigens status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 19683, n_MSS = 238, n_MSI = 104, p = 1.63304627964215e-18
tcga-all-msi-inferred: Analyzing BATF3 status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 16664, n_MSS = 238, n_MSI = 104, p = 3.44481854941406e-07
tcga-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 18216, n_MSS = 238, n_MSI = 104, p = 3.85299921479372e-12
tcga-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 19287, n_MSS = 238, n_MSI = 104, p = 2.10820011789546e-16
tcga-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 18544, n_MSS = 238, n_MSI = 104, p = 2.26026576976628e-13
tcga-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 18713, n_MSS = 238, n_MSI = 104, p = 4.9456731538868e-14
tcga-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 18188, n_MSS = 238, n_MSI = 104, p = 4.8745493807555e-12
tcga-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 18745, n_MSS = 238, n_MSI = 104, p = 3.69254101874333e-14

Plotting CIRC ~ status
Plotting CIITA ~ status
Plotting wnt ~ status
Plotting myc.sig ~ status
Plotting neoantigens ~ status
Plotting BATF3 ~ status
Plotting HALLMARK_IL6_JAK_STAT3_SIGNALING ~ status
Plotting HALLMARK_INTERFERON_GAMMA_RESPONSE ~ status
Plotting HALLMARK_COMPLEMENT ~ status
Plotting HALLMARK_INFLAMMATORY_RESPONSE ~ status
Plotting HALLMARK_IL2_STAT5_SIGNALING ~ status
Plotting HALLMARK_ALLOGRAFT_REJECTION ~ status
Number of rows analyzed: 20294
Number of columns analyzed: 238
tcga-mss-msi-inferred: 28 of 28 genes from data set analyzed in set CIRC: HLA-DQA1 HLA-DQA2 HLA-DRB5 CTLA4 PDCD1LG2 ICAM1 CD274 STAT1 IRF1 IFNG GNLY TBX21 CCL5 LAG3 CD247 ICOS IL18RAP CXCL9 CXCL10 HLA-DPB1 HLA-DPA1 HLA-DMB HLA-DRA HLA-DMA CD80 HLA-DOA CD4 HAVCR2
tcga-mss-msi-inferred: 85 of 88 genes from data set analyzed in set myc.sig: AKAP1 APEX1 BAX CAD CCKBR CCNB1 CCND2 CCT5 CDC25C CEBPZ CKS2 CSDA CTSC DDX10 DDX18 DDX5 DKC1 E2F1 EIF4A1 EIF4B ENO1 EXOSC8 FASN FOSL1 H2AFZ HSPA8 HSPD1 HSPE1 ID2 IMPA2 LTA4H MAT2A METTL1 MINA MSH2 MTHFD1 NAP1L1 NCL NME1 NPM1 NRAS NUP155 PA2G4 PCNA PHB POLD2 PPAT PPIA PPID PRDX3 PREP PRPS2 PSMB1 PTEN PYCR1 RPL10 RPL19 RPL22 RPL27 RPL27A RPL32 RPL5 RPL9 RPS13 RPS16 RPS19 RPS5 RPS6KA2 SFRS1 SFRS2 SFRS7 SHMT1 SLC25A3 SLC39A6 SNRPB SNRPD3 SRM TERT TFRC TOP1 TXN TYMS UBE2C UCHL1 UXT
tcga-mss-msi-inferred: 3 of 88 genes missing from data set analyzed in set myc.sig: DSCR2 HNRPA2B1 HSPA9B
tcga-mss-msi-inferred: 50 of 78 genes from data set analyzed in set wnt: PHLDA1 SLC7A5 CTPS BYSL SCD SOX4 WDR77 NLE1 PPIL1 CIRH1A ZNF511 ZNF593 DKC1 ODC1 AURKB WDR12 CDT1 NOC3L CAD XPOT YAP1 SRM NXT1 MRPS12 RHEB WDR3 CRTAP SF3A2 GEMIN5 HNRPDL TREX2 IMP4 HEATR1 SLC19A1 PDCD11 ASCL2 TDGF1 TBX3 EPHB3 ZNRF3 IL20RA RHOBTB3 GEMIN4 ID3 FUT4 PIGW APEX1 SRPRB ZNRD1 TFB2M
tcga-mss-msi-inferred: 28 of 78 genes missing from data set analyzed in set wnt: FLJ20315 NOB1P PSF1 PMSCL1 RNU3IP2 HIG2 C1orf33 LOC389362 HSPC111 MGC40397 LOC56902 SDCCAG16 FLJ10774 RAB9P40 RFP RRP41 C16orf35 CGI-96 C20orf64 C12orf14 NOL1 SKB1 C11orf5 MGC16824 ZNF278 RPC62 JTV1 ZNF339
tcga-mss-msi-inferred: 87 of 87 genes from data set analyzed in set HALLMARK_IL6_JAK_STAT3_SIGNALING: IL4R IL6ST STAT1 IL1R1 CSF2RB SOCS3 STAT3 OSMR IL2RG IFNGR1 TYK2 IL13RA1 TLR2 IFNGR2 IL10RB IL6 IL1R2 IL3RA IFNAR1 TNFRSF1A MYD88 ACVR1B CSF3R ITGB3 REG1A CXCL1 A2M CSF2RA IL15RA IRF9 PDGFC HAX1 BAK1 EBI3 INHBE CRLF2 TNFRSF1B CD14 PTPN1 PTPN2 IL1B CSF1 IL18R1 TNF PF4 CXCL13 LTBR FAS IL17RA CXCL10 IL9R STAM2 TNFRSF12A STAT2 HMOX1 LEPR CBL CD9 CXCL3 TGFB1 MAP3K8 ITGA4 CD38 JUN SOCS1 ACVRL1 PIM1 TNFRSF21 PIK3R5 GRB2 IRF1 DNTT CSF2 IL2RA PTPN11 IL12RB1 CCR1 CNTFR PLA2G2A CXCL9 CD44 IL7 CXCL11 CCL7 LTB IL17RB CD36
tcga-mss-msi-inferred: 200 of 200 genes from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: STAT1 ISG15 IFIT1 MX1 IFIT3 IFI35 IRF7 IFIT2 OAS2 TAP1 EIF2AK2 RSAD2 MX2 IRF1 OAS3 TNFSF10 IRF9 CXCL10 IFI44 BST2 XAF1 SP110 OASL PSMB8 IFI44L IFITM3 DDX60 LGALS3BP GBP4 IRF8 PSMB9 PML IFIH1 UBE2L6 IFI27 ADAR LY6E STAT2 CXCL9 IL10RA PLA2G4A TRIM21 USP18 PTGS2 EPSTI1 C1S DDX58 IL15 NLRC5 NMI IDO1 PSMB10 CXCL11 ITGB7 SAMHD1 HERC6 CMPK2 SAMD9L RTP4 PTPN2 PARP14 TNFAIP2 IFITM2 PLSCR1 SOCS1 CASP1 ICAM1 WARS PSME1 ISG20 IRF2 TRIM14 FCGR1A MARCH1 SOCS3 JAK2 HLA-DMA PARP12 TNFAIP6 TRIM26 VCAM1 CD274 CIITA NAMPT SELP GPR18 FPR1 PRIC285 PSME2 SERPING1 CCL5 RNF31 SOD2 TRIM25 LAP3 PSMA3 RNF213 PELI1 CFB CD86 TXNIP HLA-DQA1 GCH1 PNP CCL7 PTPN6 SPPL2A IL4R PNPT1 DHX58 BTG1 CASP8 IFI30 CCL2 FGL2 CASP7 SECTM1 IL15RA CD40 TRAFD1 HLA-DRB1 GBP6 LCP2 HLA-G MT2A RIPK1 KLRK1 UPP1 PSMB2 TDRD7 HIF1A EIF4E3 VAMP8 PFKP CD38 ZBP1 BANK1 TOR1B RBCK1 PDE4B MVP IL7 BPGM FTSJD2 AUTS2 B2M RIPK2 CD69 MYD88 PSMA2 PIM1 NOD1 CFH TAPBP SLC25A28 PTPN1 TNFAIP3 SSPN NUP93 MTHFD2 CDKN1A IRF4 NFKB1 BATF2 HLA-B LATS2 IRF5 SLAMF7 ISOC1 P2RY14 STAT3 NCOA3 HLA-A IL6 GZMA IFNAR2 CD74 RAPGEF6 CASP4 FAS OGFR ARL4A SRI LYSMD2 CSF2RB ST3GAL5 C1R CASP3 CMKLR1 NFKBIA METTL7B ST8SIA4 XCL1 IL2RB VAMP5 IL18BP ZNFX1 ARID5B APOL6 STAT4
tcga-mss-msi-inferred: 200 of 200 genes from data set analyzed in set HALLMARK_COMPLEMENT: C2 C1S CFB C1R SERPINE1 MMP14 SERPING1 CTSL1 F5 MMP13 F7 CTSS LGMN PLG C1QA CASP1 GZMA ADAM9 CALM3 C1QC TIMP1 DPP4 KLK1 KLKB1 CD59 CR2 MMP15 LAP3 SPOCK2 F10 CTSB SERPINA1 CTSO CD40LG CBLB PDP1 C4BPB PLEK GP9 PLAUR C3 F2 CASP4 STX4 CTSC USP15 CR1 DUSP6 SERPINB2 GPD2 CFH FN1 CD36 CA2 PSMB9 APOBEC3G FCN1 GZMK PDGFB CLU CASP10 LRP1 CTSD S100A9 WAS BRPF3 PLAT CDA MT3 CASP7 PRSS36 PFN1 GZMB RNF4 ZEB1 CASP5 IRF1 PGCP CDK5R1 ATOX1 PIK3CA TMPRSS6 CPM RCE1 CALM1 DOCK9 KYNU RASGRP1 USP14 LCP2 GP1BA KIF2A GNB4 LCK OLR1 PREP SEPX1 LTA4H ZFPM2 LYN ACTN2 SIRT6 APOC1 PRKCD ITGAM DGKH LTF MAFF KCNIP2 PCLO DOCK10 SH2B3 RABIF SRC HPCAL4 CD46 PRDM4 GNAI3 C9 PPP2CB IRF2 FYN JAK2 PLA2G4A PRCP USP8 RHOG L3MBTL4 LAMP2 PIM1 CXCL1 F3 GNAI2 CASP9 XPNPEP1 PLSCR1 IRF7 CD55 HSPA5 GNB2 DYRK2 PLA2G7 S100A12 GRB2 PHEX GNGT2 DOCK4 MMP12 KCNIP3 FDX1 TIMP2 MMP8 FCER1G ZFYVE20 ANXA5 CTSL2 GCA EHD1 PRSS3 COL4A2 CSRP1 PIK3R5 SERPINC1 ANG APOBEC3F GATA3 DUSP5 CASP3 USP16 CP PSEN1 LIPA PCSK9 DGKG GNG2 ME1 GMFB SCG3 PPP4C CCL5 CTSH F8 APOA4 IL6 AKAP10 ERAP2 VCPIP1 HSPA1A RAF1 NOTCH4 ADRA2B CEBPB HNF4A LGALS3 TNFAIP3 CDH13 ITIH1 TFPI2 PIK3CG S100A13
tcga-mss-msi-inferred: 200 of 200 genes from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: CXCL10 CCL2 CCL5 FPR1 CCL20 IL1A IL8 CCL7 CCL22 CXCL11 CCR7 EDN1 CD40 CXCL9 IL6 IL1B TLR2 IL1R1 CD69 ICAM1 CCRL2 AQP9 EREG C3AR1 GNA15 CMKLR1 PTGER4 LIF IL15 NAMPT OPRK1 ITGB8 PTAFR ADM PLAUR NFKB1 INHBA OSM TNFSF10 TNFSF15 IFNGR2 EMR1 IL12B CSF1 CXCL6 TNFRSF9 LYN ACVR2A LDLR BDKRB1 HRH1 F3 BST2 PTGIR CD55 CALCRL CSF3 GPR132 IL4R NLRP3 IL15RA ADORA2B GCH1 OLR1 PTGER2 CSF3R MYC RELA TNFAIP6 IL7R IL18 GABBR1 CD82 TNFSF9 NMUR1 IL2RB TLR1 LPAR1 IRAK2 RIPK2 MMP14 P2RX7 SLC11A2 SELL P2RY2 ABCA1 FFAR2 PROK2 GNAI3 TACR1 SLC7A1 CDKN1A CYBB TIMP1 HBEGF SCARF1 EBI3 NFKBIA SRI SLC7A2 CCL17 TLR3 APLNR OSMR IL10RA PSEN1 GPR183 ATP2B1 TNFRSF1B BEST1 GPC3 SCN1B ACVR1B HPN SEMA4D KLF6 CD48 CXCR6 SLC1A2 GP1BA TAPBP RGS16 SLAMF1 LCK HIF1A AHR NMI RHOG TPBG NPFFR2 IFNAR1 ICOSLG RASGRP1 IFITM1 KCNJ2 LY6E IL18R1 IL10 KCNA3 HAS2 DCBLD2 LAMP3 VIP CD70 RGS1 SLC31A1 ADRM1 KCNMB2 SERPINE1 MXD1 AXL MEFV PVR CCL24 PDE4B LCP2 PDPN IRF7 MET ATP2A2 SLC31A2 FZD5 ITGA5 SGMS2 MARCO CD14 EIF2AK2 ROS1 ATP2C1 NDP BTG2 MSR1 PTPRE RNF144B PCDH7 SPHK1 IL18RAP RTP4 RAF1 CHST2 ITGB3 KIF1B SELE NOD2 C5AR1 EMP3 CLEC5A TACR3 SLC4A4 MEP1A SELS LTA PIK3R5 STAB1 IRF1 ICAM4 P2RX4 ABI1 CX3CL1 SLC28A2
tcga-mss-msi-inferred: 198 of 200 genes from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: SOCS2 CISH PIM1 IL2RA TNFRSF4 SOCS1 TNFRSF9 XBP1 RRAGD HK2 PHLDA1 IL2RB CTLA4 NFIL3 CD83 IKZF2 IL10 TNFRSF18 DHRS3 ECM1 ADAM19 SLC2A3 HIPK2 BATF3 BHLHE40 PTGER2 DENND5A ITIH5 PHTF2 GADD45B NRP1 NCOA3 CD79B AHR TNFRSF1B NDRG1 BCL2L1 GABARAPL1 LIF TIAM1 BMPR2 MAP3K8 RHOB MYC S100A1 CAPG ST3GAL4 PENK IRF4 CST7 WLS TLR7 IKZF4 GBP4 RGS16 SPP1 IL13 SLC29A2 NFKBIZ IL4R MXD1 CSF2 FAH CTSZ ITGAE MUC1 MAPKAPK2 TNFRSF21 NT5E FLT3LG CCND2 TRAF1 LCLAT1 IL3RA CYFIP1 BCL2 FGL2 PRNP N6AMT2 PUS1 ITGAV NCS1 DCPS AMACR FAM126B PTH1R ODC1 IGF1R PTCH1 ENO3 CD81 MAFF EMP1 CDKN1C CAPN3 IL1R2 SYT11 TTC39B ANXA4 BATF P4HA1 GPR65 SLC1A5 IGF2R CKAP4 CCR4 CD44 P2RX4 GATA1 KLF6 ARL4A HOPX GPR83 ITGA6 CD48 SELP GLIPR2 SMPDL3A PLSCR1 FURIN SERPINB6 TNFSF11 GPX4 LRRC8C CCNE1 CASP3 SH3BGRL2 SNX9 PLEC BMP2 ICOS ALCAM LTB ENPP1 IL1RL1 MYO1C IFNGR1 PLIN2 IL18R1 AHNAK PRKCH TNFRSF8 SYNGR2 GALM POU2F1 EOMES NOP2 PTRH2 RHOH CDC6 MYO1E CXCL10 SNX14 IRF6 IL10RA MAP6 TNFSF10 SPRED2 SELL SERPINC1 CDCP1 RORA COCH CSF1 F2RL2 UCK2 CA2 IFITM3 UMPS HUWE1 COL6A1 ABCB1 RNH1 IRF8 GUCY1B3 AHCY PRAF2 GSTO1 TWSG1 CDC42SE2 PLAGL1 APLP1 AKAP2 PPAP2A SPRY4 SCN9A SHE PDCD2L CCND3 LRIG1 SWAP70 SLC39A8 RABGAP1L TGM2 PNP AGER ETV4 CD86
tcga-mss-msi-inferred: 2 of 200 genes missing from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: METTL20 CCDC164
tcga-mss-msi-inferred: 200 of 200 genes from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: PTPRC IL12B TGFB1 IL12A CD3E CD3D CD28 LYN HCLS1 IL18 CRTAM IFNG CD3G CD86 IL10 UBE2N BCL10 CD4 LCK NCK1 C2 HLA-A ITGB2 HLA-DQA1 CD1D CD80 HLA-DRA THY1 TLR1 HLA-G HLA-DMB IL7 IL4 TNF CD247 IL2 HLA-DMA STAT1 IRF4 SRGN INHBA TLR3 ZAP70 CD74 CD40 TRAF2 B2M BCL3 LTB IFNGR1 CCR5 CD40LG HLA-DOA GLMN IL6 HLA-E CD2 CCL5 FAS FASLG TLR6 PF4 TGFB2 CD79A INHBB ELANE SPI1 MAP3K7 IL15 CTSS CD47 PRF1 IL12RB1 LCP2 SOCS1 CDKN2A STAT4 CD7 HLA-DOB CD8A ICAM1 CCL4 GZMB CSF1 IL11 STAB1 IL2RA NLRP3 CCND3 EIF3A SIT1 IFNAR2 HDAC9 CARTPT TRAT1 CCL22 APBB1 FYB IL1B TIMP1 RPS19 JAK2 KRT1 WARS IFNGR2 CCR2 EREG MMP9 EGFR IL16 CFP WAS ITGAL KLRD1 RARS TLR2 CCND2 IL2RG ETS1 ITK NCR1 MAP4K1 CCL19 PSMB10 RPL39 EIF3J ABCE1 CD8B F2 ELF4 LY86 FCGR2B GBP2 PRKCG RPS9 MTIF2 GZMA AARS CD96 CSK HIF1A CCL2 ICOSLG NPM1 IL4R CCL11 NME1 FLNA GPR65 ACHE EIF3D IGSF6 F2R IL13 TAP1 DARS IRF7 ACVR2A CXCR3 PRKCB CXCL9 PTPN6 NCF4 UBE2D1 LIF CCR1 MBL2 DEGS1 TPD52 AKT1 RIPK2 IKBKB GCNT1 SOCS5 IRF8 TAP2 EIF4G3 ABI1 CCL7 IL2RB BRCA1 FGR IL18RAP MRPL3 CXCL13 CAPG EIF5A RPS3A GALNT1 ST8SIA4 CCL13 RPL3L LY75 TAPBP NOS2 RPL9 BCAT1 IL9 IL27RA DYRK3
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
tcga-mss-msi-inferred wnt vs CIRC: t = -5.83747701967491 df = 236 nrow = 238 cor = -0.355207458689606 pval = 1.74160613527648e-08
tcga-mss-msi-inferred tak1 vs CIRC: t = -1.35561728322973 df = 236 nrow = 238 cor = -0.0879015939994546 pval = 0.176516819155584
tcga-mss-msi-inferred wnt vs myc.sig: t = 26.389216502476 df = 236 nrow = 238 cor = 0.864226379603661 pval = 2.33796435878925e-72
tcga-mss-msi-inferred CIRC vs neoantigens: tcga-mss-msi-inferred: Analyzing CIRC vs neoantigens using Fisher's Exact Test for Count Data: p = 0.498605449474362 n = 237

tcga-mss-msi-inferred: Analyzing CIRC vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7754, n_WT = 152, n_MT = 86, p = 0.0170278702633947
tcga-mss-msi-inferred: Analyzing CIITA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 6946, n_WT = 152, n_MT = 86, p = 0.422232249365283
tcga-mss-msi-inferred: Analyzing wnt vs KRAS using Wilcoxon rank sum test with continuity correction: W = 6433, n_WT = 152, n_MT = 86, p = 0.840789578723746
tcga-mss-msi-inferred: Analyzing myc.sig vs KRAS using Wilcoxon rank sum test with continuity correction: W = 6254, n_WT = 152, n_MT = 86, p = 0.581157332574526
tcga-mss-msi-inferred: Analyzing neoantigens vs KRAS using Wilcoxon rank sum test with continuity correction: W = 5951, n_WT = 151, n_MT = 86, p = 0.285911179612945
tcga-mss-msi-inferred: Analyzing BATF3 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7852, n_WT = 152, n_MT = 86, p = 0.00993251969146726
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7525, n_WT = 152, n_MT = 86, p = 0.0527084380521111
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7446, n_WT = 152, n_MT = 86, p = 0.07467186540904
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7563, n_WT = 152, n_MT = 86, p = 0.0442435628552774
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7368, n_WT = 152, n_MT = 86, p = 0.103184564168144
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7367, n_WT = 152, n_MT = 86, p = 0.103599703363575
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7813, n_WT = 152, n_MT = 86, p = 0.012358605501968

Computing CIRC ~ KRAS
Computing CIITA ~ KRAS
Computing wnt ~ KRAS
Computing myc.sig ~ KRAS
Computing neoantigens ~ KRAS
Computing BATF3 ~ KRAS
Computing HALLMARK_IL6_JAK_STAT3_SIGNALING ~ KRAS
Computing HALLMARK_INTERFERON_GAMMA_RESPONSE ~ KRAS
Computing HALLMARK_COMPLEMENT ~ KRAS
Computing HALLMARK_INFLAMMATORY_RESPONSE ~ KRAS
Computing HALLMARK_IL2_STAT5_SIGNALING ~ KRAS
Computing HALLMARK_ALLOGRAFT_REJECTION ~ KRAS
tcga-mss-msi-inferred: Analyzing CIRC CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 212, n_CMS2 = 135, n_CMS1 = 2, p = 0.169791567234517
tcga-mss-msi-inferred: Analyzing CIITA CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 180, n_CMS2 = 135, n_CMS1 = 2, p = 0.424522491256963
tcga-mss-msi-inferred: Analyzing wnt CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 160, n_CMS2 = 135, n_CMS1 = 2, p = 0.660169937873571
tcga-mss-msi-inferred: Analyzing myc.sig CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 176, n_CMS2 = 135, n_CMS1 = 2, p = 0.467338945055947
tcga-mss-msi-inferred: Analyzing neoantigens CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 60.5, n_CMS2 = 135, n_CMS1 = 2, p = 0.186850848228163
tcga-mss-msi-inferred: Analyzing BATF3 CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 159, n_CMS2 = 135, n_CMS1 = 2, p = 0.673220286866377
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 143, n_CMS2 = 135, n_CMS1 = 2, p = 0.892931719071997
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 227, n_CMS2 = 135, n_CMS1 = 2, p = 0.100576575322048
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 158, n_CMS2 = 135, n_CMS1 = 2, p = 0.68636977866041
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 110, n_CMS2 = 135, n_CMS1 = 2, p = 0.660169937873571
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 142, n_CMS2 = 135, n_CMS1 = 2, p = 0.907137879771252
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 166, n_CMS2 = 135, n_CMS1 = 2, p = 0.584134910176087
tcga-mss-msi-inferred: Analyzing CIRC CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1225, n_CMS2 = 135, n_CMS3 = 17, p = 0.652611976350391
tcga-mss-msi-inferred: Analyzing CIITA CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 912, n_CMS2 = 135, n_CMS3 = 17, p = 0.169505831331597
tcga-mss-msi-inferred: Analyzing wnt CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1408, n_CMS2 = 135, n_CMS3 = 17, p = 0.128525645934838
tcga-mss-msi-inferred: Analyzing myc.sig CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1167, n_CMS2 = 135, n_CMS3 = 17, p = 0.911558730544977
tcga-mss-msi-inferred: Analyzing neoantigens CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 831.5, n_CMS2 = 135, n_CMS3 = 17, p = 0.0706742245324048
tcga-mss-msi-inferred: Analyzing BATF3 CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1512, n_CMS2 = 135, n_CMS3 = 17, p = 0.0333438593137421
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1125, n_CMS2 = 135, n_CMS3 = 17, p = 0.897665900433579
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1043, n_CMS2 = 135, n_CMS3 = 17, p = 0.543202958787336
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1102, n_CMS2 = 135, n_CMS3 = 17, p = 0.792499076581401
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1066, n_CMS2 = 135, n_CMS3 = 17, p = 0.635842037619104
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 929, n_CMS2 = 135, n_CMS3 = 17, p = 0.20251722957877
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1132, n_CMS2 = 135, n_CMS3 = 17, p = 0.930123910127637
tcga-mss-msi-inferred: Analyzing CIRC CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1850, n_CMS2 = 135, n_CMS4 = 64, p = 7.63081379233109e-11
tcga-mss-msi-inferred: Analyzing CIITA CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2183, n_CMS2 = 135, n_CMS4 = 64, p = 1.80030153566937e-08
tcga-mss-msi-inferred: Analyzing wnt CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 7016, n_CMS2 = 135, n_CMS4 = 64, p = 1.21842396606474e-12
tcga-mss-msi-inferred: Analyzing myc.sig CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 6901, n_CMS2 = 135, n_CMS4 = 64, p = 1.04463434506893e-11
tcga-mss-msi-inferred: Analyzing neoantigens CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 4099, n_CMS2 = 135, n_CMS4 = 64, p = 0.617130706124192
tcga-mss-msi-inferred: Analyzing BATF3 CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2200, n_CMS2 = 135, n_CMS4 = 64, p = 2.33199263703185e-08
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1808, n_CMS2 = 135, n_CMS4 = 64, p = 3.63147636286937e-11
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2140, n_CMS2 = 135, n_CMS4 = 64, p = 9.27465967334872e-09
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1211, n_CMS2 = 135, n_CMS4 = 64, p = 2.57740220450079e-16
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1162, n_CMS2 = 135, n_CMS4 = 64, p = 8.74135332339988e-17
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1193, n_CMS2 = 135, n_CMS4 = 64, p = 1.73582059592059e-16
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1798, n_CMS2 = 135, n_CMS4 = 64, p = 3.03761171381446e-11


tcga-mss-msi-inferred: Analyzing CIRC CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 77, n_CMS2 = 41, n_CMS1 = 2, p = 0.026578073089701
tcga-mss-msi-inferred: Analyzing CIITA CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 62, n_CMS2 = 41, n_CMS1 = 2, p = 0.267995570321152
tcga-mss-msi-inferred: Analyzing wnt CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 43, n_CMS2 = 41, n_CMS1 = 2, p = 0.930232558139535
tcga-mss-msi-inferred: Analyzing myc.sig CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 51, n_CMS2 = 41, n_CMS1 = 2, p = 0.602436323366556
tcga-mss-msi-inferred: Analyzing neoantigens CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 15.5, n_CMS2 = 41, n_CMS1 = 2, p = 0.149212343082899
tcga-mss-msi-inferred: Analyzing BATF3 CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 62, n_CMS2 = 41, n_CMS1 = 2, p = 0.267995570321152
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 54, n_CMS2 = 41, n_CMS1 = 2, p = 0.498338870431894
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 79, n_CMS2 = 41, n_CMS1 = 2, p = 0.0132890365448505
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 56, n_CMS2 = 41, n_CMS1 = 2, p = 0.434108527131783
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 45, n_CMS2 = 41, n_CMS1 = 2, p = 0.841638981173865
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 50, n_CMS2 = 41, n_CMS1 = 2, p = 0.640088593576966
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 60, n_CMS2 = 41, n_CMS1 = 2, p = 0.318936877076412
tcga-mss-msi-inferred: Analyzing CIRC CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 205, n_CMS2 = 41, n_CMS3 = 11, p = 0.658477609343562
tcga-mss-msi-inferred: Analyzing CIITA CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 137, n_CMS2 = 41, n_CMS3 = 11, p = 0.0476125740120781
tcga-mss-msi-inferred: Analyzing wnt CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 300, n_CMS2 = 41, n_CMS3 = 11, p = 0.097744328129793
tcga-mss-msi-inferred: Analyzing myc.sig CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 266, n_CMS2 = 41, n_CMS3 = 11, p = 0.375321129760902
tcga-mss-msi-inferred: Analyzing neoantigens CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 214.5, n_CMS2 = 41, n_CMS3 = 11, p = 0.813953891301935
tcga-mss-msi-inferred: Analyzing BATF3 CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 282, n_CMS2 = 41, n_CMS3 = 11, p = 0.212839182926178
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 207, n_CMS2 = 41, n_CMS3 = 11, p = 0.69081929336732
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 167, n_CMS2 = 41, n_CMS3 = 11, p = 0.196699544517722
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 221, n_CMS2 = 41, n_CMS3 = 11, p = 0.929619365498761
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 198, n_CMS2 = 41, n_CMS3 = 11, p = 0.550384524009462
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 184, n_CMS2 = 41, n_CMS3 = 11, p = 0.363408106677409
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 181, n_CMS2 = 41, n_CMS3 = 11, p = 0.329068640359124
tcga-mss-msi-inferred: Analyzing CIRC CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 97, n_CMS2 = 41, n_CMS4 = 21, p = 7.63705467281034e-08
tcga-mss-msi-inferred: Analyzing CIITA CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 80, n_CMS2 = 41, n_CMS4 = 21, p = 1.00202046120147e-08
tcga-mss-msi-inferred: Analyzing wnt CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 746, n_CMS2 = 41, n_CMS4 = 21, p = 5.15781784944858e-07
tcga-mss-msi-inferred: Analyzing myc.sig CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 767, n_CMS2 = 41, n_CMS4 = 21, p = 5.4307425229687e-08
tcga-mss-msi-inferred: Analyzing neoantigens CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 462, n_CMS2 = 41, n_CMS4 = 21, p = 0.644654695752475
tcga-mss-msi-inferred: Analyzing BATF3 CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 76, n_CMS2 = 41, n_CMS4 = 21, p = 5.98101697567165e-09
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 84, n_CMS2 = 41, n_CMS4 = 21, p = 1.65296016862437e-08
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 137, n_CMS2 = 41, n_CMS4 = 21, p = 4.06339675275904e-06
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 59, n_CMS2 = 41, n_CMS4 = 21, p = 5.46692746612342e-10
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 30, n_CMS2 = 41, n_CMS4 = 21, p = 3.08934627942104e-12
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 53, n_CMS2 = 41, n_CMS4 = 21, p = 2.14377517633594e-10
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 83, n_CMS2 = 41, n_CMS4 = 21, p = 1.46057086295648e-08

tcga-mss-msi-inferred: Analyzing CIRC CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1170, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.000294928921484659
tcga-mss-msi-inferred: Analyzing CIITA CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1322, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.00382284393624789
tcga-mss-msi-inferred: Analyzing wnt CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2184, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.219707786356691
tcga-mss-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2199, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.193917244807792
tcga-mss-msi-inferred: Analyzing neoantigens CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2085, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.390023118654653
tcga-mss-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1165, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.00026881143291545
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1237, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.000969845786934604
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1269, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.00165510361423727
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1189, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.000417444727757636
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1292, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.00239766196447671
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1338, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.00486461513371501
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1135, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.000152365196224475
tcga-mss-msi-inferred: Analyzing CIRC CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 5, n_CMS2-MT = 41, n_CMS1-MT = 2, p = 0.026578073089701
tcga-mss-msi-inferred: Analyzing CIITA CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 20, n_CMS2-MT = 41, n_CMS1-MT = 2, p = 0.267995570321152
tcga-mss-msi-inferred: Analyzing wnt CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 39, n_CMS2-MT = 41, n_CMS1-MT = 2, p = 0.930232558139535
tcga-mss-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 31, n_CMS2-MT = 41, n_CMS1-MT = 2, p = 0.602436323366556
tcga-mss-msi-inferred: Analyzing neoantigens CMS2-MT vs CMS1-MT using Wilcoxon rank sum test with continuity correction: W = 66.5, n_CMS2-MT = 41, n_CMS1-MT = 2, p = 0.149212343082899
tcga-mss-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 20, n_CMS2-MT = 41, n_CMS1-MT = 2, p = 0.267995570321152
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 28, n_CMS2-MT = 41, n_CMS1-MT = 2, p = 0.498338870431894
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 3, n_CMS2-MT = 41, n_CMS1-MT = 2, p = 0.0132890365448505
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 26, n_CMS2-MT = 41, n_CMS1-MT = 2, p = 0.434108527131783
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 37, n_CMS2-MT = 41, n_CMS1-MT = 2, p = 0.841638981173865
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 32, n_CMS2-MT = 41, n_CMS1-MT = 2, p = 0.640088593576966
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 22, n_CMS2-MT = 41, n_CMS1-MT = 2, p = 0.318936877076412
tcga-mss-msi-inferred: Analyzing CIRC CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 205, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.658477609343562
tcga-mss-msi-inferred: Analyzing CIITA CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 137, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.0476125740120781
tcga-mss-msi-inferred: Analyzing wnt CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 300, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.097744328129793
tcga-mss-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 266, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.375321129760902
tcga-mss-msi-inferred: Analyzing neoantigens CMS2-MT vs CMS3-MT using Wilcoxon rank sum test with continuity correction: W = 214.5, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.813953891301935
tcga-mss-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 282, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.212839182926178
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 207, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.69081929336732
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 167, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.196699544517722
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 221, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.929619365498761
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 198, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.550384524009462
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 184, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.363408106677409
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 181, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.329068640359124
tcga-mss-msi-inferred: Analyzing CIRC CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 60, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.0443100130727866
tcga-mss-msi-inferred: Analyzing CIITA CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 57, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.0343265652303365
tcga-mss-msi-inferred: Analyzing wnt CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 156, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.308557250320906
tcga-mss-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 122, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.987610142440941
tcga-mss-msi-inferred: Analyzing neoantigens CMS2-MT vs CMS3-WT using Wilcoxon rank sum test with continuity correction: W = 65, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.0667267409652141
tcga-mss-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 82, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.202169521920829
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 50, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.0179107513401772
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 45, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.0106752242801981
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 51, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.0197532533655417
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 44, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.00956976031734546
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 29, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.00136734809625974
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 52, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.0217492351390766
tcga-mss-msi-inferred: Analyzing CIRC CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 97, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 7.63705467281034e-08
tcga-mss-msi-inferred: Analyzing CIITA CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 80, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 1.00202046120147e-08
tcga-mss-msi-inferred: Analyzing wnt CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 746, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 5.15781784944858e-07
tcga-mss-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 767, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 5.4307425229687e-08
tcga-mss-msi-inferred: Analyzing neoantigens CMS2-MT vs CMS4-MT using Wilcoxon rank sum test with continuity correction: W = 462, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 0.644654695752475
tcga-mss-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 76, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 5.98101697567165e-09
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 84, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 1.65296016862437e-08
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 137, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 4.06339675275904e-06
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 59, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 5.46692746612342e-10
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 30, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 3.08934627942104e-12
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 53, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 2.14377517633594e-10
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 83, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 1.46057086295648e-08
tcga-mss-msi-inferred: Analyzing CIRC CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 162, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 1.3697721191633e-12
tcga-mss-msi-inferred: Analyzing CIITA CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 314, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 9.91702266317277e-08
tcga-mss-msi-inferred: Analyzing wnt CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 1488, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 8.90603150869881e-09
tcga-mss-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 1472, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 2.47050209606039e-08
tcga-mss-msi-inferred: Analyzing neoantigens CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 891, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 0.935788779099903
tcga-mss-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 244, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 1.07584085272758e-09
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 185, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 1.06906555631022e-11
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 199, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 3.45732815144412e-11
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 117, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 1.40383484416661e-14
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 111, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 7.11009227930935e-15
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 126, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 3.76321509911849e-14
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 138, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 1.32183051034716e-13

Computing linear model with interaction for CIRC
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept)  0.32907474 0.06289522  5.2321104 4.032068e-07
KRASMT                 KRASMT -0.02149378 0.10979890 -0.1957559 8.449897e-01
CMSCMS3               CMSCMS3 -0.38930800 0.17973806 -2.1659741 3.143429e-02
CMSCMS2               CMSCMS2 -0.38931702 0.07593011 -5.1273078 6.636326e-07
CMSCMS1               CMSCMS1 -0.03385344 0.30520465 -0.1109205 9.117849e-01
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.22229825 0.23636704 -0.9404790 3.480473e-01
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.30124359 0.13421678 -2.2444554 2.584102e-02
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept)  0.31405546 0.06305919  4.9803281 1.318629e-06
KRASMT                 KRASMT  0.01536354 0.11008515  0.1395605 8.891404e-01
CMSCMS3               CMSCMS3 -0.34584376 0.18020665 -1.9191509 5.631439e-02
CMSCMS2               CMSCMS2 -0.37578484 0.07612806 -4.9362200 1.615803e-06
CMSCMS1               CMSCMS1 -0.05704445 0.30600033 -0.1864196 8.522948e-01
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.29253532 0.23698325 -1.2344135 2.184219e-01
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.33141046 0.13456669 -2.4627971 1.458674e-02
Computing linear model with interaction for CIITA
Could not find CMS1
                  coefficient   Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept)  7.2853850  0.2011906 36.2113652 1.700177e-92
KRASMT                 KRASMT  0.4015582  0.3512270  1.1433008 2.542092e-01
CMSCMS3               CMSCMS3 -0.4259700  0.5749499 -0.7408819 4.595887e-01
CMSCMS2               CMSCMS2 -0.8097055  0.2428868 -3.3336739 1.012224e-03
CMSCMS1               CMSCMS1 -0.4971612  0.9762951 -0.5092325 6.111214e-01
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.5820706  0.7560959 -0.7698370 4.422576e-01
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -1.1342872  0.4293355 -2.6419601 8.860264e-03
Could not find CMS1
                  coefficient   Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept)  7.2562266  0.2016385 35.9863227 5.278678e-92
KRASMT                 KRASMT  0.4303104  0.3520090  1.2224416 2.229044e-01
CMSCMS3               CMSCMS3 -0.3387628  0.5762299 -0.5878953 5.572312e-01
CMSCMS2               CMSCMS2 -0.7823449  0.2434275 -3.2138716 1.514950e-03
CMSCMS1               CMSCMS1 -0.3580442  0.9784685 -0.3659230 7.147891e-01
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.6569705  0.7577791 -0.8669684 3.869442e-01
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -1.1447853  0.4302913 -2.6604892 8.402390e-03
Computing linear model with interaction for wnt
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept) -0.23742790 0.04279574 -5.5479335 8.607694e-08
KRASMT                 KRASMT -0.03886832 0.07471036 -0.5202534 6.034324e-01
CMSCMS3               CMSCMS3  0.27620128 0.12229900  2.2584099 2.494297e-02
CMSCMS2               CMSCMS2  0.31633208 0.05166505  6.1227478 4.428457e-09
CMSCMS1               CMSCMS1  0.51105165 0.20767012  2.4608820 1.466259e-02
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.02774183 0.16083101 -0.1724906 8.632172e-01
KRASMT:CMSCMS2 KRASMT:CMSCMS2  0.10509021 0.09132500  1.1507276 2.511467e-01
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept) -0.23206802 0.04333100 -5.3557046 2.220017e-07
KRASMT                 KRASMT -0.02201428 0.07564479 -0.2910217 7.713206e-01
CMSCMS3               CMSCMS3  0.32101468 0.12382864  2.5924106 1.019693e-02
CMSCMS2               CMSCMS2  0.29784443 0.05231124  5.6936983 4.132639e-08
CMSCMS1               CMSCMS1  0.42769197 0.21026752  2.0340373 4.319930e-02
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.09260302 0.16284257 -0.5686659 5.701876e-01
KRASMT:CMSCMS2 KRASMT:CMSCMS2  0.10952166 0.09246723  1.1844375 2.375724e-01
Computing linear model with interaction for myc.sig
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept) -0.24001790 0.04507804 -5.3244975 2.583438e-07
KRASMT                 KRASMT -0.05441739 0.07869467 -0.6915003 4.900113e-01
CMSCMS3               CMSCMS3  0.38105298 0.12882122  2.9579985 3.449572e-03
CMSCMS2               CMSCMS2  0.30100094 0.05442035  5.5310362 9.363943e-08
CMSCMS1               CMSCMS1  0.55630361 0.21874518  2.5431582 1.170200e-02
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.05737610 0.16940814 -0.3386856 7.351834e-01
KRASMT:CMSCMS2 KRASMT:CMSCMS2  0.14367685 0.09619537  1.4935942 1.367756e-01
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept) -0.24258563 0.04515954 -5.3717476 2.053068e-07
KRASMT                 KRASMT -0.03739504 0.07883695 -0.4743339 6.357523e-01
CMSCMS3               CMSCMS3  0.37430217 0.12905412  2.9003503 4.122132e-03
CMSCMS2               CMSCMS2  0.29743613 0.05451874  5.4556675 1.360325e-07
CMSCMS1               CMSCMS1  0.50344834 0.21914066  2.2973753 2.257793e-02
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.05825478 0.16971442 -0.3432518 7.317508e-01
KRASMT:CMSCMS2 KRASMT:CMSCMS2  0.14354217 0.09636929  1.4895012 1.378486e-01
Computing linear model with interaction for neoantigens
Could not find CMS1
                  coefficient    Estimate Std. Error    t value      Pr(>|t|)
(Intercept)       (Intercept)  1.74190665 0.04365731 39.8995373 5.577050e-100
KRASMT                 KRASMT -0.02772657 0.07621446 -0.3637967  7.163758e-01
CMSCMS3               CMSCMS3  0.20946903 0.12476117  1.6789601  9.464710e-02
CMSCMS2               CMSCMS2 -0.04152363 0.05279405 -0.7865209  4.324490e-01
CMSCMS1               CMSCMS1 -0.20234812 0.21185100 -0.9551436  3.406033e-01
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.09821633 0.16406891 -0.5986285  5.500658e-01
KRASMT:CMSCMS2 KRASMT:CMSCMS2  0.06559151 0.09321389  0.7036667  4.824198e-01
Could not find CMS1
                  coefficient    Estimate Std. Error    t value      Pr(>|t|)
(Intercept)       (Intercept)  1.74131409 0.04357604 39.9603536 4.203272e-100
KRASMT                 KRASMT -0.02838438 0.07607258 -0.3731224  7.094337e-01
CMSCMS3               CMSCMS3  0.22718512 0.12452892  1.8243564  6.951929e-02
CMSCMS2               CMSCMS2 -0.04067718 0.05269577 -0.7719248  4.410267e-01
CMSCMS1               CMSCMS1 -0.23275877 0.21145662 -1.1007400  2.722699e-01
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.13608540 0.16376348 -0.8309875  4.069245e-01
KRASMT:CMSCMS2 KRASMT:CMSCMS2  0.07146240 0.09304036  0.7680795  4.433028e-01
Computing linear model with interaction for BATF3
Could not find CMS1
                  coefficient   Estimate Std. Error   t value      Pr(>|t|)
(Intercept)       (Intercept)  4.9185997  0.1158427 42.459283 2.519802e-105
KRASMT                 KRASMT  0.2890692  0.2022317  1.429396  1.543693e-01
CMSCMS3               CMSCMS3 -0.6481772  0.3310482 -1.957954  5.155358e-02
CMSCMS2               CMSCMS2 -0.4552343  0.1398509 -3.255141  1.320173e-03
CMSCMS1               CMSCMS1 -0.6240225  0.5621372 -1.110089  2.682240e-01
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.9280978  0.4353495 -2.131845  3.417582e-02
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.8139472  0.2472054 -3.292594  1.163807e-03
Could not find CMS1
                  coefficient   Estimate Std. Error   t value      Pr(>|t|)
(Intercept)       (Intercept)  4.9027448  0.1151130 42.590708 1.404800e-105
KRASMT                 KRASMT  0.3429827  0.2009578  1.706740  8.934146e-02
CMSCMS3               CMSCMS3 -0.6587481  0.3289628 -2.002500  4.651101e-02
CMSCMS2               CMSCMS2 -0.4328718  0.1389699 -3.114860  2.095977e-03
CMSCMS1               CMSCMS1 -0.6485978  0.5585961 -1.161121  2.469045e-01
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.9550946  0.4326071 -2.207764  2.833788e-02
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.8890753  0.2456482 -3.619303  3.698070e-04
Computing linear model with interaction for HALLMARK_IL6_JAK_STAT3_SIGNALING
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept)  0.18047050 0.03924816  4.5981896 7.339916e-06
KRASMT                 KRASMT  0.06460471 0.06851721  0.9428975 3.468117e-01
CMSCMS3               CMSCMS3 -0.14609461 0.11216097 -1.3025441 1.941503e-01
CMSCMS2               CMSCMS2 -0.22989690 0.04738225 -4.8519622 2.373632e-06
CMSCMS1               CMSCMS1 -0.29825114 0.19045521 -1.5659910 1.188492e-01
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.26322313 0.14749885 -1.7845775 7.576662e-02
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.23772386 0.08375457 -2.8383388 4.977698e-03
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept)  0.16119121 0.03950448  4.0803274 6.377353e-05
KRASMT                 KRASMT  0.10073164 0.06896468  1.4606266 1.456054e-01
CMSCMS3               CMSCMS3 -0.08664648 0.11289346 -0.7675067 4.436383e-01
CMSCMS2               CMSCMS2 -0.21133898 0.04769169 -4.4313587 1.504309e-05
CMSCMS1               CMSCMS1 -0.32958151 0.19169900 -1.7192657 8.703252e-02
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.33610818 0.14846211 -2.2639324 2.459515e-02
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.26597204 0.08430155 -3.1550078 1.839195e-03
Computing linear model with interaction for HALLMARK_INTERFERON_GAMMA_RESPONSE
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept)  0.16139835 0.04341479  3.7175894 2.577103e-04
KRASMT                 KRASMT  0.02490912 0.07579106  0.3286551 7.427424e-01
CMSCMS3               CMSCMS3 -0.14114191 0.12406808 -1.1376166 2.565708e-01
CMSCMS2               CMSCMS2 -0.21565738 0.05241240 -4.1146254 5.560031e-05
CMSCMS1               CMSCMS1  0.04877230 0.21067411  0.2315059 8.171461e-01
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.19855216 0.16315746 -1.2169358 2.249880e-01
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.22633394 0.09264604 -2.4429964 1.538806e-02
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept)  0.16660181 0.04361654  3.8196930 0.0001757071
KRASMT                 KRASMT  0.01778143 0.07614328  0.2335259 0.8155794512
CMSCMS3               CMSCMS3 -0.13246696 0.12464466 -1.0627568 0.2891070578
CMSCMS2               CMSCMS2 -0.23183834 0.05265597 -4.4028882 0.0000169692
CMSCMS1               CMSCMS1  0.05403794 0.21165316  0.2553136 0.7987295629
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.20728399 0.16391569 -1.2645769 0.2074180513
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.18919499 0.09307659 -2.0326809 0.0433374912
Computing linear model with interaction for HALLMARK_COMPLEMENT
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept)  0.16984241 0.02764754  6.1431299 3.972104e-09
KRASMT                 KRASMT  0.03187963 0.04826550  0.6605055 5.096499e-01
CMSCMS3               CMSCMS3 -0.11637055 0.07900942 -1.4728694 1.422764e-01
CMSCMS2               CMSCMS2 -0.23614623 0.03337742 -7.0750290 2.168218e-11
CMSCMS1               CMSCMS1 -0.24183682 0.13416213 -1.8025714 7.288255e-02
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.22671343 0.10390243 -2.1819839 3.021512e-02
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.15014155 0.05899913 -2.5448094 1.164849e-02
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept)  0.16037431 0.02805448  5.7165312 3.679609e-08
KRASMT                 KRASMT  0.04346655 0.04897591  0.8875087 3.758156e-01
CMSCMS3               CMSCMS3 -0.12100396 0.08017235 -1.5092978 1.327187e-01
CMSCMS2               CMSCMS2 -0.22383034 0.03386870 -6.6087661 3.111057e-10
CMSCMS1               CMSCMS1 -0.23722730 0.13613686 -1.7425649 8.286659e-02
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.22348289 0.10543177 -2.1196921 3.520055e-02
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.16071729 0.05986754 -2.6845481 7.839707e-03
Computing linear model with interaction for HALLMARK_INFLAMMATORY_RESPONSE
Could not find CMS1
                  coefficient    Estimate Std. Error   t value     Pr(>|t|)
(Intercept)       (Intercept)  0.23291331 0.03536853  6.585326 3.546492e-10
KRASMT                 KRASMT  0.06686105 0.06174437  1.082869 2.801026e-01
CMSCMS3               CMSCMS3 -0.18272440 0.10107400 -1.807828 7.205732e-02
CMSCMS2               CMSCMS2 -0.30746301 0.04269858 -7.200779 1.038048e-11
CMSCMS1               CMSCMS1 -0.48578291 0.17162895 -2.830425 5.097811e-03
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.28284945 0.13291877 -2.127987 3.449830e-02
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.21852656 0.07547554 -2.895329 4.186045e-03
Could not find CMS1
                  coefficient    Estimate Std. Error   t value     Pr(>|t|)
(Intercept)       (Intercept)  0.22118083 0.03607918  6.130429 4.250743e-09
KRASMT                 KRASMT  0.07660342 0.06298497  1.216217 2.252610e-01
CMSCMS3               CMSCMS3 -0.15948517 0.10310484 -1.546825 1.234039e-01
CMSCMS2               CMSCMS2 -0.29782138 0.04355650 -6.837588 8.532882e-11
CMSCMS1               CMSCMS1 -0.50495570 0.17507741 -2.884185 4.331154e-03
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.28266002 0.13558945 -2.084676 3.830204e-02
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.21446369 0.07699204 -2.785531 5.830556e-03
Computing linear model with interaction for HALLMARK_IL2_STAT5_SIGNALING
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept)  0.14765536 0.02445420  6.0380368 6.941525e-09
KRASMT                 KRASMT  0.04110101 0.04269075  0.9627615 3.367693e-01
CMSCMS3               CMSCMS3 -0.06018289 0.06988370 -0.8611863 3.901130e-01
CMSCMS2               CMSCMS2 -0.21305273 0.02952228 -7.2166771 9.452475e-12
CMSCMS1               CMSCMS1 -0.26662411 0.11866618 -2.2468416 2.568549e-02
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.23479160 0.09190153 -2.5548171 1.132882e-02
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.13342636 0.05218464 -2.5568131 1.126601e-02
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept)  0.14097129 0.02472009  5.7027011 3.947857e-08
KRASMT                 KRASMT  0.04762050 0.04315493  1.1034777 2.710767e-01
CMSCMS3               CMSCMS3 -0.05407565 0.07064354 -0.7654719 4.448460e-01
CMSCMS2               CMSCMS2 -0.20425617 0.02984327 -6.8442957 8.212054e-11
CMSCMS1               CMSCMS1 -0.26853366 0.11995644 -2.2385932 2.622662e-02
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.23151821 0.09290077 -2.4921021 1.346875e-02
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.14209417 0.05275204 -2.6936242 7.636429e-03
Computing linear model with interaction for HALLMARK_ALLOGRAFT_REJECTION
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept)  0.19222791 0.03858473  4.9819689 1.308664e-06
KRASMT                 KRASMT  0.01791542 0.06735902  0.2659691 7.905227e-01
CMSCMS3               CMSCMS3 -0.19114345 0.11026504 -1.7334910 8.446924e-02
CMSCMS2               CMSCMS2 -0.23476991 0.04658132 -5.0400013 9.995580e-07
CMSCMS1               CMSCMS1 -0.18445204 0.18723581 -0.9851323 3.256874e-01
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.17262905 0.14500557 -1.1904994 2.351878e-01
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.22194079 0.08233881 -2.6954577 7.595945e-03
Could not find CMS1
                  coefficient    Estimate Std. Error    t value     Pr(>|t|)
(Intercept)       (Intercept)  0.18211396 0.03889045  4.6827426 5.063974e-06
KRASMT                 KRASMT  0.04088791 0.06789273  0.6022428 5.476592e-01
CMSCMS3               CMSCMS3 -0.18731426 0.11113871 -1.6854097 9.338784e-02
CMSCMS2               CMSCMS2 -0.22722414 0.04695040 -4.8396636 2.509678e-06
CMSCMS1               CMSCMS1 -0.20646966 0.18871936 -1.0940566 2.751775e-01
KRASMT:CMSCMS3 KRASMT:CMSCMS3 -0.18470116 0.14615451 -1.2637391 2.077181e-01
KRASMT:CMSCMS2 KRASMT:CMSCMS2 -0.23230769 0.08299122 -2.7991840 5.598184e-03
Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for neoantigens
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
tcga-mss-msi-inferred: Analyzing CIRC CMS4 MT vs WT using Wilcoxon rank sum test: W = 435, n_MT = 21, n_WT = 43, p = 0.820503139725541
tcga-mss-msi-inferred: Analyzing CIITA CMS4 MT vs WT using Wilcoxon rank sum test: W = 335, n_MT = 21, n_WT = 43, p = 0.0974311602090096
tcga-mss-msi-inferred: Analyzing wnt CMS4 MT vs WT using Wilcoxon rank sum test: W = 485, n_MT = 21, n_WT = 43, p = 0.639645708717878
tcga-mss-msi-inferred: Analyzing myc.sig CMS4 MT vs WT using Wilcoxon rank sum test: W = 488, n_MT = 21, n_WT = 43, p = 0.609479650061574
tcga-mss-msi-inferred: Analyzing neoantigens CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 486, n_MT = 21, n_WT = 43, p = 0.626782922983445
tcga-mss-msi-inferred: Analyzing BATF3 CMS4 MT vs WT using Wilcoxon rank sum test: W = 320, n_MT = 21, n_WT = 43, p = 0.0606763597539709
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test: W = 361, n_MT = 21, n_WT = 43, p = 0.199855105886499
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test: W = 414, n_MT = 21, n_WT = 43, p = 0.59956433985099
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS4 MT vs WT using Wilcoxon rank sum test: W = 396, n_MT = 21, n_WT = 43, p = 0.434702327399137
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test: W = 367, n_MT = 21, n_WT = 43, p = 0.231779911074771
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test: W = 385, n_MT = 21, n_WT = 43, p = 0.348189090139301
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS4 MT vs WT using Wilcoxon rank sum test: W = 419, n_MT = 21, n_WT = 43, p = 0.649835993865151
tcga-mss-msi-inferred: Analyzing CIRC CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2684, n_MT = 41, n_WT = 94, p = 0.000294928921484659
tcga-mss-msi-inferred: Analyzing CIITA CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2532, n_MT = 41, n_WT = 94, p = 0.00382284393624789
tcga-mss-msi-inferred: Analyzing wnt CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1670, n_MT = 41, n_WT = 94, p = 0.219707786356691
tcga-mss-msi-inferred: Analyzing myc.sig CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1655, n_MT = 41, n_WT = 94, p = 0.193917244807792
tcga-mss-msi-inferred: Analyzing neoantigens CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1728, n_MT = 41, n_WT = 94, p = 0.390023118654653
tcga-mss-msi-inferred: Analyzing BATF3 CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2689, n_MT = 41, n_WT = 94, p = 0.00026881143291545
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2617, n_MT = 41, n_WT = 94, p = 0.000969845786934604
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2585, n_MT = 41, n_WT = 94, p = 0.00165510361423727
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2665, n_MT = 41, n_WT = 94, p = 0.000417444727757636
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2562, n_MT = 41, n_WT = 94, p = 0.00239766196447671
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2516, n_MT = 41, n_WT = 94, p = 0.00486461513371501
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2719, n_MT = 41, n_WT = 94, p = 0.000152365196224475
tcga-mss-msi-inferred: Analyzing CIRC CMS3 MT vs WT using Wilcoxon rank sum test: W = 47, n_MT = 11, n_WT = 6, p = 0.180187459599224
tcga-mss-msi-inferred: Analyzing CIITA CMS3 MT vs WT using Wilcoxon rank sum test: W = 37, n_MT = 11, n_WT = 6, p = 0.732546864899806
tcga-mss-msi-inferred: Analyzing wnt CMS3 MT vs WT using Wilcoxon rank sum test: W = 38, n_MT = 11, n_WT = 6, p = 0.660471881060116
tcga-mss-msi-inferred: Analyzing myc.sig CMS3 MT vs WT using Wilcoxon rank sum test: W = 38, n_MT = 11, n_WT = 6, p = 0.660471881060116
tcga-mss-msi-inferred: Analyzing neoantigens CMS3 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 47.5, n_MT = 11, n_WT = 6, p = 0.15915597452002
tcga-mss-msi-inferred: Analyzing BATF3 CMS3 MT vs WT using Wilcoxon rank sum test: W = 51, n_MT = 11, n_WT = 6, p = 0.0782159017453135
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 48, n_MT = 11, n_WT = 6, p = 0.148998060762767
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 44, n_MT = 11, n_WT = 6, p = 0.301066580478345
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS3 MT vs WT using Wilcoxon rank sum test: W = 47, n_MT = 11, n_WT = 6, p = 0.180187459599224
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 48, n_MT = 11, n_WT = 6, p = 0.148998060762767
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 53, n_MT = 11, n_WT = 6, p = 0.0476729153199741
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS3 MT vs WT using Wilcoxon rank sum test: W = 45, n_MT = 11, n_WT = 6, p = 0.256140917905624

Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for neoantigens
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
Computing rectum vs left
tcga-mss-msi-inferred: Analyzing CIRC site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2210, n_rectum = 43, n_left = 118, p = 0.212213677498416
tcga-mss-msi-inferred: Analyzing CIITA site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2243, n_rectum = 43, n_left = 118, p = 0.262111661753397
tcga-mss-msi-inferred: Analyzing wnt site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 1970, n_rectum = 43, n_left = 118, p = 0.030425916983339
tcga-mss-msi-inferred: Analyzing myc.sig site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2129, n_rectum = 43, n_left = 118, p = 0.119473137030984
tcga-mss-msi-inferred: Analyzing neoantigens site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2746, n_rectum = 43, n_left = 118, p = 0.425577654191663
tcga-mss-msi-inferred: Analyzing BATF3 site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 1883, n_rectum = 43, n_left = 118, p = 0.0125279555215725
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2315, n_rectum = 43, n_left = 118, p = 0.397377502386621
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2362, n_rectum = 43, n_left = 118, p = 0.504941357622729
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2527, n_rectum = 43, n_left = 118, p = 0.971044825077366
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2588, n_rectum = 43, n_left = 118, p = 0.846996567717488
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2749, n_rectum = 43, n_left = 118, p = 0.419029644541728
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2282, n_rectum = 43, n_left = 118, p = 0.330850789352078
Computing right vs left
tcga-mss-msi-inferred: Analyzing CIRC site: right vs leftWilcoxon rank sum test with continuity correction: W = 4102, n_right = 75, n_left = 118, p = 0.393878425381178
tcga-mss-msi-inferred: Analyzing CIITA site: right vs leftWilcoxon rank sum test with continuity correction: W = 4010, n_right = 75, n_left = 118, p = 0.27315376046122
tcga-mss-msi-inferred: Analyzing wnt site: right vs leftWilcoxon rank sum test with continuity correction: W = 3995, n_right = 75, n_left = 118, p = 0.256172284353521
tcga-mss-msi-inferred: Analyzing myc.sig site: right vs leftWilcoxon rank sum test with continuity correction: W = 3891, n_right = 75, n_left = 118, p = 0.158411784720041
tcga-mss-msi-inferred: Analyzing neoantigens site: right vs leftWilcoxon rank sum test with continuity correction: W = 3488.5, n_right = 75, n_left = 118, p = 0.0192595772067348
tcga-mss-msi-inferred: Analyzing BATF3 site: right vs leftWilcoxon rank sum test with continuity correction: W = 4073, n_right = 75, n_left = 118, p = 0.352747476441094
tcga-mss-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 4443, n_right = 75, n_left = 118, p = 0.963098729294913
tcga-mss-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 4105, n_right = 75, n_left = 118, p = 0.398293033204505
tcga-mss-msi-inferred: Analyzing HALLMARK_COMPLEMENT site: right vs leftWilcoxon rank sum test with continuity correction: W = 4478, n_right = 75, n_left = 118, p = 0.889611234747813
tcga-mss-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 4528, n_right = 75, n_left = 118, p = 0.786404135286141
tcga-mss-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 4521, n_right = 75, n_left = 118, p = 0.800672536581125
tcga-mss-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: right vs leftWilcoxon rank sum test with continuity correction: W = 4171, n_right = 75, n_left = 118, p = 0.502738504340132

Plotting CIRC ~ site
Plotting CIITA ~ site
Plotting wnt ~ site
Plotting myc.sig ~ site
Plotting neoantigens ~ site
Plotting BATF3 ~ site
Plotting HALLMARK_IL6_JAK_STAT3_SIGNALING ~ site
Plotting HALLMARK_INTERFERON_GAMMA_RESPONSE ~ site
Plotting HALLMARK_COMPLEMENT ~ site
Plotting HALLMARK_INFLAMMATORY_RESPONSE ~ site
Plotting HALLMARK_IL2_STAT5_SIGNALING ~ site
Plotting HALLMARK_ALLOGRAFT_REJECTION ~ site
Overlap of MSI and CMS1 in TCGA inferred:
     
      CMS1 CMS2 CMS3 CMS4 NOLBL
  msi   74    1   42   33    19
  mss    2  214   27  105    42
Number of rows analyzed: 20294
Number of columns analyzed: 236
tcga-mss-msi-inferred-no-cms: 28 of 28 genes from data set analyzed in set CIRC: HLA-DQA1 HLA-DQA2 HLA-DRB5 CTLA4 PDCD1LG2 ICAM1 CD274 STAT1 IRF1 IFNG GNLY TBX21 CCL5 LAG3 CD247 ICOS IL18RAP CXCL9 CXCL10 HLA-DPB1 HLA-DPA1 HLA-DMB HLA-DRA HLA-DMA CD80 HLA-DOA CD4 HAVCR2
tcga-mss-msi-inferred-no-cms: 85 of 88 genes from data set analyzed in set myc.sig: AKAP1 APEX1 BAX CAD CCKBR CCNB1 CCND2 CCT5 CDC25C CEBPZ CKS2 CSDA CTSC DDX10 DDX18 DDX5 DKC1 E2F1 EIF4A1 EIF4B ENO1 EXOSC8 FASN FOSL1 H2AFZ HSPA8 HSPD1 HSPE1 ID2 IMPA2 LTA4H MAT2A METTL1 MINA MSH2 MTHFD1 NAP1L1 NCL NME1 NPM1 NRAS NUP155 PA2G4 PCNA PHB POLD2 PPAT PPIA PPID PRDX3 PREP PRPS2 PSMB1 PTEN PYCR1 RPL10 RPL19 RPL22 RPL27 RPL27A RPL32 RPL5 RPL9 RPS13 RPS16 RPS19 RPS5 RPS6KA2 SFRS1 SFRS2 SFRS7 SHMT1 SLC25A3 SLC39A6 SNRPB SNRPD3 SRM TERT TFRC TOP1 TXN TYMS UBE2C UCHL1 UXT
tcga-mss-msi-inferred-no-cms: 3 of 88 genes missing from data set analyzed in set myc.sig: DSCR2 HNRPA2B1 HSPA9B
tcga-mss-msi-inferred-no-cms: 50 of 78 genes from data set analyzed in set wnt: PHLDA1 SLC7A5 CTPS BYSL SCD SOX4 WDR77 NLE1 PPIL1 CIRH1A ZNF511 ZNF593 DKC1 ODC1 AURKB WDR12 CDT1 NOC3L CAD XPOT YAP1 SRM NXT1 MRPS12 RHEB WDR3 CRTAP SF3A2 GEMIN5 HNRPDL TREX2 IMP4 HEATR1 SLC19A1 PDCD11 ASCL2 TDGF1 TBX3 EPHB3 ZNRF3 IL20RA RHOBTB3 GEMIN4 ID3 FUT4 PIGW APEX1 SRPRB ZNRD1 TFB2M
tcga-mss-msi-inferred-no-cms: 28 of 78 genes missing from data set analyzed in set wnt: FLJ20315 NOB1P PSF1 PMSCL1 RNU3IP2 HIG2 C1orf33 LOC389362 HSPC111 MGC40397 LOC56902 SDCCAG16 FLJ10774 RAB9P40 RFP RRP41 C16orf35 CGI-96 C20orf64 C12orf14 NOL1 SKB1 C11orf5 MGC16824 ZNF278 RPC62 JTV1 ZNF339
tcga-mss-msi-inferred-no-cms: 87 of 87 genes from data set analyzed in set HALLMARK_IL6_JAK_STAT3_SIGNALING: IL4R IL6ST STAT1 IL1R1 CSF2RB SOCS3 STAT3 OSMR IL2RG IFNGR1 TYK2 IL13RA1 TLR2 IFNGR2 IL10RB IL6 IL1R2 IL3RA IFNAR1 TNFRSF1A MYD88 ACVR1B CSF3R ITGB3 REG1A CXCL1 A2M CSF2RA IL15RA IRF9 PDGFC HAX1 BAK1 EBI3 INHBE CRLF2 TNFRSF1B CD14 PTPN1 PTPN2 IL1B CSF1 IL18R1 TNF PF4 CXCL13 LTBR FAS IL17RA CXCL10 IL9R STAM2 TNFRSF12A STAT2 HMOX1 LEPR CBL CD9 CXCL3 TGFB1 MAP3K8 ITGA4 CD38 JUN SOCS1 ACVRL1 PIM1 TNFRSF21 PIK3R5 GRB2 IRF1 DNTT CSF2 IL2RA PTPN11 IL12RB1 CCR1 CNTFR PLA2G2A CXCL9 CD44 IL7 CXCL11 CCL7 LTB IL17RB CD36
tcga-mss-msi-inferred-no-cms: 200 of 200 genes from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: STAT1 ISG15 IFIT1 MX1 IFIT3 IFI35 IRF7 IFIT2 OAS2 TAP1 EIF2AK2 RSAD2 MX2 IRF1 OAS3 TNFSF10 IRF9 CXCL10 IFI44 BST2 XAF1 SP110 OASL PSMB8 IFI44L IFITM3 DDX60 LGALS3BP GBP4 IRF8 PSMB9 PML IFIH1 UBE2L6 IFI27 ADAR LY6E STAT2 CXCL9 IL10RA PLA2G4A TRIM21 USP18 PTGS2 EPSTI1 C1S DDX58 IL15 NLRC5 NMI IDO1 PSMB10 CXCL11 ITGB7 SAMHD1 HERC6 CMPK2 SAMD9L RTP4 PTPN2 PARP14 TNFAIP2 IFITM2 PLSCR1 SOCS1 CASP1 ICAM1 WARS PSME1 ISG20 IRF2 TRIM14 FCGR1A MARCH1 SOCS3 JAK2 HLA-DMA PARP12 TNFAIP6 TRIM26 VCAM1 CD274 CIITA NAMPT SELP GPR18 FPR1 PRIC285 PSME2 SERPING1 CCL5 RNF31 SOD2 TRIM25 LAP3 PSMA3 RNF213 PELI1 CFB CD86 TXNIP HLA-DQA1 GCH1 PNP CCL7 PTPN6 SPPL2A IL4R PNPT1 DHX58 BTG1 CASP8 IFI30 CCL2 FGL2 CASP7 SECTM1 IL15RA CD40 TRAFD1 HLA-DRB1 GBP6 LCP2 HLA-G MT2A RIPK1 KLRK1 UPP1 PSMB2 TDRD7 HIF1A EIF4E3 VAMP8 PFKP CD38 ZBP1 BANK1 TOR1B RBCK1 PDE4B MVP IL7 BPGM FTSJD2 AUTS2 B2M RIPK2 CD69 MYD88 PSMA2 PIM1 NOD1 CFH TAPBP SLC25A28 PTPN1 TNFAIP3 SSPN NUP93 MTHFD2 CDKN1A IRF4 NFKB1 BATF2 HLA-B LATS2 IRF5 SLAMF7 ISOC1 P2RY14 STAT3 NCOA3 HLA-A IL6 GZMA IFNAR2 CD74 RAPGEF6 CASP4 FAS OGFR ARL4A SRI LYSMD2 CSF2RB ST3GAL5 C1R CASP3 CMKLR1 NFKBIA METTL7B ST8SIA4 XCL1 IL2RB VAMP5 IL18BP ZNFX1 ARID5B APOL6 STAT4
tcga-mss-msi-inferred-no-cms: 200 of 200 genes from data set analyzed in set HALLMARK_COMPLEMENT: C2 C1S CFB C1R SERPINE1 MMP14 SERPING1 CTSL1 F5 MMP13 F7 CTSS LGMN PLG C1QA CASP1 GZMA ADAM9 CALM3 C1QC TIMP1 DPP4 KLK1 KLKB1 CD59 CR2 MMP15 LAP3 SPOCK2 F10 CTSB SERPINA1 CTSO CD40LG CBLB PDP1 C4BPB PLEK GP9 PLAUR C3 F2 CASP4 STX4 CTSC USP15 CR1 DUSP6 SERPINB2 GPD2 CFH FN1 CD36 CA2 PSMB9 APOBEC3G FCN1 GZMK PDGFB CLU CASP10 LRP1 CTSD S100A9 WAS BRPF3 PLAT CDA MT3 CASP7 PRSS36 PFN1 GZMB RNF4 ZEB1 CASP5 IRF1 PGCP CDK5R1 ATOX1 PIK3CA TMPRSS6 CPM RCE1 CALM1 DOCK9 KYNU RASGRP1 USP14 LCP2 GP1BA KIF2A GNB4 LCK OLR1 PREP SEPX1 LTA4H ZFPM2 LYN ACTN2 SIRT6 APOC1 PRKCD ITGAM DGKH LTF MAFF KCNIP2 PCLO DOCK10 SH2B3 RABIF SRC HPCAL4 CD46 PRDM4 GNAI3 C9 PPP2CB IRF2 FYN JAK2 PLA2G4A PRCP USP8 RHOG L3MBTL4 LAMP2 PIM1 CXCL1 F3 GNAI2 CASP9 XPNPEP1 PLSCR1 IRF7 CD55 HSPA5 GNB2 DYRK2 PLA2G7 S100A12 GRB2 PHEX GNGT2 DOCK4 MMP12 KCNIP3 FDX1 TIMP2 MMP8 FCER1G ZFYVE20 ANXA5 CTSL2 GCA EHD1 PRSS3 COL4A2 CSRP1 PIK3R5 SERPINC1 ANG APOBEC3F GATA3 DUSP5 CASP3 USP16 CP PSEN1 LIPA PCSK9 DGKG GNG2 ME1 GMFB SCG3 PPP4C CCL5 CTSH F8 APOA4 IL6 AKAP10 ERAP2 VCPIP1 HSPA1A RAF1 NOTCH4 ADRA2B CEBPB HNF4A LGALS3 TNFAIP3 CDH13 ITIH1 TFPI2 PIK3CG S100A13
tcga-mss-msi-inferred-no-cms: 200 of 200 genes from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: CXCL10 CCL2 CCL5 FPR1 CCL20 IL1A IL8 CCL7 CCL22 CXCL11 CCR7 EDN1 CD40 CXCL9 IL6 IL1B TLR2 IL1R1 CD69 ICAM1 CCRL2 AQP9 EREG C3AR1 GNA15 CMKLR1 PTGER4 LIF IL15 NAMPT OPRK1 ITGB8 PTAFR ADM PLAUR NFKB1 INHBA OSM TNFSF10 TNFSF15 IFNGR2 EMR1 IL12B CSF1 CXCL6 TNFRSF9 LYN ACVR2A LDLR BDKRB1 HRH1 F3 BST2 PTGIR CD55 CALCRL CSF3 GPR132 IL4R NLRP3 IL15RA ADORA2B GCH1 OLR1 PTGER2 CSF3R MYC RELA TNFAIP6 IL7R IL18 GABBR1 CD82 TNFSF9 NMUR1 IL2RB TLR1 LPAR1 IRAK2 RIPK2 MMP14 P2RX7 SLC11A2 SELL P2RY2 ABCA1 FFAR2 PROK2 GNAI3 TACR1 SLC7A1 CDKN1A CYBB TIMP1 HBEGF SCARF1 EBI3 NFKBIA SRI SLC7A2 CCL17 TLR3 APLNR OSMR IL10RA PSEN1 GPR183 ATP2B1 TNFRSF1B BEST1 GPC3 SCN1B ACVR1B HPN SEMA4D KLF6 CD48 CXCR6 SLC1A2 GP1BA TAPBP RGS16 SLAMF1 LCK HIF1A AHR NMI RHOG TPBG NPFFR2 IFNAR1 ICOSLG RASGRP1 IFITM1 KCNJ2 LY6E IL18R1 IL10 KCNA3 HAS2 DCBLD2 LAMP3 VIP CD70 RGS1 SLC31A1 ADRM1 KCNMB2 SERPINE1 MXD1 AXL MEFV PVR CCL24 PDE4B LCP2 PDPN IRF7 MET ATP2A2 SLC31A2 FZD5 ITGA5 SGMS2 MARCO CD14 EIF2AK2 ROS1 ATP2C1 NDP BTG2 MSR1 PTPRE RNF144B PCDH7 SPHK1 IL18RAP RTP4 RAF1 CHST2 ITGB3 KIF1B SELE NOD2 C5AR1 EMP3 CLEC5A TACR3 SLC4A4 MEP1A SELS LTA PIK3R5 STAB1 IRF1 ICAM4 P2RX4 ABI1 CX3CL1 SLC28A2
tcga-mss-msi-inferred-no-cms: 198 of 200 genes from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: SOCS2 CISH PIM1 IL2RA TNFRSF4 SOCS1 TNFRSF9 XBP1 RRAGD HK2 PHLDA1 IL2RB CTLA4 NFIL3 CD83 IKZF2 IL10 TNFRSF18 DHRS3 ECM1 ADAM19 SLC2A3 HIPK2 BATF3 BHLHE40 PTGER2 DENND5A ITIH5 PHTF2 GADD45B NRP1 NCOA3 CD79B AHR TNFRSF1B NDRG1 BCL2L1 GABARAPL1 LIF TIAM1 BMPR2 MAP3K8 RHOB MYC S100A1 CAPG ST3GAL4 PENK IRF4 CST7 WLS TLR7 IKZF4 GBP4 RGS16 SPP1 IL13 SLC29A2 NFKBIZ IL4R MXD1 CSF2 FAH CTSZ ITGAE MUC1 MAPKAPK2 TNFRSF21 NT5E FLT3LG CCND2 TRAF1 LCLAT1 IL3RA CYFIP1 BCL2 FGL2 PRNP N6AMT2 PUS1 ITGAV NCS1 DCPS AMACR FAM126B PTH1R ODC1 IGF1R PTCH1 ENO3 CD81 MAFF EMP1 CDKN1C CAPN3 IL1R2 SYT11 TTC39B ANXA4 BATF P4HA1 GPR65 SLC1A5 IGF2R CKAP4 CCR4 CD44 P2RX4 GATA1 KLF6 ARL4A HOPX GPR83 ITGA6 CD48 SELP GLIPR2 SMPDL3A PLSCR1 FURIN SERPINB6 TNFSF11 GPX4 LRRC8C CCNE1 CASP3 SH3BGRL2 SNX9 PLEC BMP2 ICOS ALCAM LTB ENPP1 IL1RL1 MYO1C IFNGR1 PLIN2 IL18R1 AHNAK PRKCH TNFRSF8 SYNGR2 GALM POU2F1 EOMES NOP2 PTRH2 RHOH CDC6 MYO1E CXCL10 SNX14 IRF6 IL10RA MAP6 TNFSF10 SPRED2 SELL SERPINC1 CDCP1 RORA COCH CSF1 F2RL2 UCK2 CA2 IFITM3 UMPS HUWE1 COL6A1 ABCB1 RNH1 IRF8 GUCY1B3 AHCY PRAF2 GSTO1 TWSG1 CDC42SE2 PLAGL1 APLP1 AKAP2 PPAP2A SPRY4 SCN9A SHE PDCD2L CCND3 LRIG1 SWAP70 SLC39A8 RABGAP1L TGM2 PNP AGER ETV4 CD86
tcga-mss-msi-inferred-no-cms: 2 of 200 genes missing from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: METTL20 CCDC164
tcga-mss-msi-inferred-no-cms: 200 of 200 genes from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: PTPRC IL12B TGFB1 IL12A CD3E CD3D CD28 LYN HCLS1 IL18 CRTAM IFNG CD3G CD86 IL10 UBE2N BCL10 CD4 LCK NCK1 C2 HLA-A ITGB2 HLA-DQA1 CD1D CD80 HLA-DRA THY1 TLR1 HLA-G HLA-DMB IL7 IL4 TNF CD247 IL2 HLA-DMA STAT1 IRF4 SRGN INHBA TLR3 ZAP70 CD74 CD40 TRAF2 B2M BCL3 LTB IFNGR1 CCR5 CD40LG HLA-DOA GLMN IL6 HLA-E CD2 CCL5 FAS FASLG TLR6 PF4 TGFB2 CD79A INHBB ELANE SPI1 MAP3K7 IL15 CTSS CD47 PRF1 IL12RB1 LCP2 SOCS1 CDKN2A STAT4 CD7 HLA-DOB CD8A ICAM1 CCL4 GZMB CSF1 IL11 STAB1 IL2RA NLRP3 CCND3 EIF3A SIT1 IFNAR2 HDAC9 CARTPT TRAT1 CCL22 APBB1 FYB IL1B TIMP1 RPS19 JAK2 KRT1 WARS IFNGR2 CCR2 EREG MMP9 EGFR IL16 CFP WAS ITGAL KLRD1 RARS TLR2 CCND2 IL2RG ETS1 ITK NCR1 MAP4K1 CCL19 PSMB10 RPL39 EIF3J ABCE1 CD8B F2 ELF4 LY86 FCGR2B GBP2 PRKCG RPS9 MTIF2 GZMA AARS CD96 CSK HIF1A CCL2 ICOSLG NPM1 IL4R CCL11 NME1 FLNA GPR65 ACHE EIF3D IGSF6 F2R IL13 TAP1 DARS IRF7 ACVR2A CXCR3 PRKCB CXCL9 PTPN6 NCF4 UBE2D1 LIF CCR1 MBL2 DEGS1 TPD52 AKT1 RIPK2 IKBKB GCNT1 SOCS5 IRF8 TAP2 EIF4G3 ABI1 CCL7 IL2RB BRCA1 FGR IL18RAP MRPL3 CXCL13 CAPG EIF5A RPS3A GALNT1 ST8SIA4 CCL13 RPL3L LY75 TAPBP NOS2 RPL9 BCAT1 IL9 IL27RA DYRK3
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
tcga-mss-msi-inferred-no-cms wnt vs CIRC: t = -5.99572844367793 df = 234 nrow = 236 cor = -0.36492304210627 pval = 7.61645165191764e-09
tcga-mss-msi-inferred-no-cms tak1 vs CIRC: t = -1.30864013913241 df = 234 nrow = 236 cor = -0.0852371448735814 pval = 0.191940089260213
tcga-mss-msi-inferred-no-cms wnt vs myc.sig: t = 26.3697867532818 df = 234 nrow = 236 cor = 0.864994425534086 pval = 5.00793553620202e-72
tcga-mss-msi-inferred-no-cms CIRC vs neoantigens: tcga-mss-msi-inferred-no-cms: Analyzing CIRC vs neoantigens using Fisher's Exact Test for Count Data: p = 0.498308783415166 n = 235

tcga-mss-msi-inferred-no-cms: Analyzing CIRC vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7633, n_WT = 152, n_MT = 84, p = 0.0129099807400285
tcga-mss-msi-inferred-no-cms: Analyzing CIITA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 6817, n_WT = 152, n_MT = 84, p = 0.389087383685068
tcga-mss-msi-inferred-no-cms: Analyzing wnt vs KRAS using Wilcoxon rank sum test with continuity correction: W = 6346, n_WT = 152, n_MT = 84, p = 0.940471787527196
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig vs KRAS using Wilcoxon rank sum test with continuity correction: W = 6172, n_WT = 152, n_MT = 84, p = 0.673625315540299
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens vs KRAS using Wilcoxon rank sum test with continuity correction: W = 5713.5, n_WT = 151, n_MT = 84, p = 0.208559146600745
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7690, n_WT = 152, n_MT = 84, p = 0.0093291205486529
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7348, n_WT = 152, n_MT = 84, p = 0.0550225037167386
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7365, n_WT = 152, n_MT = 84, p = 0.0508727023693265
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7399, n_WT = 152, n_MT = 84, p = 0.0433565223737982
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7143, n_WT = 152, n_MT = 84, p = 0.13092487421814
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7168, n_WT = 152, n_MT = 84, p = 0.118700964640803
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7652, n_WT = 152, n_MT = 84, p = 0.0116001785011127

Computing CIRC ~ KRAS
Computing CIITA ~ KRAS
Computing wnt ~ KRAS
Computing myc.sig ~ KRAS
Computing neoantigens ~ KRAS
Computing BATF3 ~ KRAS
Computing HALLMARK_IL6_JAK_STAT3_SIGNALING ~ KRAS
Computing HALLMARK_INTERFERON_GAMMA_RESPONSE ~ KRAS
Computing HALLMARK_COMPLEMENT ~ KRAS
Computing HALLMARK_INFLAMMATORY_RESPONSE ~ KRAS
Computing HALLMARK_IL2_STAT5_SIGNALING ~ KRAS
Computing HALLMARK_ALLOGRAFT_REJECTION ~ KRAS
tcga-mss-msi-inferred-no-cms: Analyzing CIRC CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1223, n_CMS2 = 135, n_CMS3 = 17, p = 0.661063948089389
tcga-mss-msi-inferred-no-cms: Analyzing CIITA CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 912, n_CMS2 = 135, n_CMS3 = 17, p = 0.169505831331597
tcga-mss-msi-inferred-no-cms: Analyzing wnt CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1404, n_CMS2 = 135, n_CMS3 = 17, p = 0.134508327828715
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1167, n_CMS2 = 135, n_CMS3 = 17, p = 0.911558730544977
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 831.5, n_CMS2 = 135, n_CMS3 = 17, p = 0.0706742245324048
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1512, n_CMS2 = 135, n_CMS3 = 17, p = 0.0333438593137421
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1123, n_CMS2 = 135, n_CMS3 = 17, p = 0.888421143631446
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1046, n_CMS2 = 135, n_CMS3 = 17, p = 0.554896461160205
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1103, n_CMS2 = 135, n_CMS3 = 17, p = 0.797008257347682
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1064, n_CMS2 = 135, n_CMS3 = 17, p = 0.627525874019175
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 927, n_CMS2 = 135, n_CMS3 = 17, p = 0.198406608627442
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1133, n_CMS2 = 135, n_CMS3 = 17, p = 0.934771552992318
tcga-mss-msi-inferred-no-cms: Analyzing CIRC CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1846, n_CMS2 = 135, n_CMS4 = 64, p = 7.11348210424442e-11
tcga-mss-msi-inferred-no-cms: Analyzing CIITA CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2183, n_CMS2 = 135, n_CMS4 = 64, p = 1.80030153566937e-08
tcga-mss-msi-inferred-no-cms: Analyzing wnt CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 7023, n_CMS2 = 135, n_CMS4 = 64, p = 1.06593985779953e-12
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 6900, n_CMS2 = 135, n_CMS4 = 64, p = 1.06391551070951e-11
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 4099, n_CMS2 = 135, n_CMS4 = 64, p = 0.617130706124192
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2200, n_CMS2 = 135, n_CMS4 = 64, p = 2.33199263703185e-08
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1801, n_CMS2 = 135, n_CMS4 = 64, p = 3.20500401816384e-11
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2139, n_CMS2 = 135, n_CMS4 = 64, p = 9.13134168659049e-09
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1216, n_CMS2 = 135, n_CMS4 = 64, p = 2.87540687452492e-16
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1168, n_CMS2 = 135, n_CMS4 = 64, p = 9.98768788791051e-17
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1195, n_CMS2 = 135, n_CMS4 = 64, p = 1.81395996085028e-16
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1803, n_CMS2 = 135, n_CMS4 = 64, p = 3.32157972681845e-11


tcga-mss-msi-inferred-no-cms: Analyzing CIRC CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 207, n_CMS2 = 41, n_CMS3 = 11, p = 0.69081929336732
tcga-mss-msi-inferred-no-cms: Analyzing CIITA CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 137, n_CMS2 = 41, n_CMS3 = 11, p = 0.0476125740120781
tcga-mss-msi-inferred-no-cms: Analyzing wnt CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 299, n_CMS2 = 41, n_CMS3 = 11, p = 0.102489874232738
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 267, n_CMS2 = 41, n_CMS3 = 11, p = 0.363408106677409
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 214.5, n_CMS2 = 41, n_CMS3 = 11, p = 0.813953891301935
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 282, n_CMS2 = 41, n_CMS3 = 11, p = 0.212839182926178
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 203, n_CMS2 = 41, n_CMS3 = 11, p = 0.62674482703343
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 167, n_CMS2 = 41, n_CMS3 = 11, p = 0.196699544517722
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 219, n_CMS2 = 41, n_CMS3 = 11, p = 0.894595301742633
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 198, n_CMS2 = 41, n_CMS3 = 11, p = 0.550384524009462
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 182, n_CMS2 = 41, n_CMS3 = 11, p = 0.340280838033111
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 182, n_CMS2 = 41, n_CMS3 = 11, p = 0.340280838033111
tcga-mss-msi-inferred-no-cms: Analyzing CIRC CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 97, n_CMS2 = 41, n_CMS4 = 21, p = 7.63705467281034e-08
tcga-mss-msi-inferred-no-cms: Analyzing CIITA CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 80, n_CMS2 = 41, n_CMS4 = 21, p = 1.00202046120147e-08
tcga-mss-msi-inferred-no-cms: Analyzing wnt CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 747, n_CMS2 = 41, n_CMS4 = 21, p = 4.66477224074526e-07
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 769, n_CMS2 = 41, n_CMS4 = 21, p = 4.30962301603806e-08
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 462, n_CMS2 = 41, n_CMS4 = 21, p = 0.644654695752475
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 76, n_CMS2 = 41, n_CMS4 = 21, p = 5.98101697567165e-09
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 81, n_CMS2 = 41, n_CMS4 = 21, p = 1.13719759808388e-08
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 135, n_CMS2 = 41, n_CMS4 = 21, p = 3.40486976304933e-06
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 59, n_CMS2 = 41, n_CMS4 = 21, p = 5.46692746612342e-10
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 30, n_CMS2 = 41, n_CMS4 = 21, p = 3.08934627942104e-12
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 52, n_CMS2 = 41, n_CMS4 = 21, p = 1.82402316579179e-10
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 84, n_CMS2 = 41, n_CMS4 = 21, p = 1.65296016862437e-08

tcga-mss-msi-inferred-no-cms: Analyzing CIRC CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1174, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.000317514664054919
tcga-mss-msi-inferred-no-cms: Analyzing CIITA CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1322, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.00382284393624789
tcga-mss-msi-inferred-no-cms: Analyzing wnt CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2184, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.219707786356691
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2196, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.198888989985768
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2085, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.390023118654653
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1165, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.00026881143291545
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1235, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.000937299404455511
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1261, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.00145106761387445
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1180, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.000354447122367704
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1290, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.00232266056549788
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1337, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.00479265359664384
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1143, n_CMS2-MT = 41, n_CMS2-WT = 94, p = 0.000177609080346054
tcga-mss-msi-inferred-no-cms: Analyzing CIRC CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 207, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.69081929336732
tcga-mss-msi-inferred-no-cms: Analyzing CIITA CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 137, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.0476125740120781
tcga-mss-msi-inferred-no-cms: Analyzing wnt CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 299, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.102489874232738
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 267, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.363408106677409
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens CMS2-MT vs CMS3-MT using Wilcoxon rank sum test with continuity correction: W = 214.5, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.813953891301935
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 282, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.212839182926178
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 203, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.62674482703343
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 167, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.196699544517722
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 219, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.894595301742633
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 198, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.550384524009462
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 182, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.340280838033111
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 182, n_CMS2-MT = 41, n_CMS3-MT = 11, p = 0.340280838033111
tcga-mss-msi-inferred-no-cms: Analyzing CIRC CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 60, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.0443100130727866
tcga-mss-msi-inferred-no-cms: Analyzing CIITA CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 57, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.0343265652303365
tcga-mss-msi-inferred-no-cms: Analyzing wnt CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 155, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.323945085169619
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 122, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.987610142440941
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens CMS2-MT vs CMS3-WT using Wilcoxon rank sum test with continuity correction: W = 65, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.0667267409652141
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 82, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.202169521920829
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 50, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.0179107513401772
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 45, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.0106752242801981
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 51, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.0197532533655417
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 44, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.00956976031734546
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 29, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.00136734809625974
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 52, n_CMS2-MT = 41, n_CMS3-WT = 6, p = 0.0217492351390766
tcga-mss-msi-inferred-no-cms: Analyzing CIRC CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 97, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 7.63705467281034e-08
tcga-mss-msi-inferred-no-cms: Analyzing CIITA CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 80, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 1.00202046120147e-08
tcga-mss-msi-inferred-no-cms: Analyzing wnt CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 747, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 4.66477224074526e-07
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 769, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 4.30962301603806e-08
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens CMS2-MT vs CMS4-MT using Wilcoxon rank sum test with continuity correction: W = 462, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 0.644654695752475
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 76, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 5.98101697567165e-09
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 81, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 1.13719759808388e-08
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 135, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 3.40486976304933e-06
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 59, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 5.46692746612342e-10
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 30, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 3.08934627942104e-12
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 52, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 1.82402316579179e-10
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 84, n_CMS2-MT = 41, n_CMS4-MT = 21, p = 1.65296016862437e-08
tcga-mss-msi-inferred-no-cms: Analyzing CIRC CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 164, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 1.64883998075595e-12
tcga-mss-msi-inferred-no-cms: Analyzing CIITA CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 314, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 9.91702266317277e-08
tcga-mss-msi-inferred-no-cms: Analyzing wnt CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 1490, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 7.81423651798596e-09
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 1471, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 2.62923519945471e-08
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 891, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 0.935788779099903
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 244, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 1.07584085272758e-09
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 182, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 8.25331840148176e-12
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 199, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 3.45732815144412e-11
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 119, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 1.75381436352743e-14
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 113, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 8.93886195014848e-15
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 128, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 4.66053158063655e-14
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 140, n_CMS2-MT = 41, n_CMS4-WT = 43, p = 1.61993046415862e-13

Computing linear model with interaction for CIRC
Computing linear model with interaction for CIITA
Computing linear model with interaction for wnt
Computing linear model with interaction for myc.sig
Computing linear model with interaction for neoantigens
Computing linear model with interaction for BATF3
Computing linear model with interaction for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model with interaction for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model with interaction for HALLMARK_COMPLEMENT
Computing linear model with interaction for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model with interaction for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model with interaction for HALLMARK_ALLOGRAFT_REJECTION
Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for neoantigens
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
tcga-mss-msi-inferred-no-cms: Analyzing CIRC CMS4 MT vs WT using Wilcoxon rank sum test: W = 435, n_MT = 21, n_WT = 43, p = 0.820503139725541
tcga-mss-msi-inferred-no-cms: Analyzing CIITA CMS4 MT vs WT using Wilcoxon rank sum test: W = 335, n_MT = 21, n_WT = 43, p = 0.0974311602090096
tcga-mss-msi-inferred-no-cms: Analyzing wnt CMS4 MT vs WT using Wilcoxon rank sum test: W = 484, n_MT = 21, n_WT = 43, p = 0.649835993865151
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig CMS4 MT vs WT using Wilcoxon rank sum test: W = 486, n_MT = 21, n_WT = 43, p = 0.629521849163063
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 486, n_MT = 21, n_WT = 43, p = 0.626782922983445
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 CMS4 MT vs WT using Wilcoxon rank sum test: W = 320, n_MT = 21, n_WT = 43, p = 0.0606763597539709
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test: W = 359, n_MT = 21, n_WT = 43, p = 0.189950364221571
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test: W = 413, n_MT = 21, n_WT = 43, p = 0.589721512626798
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT CMS4 MT vs WT using Wilcoxon rank sum test: W = 397, n_MT = 21, n_WT = 43, p = 0.443128936299061
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test: W = 369, n_MT = 21, n_WT = 43, p = 0.243172246472433
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test: W = 385, n_MT = 21, n_WT = 43, p = 0.348189090139301
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS4 MT vs WT using Wilcoxon rank sum test: W = 419, n_MT = 21, n_WT = 43, p = 0.649835993865151
tcga-mss-msi-inferred-no-cms: Analyzing CIRC CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2680, n_MT = 41, n_WT = 94, p = 0.000317514664054919
tcga-mss-msi-inferred-no-cms: Analyzing CIITA CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2532, n_MT = 41, n_WT = 94, p = 0.00382284393624789
tcga-mss-msi-inferred-no-cms: Analyzing wnt CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1670, n_MT = 41, n_WT = 94, p = 0.219707786356691
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1658, n_MT = 41, n_WT = 94, p = 0.198888989985768
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1728, n_MT = 41, n_WT = 94, p = 0.390023118654653
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2689, n_MT = 41, n_WT = 94, p = 0.00026881143291545
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2619, n_MT = 41, n_WT = 94, p = 0.000937299404455511
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2593, n_MT = 41, n_WT = 94, p = 0.00145106761387445
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2674, n_MT = 41, n_WT = 94, p = 0.000354447122367704
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2564, n_MT = 41, n_WT = 94, p = 0.00232266056549788
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2517, n_MT = 41, n_WT = 94, p = 0.00479265359664384
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2711, n_MT = 41, n_WT = 94, p = 0.000177609080346054
tcga-mss-msi-inferred-no-cms: Analyzing CIRC CMS3 MT vs WT using Wilcoxon rank sum test: W = 47, n_MT = 11, n_WT = 6, p = 0.180187459599224
tcga-mss-msi-inferred-no-cms: Analyzing CIITA CMS3 MT vs WT using Wilcoxon rank sum test: W = 37, n_MT = 11, n_WT = 6, p = 0.732546864899806
tcga-mss-msi-inferred-no-cms: Analyzing wnt CMS3 MT vs WT using Wilcoxon rank sum test: W = 38, n_MT = 11, n_WT = 6, p = 0.660471881060116
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig CMS3 MT vs WT using Wilcoxon rank sum test: W = 38, n_MT = 11, n_WT = 6, p = 0.660471881060116
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens CMS3 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 47.5, n_MT = 11, n_WT = 6, p = 0.15915597452002
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 CMS3 MT vs WT using Wilcoxon rank sum test: W = 51, n_MT = 11, n_WT = 6, p = 0.0782159017453135
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 47, n_MT = 11, n_WT = 6, p = 0.180187459599224
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 43, n_MT = 11, n_WT = 6, p = 0.350193923723336
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT CMS3 MT vs WT using Wilcoxon rank sum test: W = 47, n_MT = 11, n_WT = 6, p = 0.180187459599224
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 48, n_MT = 11, n_WT = 6, p = 0.148998060762767
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 53, n_MT = 11, n_WT = 6, p = 0.0476729153199741
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS3 MT vs WT using Wilcoxon rank sum test: W = 47, n_MT = 11, n_WT = 6, p = 0.180187459599224

Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for neoantigens
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
Computing rectum vs left
tcga-mss-msi-inferred-no-cms: Analyzing CIRC site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2215, n_rectum = 43, n_left = 118, p = 0.21929785206683
tcga-mss-msi-inferred-no-cms: Analyzing CIITA site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2243, n_rectum = 43, n_left = 118, p = 0.262111661753397
tcga-mss-msi-inferred-no-cms: Analyzing wnt site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 1966, n_rectum = 43, n_left = 118, p = 0.0292734494744372
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2122, n_rectum = 43, n_left = 118, p = 0.113254115674362
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2746, n_rectum = 43, n_left = 118, p = 0.425577654191663
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 1883, n_rectum = 43, n_left = 118, p = 0.0125279555215725
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2316, n_rectum = 43, n_left = 118, p = 0.399511864198462
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2362, n_rectum = 43, n_left = 118, p = 0.504941357622729
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2527, n_rectum = 43, n_left = 118, p = 0.971044825077366
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2583, n_rectum = 43, n_left = 118, p = 0.861985051625222
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2746, n_rectum = 43, n_left = 118, p = 0.425658184368623
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2283, n_rectum = 43, n_left = 118, p = 0.332754395567401
Computing right vs left
tcga-mss-msi-inferred-no-cms: Analyzing CIRC site: right vs leftWilcoxon rank sum test with continuity correction: W = 4039, n_right = 73, n_left = 118, p = 0.471189245752711
tcga-mss-msi-inferred-no-cms: Analyzing CIITA site: right vs leftWilcoxon rank sum test with continuity correction: W = 3917, n_right = 73, n_left = 118, p = 0.294100802630554
tcga-mss-msi-inferred-no-cms: Analyzing wnt site: right vs leftWilcoxon rank sum test with continuity correction: W = 3943, n_right = 73, n_left = 118, p = 0.327513931537614
tcga-mss-msi-inferred-no-cms: Analyzing myc.sig site: right vs leftWilcoxon rank sum test with continuity correction: W = 3839, n_right = 73, n_left = 118, p = 0.207932476602811
tcga-mss-msi-inferred-no-cms: Analyzing neoantigens site: right vs leftWilcoxon rank sum test with continuity correction: W = 3308, n_right = 73, n_left = 118, p = 0.0106151455194015
tcga-mss-msi-inferred-no-cms: Analyzing BATF3 site: right vs leftWilcoxon rank sum test with continuity correction: W = 3966, n_right = 73, n_left = 118, p = 0.359048197758634
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 4315, n_right = 73, n_left = 118, p = 0.983882066512942
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 4055, n_right = 73, n_left = 118, p = 0.498122148608201
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_COMPLEMENT site: right vs leftWilcoxon rank sum test with continuity correction: W = 4353, n_right = 73, n_left = 118, p = 0.902455481931492
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 4363, n_right = 73, n_left = 118, p = 0.881161997776746
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 4388, n_right = 73, n_left = 118, p = 0.82833535065673
tcga-mss-msi-inferred-no-cms: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: right vs leftWilcoxon rank sum test with continuity correction: W = 4063, n_right = 73, n_left = 118, p = 0.51188952785557

Plotting CIRC ~ site
Plotting CIITA ~ site
Plotting wnt ~ site
Plotting myc.sig ~ site
Plotting neoantigens ~ site
Plotting BATF3 ~ site
Plotting HALLMARK_IL6_JAK_STAT3_SIGNALING ~ site
Plotting HALLMARK_INTERFERON_GAMMA_RESPONSE ~ site
Plotting HALLMARK_COMPLEMENT ~ site
Plotting HALLMARK_INFLAMMATORY_RESPONSE ~ site
Plotting HALLMARK_IL2_STAT5_SIGNALING ~ site
Plotting HALLMARK_ALLOGRAFT_REJECTION ~ site
Number of rows analyzed: 20294
Number of columns analyzed: 289
tcga-mss-msi-annotated: 28 of 28 genes from data set analyzed in set CIRC: HLA-DQA1 HLA-DQA2 HLA-DRB5 CTLA4 PDCD1LG2 ICAM1 CD274 STAT1 IRF1 IFNG GNLY TBX21 CCL5 LAG3 CD247 ICOS IL18RAP CXCL9 CXCL10 HLA-DPB1 HLA-DPA1 HLA-DMB HLA-DRA HLA-DMA CD80 HLA-DOA CD4 HAVCR2
tcga-mss-msi-annotated: 85 of 88 genes from data set analyzed in set myc.sig: AKAP1 APEX1 BAX CAD CCKBR CCNB1 CCND2 CCT5 CDC25C CEBPZ CKS2 CSDA CTSC DDX10 DDX18 DDX5 DKC1 E2F1 EIF4A1 EIF4B ENO1 EXOSC8 FASN FOSL1 H2AFZ HSPA8 HSPD1 HSPE1 ID2 IMPA2 LTA4H MAT2A METTL1 MINA MSH2 MTHFD1 NAP1L1 NCL NME1 NPM1 NRAS NUP155 PA2G4 PCNA PHB POLD2 PPAT PPIA PPID PRDX3 PREP PRPS2 PSMB1 PTEN PYCR1 RPL10 RPL19 RPL22 RPL27 RPL27A RPL32 RPL5 RPL9 RPS13 RPS16 RPS19 RPS5 RPS6KA2 SFRS1 SFRS2 SFRS7 SHMT1 SLC25A3 SLC39A6 SNRPB SNRPD3 SRM TERT TFRC TOP1 TXN TYMS UBE2C UCHL1 UXT
tcga-mss-msi-annotated: 3 of 88 genes missing from data set analyzed in set myc.sig: DSCR2 HNRPA2B1 HSPA9B
tcga-mss-msi-annotated: 50 of 78 genes from data set analyzed in set wnt: PHLDA1 SLC7A5 CTPS BYSL SCD SOX4 WDR77 NLE1 PPIL1 CIRH1A ZNF511 ZNF593 DKC1 ODC1 AURKB WDR12 CDT1 NOC3L CAD XPOT YAP1 SRM NXT1 MRPS12 RHEB WDR3 CRTAP SF3A2 GEMIN5 HNRPDL TREX2 IMP4 HEATR1 SLC19A1 PDCD11 ASCL2 TDGF1 TBX3 EPHB3 ZNRF3 IL20RA RHOBTB3 GEMIN4 ID3 FUT4 PIGW APEX1 SRPRB ZNRD1 TFB2M
tcga-mss-msi-annotated: 28 of 78 genes missing from data set analyzed in set wnt: FLJ20315 NOB1P PSF1 PMSCL1 RNU3IP2 HIG2 C1orf33 LOC389362 HSPC111 MGC40397 LOC56902 SDCCAG16 FLJ10774 RAB9P40 RFP RRP41 C16orf35 CGI-96 C20orf64 C12orf14 NOL1 SKB1 C11orf5 MGC16824 ZNF278 RPC62 JTV1 ZNF339
tcga-mss-msi-annotated: 87 of 87 genes from data set analyzed in set HALLMARK_IL6_JAK_STAT3_SIGNALING: IL4R IL6ST STAT1 IL1R1 CSF2RB SOCS3 STAT3 OSMR IL2RG IFNGR1 TYK2 IL13RA1 TLR2 IFNGR2 IL10RB IL6 IL1R2 IL3RA IFNAR1 TNFRSF1A MYD88 ACVR1B CSF3R ITGB3 REG1A CXCL1 A2M CSF2RA IL15RA IRF9 PDGFC HAX1 BAK1 EBI3 INHBE CRLF2 TNFRSF1B CD14 PTPN1 PTPN2 IL1B CSF1 IL18R1 TNF PF4 CXCL13 LTBR FAS IL17RA CXCL10 IL9R STAM2 TNFRSF12A STAT2 HMOX1 LEPR CBL CD9 CXCL3 TGFB1 MAP3K8 ITGA4 CD38 JUN SOCS1 ACVRL1 PIM1 TNFRSF21 PIK3R5 GRB2 IRF1 DNTT CSF2 IL2RA PTPN11 IL12RB1 CCR1 CNTFR PLA2G2A CXCL9 CD44 IL7 CXCL11 CCL7 LTB IL17RB CD36
tcga-mss-msi-annotated: 200 of 200 genes from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: STAT1 ISG15 IFIT1 MX1 IFIT3 IFI35 IRF7 IFIT2 OAS2 TAP1 EIF2AK2 RSAD2 MX2 IRF1 OAS3 TNFSF10 IRF9 CXCL10 IFI44 BST2 XAF1 SP110 OASL PSMB8 IFI44L IFITM3 DDX60 LGALS3BP GBP4 IRF8 PSMB9 PML IFIH1 UBE2L6 IFI27 ADAR LY6E STAT2 CXCL9 IL10RA PLA2G4A TRIM21 USP18 PTGS2 EPSTI1 C1S DDX58 IL15 NLRC5 NMI IDO1 PSMB10 CXCL11 ITGB7 SAMHD1 HERC6 CMPK2 SAMD9L RTP4 PTPN2 PARP14 TNFAIP2 IFITM2 PLSCR1 SOCS1 CASP1 ICAM1 WARS PSME1 ISG20 IRF2 TRIM14 FCGR1A MARCH1 SOCS3 JAK2 HLA-DMA PARP12 TNFAIP6 TRIM26 VCAM1 CD274 CIITA NAMPT SELP GPR18 FPR1 PRIC285 PSME2 SERPING1 CCL5 RNF31 SOD2 TRIM25 LAP3 PSMA3 RNF213 PELI1 CFB CD86 TXNIP HLA-DQA1 GCH1 PNP CCL7 PTPN6 SPPL2A IL4R PNPT1 DHX58 BTG1 CASP8 IFI30 CCL2 FGL2 CASP7 SECTM1 IL15RA CD40 TRAFD1 HLA-DRB1 GBP6 LCP2 HLA-G MT2A RIPK1 KLRK1 UPP1 PSMB2 TDRD7 HIF1A EIF4E3 VAMP8 PFKP CD38 ZBP1 BANK1 TOR1B RBCK1 PDE4B MVP IL7 BPGM FTSJD2 AUTS2 B2M RIPK2 CD69 MYD88 PSMA2 PIM1 NOD1 CFH TAPBP SLC25A28 PTPN1 TNFAIP3 SSPN NUP93 MTHFD2 CDKN1A IRF4 NFKB1 BATF2 HLA-B LATS2 IRF5 SLAMF7 ISOC1 P2RY14 STAT3 NCOA3 HLA-A IL6 GZMA IFNAR2 CD74 RAPGEF6 CASP4 FAS OGFR ARL4A SRI LYSMD2 CSF2RB ST3GAL5 C1R CASP3 CMKLR1 NFKBIA METTL7B ST8SIA4 XCL1 IL2RB VAMP5 IL18BP ZNFX1 ARID5B APOL6 STAT4
tcga-mss-msi-annotated: 200 of 200 genes from data set analyzed in set HALLMARK_COMPLEMENT: C2 C1S CFB C1R SERPINE1 MMP14 SERPING1 CTSL1 F5 MMP13 F7 CTSS LGMN PLG C1QA CASP1 GZMA ADAM9 CALM3 C1QC TIMP1 DPP4 KLK1 KLKB1 CD59 CR2 MMP15 LAP3 SPOCK2 F10 CTSB SERPINA1 CTSO CD40LG CBLB PDP1 C4BPB PLEK GP9 PLAUR C3 F2 CASP4 STX4 CTSC USP15 CR1 DUSP6 SERPINB2 GPD2 CFH FN1 CD36 CA2 PSMB9 APOBEC3G FCN1 GZMK PDGFB CLU CASP10 LRP1 CTSD S100A9 WAS BRPF3 PLAT CDA MT3 CASP7 PRSS36 PFN1 GZMB RNF4 ZEB1 CASP5 IRF1 PGCP CDK5R1 ATOX1 PIK3CA TMPRSS6 CPM RCE1 CALM1 DOCK9 KYNU RASGRP1 USP14 LCP2 GP1BA KIF2A GNB4 LCK OLR1 PREP SEPX1 LTA4H ZFPM2 LYN ACTN2 SIRT6 APOC1 PRKCD ITGAM DGKH LTF MAFF KCNIP2 PCLO DOCK10 SH2B3 RABIF SRC HPCAL4 CD46 PRDM4 GNAI3 C9 PPP2CB IRF2 FYN JAK2 PLA2G4A PRCP USP8 RHOG L3MBTL4 LAMP2 PIM1 CXCL1 F3 GNAI2 CASP9 XPNPEP1 PLSCR1 IRF7 CD55 HSPA5 GNB2 DYRK2 PLA2G7 S100A12 GRB2 PHEX GNGT2 DOCK4 MMP12 KCNIP3 FDX1 TIMP2 MMP8 FCER1G ZFYVE20 ANXA5 CTSL2 GCA EHD1 PRSS3 COL4A2 CSRP1 PIK3R5 SERPINC1 ANG APOBEC3F GATA3 DUSP5 CASP3 USP16 CP PSEN1 LIPA PCSK9 DGKG GNG2 ME1 GMFB SCG3 PPP4C CCL5 CTSH F8 APOA4 IL6 AKAP10 ERAP2 VCPIP1 HSPA1A RAF1 NOTCH4 ADRA2B CEBPB HNF4A LGALS3 TNFAIP3 CDH13 ITIH1 TFPI2 PIK3CG S100A13
tcga-mss-msi-annotated: 200 of 200 genes from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: CXCL10 CCL2 CCL5 FPR1 CCL20 IL1A IL8 CCL7 CCL22 CXCL11 CCR7 EDN1 CD40 CXCL9 IL6 IL1B TLR2 IL1R1 CD69 ICAM1 CCRL2 AQP9 EREG C3AR1 GNA15 CMKLR1 PTGER4 LIF IL15 NAMPT OPRK1 ITGB8 PTAFR ADM PLAUR NFKB1 INHBA OSM TNFSF10 TNFSF15 IFNGR2 EMR1 IL12B CSF1 CXCL6 TNFRSF9 LYN ACVR2A LDLR BDKRB1 HRH1 F3 BST2 PTGIR CD55 CALCRL CSF3 GPR132 IL4R NLRP3 IL15RA ADORA2B GCH1 OLR1 PTGER2 CSF3R MYC RELA TNFAIP6 IL7R IL18 GABBR1 CD82 TNFSF9 NMUR1 IL2RB TLR1 LPAR1 IRAK2 RIPK2 MMP14 P2RX7 SLC11A2 SELL P2RY2 ABCA1 FFAR2 PROK2 GNAI3 TACR1 SLC7A1 CDKN1A CYBB TIMP1 HBEGF SCARF1 EBI3 NFKBIA SRI SLC7A2 CCL17 TLR3 APLNR OSMR IL10RA PSEN1 GPR183 ATP2B1 TNFRSF1B BEST1 GPC3 SCN1B ACVR1B HPN SEMA4D KLF6 CD48 CXCR6 SLC1A2 GP1BA TAPBP RGS16 SLAMF1 LCK HIF1A AHR NMI RHOG TPBG NPFFR2 IFNAR1 ICOSLG RASGRP1 IFITM1 KCNJ2 LY6E IL18R1 IL10 KCNA3 HAS2 DCBLD2 LAMP3 VIP CD70 RGS1 SLC31A1 ADRM1 KCNMB2 SERPINE1 MXD1 AXL MEFV PVR CCL24 PDE4B LCP2 PDPN IRF7 MET ATP2A2 SLC31A2 FZD5 ITGA5 SGMS2 MARCO CD14 EIF2AK2 ROS1 ATP2C1 NDP BTG2 MSR1 PTPRE RNF144B PCDH7 SPHK1 IL18RAP RTP4 RAF1 CHST2 ITGB3 KIF1B SELE NOD2 C5AR1 EMP3 CLEC5A TACR3 SLC4A4 MEP1A SELS LTA PIK3R5 STAB1 IRF1 ICAM4 P2RX4 ABI1 CX3CL1 SLC28A2
tcga-mss-msi-annotated: 198 of 200 genes from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: SOCS2 CISH PIM1 IL2RA TNFRSF4 SOCS1 TNFRSF9 XBP1 RRAGD HK2 PHLDA1 IL2RB CTLA4 NFIL3 CD83 IKZF2 IL10 TNFRSF18 DHRS3 ECM1 ADAM19 SLC2A3 HIPK2 BATF3 BHLHE40 PTGER2 DENND5A ITIH5 PHTF2 GADD45B NRP1 NCOA3 CD79B AHR TNFRSF1B NDRG1 BCL2L1 GABARAPL1 LIF TIAM1 BMPR2 MAP3K8 RHOB MYC S100A1 CAPG ST3GAL4 PENK IRF4 CST7 WLS TLR7 IKZF4 GBP4 RGS16 SPP1 IL13 SLC29A2 NFKBIZ IL4R MXD1 CSF2 FAH CTSZ ITGAE MUC1 MAPKAPK2 TNFRSF21 NT5E FLT3LG CCND2 TRAF1 LCLAT1 IL3RA CYFIP1 BCL2 FGL2 PRNP N6AMT2 PUS1 ITGAV NCS1 DCPS AMACR FAM126B PTH1R ODC1 IGF1R PTCH1 ENO3 CD81 MAFF EMP1 CDKN1C CAPN3 IL1R2 SYT11 TTC39B ANXA4 BATF P4HA1 GPR65 SLC1A5 IGF2R CKAP4 CCR4 CD44 P2RX4 GATA1 KLF6 ARL4A HOPX GPR83 ITGA6 CD48 SELP GLIPR2 SMPDL3A PLSCR1 FURIN SERPINB6 TNFSF11 GPX4 LRRC8C CCNE1 CASP3 SH3BGRL2 SNX9 PLEC BMP2 ICOS ALCAM LTB ENPP1 IL1RL1 MYO1C IFNGR1 PLIN2 IL18R1 AHNAK PRKCH TNFRSF8 SYNGR2 GALM POU2F1 EOMES NOP2 PTRH2 RHOH CDC6 MYO1E CXCL10 SNX14 IRF6 IL10RA MAP6 TNFSF10 SPRED2 SELL SERPINC1 CDCP1 RORA COCH CSF1 F2RL2 UCK2 CA2 IFITM3 UMPS HUWE1 COL6A1 ABCB1 RNH1 IRF8 GUCY1B3 AHCY PRAF2 GSTO1 TWSG1 CDC42SE2 PLAGL1 APLP1 AKAP2 PPAP2A SPRY4 SCN9A SHE PDCD2L CCND3 LRIG1 SWAP70 SLC39A8 RABGAP1L TGM2 PNP AGER ETV4 CD86
tcga-mss-msi-annotated: 2 of 200 genes missing from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: METTL20 CCDC164
tcga-mss-msi-annotated: 200 of 200 genes from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: PTPRC IL12B TGFB1 IL12A CD3E CD3D CD28 LYN HCLS1 IL18 CRTAM IFNG CD3G CD86 IL10 UBE2N BCL10 CD4 LCK NCK1 C2 HLA-A ITGB2 HLA-DQA1 CD1D CD80 HLA-DRA THY1 TLR1 HLA-G HLA-DMB IL7 IL4 TNF CD247 IL2 HLA-DMA STAT1 IRF4 SRGN INHBA TLR3 ZAP70 CD74 CD40 TRAF2 B2M BCL3 LTB IFNGR1 CCR5 CD40LG HLA-DOA GLMN IL6 HLA-E CD2 CCL5 FAS FASLG TLR6 PF4 TGFB2 CD79A INHBB ELANE SPI1 MAP3K7 IL15 CTSS CD47 PRF1 IL12RB1 LCP2 SOCS1 CDKN2A STAT4 CD7 HLA-DOB CD8A ICAM1 CCL4 GZMB CSF1 IL11 STAB1 IL2RA NLRP3 CCND3 EIF3A SIT1 IFNAR2 HDAC9 CARTPT TRAT1 CCL22 APBB1 FYB IL1B TIMP1 RPS19 JAK2 KRT1 WARS IFNGR2 CCR2 EREG MMP9 EGFR IL16 CFP WAS ITGAL KLRD1 RARS TLR2 CCND2 IL2RG ETS1 ITK NCR1 MAP4K1 CCL19 PSMB10 RPL39 EIF3J ABCE1 CD8B F2 ELF4 LY86 FCGR2B GBP2 PRKCG RPS9 MTIF2 GZMA AARS CD96 CSK HIF1A CCL2 ICOSLG NPM1 IL4R CCL11 NME1 FLNA GPR65 ACHE EIF3D IGSF6 F2R IL13 TAP1 DARS IRF7 ACVR2A CXCR3 PRKCB CXCL9 PTPN6 NCF4 UBE2D1 LIF CCR1 MBL2 DEGS1 TPD52 AKT1 RIPK2 IKBKB GCNT1 SOCS5 IRF8 TAP2 EIF4G3 ABI1 CCL7 IL2RB BRCA1 FGR IL18RAP MRPL3 CXCL13 CAPG EIF5A RPS3A GALNT1 ST8SIA4 CCL13 RPL3L LY75 TAPBP NOS2 RPL9 BCAT1 IL9 IL27RA DYRK3
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
tcga-mss-msi-annotated wnt vs CIRC: t = -6.48169351043605 df = 287 nrow = 289 cor = -0.357340623456176 pval = 3.94381010590036e-10
tcga-mss-msi-annotated tak1 vs CIRC: t = -1.28667906107693 df = 287 nrow = 289 cor = -0.0757321493474332 pval = 0.199243045098411
tcga-mss-msi-annotated wnt vs myc.sig: t = 32.495758885224 df = 287 nrow = 289 cor = 0.886732906569273 pval = 3.57071642866538e-98
tcga-mss-msi-annotated CIRC vs neoantigens: tcga-mss-msi-annotated: Analyzing CIRC vs neoantigens using Fisher's Exact Test for Count Data: p = 0.327160397905222 n = 288

tcga-mss-msi-annotated: Analyzing CIRC vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11491, n_WT = 178, n_MT = 111, p = 0.0196945062875836
tcga-mss-msi-annotated: Analyzing CIITA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10796, n_WT = 178, n_MT = 111, p = 0.184729392864197
tcga-mss-msi-annotated: Analyzing wnt vs KRAS using Wilcoxon rank sum test with continuity correction: W = 9589, n_WT = 178, n_MT = 111, p = 0.675248086819904
tcga-mss-msi-annotated: Analyzing myc.sig vs KRAS using Wilcoxon rank sum test with continuity correction: W = 9412, n_WT = 178, n_MT = 111, p = 0.499608605777798
tcga-mss-msi-annotated: Analyzing neoantigens vs KRAS using Wilcoxon rank sum test with continuity correction: W = 8459, n_WT = 177, n_MT = 111, p = 0.0473545964186358
tcga-mss-msi-annotated: Analyzing BATF3 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11995, n_WT = 178, n_MT = 111, p = 0.00220236699431984
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11034, n_WT = 178, n_MT = 111, p = 0.0947690910758984
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10848, n_WT = 178, n_MT = 111, p = 0.161038902539672
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11019, n_WT = 178, n_MT = 111, p = 0.0991368945856998
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10800, n_WT = 178, n_MT = 111, p = 0.182820177090512
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10722, n_WT = 178, n_MT = 111, p = 0.222752218424224
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11395, n_WT = 178, n_MT = 111, p = 0.028293759208868

Computing CIRC ~ KRAS
Computing CIITA ~ KRAS
Computing wnt ~ KRAS
Computing myc.sig ~ KRAS
Computing neoantigens ~ KRAS
Computing BATF3 ~ KRAS
Computing HALLMARK_IL6_JAK_STAT3_SIGNALING ~ KRAS
Computing HALLMARK_INTERFERON_GAMMA_RESPONSE ~ KRAS
Computing HALLMARK_COMPLEMENT ~ KRAS
Computing HALLMARK_INFLAMMATORY_RESPONSE ~ KRAS
Computing HALLMARK_IL2_STAT5_SIGNALING ~ KRAS
Computing HALLMARK_ALLOGRAFT_REJECTION ~ KRAS
tcga-mss-msi-annotated: Analyzing CIRC CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1194, n_CMS2 = 134, n_CMS1 = 11, p = 0.000652404484588809
tcga-mss-msi-annotated: Analyzing CIITA CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1212, n_CMS2 = 134, n_CMS1 = 11, p = 0.000395229377171277
tcga-mss-msi-annotated: Analyzing wnt CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 640, n_CMS2 = 134, n_CMS1 = 11, p = 0.471157176472037
tcga-mss-msi-annotated: Analyzing myc.sig CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 659, n_CMS2 = 134, n_CMS1 = 11, p = 0.562779319742071
tcga-mss-msi-annotated: Analyzing neoantigens CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1120.5, n_CMS2 = 134, n_CMS1 = 11, p = 0.00347364973534146
tcga-mss-msi-annotated: Analyzing BATF3 CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 826, n_CMS2 = 134, n_CMS1 = 11, p = 0.508702824394282
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1034, n_CMS2 = 134, n_CMS1 = 11, p = 0.0268243834632529
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1188, n_CMS2 = 134, n_CMS1 = 11, p = 0.000768123554094448
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1120, n_CMS2 = 134, n_CMS1 = 11, p = 0.00428671450600656
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1027, n_CMS2 = 134, n_CMS1 = 11, p = 0.0306341678457116
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1037, n_CMS2 = 134, n_CMS1 = 11, p = 0.0253212688144617
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1056, n_CMS2 = 134, n_CMS1 = 11, p = 0.0173905369741357
tcga-mss-msi-annotated: Analyzing CIRC CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1896, n_CMS2 = 134, n_CMS3 = 35, p = 0.0818639847645432
tcga-mss-msi-annotated: Analyzing CIITA CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1828, n_CMS2 = 134, n_CMS3 = 35, p = 0.0450936176798174
tcga-mss-msi-annotated: Analyzing wnt CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 3281, n_CMS2 = 134, n_CMS3 = 35, p = 0.00028418470597493
tcga-mss-msi-annotated: Analyzing myc.sig CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2897, n_CMS2 = 134, n_CMS3 = 35, p = 0.0323900281988977
tcga-mss-msi-annotated: Analyzing neoantigens CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1980.5, n_CMS2 = 134, n_CMS3 = 35, p = 0.175905507483851
tcga-mss-msi-annotated: Analyzing BATF3 CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2562, n_CMS2 = 134, n_CMS3 = 35, p = 0.40095354781446
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1739, n_CMS2 = 134, n_CMS3 = 35, p = 0.0188209342166727
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1665, n_CMS2 = 134, n_CMS3 = 35, p = 0.00838540297505891
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1795, n_CMS2 = 134, n_CMS3 = 35, p = 0.0330228960807365
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1570, n_CMS2 = 134, n_CMS3 = 35, p = 0.00265842637653757
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1488, n_CMS2 = 134, n_CMS3 = 35, p = 0.000891116815648571
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1760, n_CMS2 = 134, n_CMS3 = 35, p = 0.0233542958640143
tcga-mss-msi-annotated: Analyzing CIRC CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2107, n_CMS2 = 134, n_CMS4 = 81, p = 5.91150645874666e-14
tcga-mss-msi-annotated: Analyzing CIITA CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2561, n_CMS2 = 134, n_CMS4 = 81, p = 8.99767699074349e-11
tcga-mss-msi-annotated: Analyzing wnt CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 9120, n_CMS2 = 134, n_CMS4 = 81, p = 6.60445069877618e-17
tcga-mss-msi-annotated: Analyzing myc.sig CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 8946, n_CMS2 = 134, n_CMS4 = 81, p = 1.71699989545954e-15
tcga-mss-msi-annotated: Analyzing neoantigens CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 5168, n_CMS2 = 134, n_CMS4 = 81, p = 0.619702397780442
tcga-mss-msi-annotated: Analyzing BATF3 CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2445, n_CMS2 = 134, n_CMS4 = 81, p = 1.52672238992108e-11
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2144, n_CMS2 = 134, n_CMS4 = 81, p = 1.11661905323579e-13
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2547, n_CMS2 = 134, n_CMS4 = 81, p = 7.28969668107785e-11
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1381, n_CMS2 = 134, n_CMS4 = 81, p = 5.56167614957161e-20
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1357, n_CMS2 = 134, n_CMS4 = 81, p = 3.35913499864904e-20
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1380, n_CMS2 = 134, n_CMS4 = 81, p = 5.44636675099311e-20
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2069, n_CMS2 = 134, n_CMS4 = 81, p = 3.05428483436689e-14


tcga-mss-msi-annotated: Analyzing CIRC CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 195, n_CMS2 = 41, n_CMS1 = 5, p = 0.000164872763457192
tcga-mss-msi-annotated: Analyzing CIITA CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 166, n_CMS2 = 41, n_CMS1 = 5, p = 0.0227480642040804
tcga-mss-msi-annotated: Analyzing wnt CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 91, n_CMS2 = 41, n_CMS1 = 5, p = 0.70640100265985
tcga-mss-msi-annotated: Analyzing myc.sig CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 81, n_CMS2 = 41, n_CMS1 = 5, p = 0.470206908022884
tcga-mss-msi-annotated: Analyzing neoantigens CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 138.5, n_CMS2 = 41, n_CMS1 = 5, p = 0.210125907077532
tcga-mss-msi-annotated: Analyzing BATF3 CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 151, n_CMS2 = 41, n_CMS1 = 5, p = 0.0908215478488482
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 174, n_CMS2 = 41, n_CMS1 = 5, p = 0.00886227579857509
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 201, n_CMS2 = 41, n_CMS1 = 5, p = 1.75086120485514e-05
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 176, n_CMS2 = 41, n_CMS1 = 5, p = 0.00678750527082175
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 169, n_CMS2 = 41, n_CMS1 = 5, p = 0.0163092721232256
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 173, n_CMS2 = 41, n_CMS1 = 5, p = 0.0100747471829373
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 180, n_CMS2 = 41, n_CMS1 = 5, p = 0.00379645071252756
tcga-mss-msi-annotated: Analyzing CIRC CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 284, n_CMS2 = 41, n_CMS3 = 23, p = 0.00817148291138145
tcga-mss-msi-annotated: Analyzing CIITA CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 289, n_CMS2 = 41, n_CMS3 = 23, p = 0.0101263134924805
tcga-mss-msi-annotated: Analyzing wnt CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 710, n_CMS2 = 41, n_CMS3 = 23, p = 0.000649803667440001
tcga-mss-msi-annotated: Analyzing myc.sig CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 659, n_CMS2 = 41, n_CMS3 = 23, p = 0.00817148291138145
tcga-mss-msi-annotated: Analyzing neoantigens CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 433, n_CMS2 = 41, n_CMS3 = 23, p = 0.594862093429313
tcga-mss-msi-annotated: Analyzing BATF3 CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 475, n_CMS2 = 41, n_CMS3 = 23, p = 0.966782014551187
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 292, n_CMS2 = 41, n_CMS3 = 23, p = 0.0114860710658419
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 241, n_CMS2 = 41, n_CMS3 = 23, p = 0.00101007230857561
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 340, n_CMS2 = 41, n_CMS3 = 23, p = 0.0665449470009632
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 273, n_CMS2 = 41, n_CMS3 = 23, p = 0.0049957822013866
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 268, n_CMS2 = 41, n_CMS3 = 23, p = 0.00395718455982801
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 240, n_CMS2 = 41, n_CMS3 = 23, p = 0.000956792273960308
tcga-mss-msi-annotated: Analyzing CIRC CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 114, n_CMS2 = 41, n_CMS4 = 25, p = 1.10719811001573e-08
tcga-mss-msi-annotated: Analyzing CIITA CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 110, n_CMS2 = 41, n_CMS4 = 25, p = 7.21468388832661e-09
tcga-mss-msi-annotated: Analyzing wnt CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 908, n_CMS2 = 41, n_CMS4 = 25, p = 1.51700332865419e-08
tcga-mss-msi-annotated: Analyzing myc.sig CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 927, n_CMS2 = 41, n_CMS4 = 25, p = 1.87610296772545e-09
tcga-mss-msi-annotated: Analyzing neoantigens CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 513, n_CMS2 = 41, n_CMS4 = 25, p = 1
tcga-mss-msi-annotated: Analyzing BATF3 CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 93, n_CMS2 = 41, n_CMS4 = 25, p = 1.0388837191626e-09
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 92, n_CMS2 = 41, n_CMS4 = 25, p = 9.20966361344669e-10
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 159, n_CMS2 = 41, n_CMS4 = 25, p = 7.64732999616803e-07
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 63, n_CMS2 = 41, n_CMS4 = 25, p = 1.89010999221465e-11
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 36, n_CMS2 = 41, n_CMS4 = 25, p = 1.88187841846588e-13
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 54, n_CMS2 = 41, n_CMS4 = 25, p = 4.6639490221166e-12
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 103, n_CMS2 = 41, n_CMS4 = 25, p = 3.32743916568874e-09

tcga-mss-msi-annotated: Analyzing CIRC CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1157, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.000298770014942816
tcga-mss-msi-annotated: Analyzing CIITA CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1300, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.00343435427649365
tcga-mss-msi-annotated: Analyzing wnt CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2144, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.252500571360156
tcga-mss-msi-annotated: Analyzing myc.sig CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2162, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.218246047020678
tcga-mss-msi-annotated: Analyzing neoantigens CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2044.5, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.441306704341132
tcga-mss-msi-annotated: Analyzing BATF3 CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1147, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.000247680240225141
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1212, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.000805755579556724
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1224, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.000991699814615875
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1198, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.000629891589813105
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1246, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.00143931177144646
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1286, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.00275780295400965
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1109, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.000119027530235952
tcga-mss-msi-annotated: Analyzing CIRC CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 10, n_CMS2-MT = 41, n_CMS1-MT = 5, p = 0.000164872763457192
tcga-mss-msi-annotated: Analyzing CIITA CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 39, n_CMS2-MT = 41, n_CMS1-MT = 5, p = 0.0227480642040804
tcga-mss-msi-annotated: Analyzing wnt CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 114, n_CMS2-MT = 41, n_CMS1-MT = 5, p = 0.70640100265985
tcga-mss-msi-annotated: Analyzing myc.sig CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 124, n_CMS2-MT = 41, n_CMS1-MT = 5, p = 0.470206908022884
tcga-mss-msi-annotated: Analyzing neoantigens CMS2-MT vs CMS1-MT using Wilcoxon rank sum test with continuity correction: W = 66.5, n_CMS2-MT = 41, n_CMS1-MT = 5, p = 0.210125907077532
tcga-mss-msi-annotated: Analyzing BATF3 CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 54, n_CMS2-MT = 41, n_CMS1-MT = 5, p = 0.0908215478488482
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 31, n_CMS2-MT = 41, n_CMS1-MT = 5, p = 0.00886227579857509
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 4, n_CMS2-MT = 41, n_CMS1-MT = 5, p = 1.75086120485514e-05
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 29, n_CMS2-MT = 41, n_CMS1-MT = 5, p = 0.00678750527082175
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 36, n_CMS2-MT = 41, n_CMS1-MT = 5, p = 0.0163092721232256
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 32, n_CMS2-MT = 41, n_CMS1-MT = 5, p = 0.0100747471829373
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 25, n_CMS2-MT = 41, n_CMS1-MT = 5, p = 0.00379645071252756
tcga-mss-msi-annotated: Analyzing CIRC CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 30, n_CMS2-MT = 41, n_CMS1-WT = 6, p = 0.00159197986360605
tcga-mss-msi-annotated: Analyzing CIITA CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 5, n_CMS2-MT = 41, n_CMS1-WT = 6, p = 3.53897477577102e-06
tcga-mss-msi-annotated: Analyzing wnt CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 158, n_CMS2-MT = 41, n_CMS1-WT = 6, p = 0.279176122946964
tcga-mss-msi-annotated: Analyzing myc.sig CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 150, n_CMS2-MT = 41, n_CMS1-WT = 6, p = 0.407808356692895
tcga-mss-msi-annotated: Analyzing neoantigens CMS2-MT vs CMS1-WT using Wilcoxon rank sum test with continuity correction: W = 44.5, n_CMS2-MT = 41, n_CMS1-WT = 6, p = 0.0128728270353521
tcga-mss-msi-annotated: Analyzing BATF3 CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 86, n_CMS2-MT = 41, n_CMS1-WT = 6, p = 0.251661152850835
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 36, n_CMS2-MT = 41, n_CMS1-WT = 6, p = 0.00367401460274123
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 36, n_CMS2-MT = 41, n_CMS1-WT = 6, p = 0.00367401460274123
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 27, n_CMS2-MT = 41, n_CMS1-WT = 6, p = 0.00099705957761591
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 45, n_CMS2-MT = 41, n_CMS1-WT = 6, p = 0.0106752242801981
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 60, n_CMS2-MT = 41, n_CMS1-WT = 6, p = 0.0443100130727866
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 48, n_CMS2-MT = 41, n_CMS1-WT = 6, p = 0.014645208931292
tcga-mss-msi-annotated: Analyzing CIRC CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 284, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.00817148291138145
tcga-mss-msi-annotated: Analyzing CIITA CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 289, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.0101263134924805
tcga-mss-msi-annotated: Analyzing wnt CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 710, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.000649803667440001
tcga-mss-msi-annotated: Analyzing myc.sig CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 659, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.00817148291138145
tcga-mss-msi-annotated: Analyzing neoantigens CMS2-MT vs CMS3-MT using Wilcoxon rank sum test with continuity correction: W = 433, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.594862093429313
tcga-mss-msi-annotated: Analyzing BATF3 CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 475, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.966782014551187
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 292, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.0114860710658419
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 241, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.00101007230857561
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 340, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.0665449470009632
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 273, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.0049957822013866
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 268, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.00395718455982801
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 240, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.000956792273960308
tcga-mss-msi-annotated: Analyzing CIRC CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 80, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.000209402696505999
tcga-mss-msi-annotated: Analyzing CIITA CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 101, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.00148802097607671
tcga-mss-msi-annotated: Analyzing wnt CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 343, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.0391350009745337
tcga-mss-msi-annotated: Analyzing myc.sig CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 306, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.208986563515792
tcga-mss-msi-annotated: Analyzing neoantigens CMS2-MT vs CMS3-WT using Wilcoxon rank sum test with continuity correction: W = 215.5, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.523657178039454
tcga-mss-msi-annotated: Analyzing BATF3 CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 120, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.00646560459456862
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 58, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 1.61675286877525e-05
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 72, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 8.84742280923541e-05
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 76, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.00013733344839243
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 46, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 2.94281719836076e-06
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 48, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 3.98444975605763e-06
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 68, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 5.5918062287926e-05
tcga-mss-msi-annotated: Analyzing CIRC CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 114, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 1.10719811001573e-08
tcga-mss-msi-annotated: Analyzing CIITA CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 110, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 7.21468388832661e-09
tcga-mss-msi-annotated: Analyzing wnt CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 908, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 1.51700332865419e-08
tcga-mss-msi-annotated: Analyzing myc.sig CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 927, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 1.87610296772545e-09
tcga-mss-msi-annotated: Analyzing neoantigens CMS2-MT vs CMS4-MT using Wilcoxon rank sum test with continuity correction: W = 513, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 1
tcga-mss-msi-annotated: Analyzing BATF3 CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 93, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 1.0388837191626e-09
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 92, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 9.20966361344669e-10
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 159, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 7.64732999616803e-07
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 63, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 1.89010999221465e-11
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 36, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 1.88187841846588e-13
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 54, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 4.6639490221166e-12
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 103, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 3.32743916568874e-09
tcga-mss-msi-annotated: Analyzing CIRC CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 168, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 8.48215538892192e-13
tcga-mss-msi-annotated: Analyzing CIITA CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 338, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 3.38703711312013e-09
tcga-mss-msi-annotated: Analyzing wnt CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 2002, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 4.57668300652255e-10
tcga-mss-msi-annotated: Analyzing myc.sig CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 1975, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 1.58181688235684e-09
tcga-mss-msi-annotated: Analyzing neoantigens CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 1181, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 0.812344687460441
tcga-mss-msi-annotated: Analyzing BATF3 CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 250, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 5.590469888194e-11
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 211, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 7.96881180835455e-12
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 217, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 1.08094572429755e-11
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 138, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 1.67816630701288e-13
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 125, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 8.19494295403476e-14
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 140, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 1.87233665413458e-13
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 133, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 1.27515812990536e-13

Computing linear model with interaction for CIRC
Computing linear model with interaction for CIITA
Computing linear model with interaction for wnt
Computing linear model with interaction for myc.sig
Computing linear model with interaction for neoantigens
Computing linear model with interaction for BATF3
Computing linear model with interaction for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model with interaction for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model with interaction for HALLMARK_COMPLEMENT
Computing linear model with interaction for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model with interaction for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model with interaction for HALLMARK_ALLOGRAFT_REJECTION
Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for neoantigens
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
tcga-mss-msi-annotated: Analyzing CIRC CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 771, n_MT = 25, n_WT = 56, p = 0.471038684776457
tcga-mss-msi-annotated: Analyzing CIITA CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 610, n_MT = 25, n_WT = 56, p = 0.360167716906832
tcga-mss-msi-annotated: Analyzing wnt CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 670, n_MT = 25, n_WT = 56, p = 0.762951523885058
tcga-mss-msi-annotated: Analyzing myc.sig CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 708, n_MT = 25, n_WT = 56, p = 0.9388782785685
tcga-mss-msi-annotated: Analyzing neoantigens CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 683, n_MT = 25, n_WT = 56, p = 0.866016636827914
tcga-mss-msi-annotated: Analyzing BATF3 CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 649, n_MT = 25, n_WT = 56, p = 0.605637480931673
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 624, n_MT = 25, n_WT = 56, p = 0.440167772653616
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 713, n_MT = 25, n_WT = 56, p = 0.898307520633756
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 671, n_MT = 25, n_WT = 56, p = 0.770758246166222
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 632, n_MT = 25, n_WT = 56, p = 0.49011988778829
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 626, n_MT = 25, n_WT = 56, p = 0.452374667989134
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 732, n_MT = 25, n_WT = 56, p = 0.747410923408059
tcga-mss-msi-annotated: Analyzing CIRC CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2656, n_MT = 41, n_WT = 93, p = 0.000298770014942816
tcga-mss-msi-annotated: Analyzing CIITA CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2513, n_MT = 41, n_WT = 93, p = 0.00343435427649365
tcga-mss-msi-annotated: Analyzing wnt CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1669, n_MT = 41, n_WT = 93, p = 0.252500571360156
tcga-mss-msi-annotated: Analyzing myc.sig CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1651, n_MT = 41, n_WT = 93, p = 0.218246047020678
tcga-mss-msi-annotated: Analyzing neoantigens CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1727.5, n_MT = 41, n_WT = 93, p = 0.441306704341132
tcga-mss-msi-annotated: Analyzing BATF3 CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2666, n_MT = 41, n_WT = 93, p = 0.000247680240225141
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2601, n_MT = 41, n_WT = 93, p = 0.000805755579556724
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2589, n_MT = 41, n_WT = 93, p = 0.000991699814615875
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2615, n_MT = 41, n_WT = 93, p = 0.000629891589813105
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2567, n_MT = 41, n_WT = 93, p = 0.00143931177144646
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2527, n_MT = 41, n_WT = 93, p = 0.00275780295400965
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2704, n_MT = 41, n_WT = 93, p = 0.000119027530235952
tcga-mss-msi-annotated: Analyzing CIRC CMS3 MT vs WT using Wilcoxon rank sum test: W = 169, n_MT = 23, n_WT = 12, p = 0.29378493041779
tcga-mss-msi-annotated: Analyzing CIITA CMS3 MT vs WT using Wilcoxon rank sum test: W = 160, n_MT = 23, n_WT = 12, p = 0.460505855461035
tcga-mss-msi-annotated: Analyzing wnt CMS3 MT vs WT using Wilcoxon rank sum test: W = 147, n_MT = 23, n_WT = 12, p = 0.770966011458062
tcga-mss-msi-annotated: Analyzing myc.sig CMS3 MT vs WT using Wilcoxon rank sum test: W = 151, n_MT = 23, n_WT = 12, p = 0.668423000585534
tcga-mss-msi-annotated: Analyzing neoantigens CMS3 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 139, n_MT = 23, n_WT = 12, p = 0.986132610427574
tcga-mss-msi-annotated: Analyzing BATF3 CMS3 MT vs WT using Wilcoxon rank sum test: W = 197, n_MT = 23, n_WT = 12, p = 0.0408102349350795
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 175, n_MT = 23, n_WT = 12, p = 0.207875949216
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 159, n_MT = 23, n_WT = 12, p = 0.481734803615979
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS3 MT vs WT using Wilcoxon rank sum test: W = 176, n_MT = 23, n_WT = 12, p = 0.195487995831515
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 186, n_MT = 23, n_WT = 12, p = 0.0992765909307164
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 188, n_MT = 23, n_WT = 12, p = 0.0854531945404156
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS3 MT vs WT using Wilcoxon rank sum test: W = 164, n_MT = 23, n_WT = 12, p = 0.380873315870371
tcga-mss-msi-annotated: Analyzing CIRC CMS1 MT vs WT using Wilcoxon rank sum test: W = 14, n_MT = 5, n_WT = 6, p = 0.930735930735931
tcga-mss-msi-annotated: Analyzing CIITA CMS1 MT vs WT using Wilcoxon rank sum test: W = 19, n_MT = 5, n_WT = 6, p = 0.536796536796537
tcga-mss-msi-annotated: Analyzing wnt CMS1 MT vs WT using Wilcoxon rank sum test: W = 12, n_MT = 5, n_WT = 6, p = 0.662337662337662
tcga-mss-msi-annotated: Analyzing myc.sig CMS1 MT vs WT using Wilcoxon rank sum test: W = 12, n_MT = 5, n_WT = 6, p = 0.662337662337662
tcga-mss-msi-annotated: Analyzing neoantigens CMS1 MT vs WT using Wilcoxon rank sum test: W = 21, n_MT = 5, n_WT = 6, p = 0.329004329004329
tcga-mss-msi-annotated: Analyzing BATF3 CMS1 MT vs WT using Wilcoxon rank sum test: W = 14, n_MT = 5, n_WT = 6, p = 0.930735930735931
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS1 MT vs WT using Wilcoxon rank sum test: W = 9, n_MT = 5, n_WT = 6, p = 0.329004329004329
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS1 MT vs WT using Wilcoxon rank sum test: W = 14, n_MT = 5, n_WT = 6, p = 0.930735930735931
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT CMS1 MT vs WT using Wilcoxon rank sum test: W = 10, n_MT = 5, n_WT = 6, p = 0.428571428571429
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS1 MT vs WT using Wilcoxon rank sum test: W = 10, n_MT = 5, n_WT = 6, p = 0.428571428571429
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS1 MT vs WT using Wilcoxon rank sum test: W = 9, n_MT = 5, n_WT = 6, p = 0.329004329004329
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS1 MT vs WT using Wilcoxon rank sum test: W = 12, n_MT = 5, n_WT = 6, p = 0.662337662337662

Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for neoantigens
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
Computing rectum vs left
tcga-mss-msi-annotated: Analyzing CIRC site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3071, n_rectum = 58, n_left = 126, p = 0.082668688559254
tcga-mss-msi-annotated: Analyzing CIITA site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2953, n_rectum = 58, n_left = 126, p = 0.0368919659677559
tcga-mss-msi-annotated: Analyzing wnt site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3233, n_rectum = 58, n_left = 126, p = 0.210289270428802
tcga-mss-msi-annotated: Analyzing myc.sig site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3248, n_rectum = 58, n_left = 126, p = 0.227015792756712
tcga-mss-msi-annotated: Analyzing neoantigens site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3489, n_rectum = 58, n_left = 126, p = 0.62402181659268
tcga-mss-msi-annotated: Analyzing BATF3 site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2709, n_rectum = 58, n_left = 126, p = 0.00489456427659004
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3307, n_rectum = 58, n_left = 126, p = 0.301928483010129
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3290, n_rectum = 58, n_left = 126, p = 0.278828957615822
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3461, n_rectum = 58, n_left = 126, p = 0.566303695317303
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3588, n_rectum = 58, n_left = 126, p = 0.845283177044552
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3909, n_rectum = 58, n_left = 126, p = 0.448321337973614
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3206, n_rectum = 58, n_left = 126, p = 0.182462932211287
Computing right vs left
tcga-mss-msi-annotated: Analyzing CIRC site: right vs leftWilcoxon rank sum test with continuity correction: W = 5611, n_right = 103, n_left = 126, p = 0.0785059080274324
tcga-mss-msi-annotated: Analyzing CIITA site: right vs leftWilcoxon rank sum test with continuity correction: W = 5400, n_right = 103, n_left = 126, p = 0.0290737623211798
tcga-mss-msi-annotated: Analyzing wnt site: right vs leftWilcoxon rank sum test with continuity correction: W = 6319, n_right = 103, n_left = 126, p = 0.733966398878356
tcga-mss-msi-annotated: Analyzing myc.sig site: right vs leftWilcoxon rank sum test with continuity correction: W = 6197, n_right = 103, n_left = 126, p = 0.55890490832787
tcga-mss-msi-annotated: Analyzing neoantigens site: right vs leftWilcoxon rank sum test with continuity correction: W = 4522, n_right = 103, n_left = 126, p = 0.000121071371193007
tcga-mss-msi-annotated: Analyzing BATF3 site: right vs leftWilcoxon rank sum test with continuity correction: W = 6175, n_right = 103, n_left = 126, p = 0.529624240531211
tcga-mss-msi-annotated: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 6027, n_right = 103, n_left = 126, p = 0.354796623969653
tcga-mss-msi-annotated: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 5681, n_right = 103, n_left = 126, p = 0.105432423019296
tcga-mss-msi-annotated: Analyzing HALLMARK_COMPLEMENT site: right vs leftWilcoxon rank sum test with continuity correction: W = 6061, n_right = 103, n_left = 126, p = 0.391359690372369
tcga-mss-msi-annotated: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 6079, n_right = 103, n_left = 126, p = 0.411610120764203
tcga-mss-msi-annotated: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 6159, n_right = 103, n_left = 126, p = 0.508830160845956
tcga-mss-msi-annotated: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: right vs leftWilcoxon rank sum test with continuity correction: W = 5652, n_right = 103, n_left = 126, p = 0.0935004260521103

Plotting CIRC ~ site
Plotting CIITA ~ site
Plotting wnt ~ site
Plotting myc.sig ~ site
Plotting neoantigens ~ site
Plotting BATF3 ~ site
Plotting HALLMARK_IL6_JAK_STAT3_SIGNALING ~ site
Plotting HALLMARK_INTERFERON_GAMMA_RESPONSE ~ site
Plotting HALLMARK_COMPLEMENT ~ site
Plotting HALLMARK_INFLAMMATORY_RESPONSE ~ site
Plotting HALLMARK_IL2_STAT5_SIGNALING ~ site
Plotting HALLMARK_ALLOGRAFT_REJECTION ~ site
Overlap of MSI and CMS1 in TCGA annotated:
     
      CMS1 CMS2 CMS3 CMS4 NOLBL
  msi   62    1   11    6     1
  mss   14  214   58  132    60
Number of rows analyzed: 20294
Number of columns analyzed: 278
tcga-mss-msi-annotated-no-cms1: 28 of 28 genes from data set analyzed in set CIRC: HLA-DQA1 HLA-DQA2 HLA-DRB5 CTLA4 PDCD1LG2 ICAM1 CD274 STAT1 IRF1 IFNG GNLY TBX21 CCL5 LAG3 CD247 ICOS IL18RAP CXCL9 CXCL10 HLA-DPB1 HLA-DPA1 HLA-DMB HLA-DRA HLA-DMA CD80 HLA-DOA CD4 HAVCR2
tcga-mss-msi-annotated-no-cms1: 85 of 88 genes from data set analyzed in set myc.sig: AKAP1 APEX1 BAX CAD CCKBR CCNB1 CCND2 CCT5 CDC25C CEBPZ CKS2 CSDA CTSC DDX10 DDX18 DDX5 DKC1 E2F1 EIF4A1 EIF4B ENO1 EXOSC8 FASN FOSL1 H2AFZ HSPA8 HSPD1 HSPE1 ID2 IMPA2 LTA4H MAT2A METTL1 MINA MSH2 MTHFD1 NAP1L1 NCL NME1 NPM1 NRAS NUP155 PA2G4 PCNA PHB POLD2 PPAT PPIA PPID PRDX3 PREP PRPS2 PSMB1 PTEN PYCR1 RPL10 RPL19 RPL22 RPL27 RPL27A RPL32 RPL5 RPL9 RPS13 RPS16 RPS19 RPS5 RPS6KA2 SFRS1 SFRS2 SFRS7 SHMT1 SLC25A3 SLC39A6 SNRPB SNRPD3 SRM TERT TFRC TOP1 TXN TYMS UBE2C UCHL1 UXT
tcga-mss-msi-annotated-no-cms1: 3 of 88 genes missing from data set analyzed in set myc.sig: DSCR2 HNRPA2B1 HSPA9B
tcga-mss-msi-annotated-no-cms1: 50 of 78 genes from data set analyzed in set wnt: PHLDA1 SLC7A5 CTPS BYSL SCD SOX4 WDR77 NLE1 PPIL1 CIRH1A ZNF511 ZNF593 DKC1 ODC1 AURKB WDR12 CDT1 NOC3L CAD XPOT YAP1 SRM NXT1 MRPS12 RHEB WDR3 CRTAP SF3A2 GEMIN5 HNRPDL TREX2 IMP4 HEATR1 SLC19A1 PDCD11 ASCL2 TDGF1 TBX3 EPHB3 ZNRF3 IL20RA RHOBTB3 GEMIN4 ID3 FUT4 PIGW APEX1 SRPRB ZNRD1 TFB2M
tcga-mss-msi-annotated-no-cms1: 28 of 78 genes missing from data set analyzed in set wnt: FLJ20315 NOB1P PSF1 PMSCL1 RNU3IP2 HIG2 C1orf33 LOC389362 HSPC111 MGC40397 LOC56902 SDCCAG16 FLJ10774 RAB9P40 RFP RRP41 C16orf35 CGI-96 C20orf64 C12orf14 NOL1 SKB1 C11orf5 MGC16824 ZNF278 RPC62 JTV1 ZNF339
tcga-mss-msi-annotated-no-cms1: 87 of 87 genes from data set analyzed in set HALLMARK_IL6_JAK_STAT3_SIGNALING: IL4R IL6ST STAT1 IL1R1 CSF2RB SOCS3 STAT3 OSMR IL2RG IFNGR1 TYK2 IL13RA1 TLR2 IFNGR2 IL10RB IL6 IL1R2 IL3RA IFNAR1 TNFRSF1A MYD88 ACVR1B CSF3R ITGB3 REG1A CXCL1 A2M CSF2RA IL15RA IRF9 PDGFC HAX1 BAK1 EBI3 INHBE CRLF2 TNFRSF1B CD14 PTPN1 PTPN2 IL1B CSF1 IL18R1 TNF PF4 CXCL13 LTBR FAS IL17RA CXCL10 IL9R STAM2 TNFRSF12A STAT2 HMOX1 LEPR CBL CD9 CXCL3 TGFB1 MAP3K8 ITGA4 CD38 JUN SOCS1 ACVRL1 PIM1 TNFRSF21 PIK3R5 GRB2 IRF1 DNTT CSF2 IL2RA PTPN11 IL12RB1 CCR1 CNTFR PLA2G2A CXCL9 CD44 IL7 CXCL11 CCL7 LTB IL17RB CD36
tcga-mss-msi-annotated-no-cms1: 200 of 200 genes from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: STAT1 ISG15 IFIT1 MX1 IFIT3 IFI35 IRF7 IFIT2 OAS2 TAP1 EIF2AK2 RSAD2 MX2 IRF1 OAS3 TNFSF10 IRF9 CXCL10 IFI44 BST2 XAF1 SP110 OASL PSMB8 IFI44L IFITM3 DDX60 LGALS3BP GBP4 IRF8 PSMB9 PML IFIH1 UBE2L6 IFI27 ADAR LY6E STAT2 CXCL9 IL10RA PLA2G4A TRIM21 USP18 PTGS2 EPSTI1 C1S DDX58 IL15 NLRC5 NMI IDO1 PSMB10 CXCL11 ITGB7 SAMHD1 HERC6 CMPK2 SAMD9L RTP4 PTPN2 PARP14 TNFAIP2 IFITM2 PLSCR1 SOCS1 CASP1 ICAM1 WARS PSME1 ISG20 IRF2 TRIM14 FCGR1A MARCH1 SOCS3 JAK2 HLA-DMA PARP12 TNFAIP6 TRIM26 VCAM1 CD274 CIITA NAMPT SELP GPR18 FPR1 PRIC285 PSME2 SERPING1 CCL5 RNF31 SOD2 TRIM25 LAP3 PSMA3 RNF213 PELI1 CFB CD86 TXNIP HLA-DQA1 GCH1 PNP CCL7 PTPN6 SPPL2A IL4R PNPT1 DHX58 BTG1 CASP8 IFI30 CCL2 FGL2 CASP7 SECTM1 IL15RA CD40 TRAFD1 HLA-DRB1 GBP6 LCP2 HLA-G MT2A RIPK1 KLRK1 UPP1 PSMB2 TDRD7 HIF1A EIF4E3 VAMP8 PFKP CD38 ZBP1 BANK1 TOR1B RBCK1 PDE4B MVP IL7 BPGM FTSJD2 AUTS2 B2M RIPK2 CD69 MYD88 PSMA2 PIM1 NOD1 CFH TAPBP SLC25A28 PTPN1 TNFAIP3 SSPN NUP93 MTHFD2 CDKN1A IRF4 NFKB1 BATF2 HLA-B LATS2 IRF5 SLAMF7 ISOC1 P2RY14 STAT3 NCOA3 HLA-A IL6 GZMA IFNAR2 CD74 RAPGEF6 CASP4 FAS OGFR ARL4A SRI LYSMD2 CSF2RB ST3GAL5 C1R CASP3 CMKLR1 NFKBIA METTL7B ST8SIA4 XCL1 IL2RB VAMP5 IL18BP ZNFX1 ARID5B APOL6 STAT4
tcga-mss-msi-annotated-no-cms1: 200 of 200 genes from data set analyzed in set HALLMARK_COMPLEMENT: C2 C1S CFB C1R SERPINE1 MMP14 SERPING1 CTSL1 F5 MMP13 F7 CTSS LGMN PLG C1QA CASP1 GZMA ADAM9 CALM3 C1QC TIMP1 DPP4 KLK1 KLKB1 CD59 CR2 MMP15 LAP3 SPOCK2 F10 CTSB SERPINA1 CTSO CD40LG CBLB PDP1 C4BPB PLEK GP9 PLAUR C3 F2 CASP4 STX4 CTSC USP15 CR1 DUSP6 SERPINB2 GPD2 CFH FN1 CD36 CA2 PSMB9 APOBEC3G FCN1 GZMK PDGFB CLU CASP10 LRP1 CTSD S100A9 WAS BRPF3 PLAT CDA MT3 CASP7 PRSS36 PFN1 GZMB RNF4 ZEB1 CASP5 IRF1 PGCP CDK5R1 ATOX1 PIK3CA TMPRSS6 CPM RCE1 CALM1 DOCK9 KYNU RASGRP1 USP14 LCP2 GP1BA KIF2A GNB4 LCK OLR1 PREP SEPX1 LTA4H ZFPM2 LYN ACTN2 SIRT6 APOC1 PRKCD ITGAM DGKH LTF MAFF KCNIP2 PCLO DOCK10 SH2B3 RABIF SRC HPCAL4 CD46 PRDM4 GNAI3 C9 PPP2CB IRF2 FYN JAK2 PLA2G4A PRCP USP8 RHOG L3MBTL4 LAMP2 PIM1 CXCL1 F3 GNAI2 CASP9 XPNPEP1 PLSCR1 IRF7 CD55 HSPA5 GNB2 DYRK2 PLA2G7 S100A12 GRB2 PHEX GNGT2 DOCK4 MMP12 KCNIP3 FDX1 TIMP2 MMP8 FCER1G ZFYVE20 ANXA5 CTSL2 GCA EHD1 PRSS3 COL4A2 CSRP1 PIK3R5 SERPINC1 ANG APOBEC3F GATA3 DUSP5 CASP3 USP16 CP PSEN1 LIPA PCSK9 DGKG GNG2 ME1 GMFB SCG3 PPP4C CCL5 CTSH F8 APOA4 IL6 AKAP10 ERAP2 VCPIP1 HSPA1A RAF1 NOTCH4 ADRA2B CEBPB HNF4A LGALS3 TNFAIP3 CDH13 ITIH1 TFPI2 PIK3CG S100A13
tcga-mss-msi-annotated-no-cms1: 200 of 200 genes from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: CXCL10 CCL2 CCL5 FPR1 CCL20 IL1A IL8 CCL7 CCL22 CXCL11 CCR7 EDN1 CD40 CXCL9 IL6 IL1B TLR2 IL1R1 CD69 ICAM1 CCRL2 AQP9 EREG C3AR1 GNA15 CMKLR1 PTGER4 LIF IL15 NAMPT OPRK1 ITGB8 PTAFR ADM PLAUR NFKB1 INHBA OSM TNFSF10 TNFSF15 IFNGR2 EMR1 IL12B CSF1 CXCL6 TNFRSF9 LYN ACVR2A LDLR BDKRB1 HRH1 F3 BST2 PTGIR CD55 CALCRL CSF3 GPR132 IL4R NLRP3 IL15RA ADORA2B GCH1 OLR1 PTGER2 CSF3R MYC RELA TNFAIP6 IL7R IL18 GABBR1 CD82 TNFSF9 NMUR1 IL2RB TLR1 LPAR1 IRAK2 RIPK2 MMP14 P2RX7 SLC11A2 SELL P2RY2 ABCA1 FFAR2 PROK2 GNAI3 TACR1 SLC7A1 CDKN1A CYBB TIMP1 HBEGF SCARF1 EBI3 NFKBIA SRI SLC7A2 CCL17 TLR3 APLNR OSMR IL10RA PSEN1 GPR183 ATP2B1 TNFRSF1B BEST1 GPC3 SCN1B ACVR1B HPN SEMA4D KLF6 CD48 CXCR6 SLC1A2 GP1BA TAPBP RGS16 SLAMF1 LCK HIF1A AHR NMI RHOG TPBG NPFFR2 IFNAR1 ICOSLG RASGRP1 IFITM1 KCNJ2 LY6E IL18R1 IL10 KCNA3 HAS2 DCBLD2 LAMP3 VIP CD70 RGS1 SLC31A1 ADRM1 KCNMB2 SERPINE1 MXD1 AXL MEFV PVR CCL24 PDE4B LCP2 PDPN IRF7 MET ATP2A2 SLC31A2 FZD5 ITGA5 SGMS2 MARCO CD14 EIF2AK2 ROS1 ATP2C1 NDP BTG2 MSR1 PTPRE RNF144B PCDH7 SPHK1 IL18RAP RTP4 RAF1 CHST2 ITGB3 KIF1B SELE NOD2 C5AR1 EMP3 CLEC5A TACR3 SLC4A4 MEP1A SELS LTA PIK3R5 STAB1 IRF1 ICAM4 P2RX4 ABI1 CX3CL1 SLC28A2
tcga-mss-msi-annotated-no-cms1: 198 of 200 genes from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: SOCS2 CISH PIM1 IL2RA TNFRSF4 SOCS1 TNFRSF9 XBP1 RRAGD HK2 PHLDA1 IL2RB CTLA4 NFIL3 CD83 IKZF2 IL10 TNFRSF18 DHRS3 ECM1 ADAM19 SLC2A3 HIPK2 BATF3 BHLHE40 PTGER2 DENND5A ITIH5 PHTF2 GADD45B NRP1 NCOA3 CD79B AHR TNFRSF1B NDRG1 BCL2L1 GABARAPL1 LIF TIAM1 BMPR2 MAP3K8 RHOB MYC S100A1 CAPG ST3GAL4 PENK IRF4 CST7 WLS TLR7 IKZF4 GBP4 RGS16 SPP1 IL13 SLC29A2 NFKBIZ IL4R MXD1 CSF2 FAH CTSZ ITGAE MUC1 MAPKAPK2 TNFRSF21 NT5E FLT3LG CCND2 TRAF1 LCLAT1 IL3RA CYFIP1 BCL2 FGL2 PRNP N6AMT2 PUS1 ITGAV NCS1 DCPS AMACR FAM126B PTH1R ODC1 IGF1R PTCH1 ENO3 CD81 MAFF EMP1 CDKN1C CAPN3 IL1R2 SYT11 TTC39B ANXA4 BATF P4HA1 GPR65 SLC1A5 IGF2R CKAP4 CCR4 CD44 P2RX4 GATA1 KLF6 ARL4A HOPX GPR83 ITGA6 CD48 SELP GLIPR2 SMPDL3A PLSCR1 FURIN SERPINB6 TNFSF11 GPX4 LRRC8C CCNE1 CASP3 SH3BGRL2 SNX9 PLEC BMP2 ICOS ALCAM LTB ENPP1 IL1RL1 MYO1C IFNGR1 PLIN2 IL18R1 AHNAK PRKCH TNFRSF8 SYNGR2 GALM POU2F1 EOMES NOP2 PTRH2 RHOH CDC6 MYO1E CXCL10 SNX14 IRF6 IL10RA MAP6 TNFSF10 SPRED2 SELL SERPINC1 CDCP1 RORA COCH CSF1 F2RL2 UCK2 CA2 IFITM3 UMPS HUWE1 COL6A1 ABCB1 RNH1 IRF8 GUCY1B3 AHCY PRAF2 GSTO1 TWSG1 CDC42SE2 PLAGL1 APLP1 AKAP2 PPAP2A SPRY4 SCN9A SHE PDCD2L CCND3 LRIG1 SWAP70 SLC39A8 RABGAP1L TGM2 PNP AGER ETV4 CD86
tcga-mss-msi-annotated-no-cms1: 2 of 200 genes missing from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: METTL20 CCDC164
tcga-mss-msi-annotated-no-cms1: 200 of 200 genes from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: PTPRC IL12B TGFB1 IL12A CD3E CD3D CD28 LYN HCLS1 IL18 CRTAM IFNG CD3G CD86 IL10 UBE2N BCL10 CD4 LCK NCK1 C2 HLA-A ITGB2 HLA-DQA1 CD1D CD80 HLA-DRA THY1 TLR1 HLA-G HLA-DMB IL7 IL4 TNF CD247 IL2 HLA-DMA STAT1 IRF4 SRGN INHBA TLR3 ZAP70 CD74 CD40 TRAF2 B2M BCL3 LTB IFNGR1 CCR5 CD40LG HLA-DOA GLMN IL6 HLA-E CD2 CCL5 FAS FASLG TLR6 PF4 TGFB2 CD79A INHBB ELANE SPI1 MAP3K7 IL15 CTSS CD47 PRF1 IL12RB1 LCP2 SOCS1 CDKN2A STAT4 CD7 HLA-DOB CD8A ICAM1 CCL4 GZMB CSF1 IL11 STAB1 IL2RA NLRP3 CCND3 EIF3A SIT1 IFNAR2 HDAC9 CARTPT TRAT1 CCL22 APBB1 FYB IL1B TIMP1 RPS19 JAK2 KRT1 WARS IFNGR2 CCR2 EREG MMP9 EGFR IL16 CFP WAS ITGAL KLRD1 RARS TLR2 CCND2 IL2RG ETS1 ITK NCR1 MAP4K1 CCL19 PSMB10 RPL39 EIF3J ABCE1 CD8B F2 ELF4 LY86 FCGR2B GBP2 PRKCG RPS9 MTIF2 GZMA AARS CD96 CSK HIF1A CCL2 ICOSLG NPM1 IL4R CCL11 NME1 FLNA GPR65 ACHE EIF3D IGSF6 F2R IL13 TAP1 DARS IRF7 ACVR2A CXCR3 PRKCB CXCL9 PTPN6 NCF4 UBE2D1 LIF CCR1 MBL2 DEGS1 TPD52 AKT1 RIPK2 IKBKB GCNT1 SOCS5 IRF8 TAP2 EIF4G3 ABI1 CCL7 IL2RB BRCA1 FGR IL18RAP MRPL3 CXCL13 CAPG EIF5A RPS3A GALNT1 ST8SIA4 CCL13 RPL3L LY75 TAPBP NOS2 RPL9 BCAT1 IL9 IL27RA DYRK3
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
tcga-mss-msi-annotated-no-cms1 wnt vs CIRC: t = -7.16772312556457 df = 276 nrow = 278 cor = -0.39614815084246 pval = 6.9847963099518e-12
tcga-mss-msi-annotated-no-cms1 tak1 vs CIRC: t = -1.07297584012558 df = 276 nrow = 278 cor = -0.064451273208696 pval = 0.28421919478325
tcga-mss-msi-annotated-no-cms1 wnt vs myc.sig: t = 32.1863024961148 df = 276 nrow = 278 cor = 0.888609825973405 pval = 2.01588326488796e-95
tcga-mss-msi-annotated-no-cms1 CIRC vs neoantigens: tcga-mss-msi-annotated-no-cms1: Analyzing CIRC vs neoantigens using Fisher's Exact Test for Count Data: p = 0.359994821425093 n = 277

tcga-mss-msi-annotated-no-cms1: Analyzing CIRC vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10750, n_WT = 172, n_MT = 106, p = 0.0121093598372082
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 9914, n_WT = 172, n_MT = 106, p = 0.220611388718154
tcga-mss-msi-annotated-no-cms1: Analyzing wnt vs KRAS using Wilcoxon rank sum test with continuity correction: W = 8911, n_WT = 172, n_MT = 106, p = 0.753446879521153
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig vs KRAS using Wilcoxon rank sum test with continuity correction: W = 8719, n_WT = 172, n_MT = 106, p = 0.542526981634952
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens vs KRAS using Wilcoxon rank sum test with continuity correction: W = 7663, n_WT = 171, n_MT = 106, p = 0.0307807802805391
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11129, n_WT = 172, n_MT = 106, p = 0.00199444192782121
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10326, n_WT = 172, n_MT = 106, p = 0.0632106214957842
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10211, n_WT = 172, n_MT = 106, p = 0.092748316381672
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10317, n_WT = 172, n_MT = 106, p = 0.0652000882706434
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10079, n_WT = 172, n_MT = 106, p = 0.139318822032648
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10056, n_WT = 172, n_MT = 106, p = 0.149018769016399
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10701, n_WT = 172, n_MT = 106, p = 0.014946170604266

Computing CIRC ~ KRAS
Computing CIITA ~ KRAS
Computing wnt ~ KRAS
Computing myc.sig ~ KRAS
Computing neoantigens ~ KRAS
Computing BATF3 ~ KRAS
Computing HALLMARK_IL6_JAK_STAT3_SIGNALING ~ KRAS
Computing HALLMARK_INTERFERON_GAMMA_RESPONSE ~ KRAS
Computing HALLMARK_COMPLEMENT ~ KRAS
Computing HALLMARK_INFLAMMATORY_RESPONSE ~ KRAS
Computing HALLMARK_IL2_STAT5_SIGNALING ~ KRAS
Computing HALLMARK_ALLOGRAFT_REJECTION ~ KRAS
tcga-mss-msi-annotated-no-cms1: Analyzing CIRC CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1906, n_CMS2 = 134, n_CMS3 = 35, p = 0.0889098757704261
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1828, n_CMS2 = 134, n_CMS3 = 35, p = 0.0450936176798174
tcga-mss-msi-annotated-no-cms1: Analyzing wnt CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 3280, n_CMS2 = 134, n_CMS3 = 35, p = 0.000288485483160944
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2890, n_CMS2 = 134, n_CMS3 = 35, p = 0.034651543818701
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1980.5, n_CMS2 = 134, n_CMS3 = 35, p = 0.175905507483851
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2562, n_CMS2 = 134, n_CMS3 = 35, p = 0.40095354781446
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1739, n_CMS2 = 134, n_CMS3 = 35, p = 0.0188209342166727
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1676, n_CMS2 = 134, n_CMS3 = 35, p = 0.00950129535412856
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1793, n_CMS2 = 134, n_CMS3 = 35, p = 0.0323900281988977
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1574, n_CMS2 = 134, n_CMS3 = 35, p = 0.00279725293952069
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1485, n_CMS2 = 134, n_CMS3 = 35, p = 0.000854649321034387
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1773, n_CMS2 = 134, n_CMS3 = 35, p = 0.0266125292621395
tcga-mss-msi-annotated-no-cms1: Analyzing CIRC CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2117, n_CMS2 = 134, n_CMS4 = 81, p = 7.02496068606718e-14
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2561, n_CMS2 = 134, n_CMS4 = 81, p = 8.99767699074349e-11
tcga-mss-msi-annotated-no-cms1: Analyzing wnt CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 9122, n_CMS2 = 134, n_CMS4 = 81, p = 6.35604837624754e-17
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 8925, n_CMS2 = 134, n_CMS4 = 81, p = 2.51797147984181e-15
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 5168, n_CMS2 = 134, n_CMS4 = 81, p = 0.619702397780442
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2445, n_CMS2 = 134, n_CMS4 = 81, p = 1.52672238992108e-11
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2133, n_CMS2 = 134, n_CMS4 = 81, p = 9.2491577056842e-14
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2553, n_CMS2 = 134, n_CMS4 = 81, p = 7.97888303566871e-11
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1393, n_CMS2 = 134, n_CMS4 = 81, p = 7.14858384596838e-20
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1356, n_CMS2 = 134, n_CMS4 = 81, p = 3.28909097369492e-20
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1386, n_CMS2 = 134, n_CMS4 = 81, p = 6.1754241984516e-20
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2071, n_CMS2 = 134, n_CMS4 = 81, p = 3.16287792002351e-14


tcga-mss-msi-annotated-no-cms1: Analyzing CIRC CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 284, n_CMS2 = 41, n_CMS3 = 23, p = 0.00817148291138145
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 289, n_CMS2 = 41, n_CMS3 = 23, p = 0.0101263134924805
tcga-mss-msi-annotated-no-cms1: Analyzing wnt CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 708, n_CMS2 = 41, n_CMS3 = 23, p = 0.000726750121485624
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 656, n_CMS2 = 41, n_CMS3 = 23, p = 0.00930005100463402
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 433, n_CMS2 = 41, n_CMS3 = 23, p = 0.594862093429313
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 475, n_CMS2 = 41, n_CMS3 = 23, p = 0.966782014551187
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 288, n_CMS2 = 41, n_CMS3 = 23, p = 0.00970548311855106
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 241, n_CMS2 = 41, n_CMS3 = 23, p = 0.00101007230857561
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 335, n_CMS2 = 41, n_CMS3 = 23, p = 0.056633987799559
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 276, n_CMS2 = 41, n_CMS3 = 23, p = 0.00572925035068395
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 267, n_CMS2 = 41, n_CMS3 = 23, p = 0.00377424898719277
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 242, n_CMS2 = 41, n_CMS3 = 23, p = 0.00106603428497576
tcga-mss-msi-annotated-no-cms1: Analyzing CIRC CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 116, n_CMS2 = 41, n_CMS4 = 25, p = 1.36664401884186e-08
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 110, n_CMS2 = 41, n_CMS4 = 25, p = 7.21468388832661e-09
tcga-mss-msi-annotated-no-cms1: Analyzing wnt CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 909, n_CMS2 = 41, n_CMS4 = 25, p = 1.36664401884186e-08
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 926, n_CMS2 = 41, n_CMS4 = 25, p = 2.1068735391955e-09
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test with continuity correction: W = 513, n_CMS2 = 41, n_CMS4 = 25, p = 1
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 93, n_CMS2 = 41, n_CMS4 = 25, p = 1.0388837191626e-09
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 92, n_CMS2 = 41, n_CMS4 = 25, p = 9.20966361344669e-10
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 159, n_CMS2 = 41, n_CMS4 = 25, p = 7.64732999616803e-07
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 62, n_CMS2 = 41, n_CMS4 = 25, p = 1.62673547392586e-11
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 35, n_CMS2 = 41, n_CMS4 = 25, p = 1.54180195986397e-13
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 55, n_CMS2 = 41, n_CMS4 = 25, p = 5.47969594069469e-12
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 103, n_CMS2 = 41, n_CMS4 = 25, p = 3.32743916568874e-09

tcga-mss-msi-annotated-no-cms1: Analyzing CIRC CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1153, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.000277251372958375
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1300, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.00343435427649365
tcga-mss-msi-annotated-no-cms1: Analyzing wnt CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2144, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.252500571360156
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2164, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.214656759588873
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 2044.5, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.441306704341132
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1147, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.000247680240225141
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1209, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.000764619175273825
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1229, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.00108031462601781
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1179, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.000447866615747607
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1246, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.00143931177144646
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1290, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.00293747778801279
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1105, n_CMS2-MT = 41, n_CMS2-WT = 93, p = 0.000109986818447646
tcga-mss-msi-annotated-no-cms1: Analyzing CIRC CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 284, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.00817148291138145
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 289, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.0101263134924805
tcga-mss-msi-annotated-no-cms1: Analyzing wnt CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 708, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.000726750121485624
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 656, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.00930005100463402
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens CMS2-MT vs CMS3-MT using Wilcoxon rank sum test with continuity correction: W = 433, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.594862093429313
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 475, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.966782014551187
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 288, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.00970548311855106
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 241, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.00101007230857561
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 335, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.056633987799559
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 276, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.00572925035068395
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 267, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.00377424898719277
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 242, n_CMS2-MT = 41, n_CMS3-MT = 23, p = 0.00106603428497576
tcga-mss-msi-annotated-no-cms1: Analyzing CIRC CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 82, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.000256939599340014
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 101, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.00148802097607671
tcga-mss-msi-annotated-no-cms1: Analyzing wnt CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 345, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.0350880781916273
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 307, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.201325110948483
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens CMS2-MT vs CMS3-WT using Wilcoxon rank sum test with continuity correction: W = 215.5, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.523657178039454
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 120, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.00646560459456862
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 59, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 1.84242605400029e-05
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 74, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.00011048374523958
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 76, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 0.00013733344839243
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 46, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 2.94281719836076e-06
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 48, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 3.98444975605763e-06
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 67, n_CMS2-MT = 41, n_CMS3-WT = 12, p = 4.97008627052545e-05
tcga-mss-msi-annotated-no-cms1: Analyzing CIRC CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 116, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 1.36664401884186e-08
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 110, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 7.21468388832661e-09
tcga-mss-msi-annotated-no-cms1: Analyzing wnt CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 909, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 1.36664401884186e-08
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 926, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 2.1068735391955e-09
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens CMS2-MT vs CMS4-MT using Wilcoxon rank sum test with continuity correction: W = 513, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 1
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 93, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 1.0388837191626e-09
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 92, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 9.20966361344669e-10
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 159, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 7.64732999616803e-07
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 62, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 1.62673547392586e-11
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 35, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 1.54180195986397e-13
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 55, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 5.47969594069469e-12
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 103, n_CMS2-MT = 41, n_CMS4-MT = 25, p = 3.32743916568874e-09
tcga-mss-msi-annotated-no-cms1: Analyzing CIRC CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 170, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 9.43385655331673e-13
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 338, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 3.38703711312013e-09
tcga-mss-msi-annotated-no-cms1: Analyzing wnt CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 2011, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 3.00157232116044e-10
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 1971, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 1.89472912662226e-09
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 1181, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 0.812344687460441
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 250, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 5.590469888194e-11
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 204, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 5.57033185116059e-12
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 218, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 1.13708456694448e-11
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 137, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 1.58864317824933e-13
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 123, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 7.33353837443465e-14
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 141, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 1.97753531383431e-13
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 131, n_CMS2-MT = 41, n_CMS4-WT = 56, p = 1.14207916593188e-13

Computing linear model with interaction for CIRC
Computing linear model with interaction for CIITA
Computing linear model with interaction for wnt
Computing linear model with interaction for myc.sig
Computing linear model with interaction for neoantigens
Computing linear model with interaction for BATF3
Computing linear model with interaction for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model with interaction for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model with interaction for HALLMARK_COMPLEMENT
Computing linear model with interaction for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model with interaction for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model with interaction for HALLMARK_ALLOGRAFT_REJECTION
Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for neoantigens
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
tcga-mss-msi-annotated-no-cms1: Analyzing CIRC CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 773, n_MT = 25, n_WT = 56, p = 0.458549136308975
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 610, n_MT = 25, n_WT = 56, p = 0.360167716906832
tcga-mss-msi-annotated-no-cms1: Analyzing wnt CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 672, n_MT = 25, n_WT = 56, p = 0.778588259881065
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 709, n_MT = 25, n_WT = 56, p = 0.930748004808526
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 683, n_MT = 25, n_WT = 56, p = 0.866016636827914
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 649, n_MT = 25, n_WT = 56, p = 0.605637480931673
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 629, n_MT = 25, n_WT = 56, p = 0.471038684776457
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 714, n_MT = 25, n_WT = 56, p = 0.890221741641227
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 667, n_MT = 25, n_WT = 56, p = 0.739678511625657
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 632, n_MT = 25, n_WT = 56, p = 0.49011988778829
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 627, n_MT = 25, n_WT = 56, p = 0.458549136308975
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 728, n_MT = 25, n_WT = 56, p = 0.778588259881065
tcga-mss-msi-annotated-no-cms1: Analyzing CIRC CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2660, n_MT = 41, n_WT = 93, p = 0.000277251372958375
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2513, n_MT = 41, n_WT = 93, p = 0.00343435427649365
tcga-mss-msi-annotated-no-cms1: Analyzing wnt CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1669, n_MT = 41, n_WT = 93, p = 0.252500571360156
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1649, n_MT = 41, n_WT = 93, p = 0.214656759588873
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1727.5, n_MT = 41, n_WT = 93, p = 0.441306704341132
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2666, n_MT = 41, n_WT = 93, p = 0.000247680240225141
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2604, n_MT = 41, n_WT = 93, p = 0.000764619175273825
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2584, n_MT = 41, n_WT = 93, p = 0.00108031462601781
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2634, n_MT = 41, n_WT = 93, p = 0.000447866615747607
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2567, n_MT = 41, n_WT = 93, p = 0.00143931177144646
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2523, n_MT = 41, n_WT = 93, p = 0.00293747778801279
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2708, n_MT = 41, n_WT = 93, p = 0.000109986818447646
tcga-mss-msi-annotated-no-cms1: Analyzing CIRC CMS3 MT vs WT using Wilcoxon rank sum test: W = 169, n_MT = 23, n_WT = 12, p = 0.29378493041779
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA CMS3 MT vs WT using Wilcoxon rank sum test: W = 160, n_MT = 23, n_WT = 12, p = 0.460505855461035
tcga-mss-msi-annotated-no-cms1: Analyzing wnt CMS3 MT vs WT using Wilcoxon rank sum test: W = 147, n_MT = 23, n_WT = 12, p = 0.770966011458062
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig CMS3 MT vs WT using Wilcoxon rank sum test: W = 151, n_MT = 23, n_WT = 12, p = 0.668423000585534
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens CMS3 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 139, n_MT = 23, n_WT = 12, p = 0.986132610427574
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 CMS3 MT vs WT using Wilcoxon rank sum test: W = 197, n_MT = 23, n_WT = 12, p = 0.0408102349350795
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 175, n_MT = 23, n_WT = 12, p = 0.207875949216
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 159, n_MT = 23, n_WT = 12, p = 0.481734803615979
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS3 MT vs WT using Wilcoxon rank sum test: W = 176, n_MT = 23, n_WT = 12, p = 0.195487995831515
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 185, n_MT = 23, n_WT = 12, p = 0.106806360774822
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 189, n_MT = 23, n_WT = 12, p = 0.0791312236368835
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS3 MT vs WT using Wilcoxon rank sum test: W = 163, n_MT = 23, n_WT = 12, p = 0.39996929001771

Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for neoantigens
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
Computing rectum vs left
tcga-mss-msi-annotated-no-cms1: Analyzing CIRC site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2884, n_rectum = 54, n_left = 125, p = 0.123196898062462
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2863, n_rectum = 54, n_left = 125, p = 0.107947049342366
tcga-mss-msi-annotated-no-cms1: Analyzing wnt site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3074, n_rectum = 54, n_left = 125, p = 0.344975298775732
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3066, n_rectum = 54, n_left = 125, p = 0.332284826738317
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3435, n_rectum = 54, n_left = 125, p = 0.851644256351317
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2411, n_rectum = 54, n_left = 125, p = 0.00246187560180445
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3051, n_rectum = 54, n_left = 125, p = 0.309314050590413
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3041, n_rectum = 54, n_left = 125, p = 0.294597426673645
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3199, n_rectum = 54, n_left = 125, p = 0.581261299930204
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3284, n_rectum = 54, n_left = 125, p = 0.776093084725128
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3560, n_rectum = 54, n_left = 125, p = 0.562030909844561
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2945, n_rectum = 54, n_left = 125, p = 0.177083905981862
Computing right vs left
tcga-mss-msi-annotated-no-cms1: Analyzing CIRC site: right vs leftWilcoxon rank sum test with continuity correction: W = 5344, n_right = 97, n_left = 125, p = 0.130383360286549
tcga-mss-msi-annotated-no-cms1: Analyzing CIITA site: right vs leftWilcoxon rank sum test with continuity correction: W = 5110, n_right = 97, n_left = 125, p = 0.0449039001189254
tcga-mss-msi-annotated-no-cms1: Analyzing wnt site: right vs leftWilcoxon rank sum test with continuity correction: W = 5945, n_right = 97, n_left = 125, p = 0.805310028223077
tcga-mss-msi-annotated-no-cms1: Analyzing myc.sig site: right vs leftWilcoxon rank sum test with continuity correction: W = 5818, n_right = 97, n_left = 125, p = 0.607232110254066
tcga-mss-msi-annotated-no-cms1: Analyzing neoantigens site: right vs leftWilcoxon rank sum test with continuity correction: W = 4205, n_right = 97, n_left = 125, p = 0.000139558312774605
tcga-mss-msi-annotated-no-cms1: Analyzing BATF3 site: right vs leftWilcoxon rank sum test with continuity correction: W = 5638, n_right = 97, n_left = 125, p = 0.371734154752316
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 5707, n_right = 97, n_left = 125, p = 0.454539032985177
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 5443, n_right = 97, n_left = 125, p = 0.192222960586798
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_COMPLEMENT site: right vs leftWilcoxon rank sum test with continuity correction: W = 5704, n_right = 97, n_left = 125, p = 0.450735584683877
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 5695, n_right = 97, n_left = 125, p = 0.439434011382587
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 5777, n_right = 97, n_left = 125, p = 0.548238311371596
tcga-mss-msi-annotated-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: right vs leftWilcoxon rank sum test with continuity correction: W = 5307, n_right = 97, n_left = 125, p = 0.111713405654066

Plotting CIRC ~ site
Plotting CIITA ~ site
Plotting wnt ~ site
Plotting myc.sig ~ site
Plotting neoantigens ~ site
Plotting BATF3 ~ site
Plotting HALLMARK_IL6_JAK_STAT3_SIGNALING ~ site
Plotting HALLMARK_INTERFERON_GAMMA_RESPONSE ~ site
Plotting HALLMARK_COMPLEMENT ~ site
Plotting HALLMARK_INFLAMMATORY_RESPONSE ~ site
Plotting HALLMARK_IL2_STAT5_SIGNALING ~ site
Plotting HALLMARK_ALLOGRAFT_REJECTION ~ site
There were 50 or more warnings (use warnings() to see the first 50)
Doing KFS analysis
Number of rows analyzed: 20534
Number of columns analyzed: 290
kfs-all: 26 of 28 genes from data set analyzed in set CIRC: HLA-DQA1 CTLA4 PDCD1LG2 ICAM1 CD274 STAT1 IRF1 IFNG GNLY TBX21 CCL5 LAG3 CD247 ICOS IL18RAP CXCL9 CXCL10 HLA-DPB1 HLA-DPA1 HLA-DMB HLA-DRA HLA-DMA CD80 HLA-DOA CD4 HAVCR2
kfs-all: 2 of 28 genes missing from data set analyzed in set CIRC: HLA-DQA2 HLA-DRB5
kfs-all: 75 of 88 genes from data set analyzed in set myc.sig: AKAP1 APEX1 BAX CAD CCKBR CCNB1 CCND2 CCT5 CDC25C CEBPZ CKS2 CTSC DDX10 DDX18 DDX5 E2F1 EIF4B ENO1 EXOSC8 FASN FOSL1 H2AFZ HSPD1 HSPE1 ID2 IMPA2 LTA4H MAT2A METTL1 MINA MSH2 MTHFD1 NAP1L1 NCL NME1 NPM1 NRAS NUP155 PA2G4 PCNA PHB POLD2 PPAT PPIA PPID PRDX3 PREP PRPS2 PSMB1 PTEN PYCR1 RPL19 RPL22 RPL27 RPL27A RPL32 RPL9 RPS16 RPS19 RPS5 RPS6KA2 SHMT1 SLC25A3 SLC39A6 SNRPB SNRPD3 SRM TERT TFRC TOP1 TXN TYMS UBE2C UCHL1 UXT
kfs-all: 13 of 88 genes missing from data set analyzed in set myc.sig: CSDA DKC1 DSCR2 EIF4A1 HNRPA2B1 HSPA8 HSPA9B RPL10 RPL5 RPS13 SFRS1 SFRS2 SFRS7
kfs-all: 44 of 78 genes from data set analyzed in set wnt: PHLDA1 SLC7A5 BYSL SCD SOX4 WDR77 NLE1 PPIL1 ZNF511 ZNF593 ODC1 AURKB WDR12 CDT1 NOC3L CAD XPOT YAP1 SRM NXT1 MRPS12 RHEB WDR3 CRTAP SF3A2 GEMIN5 IMP4 HEATR1 SLC19A1 PDCD11 ASCL2 TBX3 EPHB3 ZNRF3 IL20RA RHOBTB3 GEMIN4 ID3 FUT4 PIGW APEX1 SRPRB ZNRD1 TFB2M
kfs-all: 34 of 78 genes missing from data set analyzed in set wnt: FLJ20315 CTPS NOB1P PSF1 PMSCL1 RNU3IP2 CIRH1A HIG2 C1orf33 DKC1 LOC389362 HSPC111 MGC40397 LOC56902 SDCCAG16 FLJ10774 RAB9P40 RFP RRP41 HNRPDL C16orf35 TREX2 CGI-96 C20orf64 C12orf14 NOL1 TDGF1 SKB1 C11orf5 MGC16824 ZNF278 RPC62 JTV1 ZNF339
kfs-all: 87 of 87 genes from data set analyzed in set HALLMARK_IL6_JAK_STAT3_SIGNALING: IL4R IL6ST STAT1 IL1R1 CSF2RB SOCS3 STAT3 OSMR IL2RG IFNGR1 TYK2 IL13RA1 TLR2 IFNGR2 IL10RB IL6 IL1R2 IL3RA IFNAR1 TNFRSF1A MYD88 ACVR1B CSF3R ITGB3 REG1A CXCL1 A2M CSF2RA IL15RA IRF9 PDGFC HAX1 BAK1 EBI3 INHBE CRLF2 TNFRSF1B CD14 PTPN1 PTPN2 IL1B CSF1 IL18R1 TNF PF4 CXCL13 LTBR FAS IL17RA CXCL10 IL9R STAM2 TNFRSF12A STAT2 HMOX1 LEPR CBL CD9 CXCL3 TGFB1 MAP3K8 ITGA4 CD38 JUN SOCS1 ACVRL1 PIM1 TNFRSF21 PIK3R5 GRB2 IRF1 DNTT CSF2 IL2RA PTPN11 IL12RB1 CCR1 CNTFR PLA2G2A CXCL9 CD44 IL7 CXCL11 CCL7 LTB IL17RB CD36
kfs-all: 194 of 200 genes from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: STAT1 ISG15 IFIT1 MX1 IFIT3 IFI35 IRF7 IFIT2 OAS2 TAP1 EIF2AK2 RSAD2 MX2 IRF1 OAS3 TNFSF10 IRF9 CXCL10 IFI44 BST2 XAF1 SP110 OASL PSMB8 IFI44L IFITM3 DDX60 LGALS3BP GBP4 IRF8 PSMB9 PML IFIH1 UBE2L6 IFI27 ADAR LY6E STAT2 CXCL9 IL10RA PLA2G4A TRIM21 USP18 PTGS2 EPSTI1 C1S DDX58 IL15 NLRC5 NMI IDO1 PSMB10 CXCL11 ITGB7 SAMHD1 HERC6 CMPK2 SAMD9L RTP4 PTPN2 PARP14 TNFAIP2 IFITM2 PLSCR1 SOCS1 CASP1 ICAM1 WARS PSME1 ISG20 IRF2 TRIM14 FCGR1A MARCH1 SOCS3 JAK2 HLA-DMA PARP12 TNFAIP6 TRIM26 VCAM1 CD274 CIITA NAMPT SELP GPR18 FPR1 SERPING1 CCL5 RNF31 SOD2 TRIM25 LAP3 PSMA3 RNF213 PELI1 CFB CD86 TXNIP HLA-DQA1 GCH1 PNP CCL7 PTPN6 SPPL2A IL4R PNPT1 DHX58 BTG1 CASP8 CCL2 FGL2 CASP7 SECTM1 IL15RA CD40 TRAFD1 GBP6 LCP2 HLA-G MT2A RIPK1 UPP1 PSMB2 TDRD7 HIF1A EIF4E3 VAMP8 PFKP CD38 ZBP1 BANK1 TOR1B RBCK1 PDE4B MVP IL7 BPGM AUTS2 B2M RIPK2 CD69 MYD88 PSMA2 PIM1 NOD1 CFH TAPBP SLC25A28 PTPN1 TNFAIP3 SSPN NUP93 MTHFD2 CDKN1A IRF4 NFKB1 BATF2 HLA-B LATS2 IRF5 SLAMF7 ISOC1 P2RY14 STAT3 NCOA3 HLA-A IL6 GZMA IFNAR2 CD74 RAPGEF6 CASP4 FAS OGFR ARL4A SRI LYSMD2 CSF2RB ST3GAL5 C1R CASP3 CMKLR1 NFKBIA METTL7B ST8SIA4 XCL1 IL2RB VAMP5 IL18BP ZNFX1 ARID5B APOL6 STAT4
kfs-all: 6 of 200 genes missing from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: PRIC285 PSME2 IFI30 HLA-DRB1 KLRK1 FTSJD2
kfs-all: 193 of 200 genes from data set analyzed in set HALLMARK_COMPLEMENT: C2 C1S CFB C1R SERPINE1 MMP14 SERPING1 F5 MMP13 F7 CTSS LGMN PLG C1QA CASP1 GZMA ADAM9 CALM3 C1QC TIMP1 DPP4 KLK1 KLKB1 CD59 CR2 MMP15 LAP3 SPOCK2 F10 CTSB SERPINA1 CTSO CD40LG CBLB PDP1 C4BPB PLEK GP9 PLAUR C3 F2 CASP4 STX4 CTSC CR1 DUSP6 SERPINB2 GPD2 CFH FN1 CD36 CA2 PSMB9 APOBEC3G FCN1 GZMK PDGFB CLU CASP10 LRP1 CTSD S100A9 WAS BRPF3 PLAT CDA MT3 CASP7 PRSS36 PFN1 GZMB RNF4 ZEB1 CASP5 IRF1 CDK5R1 ATOX1 PIK3CA TMPRSS6 CPM RCE1 CALM1 DOCK9 KYNU RASGRP1 USP14 LCP2 GP1BA KIF2A GNB4 LCK OLR1 PREP LTA4H ZFPM2 LYN ACTN2 SIRT6 APOC1 PRKCD ITGAM DGKH LTF MAFF KCNIP2 PCLO DOCK10 SH2B3 RABIF SRC HPCAL4 CD46 PRDM4 GNAI3 C9 PPP2CB IRF2 FYN JAK2 PLA2G4A PRCP USP8 RHOG L3MBTL4 LAMP2 PIM1 CXCL1 F3 GNAI2 CASP9 XPNPEP1 PLSCR1 IRF7 CD55 HSPA5 GNB2 DYRK2 PLA2G7 S100A12 GRB2 PHEX GNGT2 DOCK4 MMP12 KCNIP3 FDX1 TIMP2 MMP8 FCER1G ANXA5 GCA EHD1 PRSS3 COL4A2 CSRP1 PIK3R5 SERPINC1 ANG APOBEC3F GATA3 DUSP5 CASP3 USP16 CP PSEN1 LIPA PCSK9 DGKG GNG2 ME1 GMFB SCG3 PPP4C CCL5 CTSH F8 APOA4 IL6 AKAP10 ERAP2 VCPIP1 RAF1 NOTCH4 ADRA2B CEBPB HNF4A LGALS3 TNFAIP3 CDH13 ITIH1 TFPI2 PIK3CG S100A13
kfs-all: 7 of 200 genes missing from data set analyzed in set HALLMARK_COMPLEMENT: CTSL1 USP15 PGCP SEPX1 ZFYVE20 CTSL2 HSPA1A
kfs-all: 197 of 200 genes from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: CXCL10 CCL2 CCL5 FPR1 CCL20 IL1A CCL7 CCL22 CXCL11 CCR7 EDN1 CD40 CXCL9 IL6 IL1B TLR2 IL1R1 CD69 ICAM1 CCRL2 AQP9 EREG C3AR1 GNA15 CMKLR1 PTGER4 LIF IL15 NAMPT OPRK1 ITGB8 PTAFR ADM PLAUR NFKB1 INHBA OSM TNFSF10 TNFSF15 IFNGR2 IL12B CSF1 CXCL6 TNFRSF9 LYN ACVR2A LDLR BDKRB1 HRH1 F3 BST2 PTGIR CD55 CALCRL CSF3 GPR132 IL4R NLRP3 IL15RA ADORA2B GCH1 OLR1 PTGER2 CSF3R MYC RELA TNFAIP6 IL7R IL18 GABBR1 CD82 TNFSF9 NMUR1 IL2RB TLR1 LPAR1 IRAK2 RIPK2 MMP14 P2RX7 SLC11A2 SELL P2RY2 ABCA1 FFAR2 PROK2 GNAI3 TACR1 SLC7A1 CDKN1A CYBB TIMP1 HBEGF SCARF1 EBI3 NFKBIA SRI SLC7A2 CCL17 TLR3 APLNR OSMR IL10RA PSEN1 GPR183 ATP2B1 TNFRSF1B BEST1 GPC3 SCN1B ACVR1B HPN SEMA4D KLF6 CD48 CXCR6 SLC1A2 GP1BA TAPBP RGS16 SLAMF1 LCK HIF1A AHR NMI RHOG TPBG NPFFR2 IFNAR1 ICOSLG RASGRP1 IFITM1 KCNJ2 LY6E IL18R1 IL10 KCNA3 HAS2 DCBLD2 LAMP3 VIP CD70 RGS1 SLC31A1 ADRM1 KCNMB2 SERPINE1 MXD1 AXL MEFV PVR CCL24 PDE4B LCP2 PDPN IRF7 MET ATP2A2 SLC31A2 FZD5 ITGA5 SGMS2 MARCO CD14 EIF2AK2 ROS1 ATP2C1 NDP BTG2 MSR1 PTPRE RNF144B PCDH7 SPHK1 IL18RAP RTP4 RAF1 CHST2 ITGB3 KIF1B SELE NOD2 C5AR1 EMP3 CLEC5A TACR3 SLC4A4 MEP1A LTA PIK3R5 STAB1 IRF1 ICAM4 P2RX4 ABI1 CX3CL1 SLC28A2
kfs-all: 3 of 200 genes missing from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: IL8 EMR1 SELS
kfs-all: 194 of 200 genes from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: SOCS2 CISH PIM1 IL2RA TNFRSF4 SOCS1 TNFRSF9 XBP1 RRAGD HK2 PHLDA1 IL2RB CTLA4 NFIL3 CD83 IKZF2 IL10 TNFRSF18 DHRS3 ECM1 ADAM19 SLC2A3 HIPK2 BATF3 BHLHE40 PTGER2 DENND5A ITIH5 PHTF2 GADD45B NRP1 NCOA3 CD79B AHR TNFRSF1B NDRG1 BCL2L1 GABARAPL1 LIF TIAM1 BMPR2 MAP3K8 RHOB MYC S100A1 CAPG ST3GAL4 PENK IRF4 CST7 WLS TLR7 IKZF4 GBP4 RGS16 SPP1 IL13 SLC29A2 NFKBIZ IL4R MXD1 CSF2 FAH CTSZ ITGAE MUC1 MAPKAPK2 TNFRSF21 NT5E FLT3LG CCND2 TRAF1 LCLAT1 IL3RA CYFIP1 BCL2 FGL2 PRNP PUS1 ITGAV NCS1 DCPS AMACR FAM126B PTH1R ODC1 IGF1R PTCH1 ENO3 CD81 MAFF EMP1 CDKN1C CAPN3 IL1R2 SYT11 TTC39B ANXA4 BATF P4HA1 GPR65 SLC1A5 IGF2R CKAP4 CCR4 CD44 P2RX4 GATA1 KLF6 ARL4A HOPX GPR83 ITGA6 CD48 SELP GLIPR2 SMPDL3A PLSCR1 FURIN SERPINB6 TNFSF11 GPX4 LRRC8C CCNE1 CASP3 SH3BGRL2 SNX9 PLEC BMP2 ICOS ALCAM LTB ENPP1 IL1RL1 MYO1C IFNGR1 PLIN2 IL18R1 AHNAK PRKCH TNFRSF8 SYNGR2 GALM POU2F1 EOMES NOP2 PTRH2 RHOH CDC6 MYO1E CXCL10 SNX14 IRF6 IL10RA MAP6 TNFSF10 SPRED2 SELL SERPINC1 CDCP1 RORA COCH CSF1 F2RL2 CA2 IFITM3 UMPS HUWE1 COL6A1 ABCB1 RNH1 IRF8 GUCY1B3 AHCY PRAF2 GSTO1 TWSG1 CDC42SE2 PLAGL1 APLP1 SPRY4 SCN9A SHE PDCD2L CCND3 LRIG1 SWAP70 SLC39A8 RABGAP1L TGM2 PNP AGER ETV4 CD86
kfs-all: 6 of 200 genes missing from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: METTL20 N6AMT2 CCDC164 UCK2 AKAP2 PPAP2A
kfs-all: 198 of 200 genes from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: PTPRC IL12B TGFB1 IL12A CD3E CD3D CD28 LYN HCLS1 IL18 CRTAM IFNG CD3G CD86 IL10 UBE2N BCL10 CD4 LCK NCK1 C2 HLA-A ITGB2 HLA-DQA1 CD1D CD80 HLA-DRA THY1 TLR1 HLA-G HLA-DMB IL7 IL4 TNF CD247 IL2 HLA-DMA STAT1 IRF4 SRGN INHBA TLR3 ZAP70 CD74 CD40 TRAF2 B2M LTB IFNGR1 CCR5 CD40LG HLA-DOA GLMN IL6 HLA-E CD2 CCL5 FAS FASLG TLR6 PF4 TGFB2 CD79A INHBB ELANE SPI1 MAP3K7 IL15 CTSS CD47 PRF1 IL12RB1 LCP2 SOCS1 CDKN2A STAT4 CD7 HLA-DOB CD8A ICAM1 CCL4 GZMB CSF1 IL11 STAB1 IL2RA NLRP3 CCND3 EIF3A SIT1 IFNAR2 HDAC9 CARTPT TRAT1 CCL22 APBB1 FYB IL1B TIMP1 RPS19 JAK2 KRT1 WARS IFNGR2 CCR2 EREG MMP9 EGFR IL16 CFP WAS ITGAL KLRD1 RARS TLR2 CCND2 IL2RG ETS1 ITK NCR1 MAP4K1 CCL19 PSMB10 RPL39 EIF3J ABCE1 CD8B F2 ELF4 LY86 FCGR2B GBP2 PRKCG RPS9 MTIF2 GZMA AARS CD96 CSK HIF1A CCL2 ICOSLG NPM1 IL4R CCL11 NME1 FLNA GPR65 ACHE EIF3D IGSF6 F2R IL13 TAP1 DARS IRF7 ACVR2A CXCR3 PRKCB CXCL9 PTPN6 NCF4 UBE2D1 LIF CCR1 MBL2 DEGS1 TPD52 AKT1 RIPK2 IKBKB GCNT1 SOCS5 IRF8 TAP2 EIF4G3 ABI1 CCL7 IL2RB BRCA1 FGR IL18RAP MRPL3 CXCL13 CAPG EIF5A GALNT1 ST8SIA4 CCL13 RPL3L LY75 TAPBP NOS2 RPL9 BCAT1 IL9 IL27RA DYRK3
kfs-all: 2 of 200 genes missing from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: BCL3 RPS3A
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
kfs-all wnt vs CIRC: t = -4.09851997685246 df = 288 nrow = 290 cor = -0.234758375311116 pval = 5.41194167783526e-05
kfs-all tak1 vs CIRC: t = -0.274339048635223 df = 288 nrow = 290 cor = -0.0161634716390661 pval = 0.784020752365827
kfs-all wnt vs myc.sig: t = 36.8247724188401 df = 288 nrow = 290 cor = 0.908198394193576 pval = 5.93740129656503e-111

kfs-all: Analyzing CIRC vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12055, n_WT = 175, n_MT = 115, p = 0.00435205481997611
kfs-all: Analyzing CIITA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 9670, n_WT = 175, n_MT = 115, p = 0.574710007860122
kfs-all: Analyzing wnt vs KRAS using Wilcoxon rank sum test with continuity correction: W = 8981, n_WT = 175, n_MT = 115, p = 0.121767434795557
kfs-all: Analyzing myc.sig vs KRAS using Wilcoxon rank sum test with continuity correction: W = 9489, n_WT = 175, n_MT = 115, p = 0.412090216798062
kfs-all: Analyzing BATF3 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10409, n_WT = 175, n_MT = 115, p = 0.620401285842809
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11781, n_WT = 175, n_MT = 115, p = 0.013923495577826
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12719, n_WT = 175, n_MT = 115, p = 0.000143572594451922
kfs-all: Analyzing HALLMARK_COMPLEMENT vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11450, n_WT = 175, n_MT = 115, p = 0.0470976342185448
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11713, n_WT = 175, n_MT = 115, p = 0.0181819133468992
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11057, n_WT = 175, n_MT = 115, p = 0.154776365803811
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11740, n_WT = 175, n_MT = 115, p = 0.0163708273384452

Computing CIRC ~ KRAS
Computing CIITA ~ KRAS
Computing wnt ~ KRAS
Computing myc.sig ~ KRAS
Computing BATF3 ~ KRAS
Computing HALLMARK_IL6_JAK_STAT3_SIGNALING ~ KRAS
Computing HALLMARK_INTERFERON_GAMMA_RESPONSE ~ KRAS
Computing HALLMARK_COMPLEMENT ~ KRAS
Computing HALLMARK_INFLAMMATORY_RESPONSE ~ KRAS
Computing HALLMARK_IL2_STAT5_SIGNALING ~ KRAS
Computing HALLMARK_ALLOGRAFT_REJECTION ~ KRAS
kfs-all: Analyzing CIRC CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2055, n_CMS2 = 106, n_CMS1 = 26, p = 0.000108509453977755
kfs-all: Analyzing CIITA CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1708, n_CMS2 = 106, n_CMS1 = 26, p = 0.059389259866288
kfs-all: Analyzing wnt CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1222, n_CMS2 = 106, n_CMS1 = 26, p = 0.373613791737769
kfs-all: Analyzing myc.sig CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1454, n_CMS2 = 106, n_CMS1 = 26, p = 0.665749798885651
kfs-all: Analyzing BATF3 CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1515, n_CMS2 = 106, n_CMS1 = 26, p = 0.434795288247031
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2039, n_CMS2 = 106, n_CMS1 = 26, p = 0.000157343235652876
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2148, n_CMS2 = 106, n_CMS1 = 26, p = 1.0683838440065e-05
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2320, n_CMS2 = 106, n_CMS1 = 26, p = 7.16506270922477e-08
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2337, n_CMS2 = 106, n_CMS1 = 26, p = 4.15225172153869e-08
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2160, n_CMS2 = 106, n_CMS1 = 26, p = 7.76693322397367e-06
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2070, n_CMS2 = 106, n_CMS1 = 26, p = 7.60378857272565e-05
kfs-all: Analyzing CIRC CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2447, n_CMS2 = 106, n_CMS3 = 48, p = 0.706600913570282
kfs-all: Analyzing CIITA CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1819, n_CMS2 = 106, n_CMS3 = 48, p = 0.00471165536490251
kfs-all: Analyzing wnt CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 3720, n_CMS2 = 106, n_CMS3 = 48, p = 4.53195296903507e-06
kfs-all: Analyzing myc.sig CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 3576, n_CMS2 = 106, n_CMS3 = 48, p = 5.73024749297041e-05
kfs-all: Analyzing BATF3 CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2973, n_CMS2 = 106, n_CMS3 = 48, p = 0.0946262492626068
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2195, n_CMS2 = 106, n_CMS3 = 48, p = 0.174013190073611
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2270, n_CMS2 = 106, n_CMS3 = 48, p = 0.286033816134859
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2088, n_CMS2 = 106, n_CMS3 = 48, p = 0.0756004392041783
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1992, n_CMS2 = 106, n_CMS3 = 48, p = 0.0314541841595896
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2309, n_CMS2 = 106, n_CMS3 = 48, p = 0.360332122432123
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2296, n_CMS2 = 106, n_CMS3 = 48, p = 0.334323208818948
kfs-all: Analyzing CIRC CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2225, n_CMS2 = 106, n_CMS4 = 78, p = 9.01166130485262e-08
kfs-all: Analyzing CIITA CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 3631, n_CMS2 = 106, n_CMS4 = 78, p = 0.159286680025273
kfs-all: Analyzing wnt CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 7047, n_CMS2 = 106, n_CMS4 = 78, p = 3.41319519599451e-16
kfs-all: Analyzing myc.sig CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 7284, n_CMS2 = 106, n_CMS4 = 78, p = 1.1286075290163e-18
kfs-all: Analyzing BATF3 CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2067, n_CMS2 = 106, n_CMS4 = 78, p = 7.11649613173999e-09
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2012, n_CMS2 = 106, n_CMS4 = 78, p = 2.8121505992338e-09
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2101, n_CMS2 = 106, n_CMS4 = 78, p = 1.24884928095046e-08
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1071, n_CMS2 = 106, n_CMS4 = 78, p = 9.66268088665212e-18
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1100, n_CMS2 = 106, n_CMS4 = 78, p = 1.95114563738565e-17
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1105, n_CMS2 = 106, n_CMS4 = 78, p = 2.20101544922564e-17
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1832, n_CMS2 = 106, n_CMS4 = 78, p = 1.14557705421274e-10


kfs-all: Analyzing CIRC CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 179, n_CMS2 = 36, n_CMS1 = 6, p = 0.0085501009762884
kfs-all: Analyzing CIITA CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 150, n_CMS2 = 36, n_CMS1 = 6, p = 0.138669400543598
kfs-all: Analyzing wnt CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 83, n_CMS2 = 36, n_CMS1 = 6, p = 0.388006296863806
kfs-all: Analyzing myc.sig CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 112, n_CMS2 = 36, n_CMS1 = 6, p = 0.902446268299927
kfs-all: Analyzing BATF3 CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 131, n_CMS2 = 36, n_CMS1 = 6, p = 0.428381561886055
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 159, n_CMS2 = 36, n_CMS1 = 6, p = 0.0687515655423229
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 168, n_CMS2 = 36, n_CMS1 = 6, p = 0.0298064007948475
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 159, n_CMS2 = 36, n_CMS1 = 6, p = 0.0687515655423229
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 180, n_CMS2 = 36, n_CMS1 = 6, p = 0.00752032202609866
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 150, n_CMS2 = 36, n_CMS1 = 6, p = 0.138669400543598
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 162, n_CMS2 = 36, n_CMS1 = 6, p = 0.052883972011058
kfs-all: Analyzing CIRC CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 432, n_CMS2 = 36, n_CMS3 = 30, p = 0.167330833537003
kfs-all: Analyzing CIITA CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 345, n_CMS2 = 36, n_CMS3 = 30, p = 0.0115762456248918
kfs-all: Analyzing wnt CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 744, n_CMS2 = 36, n_CMS3 = 30, p = 0.00815496429418493
kfs-all: Analyzing myc.sig CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 697, n_CMS2 = 36, n_CMS3 = 30, p = 0.0433309216347485
kfs-all: Analyzing BATF3 CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 514, n_CMS2 = 36, n_CMS3 = 30, p = 0.744285955061452
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 407, n_CMS2 = 36, n_CMS3 = 30, p = 0.0880178541351454
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 436, n_CMS2 = 36, n_CMS3 = 30, p = 0.183842298214124
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 435, n_CMS2 = 36, n_CMS3 = 30, p = 0.17960704734639
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 355, n_CMS2 = 36, n_CMS3 = 30, p = 0.0167911866096465
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 438, n_CMS2 = 36, n_CMS3 = 30, p = 0.192530672607381
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 423, n_CMS2 = 36, n_CMS3 = 30, p = 0.134235006264346
kfs-all: Analyzing CIRC CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 264, n_CMS2 = 36, n_CMS4 = 28, p = 0.000945776643221886
kfs-all: Analyzing CIITA CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 456, n_CMS2 = 36, n_CMS4 = 28, p = 0.522948629742605
kfs-all: Analyzing wnt CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 806, n_CMS2 = 36, n_CMS4 = 28, p = 2.23767781099567e-05
kfs-all: Analyzing myc.sig CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 871, n_CMS2 = 36, n_CMS4 = 28, p = 1.14854334717033e-07
kfs-all: Analyzing BATF3 CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 220, n_CMS2 = 36, n_CMS4 = 28, p = 7.41618516787812e-05
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 258, n_CMS2 = 36, n_CMS4 = 28, p = 0.000688438453361575
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 284, n_CMS2 = 36, n_CMS4 = 28, p = 0.00256179172326456
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 148, n_CMS2 = 36, n_CMS4 = 28, p = 3.16211149632901e-07
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 143, n_CMS2 = 36, n_CMS4 = 28, p = 2.0094702464804e-07
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 142, n_CMS2 = 36, n_CMS4 = 28, p = 1.8327579451442e-07
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 240, n_CMS2 = 36, n_CMS4 = 28, p = 0.000251432366830623

kfs-all: Analyzing CIRC CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 952, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.0402311195102744
kfs-all: Analyzing CIITA CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1251, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.954780603432468
kfs-all: Analyzing wnt CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1291, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.838768454068382
kfs-all: Analyzing myc.sig CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1241, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.901777974509518
kfs-all: Analyzing BATF3 CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1059, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.181040344910199
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1035, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.134220194393552
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 969, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.0526282162650264
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1140, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.425335867693919
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1015, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.102871804158444
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1160, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.506833689700493
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1025, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.11772915295131
kfs-all: Analyzing CIRC CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 37, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.0085501009762884
kfs-all: Analyzing CIITA CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 66, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.138669400543598
kfs-all: Analyzing wnt CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 133, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.388006296863806
kfs-all: Analyzing myc.sig CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 104, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.902446268299927
kfs-all: Analyzing BATF3 CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 85, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.428381561886055
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 57, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.0687515655423229
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 48, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.0298064007948475
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 57, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.0687515655423229
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 36, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.00752032202609866
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 66, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.138669400543598
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 54, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.052883972011058
kfs-all: Analyzing CIRC CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 149, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.000193518969796467
kfs-all: Analyzing CIITA CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 276, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.15456969860761
kfs-all: Analyzing wnt CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 403, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.470740294032794
kfs-all: Analyzing myc.sig CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 329, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.60499742844703
kfs-all: Analyzing BATF3 CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 292, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.250836000186168
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 160, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.000440621798458705
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 103, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 3.04070015214816e-06
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 93, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 1.02351262850619e-06
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 84, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 3.57660215572434e-07
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 115, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 1.01872045308901e-05
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 150, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.000209049502882481
kfs-all: Analyzing CIRC CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 432, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.167330833537003
kfs-all: Analyzing CIITA CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 345, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.0115762456248918
kfs-all: Analyzing wnt CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 744, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.00815496429418493
kfs-all: Analyzing myc.sig CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 697, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.0433309216347485
kfs-all: Analyzing BATF3 CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 514, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.744285955061452
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 407, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.0880178541351454
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 436, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.183842298214124
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 435, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.17960704734639
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 355, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.0167911866096465
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 438, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.192530672607381
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 423, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.134235006264346
kfs-all: Analyzing CIRC CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 237, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.113046655204864
kfs-all: Analyzing CIITA CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 262, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.261854610214589
kfs-all: Analyzing wnt CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 537, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 4.25229774198858e-05
kfs-all: Analyzing myc.sig CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 514, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.000318907762494862
kfs-all: Analyzing BATF3 CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 395, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.197778912550364
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 233, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.0970643232253432
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 190, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.0133017208645843
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 224, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.0675744351382051
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 219, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.0546122577341001
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 308, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.778174222457639
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 247, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.161846910627486
kfs-all: Analyzing CIRC CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 264, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 0.000945776643221886
kfs-all: Analyzing CIITA CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 456, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 0.522948629742605
kfs-all: Analyzing wnt CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 806, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 2.23767781099567e-05
kfs-all: Analyzing myc.sig CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 871, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 1.14854334717033e-07
kfs-all: Analyzing BATF3 CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 220, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 7.41618516787812e-05
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 258, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 0.000688438453361575
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 284, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 0.00256179172326456
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 148, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 3.16211149632901e-07
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 143, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 2.0094702464804e-07
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 142, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 1.8327579451442e-07
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 240, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 0.000251432366830623
kfs-all: Analyzing CIRC CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 298, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 1.39893617147937e-07
kfs-all: Analyzing CIITA CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 767, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 0.246100317408581
kfs-all: Analyzing wnt CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 1608, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 5.89223906659432e-10
kfs-all: Analyzing myc.sig CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 1596, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 1.14157512606275e-09
kfs-all: Analyzing BATF3 CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 444, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 6.68186088886668e-05
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 330, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 6.18761237001398e-07
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 269, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 3.40455253289366e-08
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 221, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 2.86018873351893e-09
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 184, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 3.7687374891401e-10
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 204, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 1.14157512606275e-09
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 294, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 1.15547338770202e-07

Computing linear model with interaction for CIRC
Computing linear model with interaction for CIITA
Computing linear model with interaction for wnt
Computing linear model with interaction for myc.sig
Computing linear model with interaction for BATF3
Computing linear model with interaction for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model with interaction for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model with interaction for HALLMARK_COMPLEMENT
Computing linear model with interaction for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model with interaction for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model with interaction for HALLMARK_ALLOGRAFT_REJECTION
Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
kfs-all: Analyzing CIRC CMS1 MT vs WT using Wilcoxon rank sum test: W = 74, n_MT = 6, n_WT = 20, p = 0.421482864961126
kfs-all: Analyzing CIITA CMS1 MT vs WT using Wilcoxon rank sum test: W = 57, n_MT = 6, n_WT = 20, p = 0.882274247491639
kfs-all: Analyzing wnt CMS1 MT vs WT using Wilcoxon rank sum test: W = 65, n_MT = 6, n_WT = 20, p = 0.78974069408852
kfs-all: Analyzing myc.sig CMS1 MT vs WT using Wilcoxon rank sum test: W = 67, n_MT = 6, n_WT = 20, p = 0.699943534726143
kfs-all: Analyzing BATF3 CMS1 MT vs WT using Wilcoxon rank sum test: W = 63, n_MT = 6, n_WT = 20, p = 0.882274247491639
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS1 MT vs WT using Wilcoxon rank sum test: W = 79, n_MT = 6, n_WT = 20, p = 0.268079746340616
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS1 MT vs WT using Wilcoxon rank sum test: W = 85, n_MT = 6, n_WT = 20, p = 0.138956695478435
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS1 MT vs WT using Wilcoxon rank sum test: W = 97, n_MT = 6, n_WT = 20, p = 0.023298440689745
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS1 MT vs WT using Wilcoxon rank sum test: W = 83, n_MT = 6, n_WT = 20, p = 0.175589627763541
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS1 MT vs WT using Wilcoxon rank sum test: W = 99, n_MT = 6, n_WT = 20, p = 0.0160100768796421
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS1 MT vs WT using Wilcoxon rank sum test: W = 85, n_MT = 6, n_WT = 20, p = 0.138956695478435
kfs-all: Analyzing CIRC CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1568, n_MT = 36, n_WT = 70, p = 0.0402311195102744
kfs-all: Analyzing CIITA CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1269, n_MT = 36, n_WT = 70, p = 0.954780603432468
kfs-all: Analyzing wnt CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1229, n_MT = 36, n_WT = 70, p = 0.838768454068382
kfs-all: Analyzing myc.sig CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1279, n_MT = 36, n_WT = 70, p = 0.901777974509518
kfs-all: Analyzing BATF3 CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1461, n_MT = 36, n_WT = 70, p = 0.181040344910199
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1485, n_MT = 36, n_WT = 70, p = 0.134220194393552
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1551, n_MT = 36, n_WT = 70, p = 0.0526282162650264
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1380, n_MT = 36, n_WT = 70, p = 0.425335867693919
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1505, n_MT = 36, n_WT = 70, p = 0.102871804158444
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1360, n_MT = 36, n_WT = 70, p = 0.506833689700493
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1495, n_MT = 36, n_WT = 70, p = 0.11772915295131
kfs-all: Analyzing CIRC CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 877, n_MT = 28, n_WT = 50, p = 0.0659924170857015
kfs-all: Analyzing CIITA CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 751, n_MT = 28, n_WT = 50, p = 0.598872475857331
kfs-all: Analyzing wnt CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 529, n_MT = 28, n_WT = 50, p = 0.075736636871889
kfs-all: Analyzing myc.sig CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 607, n_MT = 28, n_WT = 50, p = 0.33529324416062
kfs-all: Analyzing BATF3 CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 677, n_MT = 28, n_WT = 50, p = 0.814700445451032
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 845, n_MT = 28, n_WT = 50, p = 0.132284515601839
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 966, n_MT = 28, n_WT = 50, p = 0.0056831252945491
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 714, n_MT = 28, n_WT = 50, p = 0.888170215453213
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 791, n_MT = 28, n_WT = 50, p = 0.345847554223562
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 740, n_MT = 28, n_WT = 50, p = 0.68074739764577
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 841, n_MT = 28, n_WT = 50, p = 0.143333693922718
kfs-all: Analyzing CIRC CMS3 MT vs WT using Wilcoxon rank sum test: W = 287, n_MT = 30, n_WT = 18, p = 0.727911950381983
kfs-all: Analyzing CIITA CMS3 MT vs WT using Wilcoxon rank sum test: W = 243, n_MT = 30, n_WT = 18, p = 0.576078877235431
kfs-all: Analyzing wnt CMS3 MT vs WT using Wilcoxon rank sum test: W = 145, n_MT = 30, n_WT = 18, p = 0.00710750551922749
kfs-all: Analyzing myc.sig CMS3 MT vs WT using Wilcoxon rank sum test: W = 172, n_MT = 30, n_WT = 18, p = 0.036955607906606
kfs-all: Analyzing BATF3 CMS3 MT vs WT using Wilcoxon rank sum test: W = 194, n_MT = 30, n_WT = 18, p = 0.108390322155793
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 274, n_MT = 30, n_WT = 18, p = 0.941194342744294
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 334, n_MT = 30, n_WT = 18, p = 0.178071052462238
kfs-all: Analyzing HALLMARK_COMPLEMENT CMS3 MT vs WT using Wilcoxon rank sum test: W = 317, n_MT = 30, n_WT = 18, p = 0.325458469104126
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 286, n_MT = 30, n_WT = 18, p = 0.743816557090784
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 237, n_MT = 30, n_WT = 18, p = 0.492658961389714
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS3 MT vs WT using Wilcoxon rank sum test: W = 261, n_MT = 30, n_WT = 18, p = 0.85780490578066

Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
Computing rectum vs left
kfs-all: Analyzing CIRC site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2636, n_rectum = 188, n_left = 28, p = 0.990948894920794
kfs-all: Analyzing CIITA site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2708, n_rectum = 188, n_left = 28, p = 0.806681835189559
kfs-all: Analyzing wnt site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2590, n_rectum = 188, n_left = 28, p = 0.893000200453283
kfs-all: Analyzing myc.sig site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2704, n_rectum = 188, n_left = 28, p = 0.816736705743576
kfs-all: Analyzing BATF3 site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3294, n_rectum = 188, n_left = 28, p = 0.0320297685713912
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2478, n_rectum = 188, n_left = 28, p = 0.618821876377818
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2527, n_rectum = 188, n_left = 28, p = 0.734833443487019
kfs-all: Analyzing HALLMARK_COMPLEMENT site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2692, n_rectum = 188, n_left = 28, p = 0.847076395966555
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2741, n_rectum = 188, n_left = 28, p = 0.725087442472629
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2511, n_rectum = 188, n_left = 28, p = 0.696121100559936
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2578, n_rectum = 188, n_left = 28, p = 0.862334669993729
Computing right vs left
kfs-all: Analyzing CIRC site: right vs leftWilcoxon rank sum test with continuity correction: W = 899, n_right = 74, n_left = 28, p = 0.306047065766897
kfs-all: Analyzing CIITA site: right vs leftWilcoxon rank sum test with continuity correction: W = 790, n_right = 74, n_left = 28, p = 0.0656371874400753
kfs-all: Analyzing wnt site: right vs leftWilcoxon rank sum test with continuity correction: W = 964, n_right = 74, n_left = 28, p = 0.591857559582254
kfs-all: Analyzing myc.sig site: right vs leftWilcoxon rank sum test with continuity correction: W = 944, n_right = 74, n_left = 28, p = 0.49263928260657
kfs-all: Analyzing BATF3 site: right vs leftWilcoxon rank sum test with continuity correction: W = 1171, n_right = 74, n_left = 28, p = 0.313188284327246
kfs-all: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 920, n_right = 74, n_left = 28, p = 0.386445078738186
kfs-all: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 880, n_right = 74, n_left = 28, p = 0.243604699798794
kfs-all: Analyzing HALLMARK_COMPLEMENT site: right vs leftWilcoxon rank sum test with continuity correction: W = 976, n_right = 74, n_left = 28, p = 0.655479100105231
kfs-all: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 999, n_right = 74, n_left = 28, p = 0.784317501590637
kfs-all: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 958, n_right = 74, n_left = 28, p = 0.561147843501288
kfs-all: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: right vs leftWilcoxon rank sum test with continuity correction: W = 912, n_right = 74, n_left = 28, p = 0.354409296147732

Plotting CIRC ~ site
Plotting CIITA ~ site
Plotting wnt ~ site
Plotting myc.sig ~ site
Plotting BATF3 ~ site
Plotting HALLMARK_IL6_JAK_STAT3_SIGNALING ~ site
Plotting HALLMARK_INTERFERON_GAMMA_RESPONSE ~ site
Plotting HALLMARK_COMPLEMENT ~ site
Plotting HALLMARK_INFLAMMATORY_RESPONSE ~ site
Plotting HALLMARK_IL2_STAT5_SIGNALING ~ site
Plotting HALLMARK_ALLOGRAFT_REJECTION ~ site
MSI nrow =  307 
  clusters Freq
1        1   79
2        2  228
MSI clusters: 1
MSS clusters: 2
[1] 9.031144e-14
[1] 1.236511e-13
Has CMS
Has TYMS
[1] 1.00 5.00 0.25 0.25 2.00
[1] 1.0 5.0 5.0 0.5 1.0 0.5
     [,1] [,2] [,3] [,4] [,5]
[1,]   NA    2    4    6   NA
[2,]    1    3    5    7    9
[3,]    1    3    5    7   10
[4,]   NA   NA   NA   NA   NA
[5,]   NA    8   NA   NA   NA
[6,]   NA   NA   NA   NA   NA
[1] 10
Beeswarm: TYMS vs Inferred.Status W = 10472 p = 0.031133557676555 n_MSI = 79, n_MSS = 228
Number of rows analyzed: 20534
Number of columns analyzed: 290
kfs-all-msi-inferred: 26 of 28 genes from data set analyzed in set CIRC: HLA-DQA1 CTLA4 PDCD1LG2 ICAM1 CD274 STAT1 IRF1 IFNG GNLY TBX21 CCL5 LAG3 CD247 ICOS IL18RAP CXCL9 CXCL10 HLA-DPB1 HLA-DPA1 HLA-DMB HLA-DRA HLA-DMA CD80 HLA-DOA CD4 HAVCR2
kfs-all-msi-inferred: 2 of 28 genes missing from data set analyzed in set CIRC: HLA-DQA2 HLA-DRB5
kfs-all-msi-inferred: 75 of 88 genes from data set analyzed in set myc.sig: AKAP1 APEX1 BAX CAD CCKBR CCNB1 CCND2 CCT5 CDC25C CEBPZ CKS2 CTSC DDX10 DDX18 DDX5 E2F1 EIF4B ENO1 EXOSC8 FASN FOSL1 H2AFZ HSPD1 HSPE1 ID2 IMPA2 LTA4H MAT2A METTL1 MINA MSH2 MTHFD1 NAP1L1 NCL NME1 NPM1 NRAS NUP155 PA2G4 PCNA PHB POLD2 PPAT PPIA PPID PRDX3 PREP PRPS2 PSMB1 PTEN PYCR1 RPL19 RPL22 RPL27 RPL27A RPL32 RPL9 RPS16 RPS19 RPS5 RPS6KA2 SHMT1 SLC25A3 SLC39A6 SNRPB SNRPD3 SRM TERT TFRC TOP1 TXN TYMS UBE2C UCHL1 UXT
kfs-all-msi-inferred: 13 of 88 genes missing from data set analyzed in set myc.sig: CSDA DKC1 DSCR2 EIF4A1 HNRPA2B1 HSPA8 HSPA9B RPL10 RPL5 RPS13 SFRS1 SFRS2 SFRS7
kfs-all-msi-inferred: 44 of 78 genes from data set analyzed in set wnt: PHLDA1 SLC7A5 BYSL SCD SOX4 WDR77 NLE1 PPIL1 ZNF511 ZNF593 ODC1 AURKB WDR12 CDT1 NOC3L CAD XPOT YAP1 SRM NXT1 MRPS12 RHEB WDR3 CRTAP SF3A2 GEMIN5 IMP4 HEATR1 SLC19A1 PDCD11 ASCL2 TBX3 EPHB3 ZNRF3 IL20RA RHOBTB3 GEMIN4 ID3 FUT4 PIGW APEX1 SRPRB ZNRD1 TFB2M
kfs-all-msi-inferred: 34 of 78 genes missing from data set analyzed in set wnt: FLJ20315 CTPS NOB1P PSF1 PMSCL1 RNU3IP2 CIRH1A HIG2 C1orf33 DKC1 LOC389362 HSPC111 MGC40397 LOC56902 SDCCAG16 FLJ10774 RAB9P40 RFP RRP41 HNRPDL C16orf35 TREX2 CGI-96 C20orf64 C12orf14 NOL1 TDGF1 SKB1 C11orf5 MGC16824 ZNF278 RPC62 JTV1 ZNF339
kfs-all-msi-inferred: 87 of 87 genes from data set analyzed in set HALLMARK_IL6_JAK_STAT3_SIGNALING: IL4R IL6ST STAT1 IL1R1 CSF2RB SOCS3 STAT3 OSMR IL2RG IFNGR1 TYK2 IL13RA1 TLR2 IFNGR2 IL10RB IL6 IL1R2 IL3RA IFNAR1 TNFRSF1A MYD88 ACVR1B CSF3R ITGB3 REG1A CXCL1 A2M CSF2RA IL15RA IRF9 PDGFC HAX1 BAK1 EBI3 INHBE CRLF2 TNFRSF1B CD14 PTPN1 PTPN2 IL1B CSF1 IL18R1 TNF PF4 CXCL13 LTBR FAS IL17RA CXCL10 IL9R STAM2 TNFRSF12A STAT2 HMOX1 LEPR CBL CD9 CXCL3 TGFB1 MAP3K8 ITGA4 CD38 JUN SOCS1 ACVRL1 PIM1 TNFRSF21 PIK3R5 GRB2 IRF1 DNTT CSF2 IL2RA PTPN11 IL12RB1 CCR1 CNTFR PLA2G2A CXCL9 CD44 IL7 CXCL11 CCL7 LTB IL17RB CD36
kfs-all-msi-inferred: 194 of 200 genes from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: STAT1 ISG15 IFIT1 MX1 IFIT3 IFI35 IRF7 IFIT2 OAS2 TAP1 EIF2AK2 RSAD2 MX2 IRF1 OAS3 TNFSF10 IRF9 CXCL10 IFI44 BST2 XAF1 SP110 OASL PSMB8 IFI44L IFITM3 DDX60 LGALS3BP GBP4 IRF8 PSMB9 PML IFIH1 UBE2L6 IFI27 ADAR LY6E STAT2 CXCL9 IL10RA PLA2G4A TRIM21 USP18 PTGS2 EPSTI1 C1S DDX58 IL15 NLRC5 NMI IDO1 PSMB10 CXCL11 ITGB7 SAMHD1 HERC6 CMPK2 SAMD9L RTP4 PTPN2 PARP14 TNFAIP2 IFITM2 PLSCR1 SOCS1 CASP1 ICAM1 WARS PSME1 ISG20 IRF2 TRIM14 FCGR1A MARCH1 SOCS3 JAK2 HLA-DMA PARP12 TNFAIP6 TRIM26 VCAM1 CD274 CIITA NAMPT SELP GPR18 FPR1 SERPING1 CCL5 RNF31 SOD2 TRIM25 LAP3 PSMA3 RNF213 PELI1 CFB CD86 TXNIP HLA-DQA1 GCH1 PNP CCL7 PTPN6 SPPL2A IL4R PNPT1 DHX58 BTG1 CASP8 CCL2 FGL2 CASP7 SECTM1 IL15RA CD40 TRAFD1 GBP6 LCP2 HLA-G MT2A RIPK1 UPP1 PSMB2 TDRD7 HIF1A EIF4E3 VAMP8 PFKP CD38 ZBP1 BANK1 TOR1B RBCK1 PDE4B MVP IL7 BPGM AUTS2 B2M RIPK2 CD69 MYD88 PSMA2 PIM1 NOD1 CFH TAPBP SLC25A28 PTPN1 TNFAIP3 SSPN NUP93 MTHFD2 CDKN1A IRF4 NFKB1 BATF2 HLA-B LATS2 IRF5 SLAMF7 ISOC1 P2RY14 STAT3 NCOA3 HLA-A IL6 GZMA IFNAR2 CD74 RAPGEF6 CASP4 FAS OGFR ARL4A SRI LYSMD2 CSF2RB ST3GAL5 C1R CASP3 CMKLR1 NFKBIA METTL7B ST8SIA4 XCL1 IL2RB VAMP5 IL18BP ZNFX1 ARID5B APOL6 STAT4
kfs-all-msi-inferred: 6 of 200 genes missing from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: PRIC285 PSME2 IFI30 HLA-DRB1 KLRK1 FTSJD2
kfs-all-msi-inferred: 193 of 200 genes from data set analyzed in set HALLMARK_COMPLEMENT: C2 C1S CFB C1R SERPINE1 MMP14 SERPING1 F5 MMP13 F7 CTSS LGMN PLG C1QA CASP1 GZMA ADAM9 CALM3 C1QC TIMP1 DPP4 KLK1 KLKB1 CD59 CR2 MMP15 LAP3 SPOCK2 F10 CTSB SERPINA1 CTSO CD40LG CBLB PDP1 C4BPB PLEK GP9 PLAUR C3 F2 CASP4 STX4 CTSC CR1 DUSP6 SERPINB2 GPD2 CFH FN1 CD36 CA2 PSMB9 APOBEC3G FCN1 GZMK PDGFB CLU CASP10 LRP1 CTSD S100A9 WAS BRPF3 PLAT CDA MT3 CASP7 PRSS36 PFN1 GZMB RNF4 ZEB1 CASP5 IRF1 CDK5R1 ATOX1 PIK3CA TMPRSS6 CPM RCE1 CALM1 DOCK9 KYNU RASGRP1 USP14 LCP2 GP1BA KIF2A GNB4 LCK OLR1 PREP LTA4H ZFPM2 LYN ACTN2 SIRT6 APOC1 PRKCD ITGAM DGKH LTF MAFF KCNIP2 PCLO DOCK10 SH2B3 RABIF SRC HPCAL4 CD46 PRDM4 GNAI3 C9 PPP2CB IRF2 FYN JAK2 PLA2G4A PRCP USP8 RHOG L3MBTL4 LAMP2 PIM1 CXCL1 F3 GNAI2 CASP9 XPNPEP1 PLSCR1 IRF7 CD55 HSPA5 GNB2 DYRK2 PLA2G7 S100A12 GRB2 PHEX GNGT2 DOCK4 MMP12 KCNIP3 FDX1 TIMP2 MMP8 FCER1G ANXA5 GCA EHD1 PRSS3 COL4A2 CSRP1 PIK3R5 SERPINC1 ANG APOBEC3F GATA3 DUSP5 CASP3 USP16 CP PSEN1 LIPA PCSK9 DGKG GNG2 ME1 GMFB SCG3 PPP4C CCL5 CTSH F8 APOA4 IL6 AKAP10 ERAP2 VCPIP1 RAF1 NOTCH4 ADRA2B CEBPB HNF4A LGALS3 TNFAIP3 CDH13 ITIH1 TFPI2 PIK3CG S100A13
kfs-all-msi-inferred: 7 of 200 genes missing from data set analyzed in set HALLMARK_COMPLEMENT: CTSL1 USP15 PGCP SEPX1 ZFYVE20 CTSL2 HSPA1A
kfs-all-msi-inferred: 197 of 200 genes from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: CXCL10 CCL2 CCL5 FPR1 CCL20 IL1A CCL7 CCL22 CXCL11 CCR7 EDN1 CD40 CXCL9 IL6 IL1B TLR2 IL1R1 CD69 ICAM1 CCRL2 AQP9 EREG C3AR1 GNA15 CMKLR1 PTGER4 LIF IL15 NAMPT OPRK1 ITGB8 PTAFR ADM PLAUR NFKB1 INHBA OSM TNFSF10 TNFSF15 IFNGR2 IL12B CSF1 CXCL6 TNFRSF9 LYN ACVR2A LDLR BDKRB1 HRH1 F3 BST2 PTGIR CD55 CALCRL CSF3 GPR132 IL4R NLRP3 IL15RA ADORA2B GCH1 OLR1 PTGER2 CSF3R MYC RELA TNFAIP6 IL7R IL18 GABBR1 CD82 TNFSF9 NMUR1 IL2RB TLR1 LPAR1 IRAK2 RIPK2 MMP14 P2RX7 SLC11A2 SELL P2RY2 ABCA1 FFAR2 PROK2 GNAI3 TACR1 SLC7A1 CDKN1A CYBB TIMP1 HBEGF SCARF1 EBI3 NFKBIA SRI SLC7A2 CCL17 TLR3 APLNR OSMR IL10RA PSEN1 GPR183 ATP2B1 TNFRSF1B BEST1 GPC3 SCN1B ACVR1B HPN SEMA4D KLF6 CD48 CXCR6 SLC1A2 GP1BA TAPBP RGS16 SLAMF1 LCK HIF1A AHR NMI RHOG TPBG NPFFR2 IFNAR1 ICOSLG RASGRP1 IFITM1 KCNJ2 LY6E IL18R1 IL10 KCNA3 HAS2 DCBLD2 LAMP3 VIP CD70 RGS1 SLC31A1 ADRM1 KCNMB2 SERPINE1 MXD1 AXL MEFV PVR CCL24 PDE4B LCP2 PDPN IRF7 MET ATP2A2 SLC31A2 FZD5 ITGA5 SGMS2 MARCO CD14 EIF2AK2 ROS1 ATP2C1 NDP BTG2 MSR1 PTPRE RNF144B PCDH7 SPHK1 IL18RAP RTP4 RAF1 CHST2 ITGB3 KIF1B SELE NOD2 C5AR1 EMP3 CLEC5A TACR3 SLC4A4 MEP1A LTA PIK3R5 STAB1 IRF1 ICAM4 P2RX4 ABI1 CX3CL1 SLC28A2
kfs-all-msi-inferred: 3 of 200 genes missing from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: IL8 EMR1 SELS
kfs-all-msi-inferred: 194 of 200 genes from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: SOCS2 CISH PIM1 IL2RA TNFRSF4 SOCS1 TNFRSF9 XBP1 RRAGD HK2 PHLDA1 IL2RB CTLA4 NFIL3 CD83 IKZF2 IL10 TNFRSF18 DHRS3 ECM1 ADAM19 SLC2A3 HIPK2 BATF3 BHLHE40 PTGER2 DENND5A ITIH5 PHTF2 GADD45B NRP1 NCOA3 CD79B AHR TNFRSF1B NDRG1 BCL2L1 GABARAPL1 LIF TIAM1 BMPR2 MAP3K8 RHOB MYC S100A1 CAPG ST3GAL4 PENK IRF4 CST7 WLS TLR7 IKZF4 GBP4 RGS16 SPP1 IL13 SLC29A2 NFKBIZ IL4R MXD1 CSF2 FAH CTSZ ITGAE MUC1 MAPKAPK2 TNFRSF21 NT5E FLT3LG CCND2 TRAF1 LCLAT1 IL3RA CYFIP1 BCL2 FGL2 PRNP PUS1 ITGAV NCS1 DCPS AMACR FAM126B PTH1R ODC1 IGF1R PTCH1 ENO3 CD81 MAFF EMP1 CDKN1C CAPN3 IL1R2 SYT11 TTC39B ANXA4 BATF P4HA1 GPR65 SLC1A5 IGF2R CKAP4 CCR4 CD44 P2RX4 GATA1 KLF6 ARL4A HOPX GPR83 ITGA6 CD48 SELP GLIPR2 SMPDL3A PLSCR1 FURIN SERPINB6 TNFSF11 GPX4 LRRC8C CCNE1 CASP3 SH3BGRL2 SNX9 PLEC BMP2 ICOS ALCAM LTB ENPP1 IL1RL1 MYO1C IFNGR1 PLIN2 IL18R1 AHNAK PRKCH TNFRSF8 SYNGR2 GALM POU2F1 EOMES NOP2 PTRH2 RHOH CDC6 MYO1E CXCL10 SNX14 IRF6 IL10RA MAP6 TNFSF10 SPRED2 SELL SERPINC1 CDCP1 RORA COCH CSF1 F2RL2 CA2 IFITM3 UMPS HUWE1 COL6A1 ABCB1 RNH1 IRF8 GUCY1B3 AHCY PRAF2 GSTO1 TWSG1 CDC42SE2 PLAGL1 APLP1 SPRY4 SCN9A SHE PDCD2L CCND3 LRIG1 SWAP70 SLC39A8 RABGAP1L TGM2 PNP AGER ETV4 CD86
kfs-all-msi-inferred: 6 of 200 genes missing from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: METTL20 N6AMT2 CCDC164 UCK2 AKAP2 PPAP2A
kfs-all-msi-inferred: 198 of 200 genes from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: PTPRC IL12B TGFB1 IL12A CD3E CD3D CD28 LYN HCLS1 IL18 CRTAM IFNG CD3G CD86 IL10 UBE2N BCL10 CD4 LCK NCK1 C2 HLA-A ITGB2 HLA-DQA1 CD1D CD80 HLA-DRA THY1 TLR1 HLA-G HLA-DMB IL7 IL4 TNF CD247 IL2 HLA-DMA STAT1 IRF4 SRGN INHBA TLR3 ZAP70 CD74 CD40 TRAF2 B2M LTB IFNGR1 CCR5 CD40LG HLA-DOA GLMN IL6 HLA-E CD2 CCL5 FAS FASLG TLR6 PF4 TGFB2 CD79A INHBB ELANE SPI1 MAP3K7 IL15 CTSS CD47 PRF1 IL12RB1 LCP2 SOCS1 CDKN2A STAT4 CD7 HLA-DOB CD8A ICAM1 CCL4 GZMB CSF1 IL11 STAB1 IL2RA NLRP3 CCND3 EIF3A SIT1 IFNAR2 HDAC9 CARTPT TRAT1 CCL22 APBB1 FYB IL1B TIMP1 RPS19 JAK2 KRT1 WARS IFNGR2 CCR2 EREG MMP9 EGFR IL16 CFP WAS ITGAL KLRD1 RARS TLR2 CCND2 IL2RG ETS1 ITK NCR1 MAP4K1 CCL19 PSMB10 RPL39 EIF3J ABCE1 CD8B F2 ELF4 LY86 FCGR2B GBP2 PRKCG RPS9 MTIF2 GZMA AARS CD96 CSK HIF1A CCL2 ICOSLG NPM1 IL4R CCL11 NME1 FLNA GPR65 ACHE EIF3D IGSF6 F2R IL13 TAP1 DARS IRF7 ACVR2A CXCR3 PRKCB CXCL9 PTPN6 NCF4 UBE2D1 LIF CCR1 MBL2 DEGS1 TPD52 AKT1 RIPK2 IKBKB GCNT1 SOCS5 IRF8 TAP2 EIF4G3 ABI1 CCL7 IL2RB BRCA1 FGR IL18RAP MRPL3 CXCL13 CAPG EIF5A GALNT1 ST8SIA4 CCL13 RPL3L LY75 TAPBP NOS2 RPL9 BCAT1 IL9 IL27RA DYRK3
kfs-all-msi-inferred: 2 of 200 genes missing from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: BCL3 RPS3A
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
kfs-all-msi-inferred wnt vs CIRC: t = -4.09851997685246 df = 288 nrow = 290 cor = -0.234758375311116 pval = 5.41194167783526e-05
kfs-all-msi-inferred tak1 vs CIRC: t = -0.274339048635223 df = 288 nrow = 290 cor = -0.0161634716390661 pval = 0.784020752365827
kfs-all-msi-inferred wnt vs myc.sig: t = 36.8247724188401 df = 288 nrow = 290 cor = 0.908198394193576 pval = 5.93740129656503e-111

kfs-all-msi-inferred: Analyzing CIRC vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12055, n_WT = 175, n_MT = 115, p = 0.00435205481997611
kfs-all-msi-inferred: Analyzing CIITA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 9670, n_WT = 175, n_MT = 115, p = 0.574710007860122
kfs-all-msi-inferred: Analyzing wnt vs KRAS using Wilcoxon rank sum test with continuity correction: W = 8981, n_WT = 175, n_MT = 115, p = 0.121767434795557
kfs-all-msi-inferred: Analyzing myc.sig vs KRAS using Wilcoxon rank sum test with continuity correction: W = 9489, n_WT = 175, n_MT = 115, p = 0.412090216798062
kfs-all-msi-inferred: Analyzing BATF3 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 10409, n_WT = 175, n_MT = 115, p = 0.620401285842809
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11781, n_WT = 175, n_MT = 115, p = 0.013923495577826
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 12719, n_WT = 175, n_MT = 115, p = 0.000143572594451922
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11450, n_WT = 175, n_MT = 115, p = 0.0470976342185448
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11713, n_WT = 175, n_MT = 115, p = 0.0181819133468992
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11057, n_WT = 175, n_MT = 115, p = 0.154776365803811
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11740, n_WT = 175, n_MT = 115, p = 0.0163708273384452

Computing CIRC ~ KRAS
Computing CIITA ~ KRAS
Computing wnt ~ KRAS
Computing myc.sig ~ KRAS
Computing BATF3 ~ KRAS
Computing HALLMARK_IL6_JAK_STAT3_SIGNALING ~ KRAS
Computing HALLMARK_INTERFERON_GAMMA_RESPONSE ~ KRAS
Computing HALLMARK_COMPLEMENT ~ KRAS
Computing HALLMARK_INFLAMMATORY_RESPONSE ~ KRAS
Computing HALLMARK_IL2_STAT5_SIGNALING ~ KRAS
Computing HALLMARK_ALLOGRAFT_REJECTION ~ KRAS
kfs-all-msi-inferred: Analyzing CIRC CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2055, n_CMS2 = 106, n_CMS1 = 26, p = 0.000108509453977755
kfs-all-msi-inferred: Analyzing CIITA CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1708, n_CMS2 = 106, n_CMS1 = 26, p = 0.059389259866288
kfs-all-msi-inferred: Analyzing wnt CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1222, n_CMS2 = 106, n_CMS1 = 26, p = 0.373613791737769
kfs-all-msi-inferred: Analyzing myc.sig CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1454, n_CMS2 = 106, n_CMS1 = 26, p = 0.665749798885651
kfs-all-msi-inferred: Analyzing BATF3 CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1515, n_CMS2 = 106, n_CMS1 = 26, p = 0.434795288247031
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2039, n_CMS2 = 106, n_CMS1 = 26, p = 0.000157343235652876
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2148, n_CMS2 = 106, n_CMS1 = 26, p = 1.0683838440065e-05
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2320, n_CMS2 = 106, n_CMS1 = 26, p = 7.16506270922477e-08
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2337, n_CMS2 = 106, n_CMS1 = 26, p = 4.15225172153869e-08
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2160, n_CMS2 = 106, n_CMS1 = 26, p = 7.76693322397367e-06
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2070, n_CMS2 = 106, n_CMS1 = 26, p = 7.60378857272565e-05
kfs-all-msi-inferred: Analyzing CIRC CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2447, n_CMS2 = 106, n_CMS3 = 48, p = 0.706600913570282
kfs-all-msi-inferred: Analyzing CIITA CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1819, n_CMS2 = 106, n_CMS3 = 48, p = 0.00471165536490251
kfs-all-msi-inferred: Analyzing wnt CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 3720, n_CMS2 = 106, n_CMS3 = 48, p = 4.53195296903507e-06
kfs-all-msi-inferred: Analyzing myc.sig CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 3576, n_CMS2 = 106, n_CMS3 = 48, p = 5.73024749297041e-05
kfs-all-msi-inferred: Analyzing BATF3 CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2973, n_CMS2 = 106, n_CMS3 = 48, p = 0.0946262492626068
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2195, n_CMS2 = 106, n_CMS3 = 48, p = 0.174013190073611
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2270, n_CMS2 = 106, n_CMS3 = 48, p = 0.286033816134859
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2088, n_CMS2 = 106, n_CMS3 = 48, p = 0.0756004392041783
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1992, n_CMS2 = 106, n_CMS3 = 48, p = 0.0314541841595896
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2309, n_CMS2 = 106, n_CMS3 = 48, p = 0.360332122432123
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2296, n_CMS2 = 106, n_CMS3 = 48, p = 0.334323208818948
kfs-all-msi-inferred: Analyzing CIRC CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2225, n_CMS2 = 106, n_CMS4 = 78, p = 9.01166130485262e-08
kfs-all-msi-inferred: Analyzing CIITA CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 3631, n_CMS2 = 106, n_CMS4 = 78, p = 0.159286680025273
kfs-all-msi-inferred: Analyzing wnt CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 7047, n_CMS2 = 106, n_CMS4 = 78, p = 3.41319519599451e-16
kfs-all-msi-inferred: Analyzing myc.sig CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 7284, n_CMS2 = 106, n_CMS4 = 78, p = 1.1286075290163e-18
kfs-all-msi-inferred: Analyzing BATF3 CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2067, n_CMS2 = 106, n_CMS4 = 78, p = 7.11649613173999e-09
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2012, n_CMS2 = 106, n_CMS4 = 78, p = 2.8121505992338e-09
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2101, n_CMS2 = 106, n_CMS4 = 78, p = 1.24884928095046e-08
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1071, n_CMS2 = 106, n_CMS4 = 78, p = 9.66268088665212e-18
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1100, n_CMS2 = 106, n_CMS4 = 78, p = 1.95114563738565e-17
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1105, n_CMS2 = 106, n_CMS4 = 78, p = 2.20101544922564e-17
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1832, n_CMS2 = 106, n_CMS4 = 78, p = 1.14557705421274e-10


kfs-all-msi-inferred: Analyzing CIRC CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 179, n_CMS2 = 36, n_CMS1 = 6, p = 0.0085501009762884
kfs-all-msi-inferred: Analyzing CIITA CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 150, n_CMS2 = 36, n_CMS1 = 6, p = 0.138669400543598
kfs-all-msi-inferred: Analyzing wnt CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 83, n_CMS2 = 36, n_CMS1 = 6, p = 0.388006296863806
kfs-all-msi-inferred: Analyzing myc.sig CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 112, n_CMS2 = 36, n_CMS1 = 6, p = 0.902446268299927
kfs-all-msi-inferred: Analyzing BATF3 CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 131, n_CMS2 = 36, n_CMS1 = 6, p = 0.428381561886055
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 159, n_CMS2 = 36, n_CMS1 = 6, p = 0.0687515655423229
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 168, n_CMS2 = 36, n_CMS1 = 6, p = 0.0298064007948475
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 159, n_CMS2 = 36, n_CMS1 = 6, p = 0.0687515655423229
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 180, n_CMS2 = 36, n_CMS1 = 6, p = 0.00752032202609866
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 150, n_CMS2 = 36, n_CMS1 = 6, p = 0.138669400543598
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 162, n_CMS2 = 36, n_CMS1 = 6, p = 0.052883972011058
kfs-all-msi-inferred: Analyzing CIRC CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 432, n_CMS2 = 36, n_CMS3 = 30, p = 0.167330833537003
kfs-all-msi-inferred: Analyzing CIITA CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 345, n_CMS2 = 36, n_CMS3 = 30, p = 0.0115762456248918
kfs-all-msi-inferred: Analyzing wnt CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 744, n_CMS2 = 36, n_CMS3 = 30, p = 0.00815496429418493
kfs-all-msi-inferred: Analyzing myc.sig CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 697, n_CMS2 = 36, n_CMS3 = 30, p = 0.0433309216347485
kfs-all-msi-inferred: Analyzing BATF3 CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 514, n_CMS2 = 36, n_CMS3 = 30, p = 0.744285955061452
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 407, n_CMS2 = 36, n_CMS3 = 30, p = 0.0880178541351454
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 436, n_CMS2 = 36, n_CMS3 = 30, p = 0.183842298214124
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 435, n_CMS2 = 36, n_CMS3 = 30, p = 0.17960704734639
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 355, n_CMS2 = 36, n_CMS3 = 30, p = 0.0167911866096465
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 438, n_CMS2 = 36, n_CMS3 = 30, p = 0.192530672607381
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 423, n_CMS2 = 36, n_CMS3 = 30, p = 0.134235006264346
kfs-all-msi-inferred: Analyzing CIRC CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 264, n_CMS2 = 36, n_CMS4 = 28, p = 0.000945776643221886
kfs-all-msi-inferred: Analyzing CIITA CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 456, n_CMS2 = 36, n_CMS4 = 28, p = 0.522948629742605
kfs-all-msi-inferred: Analyzing wnt CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 806, n_CMS2 = 36, n_CMS4 = 28, p = 2.23767781099567e-05
kfs-all-msi-inferred: Analyzing myc.sig CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 871, n_CMS2 = 36, n_CMS4 = 28, p = 1.14854334717033e-07
kfs-all-msi-inferred: Analyzing BATF3 CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 220, n_CMS2 = 36, n_CMS4 = 28, p = 7.41618516787812e-05
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 258, n_CMS2 = 36, n_CMS4 = 28, p = 0.000688438453361575
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 284, n_CMS2 = 36, n_CMS4 = 28, p = 0.00256179172326456
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 148, n_CMS2 = 36, n_CMS4 = 28, p = 3.16211149632901e-07
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 143, n_CMS2 = 36, n_CMS4 = 28, p = 2.0094702464804e-07
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 142, n_CMS2 = 36, n_CMS4 = 28, p = 1.8327579451442e-07
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 240, n_CMS2 = 36, n_CMS4 = 28, p = 0.000251432366830623

kfs-all-msi-inferred: Analyzing CIRC CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 952, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.0402311195102744
kfs-all-msi-inferred: Analyzing CIITA CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1251, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.954780603432468
kfs-all-msi-inferred: Analyzing wnt CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1291, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.838768454068382
kfs-all-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1241, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.901777974509518
kfs-all-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1059, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.181040344910199
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1035, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.134220194393552
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 969, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.0526282162650264
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1140, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.425335867693919
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1015, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.102871804158444
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1160, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.506833689700493
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1025, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.11772915295131
kfs-all-msi-inferred: Analyzing CIRC CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 37, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.0085501009762884
kfs-all-msi-inferred: Analyzing CIITA CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 66, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.138669400543598
kfs-all-msi-inferred: Analyzing wnt CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 133, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.388006296863806
kfs-all-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 104, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.902446268299927
kfs-all-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 85, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.428381561886055
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 57, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.0687515655423229
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 48, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.0298064007948475
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 57, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.0687515655423229
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 36, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.00752032202609866
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 66, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.138669400543598
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 54, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.052883972011058
kfs-all-msi-inferred: Analyzing CIRC CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 149, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.000193518969796467
kfs-all-msi-inferred: Analyzing CIITA CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 276, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.15456969860761
kfs-all-msi-inferred: Analyzing wnt CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 403, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.470740294032794
kfs-all-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 329, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.60499742844703
kfs-all-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 292, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.250836000186168
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 160, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.000440621798458705
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 103, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 3.04070015214816e-06
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 93, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 1.02351262850619e-06
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 84, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 3.57660215572434e-07
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 115, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 1.01872045308901e-05
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 150, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.000209049502882481
kfs-all-msi-inferred: Analyzing CIRC CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 432, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.167330833537003
kfs-all-msi-inferred: Analyzing CIITA CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 345, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.0115762456248918
kfs-all-msi-inferred: Analyzing wnt CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 744, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.00815496429418493
kfs-all-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 697, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.0433309216347485
kfs-all-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 514, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.744285955061452
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 407, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.0880178541351454
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 436, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.183842298214124
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 435, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.17960704734639
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 355, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.0167911866096465
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 438, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.192530672607381
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 423, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.134235006264346
kfs-all-msi-inferred: Analyzing CIRC CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 237, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.113046655204864
kfs-all-msi-inferred: Analyzing CIITA CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 262, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.261854610214589
kfs-all-msi-inferred: Analyzing wnt CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 537, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 4.25229774198858e-05
kfs-all-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 514, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.000318907762494862
kfs-all-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 395, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.197778912550364
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 233, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.0970643232253432
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 190, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.0133017208645843
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 224, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.0675744351382051
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 219, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.0546122577341001
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 308, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.778174222457639
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 247, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.161846910627486
kfs-all-msi-inferred: Analyzing CIRC CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 264, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 0.000945776643221886
kfs-all-msi-inferred: Analyzing CIITA CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 456, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 0.522948629742605
kfs-all-msi-inferred: Analyzing wnt CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 806, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 2.23767781099567e-05
kfs-all-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 871, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 1.14854334717033e-07
kfs-all-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 220, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 7.41618516787812e-05
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 258, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 0.000688438453361575
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 284, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 0.00256179172326456
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 148, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 3.16211149632901e-07
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 143, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 2.0094702464804e-07
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 142, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 1.8327579451442e-07
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 240, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 0.000251432366830623
kfs-all-msi-inferred: Analyzing CIRC CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 298, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 1.39893617147937e-07
kfs-all-msi-inferred: Analyzing CIITA CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 767, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 0.246100317408581
kfs-all-msi-inferred: Analyzing wnt CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 1608, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 5.89223906659432e-10
kfs-all-msi-inferred: Analyzing myc.sig CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 1596, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 1.14157512606275e-09
kfs-all-msi-inferred: Analyzing BATF3 CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 444, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 6.68186088886668e-05
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 330, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 6.18761237001398e-07
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 269, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 3.40455253289366e-08
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 221, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 2.86018873351893e-09
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 184, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 3.7687374891401e-10
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 204, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 1.14157512606275e-09
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 294, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 1.15547338770202e-07

Computing linear model with interaction for CIRC
Computing linear model with interaction for CIITA
Computing linear model with interaction for wnt
Computing linear model with interaction for myc.sig
Computing linear model with interaction for BATF3
Computing linear model with interaction for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model with interaction for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model with interaction for HALLMARK_COMPLEMENT
Computing linear model with interaction for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model with interaction for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model with interaction for HALLMARK_ALLOGRAFT_REJECTION
Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
kfs-all-msi-inferred: Analyzing CIRC CMS1 MT vs WT using Wilcoxon rank sum test: W = 74, n_MT = 6, n_WT = 20, p = 0.421482864961126
kfs-all-msi-inferred: Analyzing CIITA CMS1 MT vs WT using Wilcoxon rank sum test: W = 57, n_MT = 6, n_WT = 20, p = 0.882274247491639
kfs-all-msi-inferred: Analyzing wnt CMS1 MT vs WT using Wilcoxon rank sum test: W = 65, n_MT = 6, n_WT = 20, p = 0.78974069408852
kfs-all-msi-inferred: Analyzing myc.sig CMS1 MT vs WT using Wilcoxon rank sum test: W = 67, n_MT = 6, n_WT = 20, p = 0.699943534726143
kfs-all-msi-inferred: Analyzing BATF3 CMS1 MT vs WT using Wilcoxon rank sum test: W = 63, n_MT = 6, n_WT = 20, p = 0.882274247491639
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS1 MT vs WT using Wilcoxon rank sum test: W = 79, n_MT = 6, n_WT = 20, p = 0.268079746340616
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS1 MT vs WT using Wilcoxon rank sum test: W = 85, n_MT = 6, n_WT = 20, p = 0.138956695478435
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS1 MT vs WT using Wilcoxon rank sum test: W = 97, n_MT = 6, n_WT = 20, p = 0.023298440689745
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS1 MT vs WT using Wilcoxon rank sum test: W = 83, n_MT = 6, n_WT = 20, p = 0.175589627763541
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS1 MT vs WT using Wilcoxon rank sum test: W = 99, n_MT = 6, n_WT = 20, p = 0.0160100768796421
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS1 MT vs WT using Wilcoxon rank sum test: W = 85, n_MT = 6, n_WT = 20, p = 0.138956695478435
kfs-all-msi-inferred: Analyzing CIRC CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1568, n_MT = 36, n_WT = 70, p = 0.0402311195102744
kfs-all-msi-inferred: Analyzing CIITA CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1269, n_MT = 36, n_WT = 70, p = 0.954780603432468
kfs-all-msi-inferred: Analyzing wnt CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1229, n_MT = 36, n_WT = 70, p = 0.838768454068382
kfs-all-msi-inferred: Analyzing myc.sig CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1279, n_MT = 36, n_WT = 70, p = 0.901777974509518
kfs-all-msi-inferred: Analyzing BATF3 CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1461, n_MT = 36, n_WT = 70, p = 0.181040344910199
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1485, n_MT = 36, n_WT = 70, p = 0.134220194393552
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1551, n_MT = 36, n_WT = 70, p = 0.0526282162650264
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1380, n_MT = 36, n_WT = 70, p = 0.425335867693919
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1505, n_MT = 36, n_WT = 70, p = 0.102871804158444
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1360, n_MT = 36, n_WT = 70, p = 0.506833689700493
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1495, n_MT = 36, n_WT = 70, p = 0.11772915295131
kfs-all-msi-inferred: Analyzing CIRC CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 877, n_MT = 28, n_WT = 50, p = 0.0659924170857015
kfs-all-msi-inferred: Analyzing CIITA CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 751, n_MT = 28, n_WT = 50, p = 0.598872475857331
kfs-all-msi-inferred: Analyzing wnt CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 529, n_MT = 28, n_WT = 50, p = 0.075736636871889
kfs-all-msi-inferred: Analyzing myc.sig CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 607, n_MT = 28, n_WT = 50, p = 0.33529324416062
kfs-all-msi-inferred: Analyzing BATF3 CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 677, n_MT = 28, n_WT = 50, p = 0.814700445451032
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 845, n_MT = 28, n_WT = 50, p = 0.132284515601839
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 966, n_MT = 28, n_WT = 50, p = 0.0056831252945491
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 714, n_MT = 28, n_WT = 50, p = 0.888170215453213
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 791, n_MT = 28, n_WT = 50, p = 0.345847554223562
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 740, n_MT = 28, n_WT = 50, p = 0.68074739764577
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 841, n_MT = 28, n_WT = 50, p = 0.143333693922718
kfs-all-msi-inferred: Analyzing CIRC CMS3 MT vs WT using Wilcoxon rank sum test: W = 287, n_MT = 30, n_WT = 18, p = 0.727911950381983
kfs-all-msi-inferred: Analyzing CIITA CMS3 MT vs WT using Wilcoxon rank sum test: W = 243, n_MT = 30, n_WT = 18, p = 0.576078877235431
kfs-all-msi-inferred: Analyzing wnt CMS3 MT vs WT using Wilcoxon rank sum test: W = 145, n_MT = 30, n_WT = 18, p = 0.00710750551922749
kfs-all-msi-inferred: Analyzing myc.sig CMS3 MT vs WT using Wilcoxon rank sum test: W = 172, n_MT = 30, n_WT = 18, p = 0.036955607906606
kfs-all-msi-inferred: Analyzing BATF3 CMS3 MT vs WT using Wilcoxon rank sum test: W = 194, n_MT = 30, n_WT = 18, p = 0.108390322155793
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 274, n_MT = 30, n_WT = 18, p = 0.941194342744294
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 334, n_MT = 30, n_WT = 18, p = 0.178071052462238
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT CMS3 MT vs WT using Wilcoxon rank sum test: W = 317, n_MT = 30, n_WT = 18, p = 0.325458469104126
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 286, n_MT = 30, n_WT = 18, p = 0.743816557090784
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 237, n_MT = 30, n_WT = 18, p = 0.492658961389714
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS3 MT vs WT using Wilcoxon rank sum test: W = 261, n_MT = 30, n_WT = 18, p = 0.85780490578066

Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
Computing rectum vs left
kfs-all-msi-inferred: Analyzing CIRC site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2636, n_rectum = 188, n_left = 28, p = 0.990948894920794
kfs-all-msi-inferred: Analyzing CIITA site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2708, n_rectum = 188, n_left = 28, p = 0.806681835189559
kfs-all-msi-inferred: Analyzing wnt site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2590, n_rectum = 188, n_left = 28, p = 0.893000200453283
kfs-all-msi-inferred: Analyzing myc.sig site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2704, n_rectum = 188, n_left = 28, p = 0.816736705743576
kfs-all-msi-inferred: Analyzing BATF3 site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3294, n_rectum = 188, n_left = 28, p = 0.0320297685713912
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2478, n_rectum = 188, n_left = 28, p = 0.618821876377818
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2527, n_rectum = 188, n_left = 28, p = 0.734833443487019
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2692, n_rectum = 188, n_left = 28, p = 0.847076395966555
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2741, n_rectum = 188, n_left = 28, p = 0.725087442472629
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2511, n_rectum = 188, n_left = 28, p = 0.696121100559936
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2578, n_rectum = 188, n_left = 28, p = 0.862334669993729
Computing right vs left
kfs-all-msi-inferred: Analyzing CIRC site: right vs leftWilcoxon rank sum test with continuity correction: W = 899, n_right = 74, n_left = 28, p = 0.306047065766897
kfs-all-msi-inferred: Analyzing CIITA site: right vs leftWilcoxon rank sum test with continuity correction: W = 790, n_right = 74, n_left = 28, p = 0.0656371874400753
kfs-all-msi-inferred: Analyzing wnt site: right vs leftWilcoxon rank sum test with continuity correction: W = 964, n_right = 74, n_left = 28, p = 0.591857559582254
kfs-all-msi-inferred: Analyzing myc.sig site: right vs leftWilcoxon rank sum test with continuity correction: W = 944, n_right = 74, n_left = 28, p = 0.49263928260657
kfs-all-msi-inferred: Analyzing BATF3 site: right vs leftWilcoxon rank sum test with continuity correction: W = 1171, n_right = 74, n_left = 28, p = 0.313188284327246
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 920, n_right = 74, n_left = 28, p = 0.386445078738186
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 880, n_right = 74, n_left = 28, p = 0.243604699798794
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT site: right vs leftWilcoxon rank sum test with continuity correction: W = 976, n_right = 74, n_left = 28, p = 0.655479100105231
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: right vs leftWilcoxon rank sum test with continuity correction: W = 999, n_right = 74, n_left = 28, p = 0.784317501590637
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: right vs leftWilcoxon rank sum test with continuity correction: W = 958, n_right = 74, n_left = 28, p = 0.561147843501288
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: right vs leftWilcoxon rank sum test with continuity correction: W = 912, n_right = 74, n_left = 28, p = 0.354409296147732

Plotting CIRC ~ site
Plotting CIITA ~ site
Plotting wnt ~ site
Plotting myc.sig ~ site
Plotting BATF3 ~ site
Plotting HALLMARK_IL6_JAK_STAT3_SIGNALING ~ site
Plotting HALLMARK_INTERFERON_GAMMA_RESPONSE ~ site
Plotting HALLMARK_COMPLEMENT ~ site
Plotting HALLMARK_INFLAMMATORY_RESPONSE ~ site
Plotting HALLMARK_IL2_STAT5_SIGNALING ~ site
Plotting HALLMARK_ALLOGRAFT_REJECTION ~ site
Computing MSS vs MSI
kfs-all-msi-inferred: Analyzing CIRC status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 10105, n_MSS = 220, n_MSI = 70, p = 8.33103437971168e-05
kfs-all-msi-inferred: Analyzing CIITA status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 8881, n_MSS = 220, n_MSI = 70, p = 0.0533910080650575
kfs-all-msi-inferred: Analyzing wnt status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 5068, n_MSS = 220, n_MSI = 70, p = 1.66135403273842e-05
kfs-all-msi-inferred: Analyzing myc.sig status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 5521, n_MSS = 220, n_MSI = 70, p = 0.000364063518992983
kfs-all-msi-inferred: Analyzing BATF3 status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 10667, n_MSS = 220, n_MSI = 70, p = 1.20802451716653e-06
kfs-all-msi-inferred: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 10115, n_MSS = 220, n_MSI = 70, p = 7.78136436087746e-05
kfs-all-msi-inferred: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 9794, n_MSS = 220, n_MSI = 70, p = 0.000613085420711982
kfs-all-msi-inferred: Analyzing HALLMARK_COMPLEMENT status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 10946, n_MSS = 220, n_MSI = 70, p = 1.09105255924334e-07
kfs-all-msi-inferred: Analyzing HALLMARK_INFLAMMATORY_RESPONSE status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 11207, n_MSS = 220, n_MSI = 70, p = 9.58230297384295e-09
kfs-all-msi-inferred: Analyzing HALLMARK_IL2_STAT5_SIGNALING status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 10565, n_MSS = 220, n_MSI = 70, p = 2.76689381306094e-06
kfs-all-msi-inferred: Analyzing HALLMARK_ALLOGRAFT_REJECTION status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 10259, n_MSS = 220, n_MSI = 70, p = 2.83071414782683e-05

Plotting CIRC ~ status
Plotting CIITA ~ status
Plotting wnt ~ status
Plotting myc.sig ~ status
Plotting BATF3 ~ status
Plotting HALLMARK_IL6_JAK_STAT3_SIGNALING ~ status
Plotting HALLMARK_INTERFERON_GAMMA_RESPONSE ~ status
Plotting HALLMARK_COMPLEMENT ~ status
Plotting HALLMARK_INFLAMMATORY_RESPONSE ~ status
Plotting HALLMARK_IL2_STAT5_SIGNALING ~ status
Plotting HALLMARK_ALLOGRAFT_REJECTION ~ status
Overlap of MSI and CMS1 in KFS inferred:
     
      CMS1 CMS2 CMS3 CMS4 NOLBL
  msi   22    0   12   37     8
  mss    8  110   37   48    25
Number of rows analyzed: 20534
Number of columns analyzed: 213
kfs-mss-msi-inferred-no-cms1: 26 of 28 genes from data set analyzed in set CIRC: HLA-DQA1 CTLA4 PDCD1LG2 ICAM1 CD274 STAT1 IRF1 IFNG GNLY TBX21 CCL5 LAG3 CD247 ICOS IL18RAP CXCL9 CXCL10 HLA-DPB1 HLA-DPA1 HLA-DMB HLA-DRA HLA-DMA CD80 HLA-DOA CD4 HAVCR2
kfs-mss-msi-inferred-no-cms1: 2 of 28 genes missing from data set analyzed in set CIRC: HLA-DQA2 HLA-DRB5
kfs-mss-msi-inferred-no-cms1: 75 of 88 genes from data set analyzed in set myc.sig: AKAP1 APEX1 BAX CAD CCKBR CCNB1 CCND2 CCT5 CDC25C CEBPZ CKS2 CTSC DDX10 DDX18 DDX5 E2F1 EIF4B ENO1 EXOSC8 FASN FOSL1 H2AFZ HSPD1 HSPE1 ID2 IMPA2 LTA4H MAT2A METTL1 MINA MSH2 MTHFD1 NAP1L1 NCL NME1 NPM1 NRAS NUP155 PA2G4 PCNA PHB POLD2 PPAT PPIA PPID PRDX3 PREP PRPS2 PSMB1 PTEN PYCR1 RPL19 RPL22 RPL27 RPL27A RPL32 RPL9 RPS16 RPS19 RPS5 RPS6KA2 SHMT1 SLC25A3 SLC39A6 SNRPB SNRPD3 SRM TERT TFRC TOP1 TXN TYMS UBE2C UCHL1 UXT
kfs-mss-msi-inferred-no-cms1: 13 of 88 genes missing from data set analyzed in set myc.sig: CSDA DKC1 DSCR2 EIF4A1 HNRPA2B1 HSPA8 HSPA9B RPL10 RPL5 RPS13 SFRS1 SFRS2 SFRS7
kfs-mss-msi-inferred-no-cms1: 44 of 78 genes from data set analyzed in set wnt: PHLDA1 SLC7A5 BYSL SCD SOX4 WDR77 NLE1 PPIL1 ZNF511 ZNF593 ODC1 AURKB WDR12 CDT1 NOC3L CAD XPOT YAP1 SRM NXT1 MRPS12 RHEB WDR3 CRTAP SF3A2 GEMIN5 IMP4 HEATR1 SLC19A1 PDCD11 ASCL2 TBX3 EPHB3 ZNRF3 IL20RA RHOBTB3 GEMIN4 ID3 FUT4 PIGW APEX1 SRPRB ZNRD1 TFB2M
kfs-mss-msi-inferred-no-cms1: 34 of 78 genes missing from data set analyzed in set wnt: FLJ20315 CTPS NOB1P PSF1 PMSCL1 RNU3IP2 CIRH1A HIG2 C1orf33 DKC1 LOC389362 HSPC111 MGC40397 LOC56902 SDCCAG16 FLJ10774 RAB9P40 RFP RRP41 HNRPDL C16orf35 TREX2 CGI-96 C20orf64 C12orf14 NOL1 TDGF1 SKB1 C11orf5 MGC16824 ZNF278 RPC62 JTV1 ZNF339
kfs-mss-msi-inferred-no-cms1: 87 of 87 genes from data set analyzed in set HALLMARK_IL6_JAK_STAT3_SIGNALING: IL4R IL6ST STAT1 IL1R1 CSF2RB SOCS3 STAT3 OSMR IL2RG IFNGR1 TYK2 IL13RA1 TLR2 IFNGR2 IL10RB IL6 IL1R2 IL3RA IFNAR1 TNFRSF1A MYD88 ACVR1B CSF3R ITGB3 REG1A CXCL1 A2M CSF2RA IL15RA IRF9 PDGFC HAX1 BAK1 EBI3 INHBE CRLF2 TNFRSF1B CD14 PTPN1 PTPN2 IL1B CSF1 IL18R1 TNF PF4 CXCL13 LTBR FAS IL17RA CXCL10 IL9R STAM2 TNFRSF12A STAT2 HMOX1 LEPR CBL CD9 CXCL3 TGFB1 MAP3K8 ITGA4 CD38 JUN SOCS1 ACVRL1 PIM1 TNFRSF21 PIK3R5 GRB2 IRF1 DNTT CSF2 IL2RA PTPN11 IL12RB1 CCR1 CNTFR PLA2G2A CXCL9 CD44 IL7 CXCL11 CCL7 LTB IL17RB CD36
kfs-mss-msi-inferred-no-cms1: 194 of 200 genes from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: STAT1 ISG15 IFIT1 MX1 IFIT3 IFI35 IRF7 IFIT2 OAS2 TAP1 EIF2AK2 RSAD2 MX2 IRF1 OAS3 TNFSF10 IRF9 CXCL10 IFI44 BST2 XAF1 SP110 OASL PSMB8 IFI44L IFITM3 DDX60 LGALS3BP GBP4 IRF8 PSMB9 PML IFIH1 UBE2L6 IFI27 ADAR LY6E STAT2 CXCL9 IL10RA PLA2G4A TRIM21 USP18 PTGS2 EPSTI1 C1S DDX58 IL15 NLRC5 NMI IDO1 PSMB10 CXCL11 ITGB7 SAMHD1 HERC6 CMPK2 SAMD9L RTP4 PTPN2 PARP14 TNFAIP2 IFITM2 PLSCR1 SOCS1 CASP1 ICAM1 WARS PSME1 ISG20 IRF2 TRIM14 FCGR1A MARCH1 SOCS3 JAK2 HLA-DMA PARP12 TNFAIP6 TRIM26 VCAM1 CD274 CIITA NAMPT SELP GPR18 FPR1 SERPING1 CCL5 RNF31 SOD2 TRIM25 LAP3 PSMA3 RNF213 PELI1 CFB CD86 TXNIP HLA-DQA1 GCH1 PNP CCL7 PTPN6 SPPL2A IL4R PNPT1 DHX58 BTG1 CASP8 CCL2 FGL2 CASP7 SECTM1 IL15RA CD40 TRAFD1 GBP6 LCP2 HLA-G MT2A RIPK1 UPP1 PSMB2 TDRD7 HIF1A EIF4E3 VAMP8 PFKP CD38 ZBP1 BANK1 TOR1B RBCK1 PDE4B MVP IL7 BPGM AUTS2 B2M RIPK2 CD69 MYD88 PSMA2 PIM1 NOD1 CFH TAPBP SLC25A28 PTPN1 TNFAIP3 SSPN NUP93 MTHFD2 CDKN1A IRF4 NFKB1 BATF2 HLA-B LATS2 IRF5 SLAMF7 ISOC1 P2RY14 STAT3 NCOA3 HLA-A IL6 GZMA IFNAR2 CD74 RAPGEF6 CASP4 FAS OGFR ARL4A SRI LYSMD2 CSF2RB ST3GAL5 C1R CASP3 CMKLR1 NFKBIA METTL7B ST8SIA4 XCL1 IL2RB VAMP5 IL18BP ZNFX1 ARID5B APOL6 STAT4
kfs-mss-msi-inferred-no-cms1: 6 of 200 genes missing from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: PRIC285 PSME2 IFI30 HLA-DRB1 KLRK1 FTSJD2
kfs-mss-msi-inferred-no-cms1: 193 of 200 genes from data set analyzed in set HALLMARK_COMPLEMENT: C2 C1S CFB C1R SERPINE1 MMP14 SERPING1 F5 MMP13 F7 CTSS LGMN PLG C1QA CASP1 GZMA ADAM9 CALM3 C1QC TIMP1 DPP4 KLK1 KLKB1 CD59 CR2 MMP15 LAP3 SPOCK2 F10 CTSB SERPINA1 CTSO CD40LG CBLB PDP1 C4BPB PLEK GP9 PLAUR C3 F2 CASP4 STX4 CTSC CR1 DUSP6 SERPINB2 GPD2 CFH FN1 CD36 CA2 PSMB9 APOBEC3G FCN1 GZMK PDGFB CLU CASP10 LRP1 CTSD S100A9 WAS BRPF3 PLAT CDA MT3 CASP7 PRSS36 PFN1 GZMB RNF4 ZEB1 CASP5 IRF1 CDK5R1 ATOX1 PIK3CA TMPRSS6 CPM RCE1 CALM1 DOCK9 KYNU RASGRP1 USP14 LCP2 GP1BA KIF2A GNB4 LCK OLR1 PREP LTA4H ZFPM2 LYN ACTN2 SIRT6 APOC1 PRKCD ITGAM DGKH LTF MAFF KCNIP2 PCLO DOCK10 SH2B3 RABIF SRC HPCAL4 CD46 PRDM4 GNAI3 C9 PPP2CB IRF2 FYN JAK2 PLA2G4A PRCP USP8 RHOG L3MBTL4 LAMP2 PIM1 CXCL1 F3 GNAI2 CASP9 XPNPEP1 PLSCR1 IRF7 CD55 HSPA5 GNB2 DYRK2 PLA2G7 S100A12 GRB2 PHEX GNGT2 DOCK4 MMP12 KCNIP3 FDX1 TIMP2 MMP8 FCER1G ANXA5 GCA EHD1 PRSS3 COL4A2 CSRP1 PIK3R5 SERPINC1 ANG APOBEC3F GATA3 DUSP5 CASP3 USP16 CP PSEN1 LIPA PCSK9 DGKG GNG2 ME1 GMFB SCG3 PPP4C CCL5 CTSH F8 APOA4 IL6 AKAP10 ERAP2 VCPIP1 RAF1 NOTCH4 ADRA2B CEBPB HNF4A LGALS3 TNFAIP3 CDH13 ITIH1 TFPI2 PIK3CG S100A13
kfs-mss-msi-inferred-no-cms1: 7 of 200 genes missing from data set analyzed in set HALLMARK_COMPLEMENT: CTSL1 USP15 PGCP SEPX1 ZFYVE20 CTSL2 HSPA1A
kfs-mss-msi-inferred-no-cms1: 197 of 200 genes from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: CXCL10 CCL2 CCL5 FPR1 CCL20 IL1A CCL7 CCL22 CXCL11 CCR7 EDN1 CD40 CXCL9 IL6 IL1B TLR2 IL1R1 CD69 ICAM1 CCRL2 AQP9 EREG C3AR1 GNA15 CMKLR1 PTGER4 LIF IL15 NAMPT OPRK1 ITGB8 PTAFR ADM PLAUR NFKB1 INHBA OSM TNFSF10 TNFSF15 IFNGR2 IL12B CSF1 CXCL6 TNFRSF9 LYN ACVR2A LDLR BDKRB1 HRH1 F3 BST2 PTGIR CD55 CALCRL CSF3 GPR132 IL4R NLRP3 IL15RA ADORA2B GCH1 OLR1 PTGER2 CSF3R MYC RELA TNFAIP6 IL7R IL18 GABBR1 CD82 TNFSF9 NMUR1 IL2RB TLR1 LPAR1 IRAK2 RIPK2 MMP14 P2RX7 SLC11A2 SELL P2RY2 ABCA1 FFAR2 PROK2 GNAI3 TACR1 SLC7A1 CDKN1A CYBB TIMP1 HBEGF SCARF1 EBI3 NFKBIA SRI SLC7A2 CCL17 TLR3 APLNR OSMR IL10RA PSEN1 GPR183 ATP2B1 TNFRSF1B BEST1 GPC3 SCN1B ACVR1B HPN SEMA4D KLF6 CD48 CXCR6 SLC1A2 GP1BA TAPBP RGS16 SLAMF1 LCK HIF1A AHR NMI RHOG TPBG NPFFR2 IFNAR1 ICOSLG RASGRP1 IFITM1 KCNJ2 LY6E IL18R1 IL10 KCNA3 HAS2 DCBLD2 LAMP3 VIP CD70 RGS1 SLC31A1 ADRM1 KCNMB2 SERPINE1 MXD1 AXL MEFV PVR CCL24 PDE4B LCP2 PDPN IRF7 MET ATP2A2 SLC31A2 FZD5 ITGA5 SGMS2 MARCO CD14 EIF2AK2 ROS1 ATP2C1 NDP BTG2 MSR1 PTPRE RNF144B PCDH7 SPHK1 IL18RAP RTP4 RAF1 CHST2 ITGB3 KIF1B SELE NOD2 C5AR1 EMP3 CLEC5A TACR3 SLC4A4 MEP1A LTA PIK3R5 STAB1 IRF1 ICAM4 P2RX4 ABI1 CX3CL1 SLC28A2
kfs-mss-msi-inferred-no-cms1: 3 of 200 genes missing from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: IL8 EMR1 SELS
kfs-mss-msi-inferred-no-cms1: 194 of 200 genes from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: SOCS2 CISH PIM1 IL2RA TNFRSF4 SOCS1 TNFRSF9 XBP1 RRAGD HK2 PHLDA1 IL2RB CTLA4 NFIL3 CD83 IKZF2 IL10 TNFRSF18 DHRS3 ECM1 ADAM19 SLC2A3 HIPK2 BATF3 BHLHE40 PTGER2 DENND5A ITIH5 PHTF2 GADD45B NRP1 NCOA3 CD79B AHR TNFRSF1B NDRG1 BCL2L1 GABARAPL1 LIF TIAM1 BMPR2 MAP3K8 RHOB MYC S100A1 CAPG ST3GAL4 PENK IRF4 CST7 WLS TLR7 IKZF4 GBP4 RGS16 SPP1 IL13 SLC29A2 NFKBIZ IL4R MXD1 CSF2 FAH CTSZ ITGAE MUC1 MAPKAPK2 TNFRSF21 NT5E FLT3LG CCND2 TRAF1 LCLAT1 IL3RA CYFIP1 BCL2 FGL2 PRNP PUS1 ITGAV NCS1 DCPS AMACR FAM126B PTH1R ODC1 IGF1R PTCH1 ENO3 CD81 MAFF EMP1 CDKN1C CAPN3 IL1R2 SYT11 TTC39B ANXA4 BATF P4HA1 GPR65 SLC1A5 IGF2R CKAP4 CCR4 CD44 P2RX4 GATA1 KLF6 ARL4A HOPX GPR83 ITGA6 CD48 SELP GLIPR2 SMPDL3A PLSCR1 FURIN SERPINB6 TNFSF11 GPX4 LRRC8C CCNE1 CASP3 SH3BGRL2 SNX9 PLEC BMP2 ICOS ALCAM LTB ENPP1 IL1RL1 MYO1C IFNGR1 PLIN2 IL18R1 AHNAK PRKCH TNFRSF8 SYNGR2 GALM POU2F1 EOMES NOP2 PTRH2 RHOH CDC6 MYO1E CXCL10 SNX14 IRF6 IL10RA MAP6 TNFSF10 SPRED2 SELL SERPINC1 CDCP1 RORA COCH CSF1 F2RL2 CA2 IFITM3 UMPS HUWE1 COL6A1 ABCB1 RNH1 IRF8 GUCY1B3 AHCY PRAF2 GSTO1 TWSG1 CDC42SE2 PLAGL1 APLP1 SPRY4 SCN9A SHE PDCD2L CCND3 LRIG1 SWAP70 SLC39A8 RABGAP1L TGM2 PNP AGER ETV4 CD86
kfs-mss-msi-inferred-no-cms1: 6 of 200 genes missing from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: METTL20 N6AMT2 CCDC164 UCK2 AKAP2 PPAP2A
kfs-mss-msi-inferred-no-cms1: 198 of 200 genes from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: PTPRC IL12B TGFB1 IL12A CD3E CD3D CD28 LYN HCLS1 IL18 CRTAM IFNG CD3G CD86 IL10 UBE2N BCL10 CD4 LCK NCK1 C2 HLA-A ITGB2 HLA-DQA1 CD1D CD80 HLA-DRA THY1 TLR1 HLA-G HLA-DMB IL7 IL4 TNF CD247 IL2 HLA-DMA STAT1 IRF4 SRGN INHBA TLR3 ZAP70 CD74 CD40 TRAF2 B2M LTB IFNGR1 CCR5 CD40LG HLA-DOA GLMN IL6 HLA-E CD2 CCL5 FAS FASLG TLR6 PF4 TGFB2 CD79A INHBB ELANE SPI1 MAP3K7 IL15 CTSS CD47 PRF1 IL12RB1 LCP2 SOCS1 CDKN2A STAT4 CD7 HLA-DOB CD8A ICAM1 CCL4 GZMB CSF1 IL11 STAB1 IL2RA NLRP3 CCND3 EIF3A SIT1 IFNAR2 HDAC9 CARTPT TRAT1 CCL22 APBB1 FYB IL1B TIMP1 RPS19 JAK2 KRT1 WARS IFNGR2 CCR2 EREG MMP9 EGFR IL16 CFP WAS ITGAL KLRD1 RARS TLR2 CCND2 IL2RG ETS1 ITK NCR1 MAP4K1 CCL19 PSMB10 RPL39 EIF3J ABCE1 CD8B F2 ELF4 LY86 FCGR2B GBP2 PRKCG RPS9 MTIF2 GZMA AARS CD96 CSK HIF1A CCL2 ICOSLG NPM1 IL4R CCL11 NME1 FLNA GPR65 ACHE EIF3D IGSF6 F2R IL13 TAP1 DARS IRF7 ACVR2A CXCR3 PRKCB CXCL9 PTPN6 NCF4 UBE2D1 LIF CCR1 MBL2 DEGS1 TPD52 AKT1 RIPK2 IKBKB GCNT1 SOCS5 IRF8 TAP2 EIF4G3 ABI1 CCL7 IL2RB BRCA1 FGR IL18RAP MRPL3 CXCL13 CAPG EIF5A GALNT1 ST8SIA4 CCL13 RPL3L LY75 TAPBP NOS2 RPL9 BCAT1 IL9 IL27RA DYRK3
kfs-mss-msi-inferred-no-cms1: 2 of 200 genes missing from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: BCL3 RPS3A
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
kfs-mss-msi-inferred-no-cms1 wnt vs CIRC: t = -2.75726555726905 df = 211 nrow = 213 cor = -0.186488055395514 pval = 0.00633966703061654
kfs-mss-msi-inferred-no-cms1 tak1 vs CIRC: t = 0.110831972976784 df = 211 nrow = 213 cor = 0.00762976559409716 pval = 0.911854941246233
kfs-mss-msi-inferred-no-cms1 wnt vs myc.sig: t = 29.7779339407055 df = 211 nrow = 213 cor = 0.898768236184452 pval = 1.67829029288094e-77

kfs-mss-msi-inferred-no-cms1: Analyzing CIRC vs KRAS using Wilcoxon rank sum test with continuity correction: W = 6124, n_WT = 124, n_MT = 89, p = 0.17229317193546
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA vs KRAS using Wilcoxon rank sum test with continuity correction: W = 4795, n_WT = 124, n_MT = 89, p = 0.103396682529844
kfs-mss-msi-inferred-no-cms1: Analyzing wnt vs KRAS using Wilcoxon rank sum test with continuity correction: W = 5106, n_WT = 124, n_MT = 89, p = 0.35362951719663
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig vs KRAS using Wilcoxon rank sum test with continuity correction: W = 5474, n_WT = 124, n_MT = 89, p = 0.921889085586911
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 vs KRAS using Wilcoxon rank sum test with continuity correction: W = 5785, n_WT = 124, n_MT = 89, p = 0.548023719910923
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 6051, n_WT = 124, n_MT = 89, p = 0.230014591563472
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 6229, n_WT = 124, n_MT = 89, p = 0.109253954613526
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT vs KRAS using Wilcoxon rank sum test with continuity correction: W = 5884, n_WT = 124, n_MT = 89, p = 0.410006331771102
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE vs KRAS using Wilcoxon rank sum test with continuity correction: W = 5901, n_WT = 124, n_MT = 89, p = 0.388576037251332
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING vs KRAS using Wilcoxon rank sum test with continuity correction: W = 5549, n_WT = 124, n_MT = 89, p = 0.945187984590843
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION vs KRAS using Wilcoxon rank sum test with continuity correction: W = 5916, n_WT = 124, n_MT = 89, p = 0.370245034875565

Computing CIRC ~ KRAS
Computing CIITA ~ KRAS
Computing wnt ~ KRAS
Computing myc.sig ~ KRAS
Computing BATF3 ~ KRAS
Computing HALLMARK_IL6_JAK_STAT3_SIGNALING ~ KRAS
Computing HALLMARK_INTERFERON_GAMMA_RESPONSE ~ KRAS
Computing HALLMARK_COMPLEMENT ~ KRAS
Computing HALLMARK_INFLAMMATORY_RESPONSE ~ KRAS
Computing HALLMARK_IL2_STAT5_SIGNALING ~ KRAS
Computing HALLMARK_ALLOGRAFT_REJECTION ~ KRAS
kfs-mss-msi-inferred-no-cms1: Analyzing CIRC CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1627, n_CMS2 = 106, n_CMS3 = 36, p = 0.188382170160593
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1287, n_CMS2 = 106, n_CMS3 = 36, p = 0.00361682841963323
kfs-mss-msi-inferred-no-cms1: Analyzing wnt CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2860, n_CMS2 = 106, n_CMS3 = 36, p = 8.12073855961141e-06
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2876, n_CMS2 = 106, n_CMS3 = 36, p = 5.70583669952408e-06
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2241, n_CMS2 = 106, n_CMS3 = 36, p = 0.118942047209547
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1485, n_CMS2 = 106, n_CMS3 = 36, p = 0.0475602506604618
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1534, n_CMS2 = 106, n_CMS3 = 36, p = 0.0798605946569845
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1489, n_CMS2 = 106, n_CMS3 = 36, p = 0.049702083625404
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1458, n_CMS2 = 106, n_CMS3 = 36, p = 0.0350404324247059
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1547, n_CMS2 = 106, n_CMS3 = 36, p = 0.0909260025039126
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1541, n_CMS2 = 106, n_CMS3 = 36, p = 0.0856745468389856
kfs-mss-msi-inferred-no-cms1: Analyzing CIRC CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1661, n_CMS2 = 106, n_CMS4 = 47, p = 0.0010361008738217
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2564, n_CMS2 = 106, n_CMS4 = 47, p = 0.774322465935564
kfs-mss-msi-inferred-no-cms1: Analyzing wnt CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 3909, n_CMS2 = 106, n_CMS4 = 47, p = 2.07081040270564e-08
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 4066, n_CMS2 = 106, n_CMS4 = 47, p = 4.75790483006961e-10
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1672, n_CMS2 = 106, n_CMS4 = 47, p = 0.0012077957683984
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1533, n_CMS2 = 106, n_CMS4 = 47, p = 0.000152627583380687
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1457, n_CMS2 = 106, n_CMS4 = 47, p = 4.36380738672635e-05
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 857, n_CMS2 = 106, n_CMS4 = 47, p = 1.04548490221055e-10
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 942, n_CMS2 = 106, n_CMS4 = 47, p = 9.12191169575349e-10
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 933, n_CMS2 = 106, n_CMS4 = 47, p = 7.2903148621516e-10
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1394, n_CMS2 = 106, n_CMS4 = 47, p = 1.44784636728747e-05


kfs-mss-msi-inferred-no-cms1: Analyzing CIRC CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 272, n_CMS2 = 36, n_CMS3 = 24, p = 0.0152782751546292
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 229, n_CMS2 = 36, n_CMS3 = 24, p = 0.00185526197907805
kfs-mss-msi-inferred-no-cms1: Analyzing wnt CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 570, n_CMS2 = 36, n_CMS3 = 24, p = 0.0373152904257622
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 576, n_CMS2 = 36, n_CMS3 = 24, p = 0.029591716851125
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 418, n_CMS2 = 36, n_CMS3 = 24, p = 0.839837218990422
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 284, n_CMS2 = 36, n_CMS3 = 24, p = 0.0252318638891893
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 268, n_CMS2 = 36, n_CMS3 = 24, p = 0.0128223414437721
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 331, n_CMS2 = 36, n_CMS3 = 24, p = 0.130131804935774
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 278, n_CMS2 = 36, n_CMS3 = 24, p = 0.0197218742409735
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 310, n_CMS2 = 36, n_CMS3 = 24, p = 0.0664806255965985
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 292, n_CMS2 = 36, n_CMS3 = 24, p = 0.034572140931041
kfs-mss-msi-inferred-no-cms1: Analyzing CIRC CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 201, n_CMS2 = 36, n_CMS4 = 17, p = 0.0456951107186725
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 327, n_CMS2 = 36, n_CMS4 = 17, p = 0.698883339900443
kfs-mss-msi-inferred-no-cms1: Analyzing wnt CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 433, n_CMS2 = 36, n_CMS4 = 17, p = 0.0148704139547061
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 485, n_CMS2 = 36, n_CMS4 = 17, p = 0.000432904324709721
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 181, n_CMS2 = 36, n_CMS4 = 17, p = 0.0166042279780799
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 195, n_CMS2 = 36, n_CMS4 = 17, p = 0.0342982719400389
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 194, n_CMS2 = 36, n_CMS4 = 17, p = 0.0326521078352124
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 121, n_CMS2 = 36, n_CMS4 = 17, p = 0.000261710993594566
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 120, n_CMS2 = 36, n_CMS4 = 17, p = 0.000240119662499464
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 120, n_CMS2 = 36, n_CMS4 = 17, p = 0.000240119662499464
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 182, n_CMS2 = 36, n_CMS4 = 17, p = 0.0175343415509325

kfs-mss-msi-inferred-no-cms1: Analyzing CIRC CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 960, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.0457167565711404
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1251, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.954780603432468
kfs-mss-msi-inferred-no-cms1: Analyzing wnt CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1245, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.922939881345723
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1219, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.787021639785716
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1059, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.181040344910199
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1010, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.0960238666288593
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 962, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.0471826594140669
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1137, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.413807482459059
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1027, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.120893448065525
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1176, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.577501364514597
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1034, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.132494730281872
kfs-mss-msi-inferred-no-cms1: Analyzing CIRC CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 272, n_CMS2-MT = 36, n_CMS3-MT = 24, p = 0.0152782751546292
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 229, n_CMS2-MT = 36, n_CMS3-MT = 24, p = 0.00185526197907805
kfs-mss-msi-inferred-no-cms1: Analyzing wnt CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 570, n_CMS2-MT = 36, n_CMS3-MT = 24, p = 0.0373152904257622
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 576, n_CMS2-MT = 36, n_CMS3-MT = 24, p = 0.029591716851125
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 418, n_CMS2-MT = 36, n_CMS3-MT = 24, p = 0.839837218990422
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 284, n_CMS2-MT = 36, n_CMS3-MT = 24, p = 0.0252318638891893
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 268, n_CMS2-MT = 36, n_CMS3-MT = 24, p = 0.0128223414437721
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 331, n_CMS2-MT = 36, n_CMS3-MT = 24, p = 0.130131804935774
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 278, n_CMS2-MT = 36, n_CMS3-MT = 24, p = 0.0197218742409735
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 310, n_CMS2-MT = 36, n_CMS3-MT = 24, p = 0.0664806255965985
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 292, n_CMS2-MT = 36, n_CMS3-MT = 24, p = 0.034572140931041
kfs-mss-msi-inferred-no-cms1: Analyzing CIRC CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 157, n_CMS2-MT = 36, n_CMS3-WT = 12, p = 0.16578094521717
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 197, n_CMS2-MT = 36, n_CMS3-WT = 12, p = 0.663689669649045
kfs-mss-msi-inferred-no-cms1: Analyzing wnt CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 404, n_CMS2-MT = 36, n_CMS3-WT = 12, p = 4.59547487893627e-07
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 392, n_CMS2-MT = 36, n_CMS3-WT = 12, p = 4.29967419707371e-06
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 263, n_CMS2-MT = 36, n_CMS3-WT = 12, p = 0.272206336946999
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 149, n_CMS2-MT = 36, n_CMS3-WT = 12, p = 0.114198444516647
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 141, n_CMS2-MT = 36, n_CMS3-WT = 12, p = 0.0758917960938096
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 138, n_CMS2-MT = 36, n_CMS3-WT = 12, p = 0.0644827164559267
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 152, n_CMS2-MT = 36, n_CMS3-WT = 12, p = 0.131869478038465
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 173, n_CMS2-MT = 36, n_CMS3-WT = 12, p = 0.316040621352718
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 161, n_CMS2-MT = 36, n_CMS3-WT = 12, p = 0.197190327152785
kfs-mss-msi-inferred-no-cms1: Analyzing CIRC CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 201, n_CMS2-MT = 36, n_CMS4-MT = 17, p = 0.0456951107186725
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 327, n_CMS2-MT = 36, n_CMS4-MT = 17, p = 0.698883339900443
kfs-mss-msi-inferred-no-cms1: Analyzing wnt CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 433, n_CMS2-MT = 36, n_CMS4-MT = 17, p = 0.0148704139547061
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 485, n_CMS2-MT = 36, n_CMS4-MT = 17, p = 0.000432904324709721
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 181, n_CMS2-MT = 36, n_CMS4-MT = 17, p = 0.0166042279780799
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 195, n_CMS2-MT = 36, n_CMS4-MT = 17, p = 0.0342982719400389
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 194, n_CMS2-MT = 36, n_CMS4-MT = 17, p = 0.0326521078352124
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 121, n_CMS2-MT = 36, n_CMS4-MT = 17, p = 0.000261710993594566
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 120, n_CMS2-MT = 36, n_CMS4-MT = 17, p = 0.000240119662499464
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 120, n_CMS2-MT = 36, n_CMS4-MT = 17, p = 0.000240119662499464
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 182, n_CMS2-MT = 36, n_CMS4-MT = 17, p = 0.0175343415509325
kfs-mss-msi-inferred-no-cms1: Analyzing CIRC CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 236, n_CMS2-MT = 36, n_CMS4-WT = 30, p = 5.40892054332495e-05
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 549, n_CMS2-MT = 36, n_CMS4-WT = 30, p = 0.913437307146807
kfs-mss-msi-inferred-no-cms1: Analyzing wnt CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 895, n_CMS2-MT = 36, n_CMS4-WT = 30, p = 1.59613435569784e-06
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 871, n_CMS2-MT = 36, n_CMS4-WT = 30, p = 9.22619154850863e-06
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 343, n_CMS2-MT = 36, n_CMS4-WT = 30, p = 0.0107230644291456
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 252, n_CMS2-MT = 36, n_CMS4-WT = 30, p = 0.000140676643638371
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 198, n_CMS2-MT = 36, n_CMS4-WT = 30, p = 4.22333429211166e-06
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 165, n_CMS2-MT = 36, n_CMS4-WT = 30, p = 3.18730858906179e-07
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 158, n_CMS2-MT = 36, n_CMS4-WT = 30, p = 1.75042910398755e-07
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 168, n_CMS2-MT = 36, n_CMS4-WT = 30, p = 4.09672082014047e-07
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2-MT vs CMS4-WT using Wilcoxon rank sum test: W = 217, n_CMS2-MT = 36, n_CMS4-WT = 30, p = 1.59193276012038e-05

Computing linear model with interaction for CIRC
Computing linear model with interaction for CIITA
Computing linear model with interaction for wnt
Computing linear model with interaction for myc.sig
Computing linear model with interaction for BATF3
Computing linear model with interaction for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model with interaction for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model with interaction for HALLMARK_COMPLEMENT
Computing linear model with interaction for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model with interaction for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model with interaction for HALLMARK_ALLOGRAFT_REJECTION
Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
kfs-mss-msi-inferred-no-cms1: Analyzing CIRC CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1560, n_MT = 36, n_WT = 70, p = 0.0457167565711404
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1269, n_MT = 36, n_WT = 70, p = 0.954780603432468
kfs-mss-msi-inferred-no-cms1: Analyzing wnt CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1275, n_MT = 36, n_WT = 70, p = 0.922939881345723
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1301, n_MT = 36, n_WT = 70, p = 0.787021639785716
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1461, n_MT = 36, n_WT = 70, p = 0.181040344910199
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1510, n_MT = 36, n_WT = 70, p = 0.0960238666288593
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1558, n_MT = 36, n_WT = 70, p = 0.0471826594140669
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1383, n_MT = 36, n_WT = 70, p = 0.413807482459059
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1493, n_MT = 36, n_WT = 70, p = 0.120893448065525
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1344, n_MT = 36, n_WT = 70, p = 0.577501364514597
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1486, n_MT = 36, n_WT = 70, p = 0.132494730281872
kfs-mss-msi-inferred-no-cms1: Analyzing CIRC CMS4 MT vs WT using Wilcoxon rank sum test: W = 334, n_MT = 17, n_WT = 30, p = 0.0821837016509765
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA CMS4 MT vs WT using Wilcoxon rank sum test: W = 271, n_MT = 17, n_WT = 30, p = 0.734134525951653
kfs-mss-msi-inferred-no-cms1: Analyzing wnt CMS4 MT vs WT using Wilcoxon rank sum test: W = 194, n_MT = 17, n_WT = 30, p = 0.182344069797273
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig CMS4 MT vs WT using Wilcoxon rank sum test: W = 239, n_MT = 17, n_WT = 30, p = 0.734134525951653
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 CMS4 MT vs WT using Wilcoxon rank sum test: W = 249, n_MT = 17, n_WT = 30, p = 0.904110035143674
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test: W = 298, n_MT = 17, n_WT = 30, p = 0.350426905737724
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test: W = 322, n_MT = 17, n_WT = 30, p = 0.142153062916961
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS4 MT vs WT using Wilcoxon rank sum test: W = 257, n_MT = 17, n_WT = 30, p = 0.973790882824464
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS4 MT vs WT using Wilcoxon rank sum test: W = 272, n_MT = 17, n_WT = 30, p = 0.717679141514421
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS4 MT vs WT using Wilcoxon rank sum test: W = 262, n_MT = 17, n_WT = 30, p = 0.886781636281401
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS4 MT vs WT using Wilcoxon rank sum test: W = 328, n_MT = 17, n_WT = 30, p = 0.1090099937046
kfs-mss-msi-inferred-no-cms1: Analyzing CIRC CMS3 MT vs WT using Wilcoxon rank sum test: W = 123, n_MT = 24, n_WT = 12, p = 0.49694009568118
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA CMS3 MT vs WT using Wilcoxon rank sum test: W = 91, n_MT = 24, n_WT = 12, p = 0.0779430487576794
kfs-mss-msi-inferred-no-cms1: Analyzing wnt CMS3 MT vs WT using Wilcoxon rank sum test: W = 42, n_MT = 24, n_WT = 12, p = 0.0003260104418254
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig CMS3 MT vs WT using Wilcoxon rank sum test: W = 60, n_MT = 24, n_WT = 12, p = 0.00396607369453015
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 CMS3 MT vs WT using Wilcoxon rank sum test: W = 105, n_MT = 24, n_WT = 12, p = 0.199402414854878
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 146, n_MT = 24, n_WT = 12, p = 0.960445617909466
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 147, n_MT = 24, n_WT = 12, p = 0.934122271252416
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT CMS3 MT vs WT using Wilcoxon rank sum test: W = 179, n_MT = 24, n_WT = 12, p = 0.250944050533136
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE CMS3 MT vs WT using Wilcoxon rank sum test: W = 143, n_MT = 24, n_WT = 12, p = 0.986810352217667
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING CMS3 MT vs WT using Wilcoxon rank sum test: W = 126, n_MT = 24, n_WT = 12, p = 0.562221969761065
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION CMS3 MT vs WT using Wilcoxon rank sum test: W = 129, n_MT = 24, n_WT = 12, p = 0.631265185918068

Computing linear model for CIRC
Computing linear model for CIITA
Computing linear model for wnt
Computing linear model for myc.sig
Computing linear model for BATF3
Computing linear model for HALLMARK_IL6_JAK_STAT3_SIGNALING
Computing linear model for HALLMARK_INTERFERON_GAMMA_RESPONSE
Computing linear model for HALLMARK_COMPLEMENT
Computing linear model for HALLMARK_INFLAMMATORY_RESPONSE
Computing linear model for HALLMARK_IL2_STAT5_SIGNALING
Computing linear model for HALLMARK_ALLOGRAFT_REJECTION
Computing rectum vs left
kfs-mss-msi-inferred-no-cms1: Analyzing CIRC site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 1643, n_rectum = 156, n_left = 20, p = 0.700552586581525
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 1670, n_rectum = 156, n_left = 20, p = 0.609746440245925
kfs-mss-msi-inferred-no-cms1: Analyzing wnt site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 1550, n_rectum = 156, n_left = 20, p = 0.964677744410486
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 1606, n_rectum = 156, n_left = 20, p = 0.832030002315773
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2199, n_rectum = 156, n_left = 20, p = 0.00291678310255527
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 1546, n_rectum = 156, n_left = 20, p = 0.949821930679799
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 1532, n_rectum = 156, n_left = 20, p = 0.897997389843257
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 1575, n_rectum = 156, n_left = 20, p = 0.946110498501233
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 1623, n_rectum = 156, n_left = 20, p = 0.770787915068532
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 1446, n_rectum = 156, n_left = 20, p = 0.596748932742427
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 1557, n_rectum = 156, n_left = 20, p = 0.990701841762805
Computing right vs left
kfs-mss-msi-inferred-no-cms1: Analyzing CIRC site: right vs leftWilcoxon rank sum test: W = 388, n_right = 37, n_left = 20, p = 0.771772849258744
kfs-mss-msi-inferred-no-cms1: Analyzing CIITA site: right vs leftWilcoxon rank sum test: W = 321, n_right = 37, n_left = 20, p = 0.420688523432052
kfs-mss-msi-inferred-no-cms1: Analyzing wnt site: right vs leftWilcoxon rank sum test: W = 334, n_right = 37, n_left = 20, p = 0.555953882610298
kfs-mss-msi-inferred-no-cms1: Analyzing myc.sig site: right vs leftWilcoxon rank sum test: W = 336, n_right = 37, n_left = 20, p = 0.578468249618006
kfs-mss-msi-inferred-no-cms1: Analyzing BATF3 site: right vs leftWilcoxon rank sum test: W = 479, n_right = 37, n_left = 20, p = 0.0693911493634615
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL6_JAK_STAT3_SIGNALING site: right vs leftWilcoxon rank sum test: W = 400, n_right = 37, n_left = 20, p = 0.62471494187678
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INTERFERON_GAMMA_RESPONSE site: right vs leftWilcoxon rank sum test: W = 370, n_right = 37, n_left = 20, p = 1
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_COMPLEMENT site: right vs leftWilcoxon rank sum test: W = 407, n_right = 37, n_left = 20, p = 0.544856447597094
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_INFLAMMATORY_RESPONSE site: right vs leftWilcoxon rank sum test: W = 407, n_right = 37, n_left = 20, p = 0.544856447597094
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_IL2_STAT5_SIGNALING site: right vs leftWilcoxon rank sum test: W = 366, n_right = 37, n_left = 20, p = 0.953750712445422
kfs-mss-msi-inferred-no-cms1: Analyzing HALLMARK_ALLOGRAFT_REJECTION site: right vs leftWilcoxon rank sum test: W = 383, n_right = 37, n_left = 20, p = 0.835886528568373

Plotting CIRC ~ site
Plotting CIITA ~ site
Plotting wnt ~ site
Plotting myc.sig ~ site
Plotting BATF3 ~ site
Plotting HALLMARK_IL6_JAK_STAT3_SIGNALING ~ site
Plotting HALLMARK_INTERFERON_GAMMA_RESPONSE ~ site
Plotting HALLMARK_COMPLEMENT ~ site
Plotting HALLMARK_INFLAMMATORY_RESPONSE ~ site
Plotting HALLMARK_IL2_STAT5_SIGNALING ~ site
Plotting HALLMARK_ALLOGRAFT_REJECTION ~ site
There were 50 or more warnings (use warnings() to see the first 50)
Reading CIRC signature again
Overlap between CIRC (n = 28) and HALLMARK_INTERFERON_GAMMA_RESPONSE (n = 200) = 9
Overlap between CIRC (n = 28) and REACTOME_INTERFERON_GAMMA_SIGNALING (n = 63) = 9
Number of rows analyzed: 20294
Number of columns analyzed: 344
tcga-all: 28 of 34 genes from data set analyzed in set B cells: MS4A1 TCL1A HLA-DOB PNOC KIAA0125 CD19 CR2 FCRL2 BLK COCH OSBPL10 TNFRSF17 ABCB4 BLNK GLDC MEF2C SPIB BCL11A GNG7 CD72 MICAL3 BACH2 CCR9 QRSL1 DTNB HLA-DQA1 SCN3A SLC15A2
tcga-all: 6 of 34 genes missing from data set analyzed in set B cells: IGHG1 IGHA1 IGHM FAM30A IGKC IGL@
tcga-all: 16 of 18 genes from data set analyzed in set T cells: PRKCQ CD3D CD3G CD28 LCK TRAT1 BCL11B CD2 ITM2A SH2D1A CD6 CD96 NCALD GIMAP5 CD3E SKAP1
tcga-all: 2 of 18 genes missing from data set analyzed in set T cells: TRBC1 TRA@
tcga-all: 27 of 27 genes from data set analyzed in set Th1 cells: IFNG LTA APBB2 DOK5 IL12RB2 APOD ZBTB32 CD38 CSF2 CTLA4 CD70 DPP4 EGFL6 BST2 DUSP5 LRP8 IL22 DGKI CCL4 GGT1 LRRN3 SYNGR3 ATP9A BTG3 CMAH HBEGF SGCB
tcga-all: 26 of 27 genes from data set analyzed in set Th2 cells: PMCH AHI1 PTGIS CXCR6 EVI5 IL26 MB NEIL3 GSTA4 PHEX SMAD2 CENPF ANK1 ADCY1 LAIR2 SNRPD1 MICAL2 DHFR WDHD1 BIRC5 SLC39A14 HELLS LIMA1 CDC25C CDC7 GATA3
tcga-all: 1 of 27 genes missing from data set analyzed in set Th2 cells: AI582773
tcga-all: 16 of 17 genes from data set analyzed in set Cytotoxic cells: KLRD1 KLRF1 GNLY CTSW KLRB1 KLRK1 NKG7 GZMH SIGIRR ZBTB16 RUNX3 APOL3 RORA APBA2 DUSP2 GZMA
tcga-all: 1 of 17 genes missing from data set analyzed in set Cytotoxic cells: WHDC1L1
tcga-all: 30 of 31 genes from data set analyzed in set iDC: CD1B VASH1 F13A1 CD1E MMP12 FABP4 CLEC10A SYT17 MS4A6A CTNS GUCA1A CARD9 ABCG2 CD1A PPARG RAP1GAP SLC7A8 GSTT1 FZD2 CSF1R HS3ST2 CH25H LMAN2L SLC26A6 BLVRB NUDT9 PREP TM7SF4 TACSTD2 CD1C
tcga-all: 1 of 31 genes missing from data set analyzed in set iDC: NM_021941
tcga-all: 26 of 31 genes from data set analyzed in set Neutrophils: CSF3R CYP4F3 VNN3 KCNJ15 MME FCGR3B DYSF FCAR CEACAM3 HIST1H2BC HPSE CREB5 S100A12 TNFRSF10C SLC22A4 SLC25A37 BST1 CRISPLD2 G0S2 SIGLEC5 CD93 MGAM ALPL FPR1 PDE4B LILRB2
tcga-all: 5 of 31 genes missing from data set analyzed in set Neutrophils: FPRL1 IL8RA IL8RB FLJ11151 KIAA0329
tcga-all: 28 of 28 genes from data set analyzed in set CIRC: HLA-DQA1 HLA-DQA2 HLA-DRB5 CTLA4 PDCD1LG2 ICAM1 CD274 STAT1 IRF1 IFNG GNLY TBX21 CCL5 LAG3 CD247 ICOS IL18RAP CXCL9 CXCL10 HLA-DPB1 HLA-DPA1 HLA-DMB HLA-DRA HLA-DMA CD80 HLA-DOA CD4 HAVCR2
tcga-all: 59 of 63 genes from data set analyzed in set REACTOME_INTERFERON_GAMMA_SIGNALING: IRF9 GBP4 GBP5 GBP6 FCGR1A FCGR1B GBP1 GBP2 HLA-A HLA-B HLA-C HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQA2 HLA-DRB1 HLA-DRB5 HLA-F HLA-G ICAM1 IRF8 IFNG IFNGR1 IFNGR2 IRF1 IRF2 IRF3 IRF4 IRF5 IRF6 IRF7 JAK1 JAK2 GBP7 CIITA MT2A NCAM1 OAS1 OAS2 OAS3 PML PRKCD B2M PTAFR PTPN1 PTPN2 PTPN6 SP100 STAT1 SUMO1 VCAM1 CAMK2A CAMK2B CAMK2D PIAS1 OASL SOCS1 SOCS3 CD44
tcga-all: 4 of 63 genes missing from data set analyzed in set REACTOME_INTERFERON_GAMMA_SIGNALING: HLA-DRB3 LOC441019 LOC646981 HLA-K
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_TNFA_SIGNALING_VIA_NFKB: JUNB CXCL2 ATF3 NFKBIA TNFAIP3 PTGS2 CXCL1 IER3 CD83 CCL20 CXCL3 MAFF NFKB2 TNFAIP2 HBEGF KLF6 BIRC3 PLAUR ZFP36 ICAM1 JUN EGR3 IL1B BCL2A1 PPP1R15A ZC3H12A SOD2 NR4A2 IL1A RELB TRAF1 BTG2 DUSP1 MAP3K8 ETS2 F3 SDC4 EGR1 IL6 TNF KDM6B NFKB1 LIF PTX3 FOSL1 NR4A1 JAG1 CCL4 GCH1 CCL2 RCAN1 DUSP2 EHD1 IER2 REL CFLAR RIPK2 NFKBIE NR4A3 PHLDA1 IER5 TNFSF9 GEM GADD45A CXCL10 PLK2 BHLHE40 EGR2 SOCS3 SLC2A6 PTGER4 DUSP5 SERPINB2 NFIL3 SERPINE1 TRIB1 TIPARP RELA BIRC2 CXCL6 LITAF TNFAIP6 CD44 INHBA PLAU MYC TNFRSF9 SGK1 TNIP1 NAMPT FOSL2 PNRC1 ID2 CD69 IL7R EFNA1 PHLDA2 PFKFB3 CCL5 YRDC IFNGR2 SQSTM1 BTG3 GADD45B KYNU G0S2 BTG1 MCL1 VEGFA MAP2K3 CDKN1A CYR61 TANK IFIT2 IL18 TUBB2A IRF1 FOS OLR1 RHOB AREG NINJ1 ZBTB10 PPAP2B KLF4 CXCL11 SAT1 CSF1 GPR183 PMEPA1 PTPRE TLR2 CXCR7 KLF10 MARCKS LAMB3 CEBPB TRIP10 F2RL1 KLF9 LDLR TGIF1 RNF19B DRAM1 B4GALT1 DNAJB4 CSF2 PDE4B SNN PLEK STAT5A DENND5A CCND1 DDX58 SPHK1 CD80 TNFAIP8 CCNL1 FUT4 CCRL2 SPSB1 TSC22D1 B4GALT5 SIK1 CLCF1 NFE2L2 FOSB PER1 NFAT5 ATP2B1 IL12B IL6ST SLC16A6 ABCA1 HES1 BCL6 IRS2 SLC2A3 CEBPD IL23A SMAD3 TAP1 MSC IFIH1 IL15RA TNIP2 BCL3 PANX1 FJX1 EDN1 EIF1 BMP2 DUSP4 PDLIM5 ICOSLG GFPT2 KLF2 TNC SERPINB8 MXD1
tcga-all: 199 of 200 genes from data set analyzed in set HALLMARK_HYPOXIA: PGK1 PDK1 GBE1 PFKL ALDOA ENO2 PGM1 NDRG1 HK2 ALDOC GPI MXI1 SLC2A1 P4HA1 ADM P4HA2 ENO1 PFKP FAM162A PFKFB3 VEGFA BNIP3L TPI1 ERO1L KDM3A CCNG2 LDHA GYS1 GAPDH BHLHE40 ANGPTL4 JUN SERPINE1 LOX GCK PPFIA4 MAFF DDIT4 SLC2A3 IGFBP3 NFIL3 FOS RBPJ HK1 CITED2 ISG20 GALK1 WSB1 PYGM STC1 ZNF292 BTG1 PLIN2 CSRP2 VLDLR JMJD6 EXT1 F3 PDK3 ANKZF1 UGP2 ALDOB STC2 ERRFI1 ENO3 PNRC1 HMOX1 PGF GAPDHS CHST2 TMEM45A BCAN ATF3 CAV1 AMPD3 GPC3 NDST1 IRS2 SAP30 GAA SDC4 STBD1 IER3 PKLR IGFBP1 PLAUR PRKCDBP WISP2 LARGE CCRN4L S100A4 RRAGD ZFP36 EGFR EDN2 IDS CDKN1A RORA DUSP1 MIF PPP1R3C DPYSL4 KDELR3 DTNA ADORA2B HS3ST1 PTRF NR3C1 KLF6 GPC4 CYR61 TNFAIP3 CA12 HEXA BGN PPP1R15A PGM2 PIM1 PRDX5 NAGK CDKN1B BRS3 TKTL1 MT1E ATP7A MT2A SDC3 TIPARP PKP1 ANXA2 PGAM2 DDIT3 PRKCA SLC37A4 CXCR4 EFNA3 CP KLF7 CTGF CHST3 TPD52 LXN B4GALNT2 PPARGC1A BCL2 GCNT2 HAS1 KLHL24 SCARB1 SLC25A1 SDC2 CASP6 VHL FOXO3 PDGFB B3GALT6 SLC2A5 SRPX EFNA1 GLRX CXCR7 PAM TGFBI DCN SIAH2 PLAC8 FBP1 TPST2 PHKG1 MYH9 CDKN1C GRHPR PCK1 INHA HSPA5 NDST2 NEDD4L TPBG XPNPEP1 IL6 SLC6A6 MAP3K1 LDHC AKAP12 TES KIF5A LALBA COL5A1 GPC1 HDLBP ILVBL NCAN TGM2 ETS1 HOXB9 SELENBP1 FOSL2 SULT2B1 TGFB3
tcga-all: 1 of 200 genes missing from data set analyzed in set HALLMARK_HYPOXIA: AK4
tcga-all: 74 of 74 genes from data set analyzed in set HALLMARK_CHOLESTEROL_HOMEOSTASIS: FDPS CYP51A1 IDI1 FDFT1 DHCR7 SQLE HMGCS1 NSDHL LSS MVD LDLR TM7SF2 ALDOC EBP SCD PMVK MVK LPL SC5DL FADS2 HMGCR HSD17B7 ANXA13 SREBF2 PCYT2 ACSS2 ATF3 ADH4 ETHE1 ECH1 CBS GUSB FASN LGALS3 ATF5 ANXA5 TP53INP1 CHKA GSTM2 ACAT2 AVPR1A PLSCR1 CLU ERRFI1 TRIB3 CXCL16 TNFRSF12A ACTG1 JAG1 LGMN FBXO6 GPX8 PNRC1 ANTXR2 MAL2 CD9 PPARG GLDC STX5 STARD4 CTNNB1 TMEM97 FAM129A PDK3 PLAUR SEMA3B GNAI1 ABCA2 ATXN2 NFIL3 ALCAM FABP5 S100A11 CPEB2
tcga-all: 199 of 200 genes from data set analyzed in set HALLMARK_MITOTIC_SPINDLE: ARHGEF2 CLASP1 KIF11 KIF23 ALS2 ARF6 MYO9B MYH9 TUBGCP3 CKAP5 RACGAP1 PREX1 ARHGEF3 NUMA1 SPTBN1 KIF2C KIF5B TTK APC CEP250 PAFAH1B1 CDC42EP2 KIF3B CCDC88A KIF15 BIRC5 CNTROB NF1 TSC1 CDC27 TUBGCP5 KIF4A MAPRE1 FGD6 BRCA2 PLK1 RASA1 NEK2 WASF1 TOP2A TRIO ARHGEF11 KATNB1 PRC1 ANLN CDK5RAP2 SMC3 TUBGCP2 ESPL1 MAP1S ARHGAP27 DOCK4 SAC3D1 INCENP ARHGAP5 GSN NET1 LRPPRC RABGAP1 FLNB ARAP3 FGD4 ABR CENPJ NCK1 CENPF KIF20B WASF2 MYH10 CENPE CYTH2 MID1 KLC1 MARK4 ARL8A CEP57 UXT ARHGAP4 CDC42EP4 SASS6 LATS1 OPHN1 WASL MAP3K11 SOS1 ABL1 TIAM1 KIF1B ITSN1 SHROOM1 NCK2 DLGAP5 BCR RANBP9 EPB41L2 SEPT9 KATNA1 TUBD1 TPX2 KIF3C SHROOM2 TUBGCP6 SPTAN1 PALLD ARFIP2 KNTC1 HOOK3 SUN2 MID1IP1 DLG1 FLNA ARHGAP10 CDC42BPA ARHGEF12 MARCKS NIN PCM1 RALBP1 EZR SSH2 CDK1 RAB3GAP1 FARP1 SYNPO RHOF ECT2 EPB41 RAPGEF6 KIF22 PCGF5 STAU1 ARHGDIA AURKA FBXO5 NUSAP1 PXN BCAR1 CD2AP AKAP13 HDAC6 AZI1 LLGL1 ATG4B PCNT ALMS1 CRIPAK KPTN DST KIFAP3 PPP4R2 ARHGAP29 RASAL2 CCNB2 PIF1 RASA2 NEDD9 SMC1A ACTN4 PKD2 CLIP2 CDC42 NDC80 TLK1 TAOK2 TBCD CAPZB DOCK2 CTTN SMC4 ARFGEF1 TUBA4A LMNB1 ABI1 ROCK1 CEP192 BUB1 GEMIN4 PLEKHG2 RICTOR BCL2L11 DYNC1H1 FSCN1 ARHGEF7 DYNLL2 MYO1E BIN1 NOTCH2 RFC1 PDLIM5 RHOT2 SORBS2 CDC42EP1 VCL CLIP1 STK38L YWHAE RAPGEF5 CEP72 CSNK1D
tcga-all: 1 of 200 genes missing from data set analyzed in set HALLMARK_MITOTIC_SPINDLE: CNTRL
tcga-all: 42 of 42 genes from data set analyzed in set HALLMARK_WNT_BETA_CATENIN_SIGNALING: MYC CTNNB1 JAG2 NOTCH1 DLL1 AXIN2 PSEN2 FZD1 NOTCH4 LEF1 AXIN1 NKD1 WNT5B CUL1 JAG1 MAML1 KAT2A GNAI1 WNT6 PTCH1 NCOR2 DKK4 HDAC2 DKK1 TCF7 WNT1 NUMB ADAM17 DVL2 PPARD NCSTN HDAC5 CCND2 FRAT1 CSNK1E RBPJ FZD8 TP53 SKP2 HEY2 HEY1 HDAC11
tcga-all: 54 of 54 genes from data set analyzed in set HALLMARK_TGF_BETA_SIGNALING: TGFBR1 SMAD7 TGFB1 SMURF2 SMURF1 BMPR2 SKIL SKI ACVR1 PMEPA1 NCOR2 SERPINE1 JUNB SMAD1 SMAD6 PPP1R15A TGIF1 FURIN SMAD3 FKBP1A MAP3K7 BMPR1A CTNNB1 HIPK2 KLF10 BMP2 ENG APC PPM1A XIAP CDH1 ID1 LEFTY2 CDKN1C TRIM33 RAB31 TJP1 SLC20A1 CDK9 ID3 NOG ARID4B IFNGR2 ID2 PPP1CA SPTBN1 WWTR1 BCAR3 THBS1 FNTA HDAC1 UBE2D3 LTBP2 RHOA
tcga-all: 87 of 87 genes from data set analyzed in set HALLMARK_IL6_JAK_STAT3_SIGNALING: IL4R IL6ST STAT1 IL1R1 CSF2RB SOCS3 STAT3 OSMR IL2RG IFNGR1 TYK2 IL13RA1 TLR2 IFNGR2 IL10RB IL6 IL1R2 IL3RA IFNAR1 TNFRSF1A MYD88 ACVR1B CSF3R ITGB3 REG1A CXCL1 A2M CSF2RA IL15RA IRF9 PDGFC HAX1 BAK1 EBI3 INHBE CRLF2 TNFRSF1B CD14 PTPN1 PTPN2 IL1B CSF1 IL18R1 TNF PF4 CXCL13 LTBR FAS IL17RA CXCL10 IL9R STAM2 TNFRSF12A STAT2 HMOX1 LEPR CBL CD9 CXCL3 TGFB1 MAP3K8 ITGA4 CD38 JUN SOCS1 ACVRL1 PIM1 TNFRSF21 PIK3R5 GRB2 IRF1 DNTT CSF2 IL2RA PTPN11 IL12RB1 CCR1 CNTFR PLA2G2A CXCL9 CD44 IL7 CXCL11 CCL7 LTB IL17RB CD36
tcga-all: 149 of 150 genes from data set analyzed in set HALLMARK_DNA_REPAIR: POLR2H POLR2A POLR2G POLR2E POLR2J POLR2F POLR2C POLR2K GTF2H3 POLR2D ERCC3 DDB2 POLR1C XPC PCNA POLR2I SUPT4H1 POLD3 POLR3GL POLR3C GTF2B POLR1D NCBP2 RDBP GTF2F1 ERCC5 LIG1 ERCC1 ERCC4 POLD4 COBRA1 RFC2 ELL TAF10 RRM2B SUPT5H RPA3 SNAPC5 SSRP1 RFC3 RPA2 TCEB3 TAF12 TH1L TAF13 TAF6 TAF9 GTF2A2 VPS37D NME1 RNMT ERCC2 POLE4 VPS37B NT5C3 SNAPC4 AAAS ZNRD1 RFC4 ITPA POM121 BRF2 RFC5 SAC3D1 CLP1 NME4 PRIM1 VPS28 TSG101 USP11 TAF1C TARBP2 POLH CETN2 POLD1 CANT1 PDE4B DGCR8 RAD51 SURF1 PNP ADA NME3 GTF3C5 NT5C AK1 GTF2H1 HCLS1 APRT ERCC8 IMPDH2 POLB SDCBP SF3A3 DAD1 UPF3B GUK1 TP53 ADRM1 SEC61A1 POLA2 FEN1 ZNF707 NUDT9 PDE6G TYMS BCAP31 DDB1 NFX1 RAD52 ADCY6 ARL6IP1 DGUOK POLL SMAD5 MPG DUT POLA1 EIF2C4 RALA ZWINT BCAM TK2 CSTF3 GTF2H5 HPRT1 BOLA2 GPX4 BRP44 CDA THOC4 MRPL40 NPR2 REV3L EDF1 DFNA5 TMED2 STX3 RAE1 UMPS EIF1B AK3 NUDT21 RBX1 GMPR2 DCTN4 COX17 CMPK2 CCNO
tcga-all: 1 of 150 genes missing from data set analyzed in set HALLMARK_DNA_REPAIR: SRSF6
tcga-all: 194 of 200 genes from data set analyzed in set HALLMARK_G2M_CHECKPOINT: AURKA CCNA2 TOP2A CCNB2 CENPA BIRC5 CDC20 PLK1 TTK PRC1 NDC80 KIF11 NUSAP1 CKS2 KIF2C MKI67 AURKB TPX2 SMC4 BUB1 CENPF RACGAP1 CENPE KIF23 UBE2C MCM6 MCM3 PTTG1 CDK1 KIF4A ESPL1 MAD2L1 NEK2 KIF22 HMMR KPNA2 CDKN3 CDC25A H2AFX CDC25B PLK4 CDC6 CCNF MCM5 LMNB1 E2F3 KIF15 CHEK1 UBE2S WHSC1 HMGB3 DBF4 TACC3 MCM2 CDKN2C CDKN1B FANCC NASP STAG1 GINS2 FBXO5 POLQ EZH2 RAD21 STMN1 SUV39H1 PRIM2 E2F1 CHAF1A NOLC1 GSPT1 BUB3 SMC1A ILF3 CDC7 INCENP CKS1B EXO1 H2AFZ TFDP1 CCND1 KPNB1 HN1 LBR HUS1 KIF20B TOP1 PDS5B STIL ABL1 DTYMK CDC27 BARD1 ATF5 CDC45 ODC1 XPO1 SFPQ TMPO PML BRCA2 CTCF CASC5 SETD8 SLC38A1 TRA2B MYBL2 TROAP PAPD7 CUL3 MAPK14 HIST1H2BK MYC AMD1 CBX1 CHMP1A DKC1 YTHDC1 CCNT1 TGFB1 ATRX LIG3 NUP50 SLC7A5 RBL1 NUMA1 RAD54L EFNA5 PRPF4B UCK2 ARID4A CUL1 UPF1 DR1 MNAT1 SMC2 RBM14 RPA2 SQLE CDK4 POLE RASAL2 HOXC10 RPS6KA5 CUL4A SLC7A1 FOXN3 HMGA1 SS18 TRAIP PRMT5 CUL5 MARCKS PBK SAP30 KATNA1 HNRNPD POLA2 HIRA HIF1A SYNCRIP TLE3 NCL RAD23B E2F2 EGF HMGN2 SNRPD1 CASP8AP2 SMARCC1 SLC12A2 NOTCH2 TNPO2 SMAD3 ZAK HSPA8 G3BP1 PTTG3P DMD MEIS1 HNRNPU MT2A NUP98 EWSR1 KIF5B MTF2 E2F4 BCL3 PURA MEIS2 PAFAH1B1 WRN H2AFV ODF2
tcga-all: 6 of 200 genes missing from data set analyzed in set HALLMARK_G2M_CHECKPOINT: SRSF1 ORC6 DDX39A ORC5 SRSF10 SRSF2
tcga-all: 161 of 161 genes from data set analyzed in set HALLMARK_APOPTOSIS: CASP3 CASP9 DFFA CASP7 CFLAR BIRC3 PMAIP1 CASP8 JUN BCL2L11 MCL1 IL1B SPTAN1 DIABLO BAX BIK IL1A BID CDKN1A GADD45A DDIT3 CDKN1B TNF GSN TNFSF10 CASP6 SQSTM1 FASLG EGR3 CD44 FAS IL18 IGFBP6 PRF1 DAP CCND1 BTG3 F2R SATB1 BNIP3L CASP4 TNFRSF12A CREBBP RHOB GPX3 PDGFRB TSPO CCND2 XIAP TIMP1 CTNNB1 IRF1 HSPB1 ADD1 TIMP2 BTG2 TIMP3 LEF1 CASP1 GPX1 BCL10 IGF2R CDC25B AIFM3 CD38 PPP3R1 HGF CLU ATF3 LGALS3 LUM LMNA GADD45B CDK2 IFNB1 RETSAT SMAD7 SOD1 PTK2 ENO2 HMOX1 IER3 BCL2L10 CD2 GCH1 MMP2 VDAC2 TAP1 PLAT IFNGR1 APP BRCA1 ROCK1 PSEN1 DCN PSEN2 SOD2 BMF EREG KRT18 TGFB2 RELA WEE1 RARA CD14 CD69 PEA15 DNAJC3 CASP2 CTH PLCB2 BMP2 HMGB2 LPPR4 H1F0 TGFBR3 EBP TXNIP ANKH RHOT2 CYLD GSTM1 GSR BGN BCL2L1 GNA15 MGMT PPT1 F2 IL6 SC5DL IFITM3 RNASEL EMP1 CAV1 DNM1L ANXA1 TOP2A ISG20 SLC20A1 MADD PPP2R5B BCAP31 ERBB3 NEDD9 SAT1 PDCD4 BCL2L2 FEZ1 ERBB2 DNAJA1 DAP3 DPYD NEFH PAK1 FDXR GPX4 ETF1 CCNA1 GUCY2D AVPR1A
tcga-all: 32 of 32 genes from data set analyzed in set HALLMARK_NOTCH_SIGNALING: JAG1 NOTCH3 NOTCH2 APH1A HES1 CCND1 FZD1 PSEN2 FZD7 DTX1 DLL1 FZD5 MAML2 NOTCH1 PSENEN WNT5A CUL1 WNT2 DTX4 SAP30 PPARD KAT2A HEYL SKP1 RBX1 TCF7L2 ARRB1 LFNG PRKCA DTX2 ST3GAL6 FBXW11
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_ADIPOGENESIS: FABP4 ADIPOQ PPARG LIPE DGAT1 LPL CPT2 CD36 GPAM ADIPOR2 ACAA2 ETFB ACOX1 ACADM HADH IDH1 SORBS1 ACADS UCK1 SCP2 DECR1 CDKN2C TALDO1 TST MCCC1 PGM1 REEP5 BCL2L13 SLC25A10 ME1 PHYH PIM3 YWHAG NDUFAB1 GPD2 ADIG ECHS1 QDPR CS ECH1 SLC25A1 ACADL TOB1 GRPEL1 CRAT GBE1 SDPR SCARB1 PEMT CHCHD10 AK2 APOE UQCR10 TANK ANGPTL4 ACO2 FAH ACLY IFNGR1 SLC5A6 JAGN1 EPHX2 IDH3G GPX3 ELMOD3 ORM1 RETSAT ESRRA HIBCH SUCLG1 STAT5A ITGA7 MRAP PLIN2 CYC1 ALDH2 RNF11 ALDOA SULT1A1 DDT SDHB CD151 SLC27A1 BCKDHA C3 LEP ADCY6 ELOVL6 LTC4S SPARCL1 FAM82A2 MTCH2 ANKRD57 SLC1A5 CMPK1 REEP6 NDUFA5 FZD4 DRAM2 MGST3 ATP1B3 RETN STOM ESYT1 GHITM DNAJC15 GADD45A VEGFB PFKL COQ3 OBFC2A CYP4B1 PPM1B ARAF PTRF COL4A1 IMMT DHRS7 COL15A1 NMT1 COQ5 LAMA4 AGPAT3 BAZ2A IDH3A LIFR PREB PTGER3 GPHN PFKFB3 GPX4 SSPN SQRDL MOSC2 DLD ITIH5 CD302 ATL2 AGPAT6 LPCAT3 TKT UQCRC1 CAT OMD DLAT MRPL15 RIOK3 RTN3 CHUK G3BP2 SDHC SAMM50 ARL4A SNCG PDCD4 COQ9 APLP2 SOD1 PTCD3 PHLDB1 ENPP2 HSPB8 AIFM1 CCNG2 PPP1R15B MDH2 ABCA1 COX7B MYLK COX8A DHRS7B FAM73B MGLL ITSN1 DHCR7 RREB1 CMBL UBC ATP5O PRDX3 DBT NDUFS3 NKIRAS1 RAB34 CIDEA UQCRQ PEX14 BCL6 COX6A1 DNAJB9 MAP4K3 ANGPT1 UBQLN1 NDUFB7 SLC19A1 ABCB8 PQLC3 POR UCP2 UQCR11
tcga-all: 197 of 200 genes from data set analyzed in set HALLMARK_ESTROGEN_RESPONSE_EARLY: GREB1 CA12 SLC9A3R1 MYB ANXA9 IGFBP4 SYBU NPY1R PDZK1 NRIP1 MLPH HSPB8 EGR3 KRT19 LRIG1 KDM4B PGR RHOBTB3 TPD52L1 ELOVL2 RET TPBG TFF1 MAPT SCNN1A ABAT FLNB XBP1 CELSR2 RAB31 MYBL1 MREG FAM102A MSMB STC2 FAM134B SIAH2 ZNF185 SLC19A2 SLC1A4 FHL2 BCL2 PMAIP1 AREG OVOL2 TSKU ADCY9 RASGRP1 MUC1 SLC27A2 FKBP4 CXCL12 TMPRSS3 RARA IL17RB CBFA2T3 TFF3 UGCG CCND1 SLC22A5 WFS1 PTGES WWC1 WISP2 MYC ITPK1 TMEM164 ARL3 MED13L SEMA3B KRT18 SLC16A1 TJP3 SLC26A2 FAIM3 SULT2B1 SNX24 TFAP2C TTC39A GJA1 PRSS23 OLFM1 RAPGEFL1 ASB13 TIPARP ABCA3 FRK DHRS2 AQP3 KCNK15 TGIF2 FOXC1 ELF3 REEP1 PEX11A PODXL KLF4 BAG1 CELSR1 PLA2G16 SLC7A5 MPPED2 TIAM1 CLDN7 MYOF RBBP8 OLFML3 GFRA1 FARP1 SVIL TGM2 CYP26B1 PAPSS2 SLC1A1 DLC1 JAK2 AFF1 KLK10 P2RY2 BLVRB CISH GLA ADD3 PDLIM3 FAM63A FOS KRT8 SLC37A1 B4GALT1 CALCR ESRP2 IGF1R NBL1 SFN OPN3 ABHD2 AR SLC39A6 SYT12 CD44 MED24 BCL11B CANT1 KRT13 KRT15 TOB1 SLC7A2 LAD1 TUBB2B SEC14L2 ENDOD1 HR SCARB1 NCOR2 RHOD INPP5F PPIF DHRS3 FDFT1 GAB2 UNC119 KLF10 HES1 FKBP5 SLC2A1 AMFR NADSYN1 INHBB BHLHE40 CALB2 FASN CHPT1 MYBBP1A ELOVL5 DYNLT3 ABLIM1 SOX3 SLC24A3 RAB17 MAST4 KCNK5 ELF1 RPS6KA2 ISG20L2 IL6ST SYNGR1 SH3BP5 ALDH3B1 THSD4 CLIC3 NXT1 NAV2 RRP12 ADCY1 DHCR7 MICB AKAP1
tcga-all: 3 of 200 genes missing from data set analyzed in set HALLMARK_ESTROGEN_RESPONSE_EARLY: KAZN DEPTOR TBC1D30
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_ESTROGEN_RESPONSE_LATE: TFF1 SLC9A3R1 TPD52L1 PRSS23 CA12 PDZK1 ANXA9 CELSR2 TJP3 PGR RET MYB TPBG EGR3 ARL3 OLFM1 NPY1R SCNN1A XBP1 AREG IL17RB NRIP1 ASS1 TFF3 FKBP4 SLC27A2 SEMA3B GPER LLGL2 AGR2 KRT19 WISP2 BLVRB FLNB PDCD4 CALCR IGFBP4 DNAJC12 TIAM1 TSPAN13 CXCL12 RAB31 PKP3 CYP26B1 FKBP5 SIAH2 ISG20 TMPRSS3 SERPINA3 WFS1 MAPT PDLIM3 RBBP8 GJB3 PRLR SLC1A4 FOS PLA2G16 SLC7A5 SERPINA5 IMPA2 DHCR7 MYOF CDH1 EMP2 OVOL2 DLG5 SOX3 CHPT1 KLK10 ELOVL5 RAPGEFL1 JAK2 SLC26A2 SLC22A5 ITPK1 PCP4 PAPSS2 NAB2 FAM102A BCL2 LSR CACNA2D2 CA2 ASCL1 ACOX2 CISH GLA PTGES PERP OPN3 KRT13 HSPB8 UGDH CLIC3 KLK11 PLAC1 ABHD2 SCARB1 DCXR CCND1 SFN ABCA3 SULT2B1 CCNA1 STIL MICB ZFP36 CAV1 NBL1 CD44 HR HOMER2 BTG3 GAL ETFB BAG1 FRK SLC16A1 AFF1 TFAP2C IGSF1 HPRT1 CDC6 FARP1 AMFR DHRS2 NXT1 S100A9 SLC29A1 SLC24A3 FOXC1 KIF20A TOB1 FDFT1 DNAJC1 TPSAB1 TSTA3 FGFR3 SGK1 ID2 GALE BATF MAPK13 FABP5 MEST JAK1 CYP4F11 KCNK5 CPE XRCC3 CXCL14 SCUBE2 CDC20 IL6ST GINS2 TRIM29 UNC13B LAMC2 LARGE SLC2A8 PLXNB1 PRKAR2B RPS6KA2 HSPA4L TFPI2 SERPINA1 TNNC1 HMGCS2 ALDH3A2 CD9 IDH2 SORD MDK ALDH3B1 PTGER3 RABEP1 KLF4 PPIF SNX10 METTL3 PLK4 COX6C ST14 NCOR2 MOCS2 NMU TH RNASEH2A CHST8 TST TOP2A CKB LTF DUSP2 PTPN6 ATP2B4 ST6GALNAC2 ADD3 DYNLT3
tcga-all: 101 of 101 genes from data set analyzed in set HALLMARK_ANDROGEN_RESPONSE: KLK3 KLK2 ACSL3 PIAS1 CAMKK2 NKX3-1 TMPRSS2 APPBP2 CENPN BMPR1B MAF FADS1 ZBTB10 HMGCR SPCS3 INSIG1 NGLY1 UBE2J1 ELK4 ABCC4 ELOVL5 ALDH1A3 TARP AZGP1 ABHD2 SAT1 DBI DHCR24 SORD STK39 TPD52 IDI1 B2M MAP7 DNAJB9 FKBP5 HERC3 PGM3 HOMER2 ELL2 UAP1 SEC24D LMAN1 PMEPA1 INPP4B RRP12 SEPP1 NDRG1 KRT19 ITGAV B4GALT1 MAK SPDEF GSR KRT8 LIFR PPAP2A STEAP4 GUCY1A3 SRP19 CCND3 IQGAP2 RAB4A SLC26A2 SMS ZMIZ1 SGK1 MERTK HPGD ANKH GNAI3 SRF SLC38A2 HMGCS1 ARID5B CDC14B TNFAIP8 XRCC5 GPD1L ACTN1 RPS6KA3 TSC22D1 PDLIM5 TMEM50A ADAMTS1 NCOA4 AKAP12 SCD PTK2B CDK6 ADRM1 H1F0 HSD17B14 VAPA CCND1 XRCC6 MYL12A UBE2I PTPN21 AKT1 PA2G4
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_MYOGENESIS: ACTA1 TNNI2 MYL1 TNNC1 TNNC2 MYH3 MYLPF TNNT3 TNNT2 CASQ2 ACTC1 MYOM1 MYL4 MYBPH MYH7 MYH8 ACTN2 TNNI1 CRYAB SGCG HRC TNNT1 DES MYOZ1 RYR1 CSRP3 ADAM12 ATP2A1 CKM SVIL MYOM2 MYL6B TPM2 MYL2 CKMT2 BIN1 MYH1 ENO3 FLII FXYD1 TPM3 DMD IGFBP3 CHRNB1 SPEG FHL1 ACTN3 TCAP MYLK MYL3 PYGM LDB3 COX6A2 FABP3 MYL7 ITGB5 CHRNA1 SSPN COL3A1 KCNH1 GJA5 MYF6 MYH2 MAPK12 PGAM2 MYOG MYH4 AEBP1 HBEGF MEF2C NOS1 CNN3 IGFBP7 CACNA1H GSN CACNG1 PPFIA4 MB SPHK1 SCHIP1 MEF2D SMTN CDKN1A GAA TPD52L1 HSPB2 SGCA BDKRB2 COX7A1 COL4A2 PLXNB2 CTF1 COL15A1 KCNH2 AGRN MYO1C SIRT2 SGCD SORBS1 VIPR1 FGF2 FKBP1B TEAD4 CASQ1 KLF5 PDLIM7 AK1 TAGLN RIT1 MEF2A ANKRD2 AKT2 LAMA2 ST5 IFRD1 NCAM1 SYNGR2 PICK1 COL6A3 CRAT DMPK MYH11 MYH9 IGF1 CKB FST GPX3 PVALB PTP4A3 ITGB1 HSPB8 ACHE CHRNG PKIA NAV2 HDAC5 ATP6AP1 CLU ACSL1 COL1A1 MRAS PDE4DIP AGL ERBB3 GABARAPL2 CAV3 BHLHE40 PPP1R3C LARGE LPIN1 CDH13 NQO1 PRNP PSEN2 DAPK2 LSP1 SLC6A8 REEP1 EIF4A2 SH2B1 MYBPC3 ITGA7 SPTAN1 SORBS3 PC SCD GNAO1 STC2 CFD RB1 BAG1 ABLIM1 PTGIS MAPRE3 OCEL1 SH3BGR NOTCH1 TSC2 TGFB1 FDPS CAMK2B EPHB3 GADD45B APP APLNR ITGB4 SOD3 FOXO4 EFS PFKM COL6A2 DTNA KIFC3 SPARC SPDEF SLN WWTR1 CD36 ADCY9 APOD
tcga-all: 96 of 96 genes from data set analyzed in set HALLMARK_PROTEIN_SECRETION: ARCN1 TMED10 COPB2 RAB14 ATP7A COPB1 LAMP2 EGFR IGF2R COPE PPT1 AP3S1 BET1 CLCN3 AP2S1 CLTC AP2M1 RER1 KIF1B ARF1 OCRL ICA1 MON2 ARFGEF2 TMED2 NAPG TMX1 PAM SCAMP1 SH3GL2 RAB2A COG2 VAMP3 ERGIC3 DOPEY1 VAMP4 VPS4B NAPA GNAS STX7 SEC22B VPS45 STX16 YKT6 SNX2 ARFGEF1 CLTA CLN5 M6PR SGMS1 USO1 TSG101 DNM1L LMAN1 YIPF6 ARFIP1 ANP32E TSPAN8 DST SCRN1 SEC31A VAMP7 SCAMP3 AP2B1 RAB22A AP3B1 TPD52 ATP6V1H GBF1 KRT18 CAV2 ATP1A1 BNIP3 ZW10 GALC ADAM10 RAB5A GOLGA4 SEC24D AP1G1 MAPK1 GOSR2 RPS6KA3 STAM ABCA1 SNAP23 SOD1 GLA ATP6V1B1 STX12 CD63 TOM1L1 SSPN ARFGAP3 RAB9A CTSC
tcga-all: 97 of 97 genes from data set analyzed in set HALLMARK_INTERFERON_ALPHA_RESPONSE: MX1 ISG15 OAS1 IFIT3 IFI44 IFI35 IRF7 RSAD2 IFI44L IFITM1 IFI27 IRF9 OASL EIF2AK2 IFIT2 CXCL10 TAP1 SP110 DDX60 UBE2L6 USP18 PSMB8 IFIH1 BST2 LGALS3BP ADAR ISG20 GBP2 IRF1 PLSCR1 PSMB9 HERC6 SAMD9 CMPK2 IFITM3 RTP4 STAT2 SAMD9L LY6E IFITM2 PRIC285 CXCL11 TRIM21 PARP14 TRIM26 PARP12 NMI RNF31 HLA-C CASP1 TRIM14 TDRD7 DHX58 PARP9 PNPT1 TRIM25 PSME1 WARS EPSTI1 UBA7 PSME2 B2M TRIM5 C1S LAP3 LAMP3 GBP4 NCOA7 TMEM140 CD74 GMPR PSMA3 PROCR IL7 IFI30 IRF2 CSF1 IL15 CNP FAM46A IL4R FTSJD2 CD47 LPAR6 MOV10 CASP8 TXNIP SLC25A28 SELL TRAFD1 BATF2 RIPK2 CCRL2 NUB1 OGFR FAM125A ELF1
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: STAT1 ISG15 IFIT1 MX1 IFIT3 IFI35 IRF7 IFIT2 OAS2 TAP1 EIF2AK2 RSAD2 MX2 IRF1 OAS3 TNFSF10 IRF9 CXCL10 IFI44 BST2 XAF1 SP110 OASL PSMB8 IFI44L IFITM3 DDX60 LGALS3BP GBP4 IRF8 PSMB9 PML IFIH1 UBE2L6 IFI27 ADAR LY6E STAT2 CXCL9 IL10RA PLA2G4A TRIM21 USP18 PTGS2 EPSTI1 C1S DDX58 IL15 NLRC5 NMI IDO1 PSMB10 CXCL11 ITGB7 SAMHD1 HERC6 CMPK2 SAMD9L RTP4 PTPN2 PARP14 TNFAIP2 IFITM2 PLSCR1 SOCS1 CASP1 ICAM1 WARS PSME1 ISG20 IRF2 TRIM14 FCGR1A MARCH1 SOCS3 JAK2 HLA-DMA PARP12 TNFAIP6 TRIM26 VCAM1 CD274 CIITA NAMPT SELP GPR18 FPR1 PRIC285 PSME2 SERPING1 CCL5 RNF31 SOD2 TRIM25 LAP3 PSMA3 RNF213 PELI1 CFB CD86 TXNIP HLA-DQA1 GCH1 PNP CCL7 PTPN6 SPPL2A IL4R PNPT1 DHX58 BTG1 CASP8 IFI30 CCL2 FGL2 CASP7 SECTM1 IL15RA CD40 TRAFD1 HLA-DRB1 GBP6 LCP2 HLA-G MT2A RIPK1 KLRK1 UPP1 PSMB2 TDRD7 HIF1A EIF4E3 VAMP8 PFKP CD38 ZBP1 BANK1 TOR1B RBCK1 PDE4B MVP IL7 BPGM FTSJD2 AUTS2 B2M RIPK2 CD69 MYD88 PSMA2 PIM1 NOD1 CFH TAPBP SLC25A28 PTPN1 TNFAIP3 SSPN NUP93 MTHFD2 CDKN1A IRF4 NFKB1 BATF2 HLA-B LATS2 IRF5 SLAMF7 ISOC1 P2RY14 STAT3 NCOA3 HLA-A IL6 GZMA IFNAR2 CD74 RAPGEF6 CASP4 FAS OGFR ARL4A SRI LYSMD2 CSF2RB ST3GAL5 C1R CASP3 CMKLR1 NFKBIA METTL7B ST8SIA4 XCL1 IL2RB VAMP5 IL18BP ZNFX1 ARID5B APOL6 STAT4
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_APICAL_JUNCTION: ACTN1 CLDN7 ACTN3 CLDN19 DLG1 TJP1 COL17A1 PVRL1 CLDN9 CDH3 CTNND1 CDH1 LIMA1 VCL SHROOM2 PVRL3 PVRL2 CLDN14 PTPRC THY1 VASP ITGB1 ZYX ACTN4 CLDN4 CADM3 ITGA3 NF2 B4GALT1 NEXN CDH6 ADAM15 PTK2 HADH LAMB3 CLDN11 CDH4 IRS1 SORBS3 CLDN8 EVL CLDN15 THBS3 PVRL4 JAM3 CDH11 ITGB4 RASA1 AKT2 TMEM8B LAMA3 RSU1 ICAM1 CLDN18 GTF2F1 TSC1 LAMC2 NRAP CTNNA1 CD99 FSCN1 COL16A1 GNAI2 TGFBI MPP5 JUP ACTN2 INSIG1 LAYN PFN1 CNN2 TAOK2 AMIGO2 MDK INPPL1 CLDN6 ARPC2 SRC PBX2 MAPK14 MAP4K2 PTEN CALB2 CNTN1 TSPAN4 VCAN CDH8 ATP1A3 EPB41L2 MYL9 SPEG ADRA1B SYK CADM2 ALOX15B CX3CL1 MYH10 DMP1 CDSN MAPK13 MYL12B RAC2 FBN1 DSC1 CD34 ICAM4 MSN MAPK11 ACTC1 TRAF1 CRB3 ITGA2 ITGA10 BAIAP2 ARHGEF6 ACTG1 MVD PDZD3 ADAM9 PCDH1 SLIT2 KRT31 SGCE GNAI1 PIK3CB NLGN2 YWHAH PARVA CRAT ADAMTS5 AMH EGFR ICAM2 CD274 CDH15 SHC1 MPZL2 WNK4 NFASC PIK3R3 SDC3 SIRPA GRB7 FLNC PARD6G COL9A1 NRXN2 ZAK SLC30A3 RHOF BMP1 MMP2 ICAM5 VWF MYH9 CD209 VCAM1 DHX16 ACTG2 NEGR1 NF1 ADAM23 PLCG1 KCNH2 CERCAM NRTN IKBKG DSC3 ACTB TUBG1 PPP2R2C HRAS MMP9 TNFRSF11B PKD1 CDK8 FYB AMIGO1 CD276 GAMT NLGN3 SKAP2 RRAS CAP1 EXOC4 ACTA1 TIAL1 LDLRAP1 VAV2 AKT3 SYMPK STX4 PECAM1 MADCAM1 ITGA9 CD86 TRO CLDN5 MPZL1 WASL
tcga-all: 44 of 44 genes from data set analyzed in set HALLMARK_APICAL_SURFACE: B4GALT1 RHCG MAL LYPD3 PKHD1 ATP6V0A4 AIM1 SHROOM2 SRPX MDGA1 TMEM8B THY1 PCSK9 EPHB4 DCBLD2 GHRL LYN GAS1 FLOT2 PLAUR AKAP7 ATP8B1 EFNA5 SLC34A3 APP GSTM3 HSPB1 SLC2A4 IL2RB RTN4RL1 NCOA6 SULF2 ADAM10 BRCA1 GATA3 AFAP1L2 IL2RG CD160 ADIPOR2 SLC22A12 NTNG1 SCUBE1 CX3CL1 CROCC
tcga-all: 36 of 36 genes from data set analyzed in set HALLMARK_HEDGEHOG_SIGNALING: SHH PTCH1 NRCAM NRP1 SCG2 AMOT UNC5C GPR56 HEY1 GLI1 THY1 SLIT1 CDK6 HEY2 NRP2 TLE3 TLE1 L1CAM PLG NKX6-1 NF1 RASA1 ETS2 RTN1 CRMP1 MYH9 VEGFA CELSR1 CNTFR ACHE PML CDK5R1 VLDLR OPHN1 LDB1 DPYSL2
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_COMPLEMENT: C2 C1S CFB C1R SERPINE1 MMP14 SERPING1 CTSL1 F5 MMP13 F7 CTSS LGMN PLG C1QA CASP1 GZMA ADAM9 CALM3 C1QC TIMP1 DPP4 KLK1 KLKB1 CD59 CR2 MMP15 LAP3 SPOCK2 F10 CTSB SERPINA1 CTSO CD40LG CBLB PDP1 C4BPB PLEK GP9 PLAUR C3 F2 CASP4 STX4 CTSC USP15 CR1 DUSP6 SERPINB2 GPD2 CFH FN1 CD36 CA2 PSMB9 APOBEC3G FCN1 GZMK PDGFB CLU CASP10 LRP1 CTSD S100A9 WAS BRPF3 PLAT CDA MT3 CASP7 PRSS36 PFN1 GZMB RNF4 ZEB1 CASP5 IRF1 PGCP CDK5R1 ATOX1 PIK3CA TMPRSS6 CPM RCE1 CALM1 DOCK9 KYNU RASGRP1 USP14 LCP2 GP1BA KIF2A GNB4 LCK OLR1 PREP SEPX1 LTA4H ZFPM2 LYN ACTN2 SIRT6 APOC1 PRKCD ITGAM DGKH LTF MAFF KCNIP2 PCLO DOCK10 SH2B3 RABIF SRC HPCAL4 CD46 PRDM4 GNAI3 C9 PPP2CB IRF2 FYN JAK2 PLA2G4A PRCP USP8 RHOG L3MBTL4 LAMP2 PIM1 CXCL1 F3 GNAI2 CASP9 XPNPEP1 PLSCR1 IRF7 CD55 HSPA5 GNB2 DYRK2 PLA2G7 S100A12 GRB2 PHEX GNGT2 DOCK4 MMP12 KCNIP3 FDX1 TIMP2 MMP8 FCER1G ZFYVE20 ANXA5 CTSL2 GCA EHD1 PRSS3 COL4A2 CSRP1 PIK3R5 SERPINC1 ANG APOBEC3F GATA3 DUSP5 CASP3 USP16 CP PSEN1 LIPA PCSK9 DGKG GNG2 ME1 GMFB SCG3 PPP4C CCL5 CTSH F8 APOA4 IL6 AKAP10 ERAP2 VCPIP1 HSPA1A RAF1 NOTCH4 ADRA2B CEBPB HNF4A LGALS3 TNFAIP3 CDH13 ITIH1 TFPI2 PIK3CG S100A13
tcga-all: 113 of 113 genes from data set analyzed in set HALLMARK_UNFOLDED_PROTEIN_RESPONSE: ATF4 HERPUD1 PARN EXOSC4 HSP90B1 XBP1 EXOSC9 HSPA5 ATF3 EXOSC1 EXOSC5 ASNS ARFGAP1 WFS1 SRPRB DNAJB9 TSPYL2 NFYA CALR KHSRP DNAJC3 EXOSC2 NOP14 ATF6 HYOU1 RRP9 NOP56 CXXC1 IGFBP1 CNOT4 DCP2 PDIA6 ATP6V0D1 PREB SEC31A GOSR2 SERP1 NFYB NHP2 DCTN1 SLC7A5 SSR1 EDEM1 EDC4 EIF2AK3 MTHFD2 SRPR NOLC1 ERN1 FKBP14 ZBTB17 WIPI1 YIF1A CCL2 DKC1 EIF4EBP1 EIF4A1 EIF2S1 TATDN2 XPOT LSM4 CHAC1 STC2 PDIA5 OBFC2A LSM1 SDAD1 EIF4A2 EIF4E IARS DDX10 GEMIN4 TARS ALDH18A1 DDIT4 HSPA9 SEC11A EIF4A3 POP4 ERO1L CEBPG BAG3 KDELR3 CEBPB CNOT2 SHC1 SPCS3 H2AFX SLC1A4 RPS14 NPM1 CNOT6 CKS1B PSAT1 EIF4G1 YWHAZ SLC30A5 SKIV2L2 KIF5B DCP1A IFIT1 IMP3 SPCS1 DNAJA4 VEGFA TTC37 TUBB2A FUS EXOSC10 EEF2 EXOC2 PAIP1 BANF1
tcga-all: 105 of 105 genes from data set analyzed in set HALLMARK_PI3K_AKT_MTOR_SIGNALING: MAPK8 PIK3R3 GRB2 NFKBIB MAP2K6 MAPK9 AKT1 MAPK1 PLCG1 TRIB3 GSK3B MAP2K3 CDKN1A RAC1 RIPK1 AKT1S1 ACTR2 PRKAR2A YWHAB HRAS PDK1 PIKFYVE TBK1 ACTR3 E2F1 MYD88 ITPR2 SQSTM1 RPS6KA1 PTPN11 MAPKAP1 PLCB1 RAF1 CAMK4 RPTOR CFL1 CDK4 TRAF2 GNGT1 UBE2N ADCY2 CDKN1B VAV3 FGF6 ECSIT RALB ARF1 MKNK1 CDK1 PTEN ARHGDIA ADRBK1 FGF17 DDIT3 IRAK4 TIAM1 CDK2 SFN PRKCB GNA14 EIF4E CLTC TSC2 FGF22 PPP1CA DUSP3 HSP90B1 IL4 STAT2 SLA EGFR PLA2G12A MAPK10 CALR THEM4 RIT1 MKNK2 PPP2R1B CAB39L ARPC3 PITX2 NCK1 IL2RG PFN1 FASLG NOD1 DAPP1 UBE2D3 CAB39 AP2M1 MAP3K7 PRKAG1 CSNK2B PRKAA2 ATF1 SLC2A1 PIN1 TNFRSF1A LCK RPS6KA3 NGF CXCR4 ACACA SMAD2 PAK4
tcga-all: 198 of 200 genes from data set analyzed in set HALLMARK_MTORC1_SIGNALING: FADS1 DDIT4 CALR HK2 PGK1 SLC7A5 CTSC ACSL3 SLC1A5 M6PR TFRC DDIT3 TMEM97 IFRD1 PLOD2 TUBA4A PSAT1 CORO1A LDHA MTHFD2 FADS2 VLDLR WARS SCD P4HA1 ACTR2 IDH1 SLC2A1 GBE1 SERPINH1 NUPR1 PSMG1 PSPH NAMPT CDKN1A BHLHE40 HSPA9 HSPA5 EGLN3 LGMN PNP XBP1 SLA HSPE1 ACLY SLC7A11 SSR1 GLA SQSTM1 PDK1 PSMC2 PRDX1 SERP1 TRIB3 NFIL3 HMGCS1 GOT1 TPI1 ELOVL6 ASNS PSMD14 PSMA4 PPA1 HPRT1 AURKA HMGCR GAPDH DHFR DHCR7 IMMT UCHL5 YKT6 INSIG1 SQLE IGFBP5 IFI30 CYP51A1 FGL2 ENO1 IDI1 CYB5B SHMT2 TXNRD1 G6PD SLC9A3R1 RAB1A EBP PNO1 PIK3R3 ACTR3 LDLR SLC2A3 UBE2D3 ELOVL5 CACYBP EDEM1 ATP6V1D TES TM7SF2 PSMA3 ITGB2 SLC1A4 TOMM40 SLC6A6 PPIA ADD3 ME1 CCNF SLC37A4 ALDOA BTG2 UFM1 CCNG1 STC1 NMT1 PSMC6 FDXR RRM2 DHCR24 PSMC4 CTH PSME3 CFP POLR3G ACACA QDPR MCM2 PSMD12 SC5DL CANX RPN1 HSPA4 FAM129A TBK1 SEC11A BCAT1 PSMB5 PSMD13 PGM1 PLK1 GLRX COPS5 ETF1 GSK3B NUP205 SORD PHGDH GMPS RRP9 EEF1E1 LTA4H SDF2L1 FKBP2 RDH11 CXCR4 MLLT11 GCLC TCEA1 MAP2K3 HSPD1 SYTL2 MCM4 PPP1R15A USO1 NFKBIB UNG GTF2H1 RPA1 HSP90B1 ERO1L GSR PITPNB EPRS SRD5A1 TUBG1 MTHFD2L ADIPOR2 NUFIP1 CDC25A PDAP1 STARD4 BUB1 ARPC5L GPI EIF2S2 CD9 ATP2A2 GGA2 HMBS RIT1 SKAP2 STIP1 DAPP1 ABCF2 NFYC ATP5G1 PFKL CCT6A
tcga-all: 2 of 200 genes missing from data set analyzed in set HALLMARK_MTORC1_SIGNALING: DDX39A AK4
tcga-all: 193 of 200 genes from data set analyzed in set HALLMARK_E2F_TARGETS: AURKA BRCA2 CENPE CKS2 DCLRE1B DNMT1 DONSON EED GINS1 GINS4 H2AFZ LIG1 MAD2L1 MCM2 MCM4 MCM5 MCM7 MELK NAA38 NASP NUDT21 NUP205 PCNA PLK4 POLE PRIM2 RAD51AP1 RFC2 RPA2 RPA3 SUV39H1 TMPO UBE2T WDR90 CDK1 MCM3 TOP2A MCM6 BIRC5 CCNB2 RRM2 HMGB2 BUB1B RFC3 EZH2 CHEK1 SMC4 MKI67 CDC20 PLK1 KIF2C DLGAP5 AURKB CDC25A TRIP13 H2AFX HMMR E2F8 BRCA1 MYBL2 POLD1 RACGAP1 CKS1B KPNA2 MSH2 CDKN3 ATAD2 RPA1 STMN1 TIPIN TK1 CDCA8 ESPL1 NCAPD2 RANBP1 MRE11A KIF4A LMNB1 KIF22 UNG SMC1A CCNE1 CDCA3 ASF1B POLA2 TIMELESS HELLS UBE2S PRKDC RAN USP1 SPAG5 POLD3 DUT TACC3 KIF18B CDC25B GINS3 NOLC1 SLBP CHEK2 SPC25 BARD1 DCTPP1 SMC3 RNASEH2A DEK CENPM RAD51C CBX5 RFC1 POLD2 DSCC1 ILF3 DEPDC1 DCK CDKN2C MYC TCF19 RAD1 LBR NBN PTTG1 UBR7 POLE4 TUBG1 CTCF RQCD1 TUBB SMC6 ZW10 PA2G4 SSRP1 NAP1L1 ANP32E HMGB3 IPO7 RAD21 CDK4 CDKN1A BRMS1L CTPS RAD50 TRA2B CSE1L PAICS STAG1 LUC7L3 PPM1D NME1 XPO1 HNRNPD PMS2 ASF1A EXOSC8 MLH1 NUP107 TP53 TFRC HMGA1 PSIP1 SNRPB CDKN1B MTHFD2 WEE1 PRDX4 PHF5A TBRG4 SHMT1 PRPS1 DIAPH3 NUP153 PSMC3IP XRCC6 PNN HUS1 RBBP7 PDS5B NOP56 MXD3 PPP1R8 GSPT1 CDKN2A AK2 CIT ING3 HN1 POP7 SYNCRIP EIF2S1 LYAR PAN2 SPC24
tcga-all: 7 of 200 genes missing from data set analyzed in set HALLMARK_E2F_TARGETS: CCP110 MMS22L ORC6 SRSF1 SRSF2 ORC2 DDX39A
tcga-all: 195 of 200 genes from data set analyzed in set HALLMARK_MYC_TARGETS_V1: PCNA PSMD8 PSMD7 SET SNRPA1 RAN G3BP1 STARD7 NPM1 BUB3 EIF3D XPO1 FBL EIF4A1 CANX NAP1L1 CBX3 CCT3 C1QBP U2AF1 UBE2L3 SSBP1 TCP1 MCM2 EIF3B PSMD14 SNRPA PWP1 APEX1 TXNL4A HNRNPR PSMB2 HPRT1 MCM6 NME1 SNRPD1 EEF1B2 HSPD1 CAD RPL18 PGK1 DDX18 RPS2 LDHA RUVBL2 RNPS1 EIF2S1 RANBP1 MCM5 IARS UBE2E1 MYC AP3S1 RFC4 DUT PSMA4 RPS3 SNRPG PHB2 SSB EIF4H CCT4 TFDP1 EIF2S2 CDK4 SNRPD3 PSMD1 GNB2L1 GOT2 PABPC4 CCT5 PRPS2 ACP1 PRPF31 CCT2 KARS DEK EIF4G2 XPOT SRM UBA2 KPNB1 PSMA7 TRA2B COX5A PA2G4 PCBP1 HNRNPA1 CCNA2 PPIA EIF3J PSMA2 SYNCRIP HDAC2 LSM2 VBP1 PSMA6 CNBP CDK2 TARDBP NOLC1 GSPT1 HNRNPA2B1 ETF1 RPL6 TOMM70A PTGES3 PSMA1 PSMC6 CTPS HSPE1 FAM120A PPM1G HNRNPD SERBP1 CSTF2 PRDX4 EIF4E ODC1 USP1 RPL22 HNRNPA3 NCBP1 RPLP0 ABCE1 EIF1AX YWHAE MCM7 YWHAQ VDAC1 SMARCC1 SNRPD2 HNRNPU HDDC2 PSMD3 RRM1 SF3A1 LSM7 ERH RPL14 PSMB3 IFRD1 NCBP2 GLO1 NDUFAB1 CUL1 NHP2 CLNS1A TRIM28 RSL1D1 HNRNPC COPS5 XRCC6 SLC25A3 MRPL9 POLE3 POLD2 H2AFZ AIMP2 NOP56 PRDX3 MRPS18B EPRS KPNA2 HSP90AB1 RPL34 SRPK1 MAD2L1 DHX15 MCM4 RPS5 CCT7 HDGF RPS6 SNRPB2 PSMC4 CDC20 TUFM RRP9 CDC45 TYMS ILF2 VDAC3 IMPDH2 SF3B3 NOP16 GNL3 EXOSC7 MRPL23 RAD23B RPS10 PHB DDX21 CYC1 PABPC1
tcga-all: 5 of 200 genes missing from data set analyzed in set HALLMARK_MYC_TARGETS_V1: SRSF2 SRSF1 SRSF3 ORC2 SRSF7
tcga-all: 58 of 58 genes from data set analyzed in set HALLMARK_MYC_TARGETS_V2: SLC19A1 MRTO4 TMEM97 RRP9 PES1 TFB2M EXOSC5 IPO4 NDUFAF4 NOC4L MYC SRM PA2G4 GNL3 NOLC1 WDR43 RABEPK NOP16 TBRG4 DDX18 NIP7 WDR74 BYSL HSPD1 PLK4 NOP2 PPAN NOP56 RCL1 NPM1 AIMP2 RRP12 PPRC1 TCOF1 MCM5 HK2 CBX3 PLK1 PHB MCM4 CDK4 DUSP2 MYBBP1A UTP20 PRMT3 FARSA MAP3K6 LAS1L PUS1 HSPE1 SLC29A2 DCTPP1 SUPV3L1 SORD IMP4 GRWD1 UNG MPHOSPH10
tcga-all: 199 of 200 genes from data set analyzed in set HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION: COL3A1 COL5A2 COL5A1 FBN1 COL1A1 FN1 COL6A3 SERPINE1 COL1A2 COL4A1 COL4A2 VCAN IGFBP3 TGFBI SPARC LUM LAMC1 LOX LAMC2 CTGF TAGLN COL7A1 LOXL2 COL6A2 ITGAV THBS2 COL16A1 NNMT TPM1 CDH2 MMP2 COL11A1 THBS1 FAP BGN SERPINH1 FSTL1 POSTN THY1 SPP1 TNC TFPI2 NID2 ITGB5 MMP3 VIM LOXL1 FBLN5 COL12A1 ELN CDH11 COMP SPOCK1 BMP1 IL32 LAMA3 TIMP1 QSOX1 TIMP3 VCAM1 CYR61 EDIL3 CALD1 MAGEE1 FBLN1 SGCB ECM1 LAMA2 FSTL3 TPM2 INHBA DAB2 EMP3 BASP1 ITGA5 MGP VEGFA CXCL1 WNT5A SDC1 PLOD2 PCOLCE GREM1 ITGB1 COL5A3 RHOB HTRA1 FGF2 SNTB1 GADD45A MEST LRRC15 TNFRSF11B CD59 ACTA2 EFEMP2 MATN2 PCOLCE2 SERPINE2 GPC1 ABI3BP FUCA1 SLIT3 LAMA1 PMEPA1 COL8A2 FBN2 IGFBP2 PFN2 SDC4 CD44 GADD45B IL8 GLIPR1 ANPEP LEPRE1 VEGFC MMP14 SGCD PLOD1 MATN3 MYL9 SLC6A8 CALU PRRX1 TNFRSF12A FMOD ID2 GEM PLAUR MYLK TGFB1 SFRP1 PLOD3 IL6 APLP1 FBLN2 MSX1 PTX3 FZD8 JUN FERMT2 DKK1 SNAI2 DST TPM4 DCN GJA1 PMP22 IGFBP4 COPA LRP1 ITGA2 FLNA MFAP5 PTHLH TGFBR3 SFRP4 LGALS1 RGS4 CDH6 SAT1 NT5E DPYSL3 PPIB TGM2 SGCG ITGB3 PDLIM4 CTHRC1 ECM2 CRLF1 AREG IL15 MCM7 GAS1 CADM1 OXTR SCG2 CXCL6 MMP1 TNFAIP3 CAPG CAP2 MXRA5 FOXC2 NTM ENO2 FAS BDNF ADAM12 PVR CXCL12 PDGFRB SLIT2 NOTCH2 GLT25D1 GPX7 WIPF1
tcga-all: 1 of 200 genes missing from data set analyzed in set HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION: PRSS2
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: CXCL10 CCL2 CCL5 FPR1 CCL20 IL1A IL8 CCL7 CCL22 CXCL11 CCR7 EDN1 CD40 CXCL9 IL6 IL1B TLR2 IL1R1 CD69 ICAM1 CCRL2 AQP9 EREG C3AR1 GNA15 CMKLR1 PTGER4 LIF IL15 NAMPT OPRK1 ITGB8 PTAFR ADM PLAUR NFKB1 INHBA OSM TNFSF10 TNFSF15 IFNGR2 EMR1 IL12B CSF1 CXCL6 TNFRSF9 LYN ACVR2A LDLR BDKRB1 HRH1 F3 BST2 PTGIR CD55 CALCRL CSF3 GPR132 IL4R NLRP3 IL15RA ADORA2B GCH1 OLR1 PTGER2 CSF3R MYC RELA TNFAIP6 IL7R IL18 GABBR1 CD82 TNFSF9 NMUR1 IL2RB TLR1 LPAR1 IRAK2 RIPK2 MMP14 P2RX7 SLC11A2 SELL P2RY2 ABCA1 FFAR2 PROK2 GNAI3 TACR1 SLC7A1 CDKN1A CYBB TIMP1 HBEGF SCARF1 EBI3 NFKBIA SRI SLC7A2 CCL17 TLR3 APLNR OSMR IL10RA PSEN1 GPR183 ATP2B1 TNFRSF1B BEST1 GPC3 SCN1B ACVR1B HPN SEMA4D KLF6 CD48 CXCR6 SLC1A2 GP1BA TAPBP RGS16 SLAMF1 LCK HIF1A AHR NMI RHOG TPBG NPFFR2 IFNAR1 ICOSLG RASGRP1 IFITM1 KCNJ2 LY6E IL18R1 IL10 KCNA3 HAS2 DCBLD2 LAMP3 VIP CD70 RGS1 SLC31A1 ADRM1 KCNMB2 SERPINE1 MXD1 AXL MEFV PVR CCL24 PDE4B LCP2 PDPN IRF7 MET ATP2A2 SLC31A2 FZD5 ITGA5 SGMS2 MARCO CD14 EIF2AK2 ROS1 ATP2C1 NDP BTG2 MSR1 PTPRE RNF144B PCDH7 SPHK1 IL18RAP RTP4 RAF1 CHST2 ITGB3 KIF1B SELE NOD2 C5AR1 EMP3 CLEC5A TACR3 SLC4A4 MEP1A SELS LTA PIK3R5 STAB1 IRF1 ICAM4 P2RX4 ABI1 CX3CL1 SLC28A2
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_XENOBIOTIC_METABOLISM: CYP1A1 FAH DCXR CYP1A2 GSTA3 CYP2J2 CYP27A1 ADH1C UGDH ASL NQO1 ALAS1 GSTM4 CYP2C18 PTS CYB5A ACOX2 EPHX1 LCAT SLC35D1 GSS FMO3 IDH1 AKR1C3 SLC22A1 GSTO1 ARG1 CDO1 FMO1 ALDH9A1 POR NDRG2 UPB1 ECH1 PTGES PDK4 AHCY COMT AOX1 CFB DDAH2 HGFAC F11 CYP26A1 MCCC2 SERPINA6 GNMT BLVRB HACL1 MAOA KYNU DHPS SERPINE1 SLC6A12 GCH1 DHRS7 PAPSS2 ALDH2 HSD11B1 SLC35B1 KARS CA2 LPIN2 CAT CYP2S1 RAP1GAP FBP1 RBP4 GCKR CDA MTHFD1 ADH7 DHRS1 VNN1 CNDP2 SLC6A6 FETUB CROT GAD1 AKR1C2 DAK IGF1 SSR3 GABARAPL1 TMBIM6 CD36 CES1 SHMT2 TMEM176B GSTT2 PLG HMOX1 SPINT2 ALDH3A1 GSR ABHD6 XDH PPARD ELOVL5 CYP4F2 RETSAT CYFIP2 PINK1 GCLC ESR1 PMM1 TDO2 MT2A ATP2A2 DDT FABP1 ACP2 ABCD2 G6PC DDC ACOX3 SAR1B FBLN1 ADH5 CRP ABCC2 ETS2 NPC1 CASP6 BPHL IL1R1 ENTPD5 TNFRSF1A IGFBP4 PYCR1 CSAD VTN ID2 ETFDH HRG TYR UPP1 BCAR1 CBR1 APOE SLC12A4 TMEM97 SLC46A3 PTGDS MPP2 PTGR1 AQP9 EPHA2 PSMB10 FAS ACOX1 GART HPRT1 PGD ABCC3 SMOX TTPA HES6 GCNT2 MAN1A1 IGFBP1 ITIH4 PROS1 TPST1 LEAP2 NFS1 PGRMC1 CYP17A1 ARPP19 SERTAD1 ARG2 HNF4A REG1A CCL25 PEMT ACO2 LONP1 NMT1 PTGES3 F10 TAT MARCH6 JUP ACP1 MBL2 TGFB2 ENPEP HSD17B2 ANGPTL3 PC PDLIM5 CYP2E1 BCAT1 ATOH8 SLC1A5 IRF8 NINJ1 AP4B1 ACSM1 ITIH1
tcga-all: 156 of 158 genes from data set analyzed in set HALLMARK_FATTY_ACID_METABOLISM: ACAA1 ACAA2 ACADL ACADM ACOT8 ACOX1 ACSL1 ALDH3A2 CCDC58 CPT2 CYP4A11 DECR1 ECH1 ELOVL5 FABP1 FABP2 HADH HIBCH HMGCL HSD17B11 IDH1 ME1 MGLL MLYCD PCBD1 RETSAT S100A10 SUCLG1 VNN1 EHHADH ALDH9A1 HADHB ECHS1 ACADS CA2 HSD17B10 ALDH1A1 ACADVL HSD17B4 CA4 ADH1C ADH7 PTS MAOA HAO2 HSD17B7 MCEE ACAT2 AUH HPGD FH HMGCS2 ALAD GPD1 ACO2 CBR1 GRHPR ACOT2 G0S2 MDH2 HSP90AA1 BCKDHB UROS YWHAH LDHA CRYZ RDH16 INMT UGDH GSTZ1 IDH3B MDH1 CRAT ETFDH CD36 SDHD ACSL5 HSDL2 HMGCS1 SDHC CD1D GCDH GPD2 ALDH3A1 SLC22A5 PDHB TDO2 FASN NBN PSME1 PPARA NCAPH2 BPHL ODC1 CA6 DLD HCCS EPHX1 DLST FMO1 AOC3 UROD CPT1A SETD8 UBE2L6 MIF SUCLG2 CPOX SMS CBR3 NTHL1 CIDEA IDI1 AADAT REEP6 HSPH1 APEX1 NSDHL ADIPOR2 ACSL4 ACSS1 ENO3 IDH3G LGALS1 METAP1 ALDOA ACSM3 LTC4S D2HGDH ADSL SUCLA2 SDHA XIST OSTC GLUL CYP4A22 GABARAPL1 AQP7 CYP1A1 PRDX6 ERP29 H2AFZ GAPDHS DHCR24 GAD2 PTPRG IL4I1 TP53INP2 PDHA1 RAP1GDS1 CEL BLVRA SERINC1 BMPR1B RDH11 ENO2
tcga-all: 2 of 158 genes missing from data set analyzed in set HALLMARK_FATTY_ACID_METABOLISM: ECI1 ECI2
tcga-all: 199 of 200 genes from data set analyzed in set HALLMARK_OXIDATIVE_PHOSPHORYLATION: NDUFS3 UQCRB NDUFS2 SDHA UQCRC1 NDUFA9 NDUFS4 NDUFS1 NDUFA2 NDUFS8 SDHB NNT ATP5O ATP5G3 NDUFS7 ATP5A1 NDUFV1 COX5B UQCRH NDUFA1 ATP5C1 ATP5B COX7B SDHD CYCS NDUFA6 NDUFAB1 COX8A ACO2 ATP5G1 CYC1 NDUFB6 ATP5E COX5A UQCRC2 COX6A1 ATP5D COX6C ATP5J NDUFB3 IDH3B OGDH NDUFB8 SURF1 COX6B1 NDUFB5 NDUFA4 NDUFB1 COX4I1 COX7C UQCRFS1 SDHC ATP6V1F COX7A2 SUCLG1 NDUFS6 NDUFA7 FH NDUFV2 OXA1L NDUFC1 UQCR11 NDUFA5 CS ATP6V1G1 ATP5F1 HCCS HADHB ATP5H PDHA1 NDUFA8 DLD OPA1 SLC25A11 ATP5I PDHB ATP5J2 NDUFB7 IDH2 MTX2 VDAC3 MDH1 ATP5G2 IMMT MDH2 SLC25A3 ATP6V1D VDAC2 ACADM COX7A2L TIMM17A ATP6V1E1 NDUFA3 SLC25A6 IDH3G ACADVL ETFA TIMM9 IDH3A TIMM8B ATP6AP1 TIMM13 UQCRQ ABCB7 VDAC1 ATP5L PHB2 DECR1 SUCLA2 GOT2 DLAT ATP6V1H NDUFB2 FDX1 HADHA ATP6V1C1 MAOB NDUFB4 UQCR10 ETFDH GPX4 PDHX MFN2 AIFM1 ACAA2 ETFB COX11 ECHS1 PMPCA ATP6V0B SLC25A5 DLST COX15 CYB5A ALAS1 SLC25A4 CPT1A SLC25A20 MTRR COX17 CYB5R3 TOMM22 ACAT1 MRPS11 ATP6V0C PDK4 TIMM10 LDHA MRPL11 FXN MRPS12 COX10 RHOT1 ACAA1 ACADSB LDHB MRPS30 ATP1B1 BDH2 SLC25A12 TIMM50 MRPL34 ISCA1 MRPL35 IDH1 HSPA9 MRPL15 MRPS15 TOMM70A TCIRG1 ISCU POLR2F NQO2 NDUFC2 MRPS22 POR ATP6V0E1 PHYH BRP44L GPI AFG3L2 HSD17B10 CASP7 PRDX3 MGST3 HTRA2 BCKDHA LRPPRC RETSAT ECH1 RHOT2 BAX MTRF1 GLUD1 SUPV3L1 GRPEL1 PDP1 ALDH6A1 OAT
tcga-all: 1 of 200 genes missing from data set analyzed in set HALLMARK_OXIDATIVE_PHOSPHORYLATION: ECI1
tcga-all: 199 of 200 genes from data set analyzed in set HALLMARK_GLYCOLYSIS: PGK1 ALDOA ENO1 TPI1 PFKP ERO1L ALDOB VEGFA MXI1 PKM2 HK2 LDHA EXT1 SLC25A10 GUSB PFKFB1 PGAM1 PYGB P4HA1 PMM2 FAM162A SDC1 EGLN3 PC B4GALT7 FBP2 IGFBP3 CHPF B3GAT3 CHST12 HS2ST1 MPI GNPDA1 AKR1A1 PPFIA4 B3GAT1 CHPF2 G6PD MDH2 CHST6 PGLS PGAM2 CHST1 GPC1 TSTA3 ALG1 GFPT1 PRPS1 GOT1 MDH1 SLC35A3 GALK1 EGFR ANGPTL4 CITED2 PLOD2 QSOX1 ME2 SPAG4 P4HA2 GAPDHS ENO2 GOT2 EXT2 SLC25A13 HMMR PDK3 CXCR4 GPC4 ECD GNE B4GALT2 FUT8 MIOX VCAN GPC3 B3GALT6 HSPA5 ME1 ADORA2B UGP2 MIF NANP ZNF292 STC2 TPST1 PGM2 GYS1 TKTL1 TGFA CHST2 PHKA2 STMN1 GALE MET LCT IRS2 POLR3K B4GALT1 EFNA3 LHX9 KDELR3 TALDO1 DPYSL4 VLDLR CD44 AGL SOX9 DDIT4 IDUA CASP6 GLCE COPB2 DSC2 HS6ST2 CDK1 PLOD1 SDC2 GMPPB PAXIP1 NSDHL RARS SLC16A3 GLRX SRD5A3 SDC3 HDLBP COL5A1 CLDN9 TFF3 STC1 KIF20A GYS2 SLC37A4 LHPP SDHC NASP AURKA B3GNT3 ISG20 LDHC ARPP19 CENPA HOMER1 BIK CYB5A HAX1 COG2 IL13RA1 NOL3 CLDN3 AGRN CLN6 TXN PAM CAPN5 PKP2 ABCB6 DCN GMPPA BPNT1 ANG GPR87 GAL3ST1 ALDH7A1 NT5E IDH1 PYGL NDUFV3 NDST3 PPP2CB PSMC4 TPBG TGFBI GALK2 CTH KIF2A CACNA1H ANKZF1 SAP30 RBCK1 ELF3 RPE B4GALT4 DEPDC1 RRAGD IER3 ALDH9A1 DLD MERTK GCLC FKBP4 SOD1 MED24 AK3 XYLT2 ARTN PPIA CHST4
tcga-all: 1 of 200 genes missing from data set analyzed in set HALLMARK_GLYCOLYSIS: AK4
tcga-all: 48 of 49 genes from data set analyzed in set HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY: GSR PRDX2 TXNRD1 SOD1 GCLC CAT GPX4 MPO PRDX1 PRDX6 GCLM TXN SOD2 PRDX4 SELS PDLIM1 TXNRD2 HBXIP G6PD MSRA MBP SRXN1 NQO1 OXSR1 GLRX2 HMOX2 FES PFKP NDUFB4 GPX3 CDKN2D MGST1 ABCC1 FTL ATOX1 STK25 EGLN2 ERCC2 SBNO2 JUNB PPP2R4 LSP1 NDUFA6 HHEX GLRX NDUFS2 PRNP IPCEF1
tcga-all: 1 of 49 genes missing from data set analyzed in set HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY: SCAF4
tcga-all: 196 of 200 genes from data set analyzed in set HALLMARK_P53_PATHWAY: CDKN1A BTG2 MDM2 CCNG1 FAS TOB1 GADD45A PHLDA3 TAP1 CDKN2B SFN ZMAT3 DDB2 EI24 PERP DDIT4 ATF3 BAX SESN1 FDXR SAT1 CDKN2A AEN PPM1D FOXO3 BTG1 TXNIP SLC19A2 IER3 TP53 NOTCH1 RRAD DCXR NINJ1 FOS S100A10 FBXW7 PLK3 XPC AK1 TRIAP1 BAK1 CCND2 APAF1 PDGFA NDRG1 RALGDS SERPINB5 DGKA CYFIP2 KLF4 IP6K2 ADA TNFSF9 KLK8 PRKAB1 STOM SOCS1 PLK2 CASP1 RCHY1 PCNA RPS27L RB1 PPP1R15A POLH RAB40C ERCC5 CDH13 DDIT3 TGFB1 FUCA1 HIST3H2A TP63 HSPA4L EPHX1 ABHD4 H2AFJ TRAF4 CTSF IER5 TAX1BP3 TSC22D1 RGS16 HRAS PVT1 ZFP36L1 SDC1 RAP2B PLXNB2 HEXIM1 PROCR SPHK1 NOL8 DEF6 SP1 JAG2 DRAM1 RPL18 CEBPA KIF13B MXD1 TRAFD1 OSGIN1 ANKRA2 HBEGF RAD51C ITGB4 TRIB3 INHBB VAMP8 VWA5A ABAT CTSD PTPRE HINT1 ALOX15B VDR IKBKAP WWP1 NUPR1 TCN2 CDKN2AIP POM121 ZNF365 EPHA2 JUN MAPKAPK3 SLC7A11 SERTAD3 IRAK1 ABCC5 UPP1 CD81 LIF RPL36 FAM162A RNF19B CDK5R1 STEAP3 PITPNC1 SLC35D1 TPRKB RRP8 IL1A PMM1 TPD52L1 IFI30 GM2A RPS12 EPS8L2 TM4SF1 BLCAP MKNK2 CD82 GNB2L1 ST14 TCHH HDAC3 CCNK RHBDF2 NUDT15 TGFA ISCU LDHB TNNI1 FGF13 RXRA APP F2R CLCA2 CGRRF1 CSRNP2 ACVR1B BMP2 GPX2 KRT17 TM7SF3 ZBTB16 PTPN14 TSPYL2 SLC3A2 S100A4 GLS2 CCND3 PRMT2 NHLH2 BAIAP2 RETSAT LRMP HIST1H1C DNTTIP2 MXD4 SEC61A1 HMOX1 RAD9A
tcga-all: 4 of 200 genes missing from data set analyzed in set HALLMARK_P53_PATHWAY: PIDD WRAP73 ADCK3 CCP110
tcga-all: 158 of 158 genes from data set analyzed in set HALLMARK_UV_RESPONSE_UP: NXF1 SLC6A8 BAK1 CDC5L HSPA2 POLR2H ALAS1 TUBA4A C4BPB CCNE1 EPHX1 GRPEL1 ICAM1 FEN1 ARRB2 JUNB CTSL2 DGAT1 ATF3 CASP3 RASGRP1 TMBIM6 FOS TAP1 E2F5 RAB27A CCND3 SLC25A4 SPR CDKN2B SHOX2 OLFM1 IGFBP2 LYN CLTB BCL2L11 LHX2 NFKBIA MSX1 H2AFX NR4A1 GLS CDC34 MMP14 STK25 PDAP1 ABCB1 BSG SEPW1 IRF1 RXRB TFRC PPIF CDKN1C HLA-F CREG1 APOM BMP2 TGFBRAP1 NAT1 CYB5R1 RRAD POLE3 IL6 YKT6 ACAA1 CLCN2 EIF2C2 SOD2 PPP1R2 RHOB RET PDLIM3 EPCAM DNAJA1 SULT1A1 CHKA CYP1A1 ATP6V1F CDO1 ALDOA NPTXR EIF2S3 CNP GRINA BID POLG2 IL6ST HYAL2 FOSB MGAT1 NKX2-5 PPAT FURIN MRPL23 HTR7 CXCL2 KLHDC3 PRPF3 DNAJB1 AP2S1 PSMC3 TST SIGMAR1 GCH1 BTG2 CEBPG TARS UROD PARP2 BTG3 DLG4 CHRNA5 NPTX2 ATP6V1C1 AQP3 PLCL1 NUPL1 TYRO3 HMOX1 RPN1 BTG1 FMO1 ASNS DDX21 KCNH2 COL2A1 MAOA TCHH CYB5B HSPA13 GGH GAL NTRK3 PPT1 FGF18 FKBP4 STIP1 EIF5 ENO2 GPX3 PRKACA PRKCD STARD3 MARK2 SLC6A12 SQSTM1 PTPRD MAPK8IP2 CDK2 ONECUT1 RFC4 CA2 TACR3 AMD1 HNRNPU WIZ CCK
tcga-all: 143 of 144 genes from data set analyzed in set HALLMARK_UV_RESPONSE_DN: TJP1 NFIB TGFBR3 TFPI MMP16 ABCC1 MAP2K5 AGGF1 PLCB4 MET IRS1 PTPRM AKT3 SIPA1L1 NR1D2 ATRN ANXA2 ADD3 CDKN1B ATXN1 CAP2 PRDM2 FAM179B SDC2 SMAD3 SLC7A1 GCNT1 RUNX1 RND3 PPAP2B NR3C1 YTHDC1 PPARG LPHN2 DLG1 ATP2B4 NIPBL PEX14 MYC RASA2 FZD2 BMPR1A LPAR1 PRKCA MGMT PRKCE RXRA LTBP1 LDLR RBPMS CACNA1A RGS4 COL5A2 PTPN21 PRKAR2B GJA1 BCKDHB ATP5S SERPINE1 AMPH MIOS CITED2 COL1A2 INSIG1 FYN WDR37 ZMIZ1 PMP22 CDON PIK3R3 NOTCH2 SYNJ2 SMAD7 MAP1B PAPD7 PTEN DYRK1A NEK7 SPOP F3 ERBB2 GRK5 DUSP1 VLDLR CAV1 COL11A1 CDC42BPA CDK13 SFMBT1 ADORA2B BHLHE40 COL3A1 KCNMA1 SYNE1 IGF1R CELF2 MTA1 EFEMP1 LAMC1 PHF3 VAV2 PIAS3 ACVR2A NRP1 MRPS31 CYR61 DAB2 MAGI2 ANXA4 COL1A1 SCHIP1 DDAH1 PDGFRB ATRX KALRN TGFBR2 PTGFR ATP2C1 ARHGEF9 NFKB1 MGLL FBLN5 PDLIM5 MAPK14 SRI INPP4B IGFBP5 ITGB3 BDNF ID1 SNAI2 SCN8A ATP2B1 FHL2 KIT APBB2 PIK3CD DLC1 MT1E DBP HAS2 SLC22A18 ICA1
tcga-all: 1 of 144 genes missing from data set analyzed in set HALLMARK_UV_RESPONSE_DN: SCAF8
tcga-all: 36 of 36 genes from data set analyzed in set HALLMARK_ANGIOGENESIS: VCAN POSTN FSTL1 LRPAP1 STC1 LPL VEGFA PF4 THBD FGFR1 TNFRSF21 CCND2 COL5A2 ITGAV SERPINA5 KCNJ8 APP JAG1 COL3A1 SPP1 NRP1 OLR1 PDGFA PTK2 SLCO2A1 PGLYRP1 VAV2 S100A4 MSX1 VTN TIMP1 APOH PRG2 JAG2 LUM CXCL6
tcga-all: 199 of 200 genes from data set analyzed in set HALLMARK_HEME_METABOLISM: ALAS2 PPOX FECH HMBS GYPB ALAD RHD GYPA SELENBP1 BLVRB GYPE GYPC EPB42 SLC4A1 RHCE RHAG TAL1 MARCH8 SPTB UROD HBQ1 DCAF11 ERMAP EIF2AK1 CPOX MPP1 GLRX5 TSPAN5 OSBP2 ANK1 NFE2 AHSP SPTA1 MAP2K3 BNIP3L SLC22A4 CLIC2 TRAK2 GCLC KEL RANBP10 TRIM10 TSPO2 UROS XK SNCA MARK3 UBAC1 CA1 CA2 BSG FOXO3 KLF1 CDC27 KAT2B NARF GCLM FBXO7 H1F0 HEBP1 HBD NUDT4 FBXO9 RAD23A TMCC2 BLVRA GATA1 RBM38 PRDX2 RNF123 MINPP1 TNS1 CTSE EPB49 HDGF XPO7 MKRN1 SMOX TFDP2 MXI1 HBB MOSPD1 SLC25A37 SLC30A1 ABCB6 SLC6A8 TFRC RCL1 TOP1 EPOR TNRC6B ACSL6 GAPVD1 MGST3 SLC30A10 CAT BCAM HBZ DARC PSMD9 ISCA1 PDZK1IP1 HIST1H4C ICAM4 MOCOS ADD1 FTCD ADD2 BMP2K BPGM CLCN3 E2F2 HAGH JHDM1D OPTN RAP1GAP CTNS NFE2L1 ELL2 SLC2A1 PIGQ KLF3 EPB41 LAMP2 TMEM9B EZH1 CTSB ATG4A MFHAS1 MYL4 RNF19A BTG2 SLC11A2 ADIPOR1 ASNS DCUN1D1 ALDH1L1 DCAF10 YPEL5 SEC14L1 USP15 RIOK3 SIDT2 FOXJ2 TCEA1 VEZF1 LPIN2 PC HBBP1 CDR2 CCND3 SLC25A38 FAM46C FBXO34 BACH1 NR3C1 AQP3 TRIM58 LMO2 PICALM NCOA4 GDE1 SLC6A9 NNT ARHGEF12 PPP2R5B C3 MARCH2 UCP2 SYNJ1 FN3K ABCG2 DAAM1 AGPAT4 CCDC28A GMPS ACP5 SLC10A3 ALDH6A1 CIR1 RBM5 HTRA2 IGSF3 BTRC PGLS PQLC1 SDCBP LRP10 NEK7 ARL2BP ENDOD1 P4HA2 HTATIP2 SLC7A11 KHNYN MBOAT2 ATP6V0A1 CAST TYR
tcga-all: 1 of 200 genes missing from data set analyzed in set HALLMARK_HEME_METABOLISM: CROCCP2
tcga-all: 138 of 138 genes from data set analyzed in set HALLMARK_COAGULATION: F2 PROC C1S MMP14 F10 PLG C1R SERPINE1 SERPING1 C2 F12 CFI MMP2 C3 F9 CTSO TMPRSS6 MMP9 PROZ MMP1 CFB BMP1 VWF FGA F11 THBD FURIN MMP11 F8 LGMN HPN CTSB MBL2 F13B TIMP1 CTSL2 MMP8 A2M MMP10 MASP2 FGG C8A PLAU ADAM9 GSN CAPN2 PLAT FN1 CTSH OLR1 SPARC RGN C8B LAMP2 C9 PROS1 CLU F2RL2 CD9 CFH PREP LTA4H GP9 DUSP14 CTSK GDA CASP9 APOC1 CRIP2 KLK8 SERPINC1 ANXA1 ITIH1 PRSS23 FBN1 MST1 F3 KLF7 CTSE ITGB3 CAPN5 CSRP1 KLKB1 MSRB2 TFPI2 MMP3 MEP1A GP1BA APOA1 SERPINA1 TF PEF1 GNG12 SIRT2 COMP HTRA1 MAFF LRP1 PF4 PGCP MMP15 RABIF HRG C8G APOC2 SERPINB2 RAPGEF3 CPN1 ITGA2 RAC1 DPP4 WDR1 THBS1 FYN PDGFB SH2B2 PECAM1 MMP7 DUSP6 CPB2 S100A13 CFD DCT LEFTY2 ANG C1QA HMGCS2 ISCU PLEK APOC3 P2RY1 USP11 TIMP3 ACOX2 HNF4A S100A1 GNB2 ARF4
tcga-all: 198 of 200 genes from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: SOCS2 CISH PIM1 IL2RA TNFRSF4 SOCS1 TNFRSF9 XBP1 RRAGD HK2 PHLDA1 IL2RB CTLA4 NFIL3 CD83 IKZF2 IL10 TNFRSF18 DHRS3 ECM1 ADAM19 SLC2A3 HIPK2 BATF3 BHLHE40 PTGER2 DENND5A ITIH5 PHTF2 GADD45B NRP1 NCOA3 CD79B AHR TNFRSF1B NDRG1 BCL2L1 GABARAPL1 LIF TIAM1 BMPR2 MAP3K8 RHOB MYC S100A1 CAPG ST3GAL4 PENK IRF4 CST7 WLS TLR7 IKZF4 GBP4 RGS16 SPP1 IL13 SLC29A2 NFKBIZ IL4R MXD1 CSF2 FAH CTSZ ITGAE MUC1 MAPKAPK2 TNFRSF21 NT5E FLT3LG CCND2 TRAF1 LCLAT1 IL3RA CYFIP1 BCL2 FGL2 PRNP N6AMT2 PUS1 ITGAV NCS1 DCPS AMACR FAM126B PTH1R ODC1 IGF1R PTCH1 ENO3 CD81 MAFF EMP1 CDKN1C CAPN3 IL1R2 SYT11 TTC39B ANXA4 BATF P4HA1 GPR65 SLC1A5 IGF2R CKAP4 CCR4 CD44 P2RX4 GATA1 KLF6 ARL4A HOPX GPR83 ITGA6 CD48 SELP GLIPR2 SMPDL3A PLSCR1 FURIN SERPINB6 TNFSF11 GPX4 LRRC8C CCNE1 CASP3 SH3BGRL2 SNX9 PLEC BMP2 ICOS ALCAM LTB ENPP1 IL1RL1 MYO1C IFNGR1 PLIN2 IL18R1 AHNAK PRKCH TNFRSF8 SYNGR2 GALM POU2F1 EOMES NOP2 PTRH2 RHOH CDC6 MYO1E CXCL10 SNX14 IRF6 IL10RA MAP6 TNFSF10 SPRED2 SELL SERPINC1 CDCP1 RORA COCH CSF1 F2RL2 UCK2 CA2 IFITM3 UMPS HUWE1 COL6A1 ABCB1 RNH1 IRF8 GUCY1B3 AHCY PRAF2 GSTO1 TWSG1 CDC42SE2 PLAGL1 APLP1 AKAP2 PPAP2A SPRY4 SCN9A SHE PDCD2L CCND3 LRIG1 SWAP70 SLC39A8 RABGAP1L TGM2 PNP AGER ETV4 CD86
tcga-all: 2 of 200 genes missing from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: METTL20 CCDC164
tcga-all: 112 of 112 genes from data set analyzed in set HALLMARK_BILE_ACID_METABOLISM: SCP2 ABCD3 SLC27A2 HSD3B7 HSD17B4 AKR1D1 ABCD2 PEX1 CYP8B1 PNPLA8 PHYH SLC27A5 CYP7B1 CYP27A1 PEX26 AGXT PEX7 CROT CYP39A1 ABCA3 CYP7A1 HACL1 PIPOX PEX6 SOD1 GNPAT HSD3B1 ABCA2 HAO1 PEX16 ABCD1 ACSL1 MLYCD ABCG8 AQP9 ISOC1 NR1H4 PEX19 NPC1 HSD17B11 AMACR CYP46A1 PEX13 IDH1 PEX11A HSD17B6 EPHX2 PRDX5 PXMP2 BBOX1 FADS2 ALDH9A1 APOA1 OPTN GSTK1 ABCG4 ALDH8A1 NR3C2 ABCA6 RETSAT FADS1 PECR PEX12 CAT GNMT ABCA9 ACSL5 LONP2 DHCR24 ABCA8 PFKM DIO1 RXRA FDXR TTR KLF1 SLC29A1 BCAR3 LCK PEX11G SLCO1A2 ALDH1A1 SULT1B1 NR1I2 GC ABCA4 SLC35B2 SLC23A1 NUDT12 ABCA1 PAOX SLC22A18 DIO2 RBP1 SLC23A2 ATXN1 GCLM NEDD4 RXRG AR BMP6 SERPINA6 LIPE EFHC1 IDH2 IDI1 CH25H ABCA5 SULT2B1 SOAT2 TFCP2L1 NR0B2
tcga-all: 102 of 104 genes from data set analyzed in set HALLMARK_PEROXISOME: ABCD3 ACOT8 ACOX1 ACSL1 ECH1 EHHADH GSTK1 HSD17B4 MLYCD PEX11A RETSAT SLC27A2 PEX13 PEX14 SCP2 HSD3B7 GNPAT ABCD2 SLC25A17 PEX2 ACAA1 HAO2 HSD17B11 CRAT PEX11B LONP2 IDH1 FIS1 PEX6 ABCB4 SOD1 ABCB1 ISOC1 YWHAH EPHX2 ABCD1 HMGCL ACSL5 ALDH9A1 DHCR24 ELOVL5 NUDT19 PRDX5 CTPS IDE SLC23A2 PEX5 BCL10 NR1I2 TSPO CNBP MSH2 DHRS3 DIO1 SLC25A4 PRDX1 IDI1 HRAS MVP ABCC8 CLN6 CAT ACSL4 IDH2 ABCC5 SOD2 SLC35B2 FDPS ALB FADS1 STS SMARCC1 ITGB1BP1 SIAH1 SLC25A19 CDK7 RXRG ALDH1A1 CADM1 SERPINA6 CLN8 RDH11 CTBP1 HSD11B2 TTR ERCC3 ATXN1 SULT2B1 CRABP2 CRABP1 TOP2A SCGB1A1 ERCC1 DLG4 PABPC1 FABP6 ABCB9 CACNA1B SEMA3C VPS4B CEL ESR2
tcga-all: 2 of 104 genes missing from data set analyzed in set HALLMARK_PEROXISOME: ECI2 UGT2B17
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: PTPRC IL12B TGFB1 IL12A CD3E CD3D CD28 LYN HCLS1 IL18 CRTAM IFNG CD3G CD86 IL10 UBE2N BCL10 CD4 LCK NCK1 C2 HLA-A ITGB2 HLA-DQA1 CD1D CD80 HLA-DRA THY1 TLR1 HLA-G HLA-DMB IL7 IL4 TNF CD247 IL2 HLA-DMA STAT1 IRF4 SRGN INHBA TLR3 ZAP70 CD74 CD40 TRAF2 B2M BCL3 LTB IFNGR1 CCR5 CD40LG HLA-DOA GLMN IL6 HLA-E CD2 CCL5 FAS FASLG TLR6 PF4 TGFB2 CD79A INHBB ELANE SPI1 MAP3K7 IL15 CTSS CD47 PRF1 IL12RB1 LCP2 SOCS1 CDKN2A STAT4 CD7 HLA-DOB CD8A ICAM1 CCL4 GZMB CSF1 IL11 STAB1 IL2RA NLRP3 CCND3 EIF3A SIT1 IFNAR2 HDAC9 CARTPT TRAT1 CCL22 APBB1 FYB IL1B TIMP1 RPS19 JAK2 KRT1 WARS IFNGR2 CCR2 EREG MMP9 EGFR IL16 CFP WAS ITGAL KLRD1 RARS TLR2 CCND2 IL2RG ETS1 ITK NCR1 MAP4K1 CCL19 PSMB10 RPL39 EIF3J ABCE1 CD8B F2 ELF4 LY86 FCGR2B GBP2 PRKCG RPS9 MTIF2 GZMA AARS CD96 CSK HIF1A CCL2 ICOSLG NPM1 IL4R CCL11 NME1 FLNA GPR65 ACHE EIF3D IGSF6 F2R IL13 TAP1 DARS IRF7 ACVR2A CXCR3 PRKCB CXCL9 PTPN6 NCF4 UBE2D1 LIF CCR1 MBL2 DEGS1 TPD52 AKT1 RIPK2 IKBKB GCNT1 SOCS5 IRF8 TAP2 EIF4G3 ABI1 CCL7 IL2RB BRCA1 FGR IL18RAP MRPL3 CXCL13 CAPG EIF5A RPS3A GALNT1 ST8SIA4 CCL13 RPL3L LY75 TAPBP NOS2 RPL9 BCAT1 IL9 IL27RA DYRK3
tcga-all: 134 of 135 genes from data set analyzed in set HALLMARK_SPERMATOGENESIS: PDHA2 TNP1 ZPBP DPEP3 ADAM2 ACTL7B GAPDHS TUBA3C LDHC DDX25 PRM2 TCP11 PIAS2 PAPOLB OAZ3 PHF7 ODF1 ACRBP YBX2 CSNK2A2 NAA11 TULP2 ADAD1 SYCP1 DDX4 MLF1 TEKT2 SPATA6 PGK2 HSPA2 ACRV1 CLPB CRISP2 FAM164C AKAP4 CCNA1 CCT6B PACRG GSG1 THEG HSPA4L CST8 DCC HSPA1L GSTM3 DNAJB8 IL13RA2 CAMK4 LPIN1 ZC3H14 COIL PHKG2 KIF2C RPL39L SLC2A5 PCSK4 AURKA MLLT10 NOS1 ART3 CCNB2 NPHP1 CLGN MAST2 MTOR CDKN3 ZNRF4 AGFG1 SNAP91 PSMG1 CHFR TNP2 EZH2 HBZ ARL4A SLC12A2 BRAF VDAC3 POMC IFT88 TKTL1 NEK2 STAM2 HIST1H1T GMCL1 MTNR1A RFC4 DBF4 PRKAR2A TTK DMC1 NCAPH PEBP1 CHRM4 TOPBP1 SCG5 NEFH MAP7 BUB1 SEPT4 PGS1 NPY5R TSN CDK1 SHE PARP2 TNNI3 PCSK1N IDE GPR182 RAD17 TLE4 ACE SIRT1 HTR5A TALDO1 NF2 CLVS1 CNIH2 GRM8 STRBP ADCYAP1 ALOX15 MEP1B SCG3 GFI1 ELOVL3 IL12RB2 DMRT1 GAD1 CFTR JAM3 IP6K1 HOXB1
tcga-all: 1 of 135 genes missing from data set analyzed in set HALLMARK_SPERMATOGENESIS: TSSK2
tcga-all: 200 of 200 genes from data set analyzed in set HALLMARK_KRAS_SIGNALING_UP: ANGPTL4 ITGA2 SPRY2 HBEGF RBP4 HSD11B1 ETV4 GLRX DUSP6 SCG5 ETV5 ITGB2 AKT2 PPBP G0S2 GABRA3 IRF8 BIRC3 FGF9 DCBLD2 INHBA TFPI TSPAN1 ADAM8 SLPI PRKG2 MMP11 MMP10 TMEM158 TNFAIP3 PRDM1 GALNT3 ETS1 MMP9 WNT7A IGFBP3 SPP1 ETV1 CLEC4A CCND2 TSPAN7 ITGBL1 EMP1 CDADC1 KIF5C TRIB2 SDCCAG8 PCP4 CFHR2 ALDH1A2 NR0B2 ALDH1A3 AMMECR1 SATB1 GUCY1A3 CSF2 APOD TOR1AIP2 CMKLR1 TMEM176B GPR124 LAPTM5 CD37 CAB39L CIDEA ZNF639 IL1B GYPC LY96 FLT4 SPON1 BMP2 PLEK2 IGF2 NR1H4 SNAP25 ACE PRRX1 C3AR1 TRAF1 TLR8 ID2 TMEM100 PLAUR GADD45G CBX8 SCN1B PTBP2 NAP1L2 AKAP12 PLAT SCG3 ANO1 IL1RL2 CXCL10 ATG10 YRDC HDAC9 PEG3 SEMA3B TNNT2 LIF CFB BTC PPP1R15A PTPRR CCL20 ARG1 RETN KLF4 MMD PDCD1LG2 HIST1H2BB HOXD11 TRIB1 F2RL1 ANXA10 TSPAN13 MTMR10 CFH LAT2 ERO1L RELN KCNN4 TMEM176A MAP4K1 PTGS2 IL33 MAFB LCP1 NGF CA2 SERPINA3 RGS16 CTSS USP12 CPE SPARCL1 ABCB1 USH1C CSF2RA BTBD3 IL2RG DNMBP IL10RA EREG SLMO2 EPHB2 FBXO4 CROT MPZL2 ANKH CBR4 DOCK2 GPRC5B RABGAP1L MALL STRN ST6GAL1 PIGR VWA5A PSMB8 F13A1 NRP1 SOX9 JUP ELTD1 ZNF277 EPB41L3 PCSK1N FUCA1 PLVAP ADAM17 AVL9 ADAMDEC1 HKDC1 MAP7 IL7R RBM4 BPGM ENG GFPT2 PLAU GNG11 PTCD2 MAP3K1 CBL CXCR4 NIN IKZF1 WDR33 MYCN FCER1G PECAM1 FAM190B SNAP91 EVI5 TNFRSF1B GPNMB TPH1
tcga-all: 198 of 200 genes from data set analyzed in set HALLMARK_KRAS_SIGNALING_DN: CDH16 SPTBN2 FGFR3 NOS1 PDE6B SIDT1 NTF3 SCN10A TAS2R4 DTNB HTR1D MAST3 SLC6A3 CLDN8 TGM1 PCDHB1 THRB YPEL1 RYR2 GDNF CAMK1D AMBN LFNG SERPINA10 ALOX12B CALCB FGGY SPRR3 ATP6V1B1 EDN1 UPK3B GAMT PRODH RYR1 GPR19 SLC29A3 EDN2 GPRC5C C5 FAM164C EDAR KCNMB1 FAM46C STAG3 KRT4 SLC25A23 INSL5 GP1BA MLL2 ABCG4 MYH7 BRDT PTGFR KCNN1 SEPP1 IFI44L PROP1 LGALS7 BMPR1B PDK2 DCC SNCB COL2A1 PPYR1 DLK2 WNT16 SLC6A14 ITGB1BP2 SLC12A3 YBX2 CKM CPB1 MAGIX ARHGDIG CALML5 KRT1 MTHFR ABCB11 MYOT CELSR2 KLK7 THNSL2 CHRNG NR4A2 CD40LG KRT13 GP2 CD207 CCR8 ZBTB16 PARK2 CPA2 MEFV CCNA1 SLC38A3 KLK8 CYP39A1 KCNQ2 SLC30A3 CHST2 ITIH3 EGF MSH5 TEX15 CLPS ENTPD7 CLSTN3 CYP11B2 CLDN16 HSD11B2 HNF1A FGF22 TFCP2L1 OXT KCND1 H2AFY2 NRIP2 RGS11 CPEB3 TG PTPRJ NUDT11 FSHB IDUA TNNI3 GTF3C5 TFF2 SSTR4 COPZ2 PDCD1 SLC16A7 KCNE2 MFSD6 KLHDC8A CNTFR IL5 NPHS1 SCGB1A1 CCDC106 PAX3 VPREB1 TSHB CACNA1F AKR1B10 P2RX6 KRT15 PAX4 BTG2 GPR3 GRID2 TCL1A PLAG1 PKP1 IRS4 IL12B EPHA5 SOX10 SNN CACNG1 SPHK2 IGFBP2 CAPN9 TCF7L1 TGFB2 SMPX LYPD3 PNMT SYNPO MX1 IFNG NR6A1 ACTC1 RSAD2 ADRA2C BARD1 HTR1B FGF16 ODZ2 CDKAL1 SHOX2 SGK1 RIBC2 SKIL NGB ASB7 MYO15A SLC5A5 KRT5 ZFP112 TFAP2B CCDC132 CD80 ATP4A ARPP21 SERPINB2 TLX1 EFHD1 P2RY4
tcga-all: 2 of 200 genes missing from data set analyzed in set HALLMARK_KRAS_SIGNALING_DN: UGT2B17 ADCK3
tcga-all: 40 of 40 genes from data set analyzed in set HALLMARK_PANCREAS_BETA_CELLS: PAX6 NEUROD1 ISL1 NKX2-2 PCSK1 NKX6-1 SLC2A2 SEC11A DCX SPCS1 FOXA2 GCK MAFB INS PDX1 ABCC8 IAPP SRP9 NEUROG3 FOXO1 AKT3 GCG DPP4 PAX4 SYT13 SCGN HNF1A STXBP1 CHGA VDR PCSK2 INSM1 SST ELP4 SRPRB PAK3 G6PC2 PKLR LMO2 SRP14
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
Warning messages:
1: In .local(expr, gset.idx.list, ...) :
  1genes with constant expression values throuhgout the samples.
2: In .local(expr, gset.idx.list, ...) :
  Since argument method!="ssgsea", genes with constant expression values are discarded.
Number of rows analyzed: 20534
Number of columns analyzed: 290
kfs-all: 31 of 34 genes from data set analyzed in set B cells: MS4A1 TCL1A HLA-DOB PNOC KIAA0125 CD19 CR2 IGHG1 FCRL2 BLK COCH OSBPL10 TNFRSF17 ABCB4 BLNK GLDC MEF2C IGHM SPIB BCL11A GNG7 IGKC CD72 MICAL3 BACH2 CCR9 QRSL1 DTNB HLA-DQA1 SCN3A SLC15A2
kfs-all: 3 of 34 genes missing from data set analyzed in set B cells: IGHA1 FAM30A IGL@
kfs-all: 16 of 18 genes from data set analyzed in set T cells: PRKCQ CD3D CD3G CD28 LCK TRAT1 BCL11B CD2 TRBC1 ITM2A SH2D1A CD6 CD96 NCALD CD3E SKAP1
kfs-all: 2 of 18 genes missing from data set analyzed in set T cells: TRA@ GIMAP5
kfs-all: 26 of 27 genes from data set analyzed in set Th1 cells: IFNG LTA APBB2 DOK5 IL12RB2 APOD ZBTB32 CD38 CSF2 CTLA4 CD70 DPP4 EGFL6 BST2 DUSP5 LRP8 IL22 DGKI CCL4 GGT1 LRRN3 SYNGR3 ATP9A BTG3 HBEGF SGCB
kfs-all: 1 of 27 genes missing from data set analyzed in set Th1 cells: CMAH
kfs-all: 26 of 27 genes from data set analyzed in set Th2 cells: PMCH AHI1 PTGIS CXCR6 EVI5 IL26 MB NEIL3 GSTA4 PHEX SMAD2 CENPF ANK1 ADCY1 LAIR2 SNRPD1 MICAL2 DHFR WDHD1 BIRC5 SLC39A14 HELLS LIMA1 CDC25C CDC7 GATA3
kfs-all: 1 of 27 genes missing from data set analyzed in set Th2 cells: AI582773
kfs-all: 15 of 17 genes from data set analyzed in set Cytotoxic cells: KLRD1 KLRF1 GNLY CTSW KLRB1 NKG7 GZMH SIGIRR ZBTB16 RUNX3 APOL3 RORA APBA2 DUSP2 GZMA
kfs-all: 2 of 17 genes missing from data set analyzed in set Cytotoxic cells: KLRK1 WHDC1L1
kfs-all: 28 of 31 genes from data set analyzed in set iDC: CD1B VASH1 F13A1 CD1E MMP12 FABP4 CLEC10A SYT17 MS4A6A CTNS GUCA1A ABCG2 CD1A PPARG RAP1GAP SLC7A8 GSTT1 FZD2 CSF1R HS3ST2 CH25H LMAN2L SLC26A6 BLVRB NUDT9 PREP TACSTD2 CD1C
kfs-all: 3 of 31 genes missing from data set analyzed in set iDC: CARD9 NM_021941 TM7SF4
kfs-all: 26 of 31 genes from data set analyzed in set Neutrophils: CSF3R CYP4F3 VNN3 KCNJ15 MME FCGR3B DYSF FCAR CEACAM3 HIST1H2BC HPSE CREB5 S100A12 TNFRSF10C SLC22A4 SLC25A37 BST1 CRISPLD2 G0S2 SIGLEC5 CD93 MGAM ALPL FPR1 PDE4B LILRB2
kfs-all: 5 of 31 genes missing from data set analyzed in set Neutrophils: FPRL1 IL8RA IL8RB FLJ11151 KIAA0329
kfs-all: 26 of 28 genes from data set analyzed in set CIRC: HLA-DQA1 CTLA4 PDCD1LG2 ICAM1 CD274 STAT1 IRF1 IFNG GNLY TBX21 CCL5 LAG3 CD247 ICOS IL18RAP CXCL9 CXCL10 HLA-DPB1 HLA-DPA1 HLA-DMB HLA-DRA HLA-DMA CD80 HLA-DOA CD4 HAVCR2
kfs-all: 2 of 28 genes missing from data set analyzed in set CIRC: HLA-DQA2 HLA-DRB5
kfs-all: 55 of 63 genes from data set analyzed in set REACTOME_INTERFERON_GAMMA_SIGNALING: IRF9 GBP4 GBP5 GBP6 FCGR1A FCGR1B GBP1 GBP2 HLA-A HLA-B HLA-C HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-F HLA-G ICAM1 IRF8 IFNG IFNGR1 IFNGR2 IRF1 IRF2 IRF3 IRF4 IRF5 IRF6 IRF7 JAK1 JAK2 CIITA MT2A NCAM1 OAS1 OAS2 OAS3 PML PRKCD B2M PTAFR PTPN1 PTPN2 PTPN6 SP100 STAT1 SUMO1 VCAM1 CAMK2A CAMK2B CAMK2D PIAS1 OASL SOCS1 SOCS3 CD44
kfs-all: 8 of 63 genes missing from data set analyzed in set REACTOME_INTERFERON_GAMMA_SIGNALING: HLA-DQA2 HLA-DRB1 HLA-DRB3 HLA-DRB5 GBP7 LOC441019 LOC646981 HLA-K
kfs-all: 194 of 200 genes from data set analyzed in set HALLMARK_TNFA_SIGNALING_VIA_NFKB: JUNB CXCL2 ATF3 NFKBIA TNFAIP3 PTGS2 CXCL1 IER3 CD83 CCL20 CXCL3 MAFF NFKB2 TNFAIP2 HBEGF KLF6 BIRC3 PLAUR ZFP36 ICAM1 JUN EGR3 IL1B BCL2A1 PPP1R15A SOD2 NR4A2 IL1A RELB TRAF1 BTG2 DUSP1 MAP3K8 ETS2 F3 SDC4 EGR1 IL6 TNF KDM6B NFKB1 LIF PTX3 FOSL1 NR4A1 JAG1 CCL4 GCH1 CCL2 RCAN1 DUSP2 EHD1 IER2 REL CFLAR RIPK2 NFKBIE NR4A3 PHLDA1 IER5 TNFSF9 GEM GADD45A CXCL10 PLK2 BHLHE40 EGR2 SOCS3 SLC2A6 PTGER4 DUSP5 SERPINB2 NFIL3 SERPINE1 TRIB1 TIPARP RELA BIRC2 CXCL6 LITAF TNFAIP6 CD44 INHBA PLAU MYC TNFRSF9 SGK1 TNIP1 NAMPT FOSL2 PNRC1 ID2 CD69 IL7R EFNA1 PHLDA2 PFKFB3 CCL5 YRDC IFNGR2 SQSTM1 BTG3 GADD45B KYNU G0S2 BTG1 MCL1 VEGFA CDKN1A CYR61 TANK IFIT2 IL18 TUBB2A IRF1 FOS OLR1 RHOB AREG NINJ1 ZBTB10 KLF4 CXCL11 SAT1 CSF1 GPR183 PMEPA1 PTPRE TLR2 KLF10 MARCKS LAMB3 CEBPB TRIP10 F2RL1 KLF9 LDLR TGIF1 RNF19B DRAM1 B4GALT1 DNAJB4 CSF2 PDE4B SNN PLEK STAT5A DENND5A CCND1 DDX58 SPHK1 CD80 TNFAIP8 CCNL1 FUT4 CCRL2 SPSB1 TSC22D1 B4GALT5 SIK1 CLCF1 NFE2L2 FOSB NFAT5 ATP2B1 IL12B IL6ST SLC16A6 ABCA1 HES1 BCL6 IRS2 SLC2A3 CEBPD IL23A SMAD3 TAP1 MSC IFIH1 IL15RA TNIP2 PANX1 FJX1 EDN1 EIF1 BMP2 DUSP4 PDLIM5 ICOSLG GFPT2 KLF2 TNC SERPINB8 MXD1
kfs-all: 6 of 200 genes missing from data set analyzed in set HALLMARK_TNFA_SIGNALING_VIA_NFKB: ZC3H12A MAP2K3 PPAP2B CXCR7 PER1 BCL3
kfs-all: 197 of 200 genes from data set analyzed in set HALLMARK_HYPOXIA: PGK1 PDK1 GBE1 PFKL ALDOA ENO2 PGM1 NDRG1 HK2 ALDOC GPI MXI1 SLC2A1 P4HA1 ADM P4HA2 ENO1 PFKP AK4 FAM162A PFKFB3 VEGFA BNIP3L TPI1 KDM3A CCNG2 LDHA GYS1 GAPDH BHLHE40 ANGPTL4 JUN SERPINE1 LOX GCK PPFIA4 MAFF DDIT4 SLC2A3 IGFBP3 NFIL3 FOS RBPJ HK1 CITED2 ISG20 GALK1 WSB1 PYGM STC1 ZNF292 BTG1 PLIN2 CSRP2 VLDLR JMJD6 EXT1 F3 PDK3 ANKZF1 UGP2 ALDOB STC2 ERRFI1 ENO3 PNRC1 HMOX1 PGF GAPDHS CHST2 TMEM45A BCAN ATF3 CAV1 AMPD3 GPC3 NDST1 IRS2 SAP30 GAA SDC4 STBD1 IER3 PKLR IGFBP1 PLAUR PRKCDBP WISP2 LARGE S100A4 RRAGD ZFP36 EGFR EDN2 IDS CDKN1A RORA DUSP1 MIF PPP1R3C DPYSL4 KDELR3 DTNA ADORA2B HS3ST1 PTRF NR3C1 KLF6 GPC4 CYR61 TNFAIP3 CA12 HEXA BGN PPP1R15A PGM2 PIM1 PRDX5 NAGK CDKN1B BRS3 TKTL1 MT1E ATP7A MT2A SDC3 TIPARP PKP1 ANXA2 PGAM2 DDIT3 PRKCA SLC37A4 CXCR4 EFNA3 CP KLF7 CTGF CHST3 TPD52 LXN B4GALNT2 PPARGC1A BCL2 GCNT2 HAS1 KLHL24 SCARB1 SLC25A1 SDC2 CASP6 VHL FOXO3 PDGFB B3GALT6 SLC2A5 SRPX EFNA1 GLRX PAM TGFBI DCN SIAH2 PLAC8 FBP1 TPST2 PHKG1 MYH9 CDKN1C GRHPR PCK1 INHA HSPA5 NDST2 NEDD4L TPBG XPNPEP1 IL6 SLC6A6 MAP3K1 LDHC AKAP12 TES KIF5A LALBA COL5A1 GPC1 HDLBP ILVBL NCAN TGM2 ETS1 HOXB9 SELENBP1 FOSL2 SULT2B1 TGFB3
kfs-all: 3 of 200 genes missing from data set analyzed in set HALLMARK_HYPOXIA: ERO1L CCRN4L CXCR7
kfs-all: 71 of 74 genes from data set analyzed in set HALLMARK_CHOLESTEROL_HOMEOSTASIS: FDPS IDI1 FDFT1 DHCR7 SQLE HMGCS1 NSDHL LSS MVD LDLR TM7SF2 ALDOC EBP SCD PMVK MVK LPL FADS2 HMGCR HSD17B7 ANXA13 SREBF2 PCYT2 ACSS2 ATF3 ADH4 ETHE1 ECH1 CBS GUSB FASN LGALS3 ATF5 ANXA5 TP53INP1 CHKA GSTM2 ACAT2 AVPR1A PLSCR1 CLU ERRFI1 TRIB3 CXCL16 TNFRSF12A JAG1 LGMN FBXO6 GPX8 PNRC1 ANTXR2 MAL2 CD9 PPARG GLDC STX5 STARD4 CTNNB1 TMEM97 FAM129A PDK3 PLAUR SEMA3B GNAI1 ABCA2 ATXN2 NFIL3 ALCAM FABP5 S100A11 CPEB2
kfs-all: 3 of 74 genes missing from data set analyzed in set HALLMARK_CHOLESTEROL_HOMEOSTASIS: CYP51A1 SC5DL ACTG1
kfs-all: 199 of 200 genes from data set analyzed in set HALLMARK_MITOTIC_SPINDLE: ARHGEF2 CLASP1 KIF11 KIF23 ALS2 ARF6 MYO9B MYH9 TUBGCP3 CKAP5 RACGAP1 PREX1 ARHGEF3 NUMA1 SPTBN1 KIF2C KIF5B TTK APC CEP250 PAFAH1B1 CDC42EP2 KIF3B CCDC88A KIF15 BIRC5 CNTROB NF1 TSC1 CDC27 CNTRL TUBGCP5 KIF4A MAPRE1 FGD6 BRCA2 PLK1 RASA1 NEK2 WASF1 TOP2A TRIO ARHGEF11 KATNB1 PRC1 ANLN CDK5RAP2 SMC3 TUBGCP2 ESPL1 MAP1S ARHGAP27 DOCK4 SAC3D1 INCENP ARHGAP5 GSN NET1 LRPPRC RABGAP1 FLNB ARAP3 FGD4 ABR CENPJ NCK1 CENPF KIF20B WASF2 MYH10 CENPE CYTH2 MID1 KLC1 MARK4 ARL8A CEP57 UXT ARHGAP4 CDC42EP4 SASS6 LATS1 OPHN1 WASL MAP3K11 SOS1 ABL1 TIAM1 KIF1B ITSN1 SHROOM1 NCK2 DLGAP5 BCR RANBP9 EPB41L2 SEPT9 KATNA1 TUBD1 TPX2 KIF3C SHROOM2 TUBGCP6 SPTAN1 PALLD ARFIP2 KNTC1 HOOK3 SUN2 MID1IP1 DLG1 FLNA ARHGAP10 CDC42BPA ARHGEF12 MARCKS NIN PCM1 RALBP1 EZR SSH2 CDK1 RAB3GAP1 FARP1 SYNPO RHOF ECT2 EPB41 RAPGEF6 KIF22 PCGF5 STAU1 ARHGDIA AURKA FBXO5 NUSAP1 PXN BCAR1 CD2AP AKAP13 HDAC6 LLGL1 ATG4B PCNT ALMS1 CRIPAK KPTN DST KIFAP3 PPP4R2 ARHGAP29 RASAL2 CCNB2 PIF1 RASA2 NEDD9 SMC1A ACTN4 PKD2 CLIP2 CDC42 NDC80 TLK1 TAOK2 TBCD CAPZB DOCK2 CTTN SMC4 ARFGEF1 TUBA4A LMNB1 ABI1 ROCK1 CEP192 BUB1 GEMIN4 PLEKHG2 RICTOR BCL2L11 DYNC1H1 FSCN1 ARHGEF7 DYNLL2 MYO1E BIN1 NOTCH2 RFC1 PDLIM5 RHOT2 SORBS2 CDC42EP1 VCL CLIP1 STK38L YWHAE RAPGEF5 CEP72 CSNK1D
kfs-all: 1 of 200 genes missing from data set analyzed in set HALLMARK_MITOTIC_SPINDLE: AZI1
kfs-all: 41 of 42 genes from data set analyzed in set HALLMARK_WNT_BETA_CATENIN_SIGNALING: MYC CTNNB1 JAG2 NOTCH1 DLL1 AXIN2 PSEN2 FZD1 NOTCH4 LEF1 AXIN1 NKD1 WNT5B CUL1 JAG1 MAML1 KAT2A GNAI1 WNT6 PTCH1 NCOR2 DKK4 HDAC2 DKK1 TCF7 WNT1 NUMB ADAM17 DVL2 PPARD NCSTN HDAC5 CCND2 FRAT1 CSNK1E RBPJ TP53 SKP2 HEY2 HEY1 HDAC11
kfs-all: 1 of 42 genes missing from data set analyzed in set HALLMARK_WNT_BETA_CATENIN_SIGNALING: FZD8
kfs-all: 53 of 54 genes from data set analyzed in set HALLMARK_TGF_BETA_SIGNALING: TGFBR1 SMAD7 TGFB1 SMURF2 SMURF1 BMPR2 SKIL SKI ACVR1 PMEPA1 NCOR2 SERPINE1 JUNB SMAD1 SMAD6 PPP1R15A TGIF1 FURIN SMAD3 FKBP1A MAP3K7 BMPR1A CTNNB1 HIPK2 KLF10 BMP2 ENG APC PPM1A XIAP CDH1 ID1 CDKN1C TRIM33 RAB31 TJP1 SLC20A1 CDK9 ID3 NOG ARID4B IFNGR2 ID2 PPP1CA SPTBN1 WWTR1 BCAR3 THBS1 FNTA HDAC1 UBE2D3 LTBP2 RHOA
kfs-all: 1 of 54 genes missing from data set analyzed in set HALLMARK_TGF_BETA_SIGNALING: LEFTY2
kfs-all: 87 of 87 genes from data set analyzed in set HALLMARK_IL6_JAK_STAT3_SIGNALING: IL4R IL6ST STAT1 IL1R1 CSF2RB SOCS3 STAT3 OSMR IL2RG IFNGR1 TYK2 IL13RA1 TLR2 IFNGR2 IL10RB IL6 IL1R2 IL3RA IFNAR1 TNFRSF1A MYD88 ACVR1B CSF3R ITGB3 REG1A CXCL1 A2M CSF2RA IL15RA IRF9 PDGFC HAX1 BAK1 EBI3 INHBE CRLF2 TNFRSF1B CD14 PTPN1 PTPN2 IL1B CSF1 IL18R1 TNF PF4 CXCL13 LTBR FAS IL17RA CXCL10 IL9R STAM2 TNFRSF12A STAT2 HMOX1 LEPR CBL CD9 CXCL3 TGFB1 MAP3K8 ITGA4 CD38 JUN SOCS1 ACVRL1 PIM1 TNFRSF21 PIK3R5 GRB2 IRF1 DNTT CSF2 IL2RA PTPN11 IL12RB1 CCR1 CNTFR PLA2G2A CXCL9 CD44 IL7 CXCL11 CCL7 LTB IL17RB CD36
kfs-all: 140 of 150 genes from data set analyzed in set HALLMARK_DNA_REPAIR: POLR2H POLR2A POLR2G POLR2E POLR2J POLR2F POLR2C POLR2K GTF2H3 POLR2D ERCC3 DDB2 POLR1C XPC PCNA POLR2I SUPT4H1 POLD3 POLR3GL POLR3C GTF2B POLR1D NCBP2 GTF2F1 ERCC5 LIG1 ERCC1 ERCC4 POLD4 RFC2 ELL TAF10 RRM2B SUPT5H RPA3 SNAPC5 SSRP1 RFC3 RPA2 TCEB3 TAF12 TAF13 TAF6 GTF2A2 VPS37D NME1 RNMT ERCC2 POLE4 VPS37B SNAPC4 AAAS ZNRD1 RFC4 ITPA POM121 BRF2 RFC5 SAC3D1 CLP1 NME4 PRIM1 VPS28 TSG101 USP11 TAF1C TARBP2 POLH CETN2 POLD1 CANT1 PDE4B RAD51 SURF1 PNP ADA NME3 GTF3C5 NT5C AK1 GTF2H1 HCLS1 APRT ERCC8 IMPDH2 POLB SDCBP SF3A3 DAD1 UPF3B GUK1 TP53 ADRM1 SEC61A1 POLA2 FEN1 NUDT9 PDE6G TYMS BCAP31 DDB1 NFX1 RAD52 ADCY6 ARL6IP1 DGUOK POLL SMAD5 MPG DUT POLA1 RALA ZWINT BCAM TK2 CSTF3 GTF2H5 HPRT1 BOLA2 GPX4 CDA MRPL40 NPR2 REV3L EDF1 DFNA5 TMED2 STX3 RAE1 UMPS EIF1B AK3 NUDT21 RBX1 SRSF6 GMPR2 DCTN4 COX17 CMPK2 CCNO
kfs-all: 10 of 150 genes missing from data set analyzed in set HALLMARK_DNA_REPAIR: RDBP COBRA1 TH1L TAF9 NT5C3 DGCR8 ZNF707 EIF2C4 BRP44 THOC4
kfs-all: 194 of 200 genes from data set analyzed in set HALLMARK_G2M_CHECKPOINT: AURKA CCNA2 TOP2A CCNB2 CENPA BIRC5 CDC20 PLK1 TTK PRC1 NDC80 KIF11 NUSAP1 CKS2 KIF2C MKI67 AURKB TPX2 SMC4 BUB1 CENPF RACGAP1 CENPE KIF23 UBE2C MCM6 MCM3 PTTG1 CDK1 KIF4A ESPL1 MAD2L1 NEK2 KIF22 HMMR KPNA2 CDKN3 CDC25A H2AFX CDC25B PLK4 CDC6 CCNF MCM5 LMNB1 E2F3 KIF15 CHEK1 UBE2S WHSC1 HMGB3 DBF4 TACC3 MCM2 CDKN2C CDKN1B FANCC NASP STAG1 GINS2 FBXO5 POLQ EZH2 RAD21 STMN1 SUV39H1 PRIM2 E2F1 CHAF1A NOLC1 GSPT1 BUB3 SMC1A ILF3 CDC7 INCENP CKS1B EXO1 H2AFZ TFDP1 CCND1 KPNB1 HN1 LBR HUS1 KIF20B TOP1 PDS5B SRSF1 STIL ABL1 DTYMK CDC27 BARD1 ATF5 CDC45 ODC1 XPO1 SFPQ TMPO PML BRCA2 CTCF CASC5 SLC38A1 TRA2B MYBL2 TROAP PAPD7 CUL3 MAPK14 HIST1H2BK MYC AMD1 CBX1 CHMP1A YTHDC1 CCNT1 TGFB1 ATRX LIG3 NUP50 SLC7A5 RBL1 NUMA1 RAD54L EFNA5 PRPF4B ARID4A CUL1 UPF1 DR1 MNAT1 SMC2 RBM14 RPA2 SQLE ORC6 CDK4 POLE RASAL2 HOXC10 RPS6KA5 CUL4A SLC7A1 FOXN3 HMGA1 SS18 TRAIP PRMT5 CUL5 DDX39A MARCKS PBK ORC5 SAP30 KATNA1 HNRNPD POLA2 HIRA HIF1A SYNCRIP TLE3 NCL RAD23B E2F2 EGF HMGN2 SRSF10 SNRPD1 CASP8AP2 SMARCC1 SLC12A2 NOTCH2 TNPO2 SMAD3 ZAK G3BP1 PTTG3P DMD MEIS1 HNRNPU MT2A NUP98 EWSR1 KIF5B MTF2 E2F4 PURA MEIS2 PAFAH1B1 WRN H2AFV ODF2
kfs-all: 6 of 200 genes missing from data set analyzed in set HALLMARK_G2M_CHECKPOINT: SETD8 DKC1 UCK2 HSPA8 SRSF2 BCL3
kfs-all: 159 of 161 genes from data set analyzed in set HALLMARK_APOPTOSIS: CASP3 CASP9 DFFA CASP7 CFLAR BIRC3 PMAIP1 CASP8 JUN BCL2L11 MCL1 IL1B SPTAN1 DIABLO BAX BIK IL1A BID CDKN1A GADD45A DDIT3 CDKN1B TNF GSN TNFSF10 CASP6 SQSTM1 FASLG EGR3 CD44 FAS IL18 IGFBP6 PRF1 DAP CCND1 BTG3 F2R SATB1 BNIP3L CASP4 TNFRSF12A CREBBP RHOB GPX3 PDGFRB TSPO CCND2 XIAP TIMP1 CTNNB1 IRF1 HSPB1 ADD1 TIMP2 BTG2 TIMP3 LEF1 CASP1 GPX1 BCL10 IGF2R CDC25B AIFM3 CD38 PPP3R1 HGF CLU ATF3 LGALS3 LUM LMNA GADD45B CDK2 IFNB1 RETSAT SMAD7 SOD1 PTK2 ENO2 HMOX1 IER3 BCL2L10 CD2 GCH1 MMP2 VDAC2 TAP1 PLAT IFNGR1 APP BRCA1 ROCK1 PSEN1 DCN PSEN2 SOD2 BMF EREG KRT18 TGFB2 RELA WEE1 RARA CD14 CD69 PEA15 DNAJC3 CASP2 CTH PLCB2 BMP2 HMGB2 H1F0 TGFBR3 EBP TXNIP ANKH RHOT2 CYLD GSTM1 GSR BGN BCL2L1 GNA15 MGMT PPT1 F2 IL6 IFITM3 RNASEL EMP1 CAV1 DNM1L ANXA1 TOP2A ISG20 SLC20A1 MADD PPP2R5B BCAP31 ERBB3 NEDD9 SAT1 PDCD4 BCL2L2 FEZ1 ERBB2 DNAJA1 DAP3 DPYD NEFH PAK1 FDXR GPX4 ETF1 CCNA1 GUCY2D AVPR1A
kfs-all: 2 of 161 genes missing from data set analyzed in set HALLMARK_APOPTOSIS: LPPR4 SC5DL
kfs-all: 32 of 32 genes from data set analyzed in set HALLMARK_NOTCH_SIGNALING: JAG1 NOTCH3 NOTCH2 APH1A HES1 CCND1 FZD1 PSEN2 FZD7 DTX1 DLL1 FZD5 MAML2 NOTCH1 PSENEN WNT5A CUL1 WNT2 DTX4 SAP30 PPARD KAT2A HEYL SKP1 RBX1 TCF7L2 ARRB1 LFNG PRKCA DTX2 ST3GAL6 FBXW11
kfs-all: 192 of 200 genes from data set analyzed in set HALLMARK_ADIPOGENESIS: FABP4 ADIPOQ PPARG LIPE DGAT1 LPL CPT2 CD36 GPAM ADIPOR2 ACAA2 ETFB ACOX1 ACADM HADH IDH1 SORBS1 ACADS UCK1 SCP2 DECR1 CDKN2C TALDO1 TST MCCC1 PGM1 REEP5 BCL2L13 SLC25A10 ME1 PHYH PIM3 YWHAG NDUFAB1 GPD2 ADIG ECHS1 QDPR CS ECH1 SLC25A1 ACADL TOB1 GRPEL1 CRAT GBE1 SDPR SCARB1 PEMT CHCHD10 AK2 APOE UQCR10 TANK ANGPTL4 ACO2 FAH ACLY IFNGR1 SLC5A6 JAGN1 EPHX2 IDH3G GPX3 ELMOD3 ORM1 RETSAT ESRRA HIBCH SUCLG1 STAT5A ITGA7 MRAP PLIN2 CYC1 ALDH2 RNF11 ALDOA SULT1A1 SDHB CD151 SLC27A1 BCKDHA C3 LEP ADCY6 ELOVL6 LTC4S SPARCL1 MTCH2 SLC1A5 CMPK1 REEP6 NDUFA5 FZD4 DRAM2 MGST3 ATP1B3 RETN STOM ESYT1 GHITM DNAJC15 GADD45A VEGFB PFKL COQ3 CYP4B1 PPM1B ARAF PTRF COL4A1 IMMT DHRS7 COL15A1 NMT1 COQ5 LAMA4 AGPAT3 BAZ2A IDH3A LIFR PREB PTGER3 GPHN PFKFB3 GPX4 SSPN SQRDL DLD ITIH5 ATL2 LPCAT3 TKT UQCRC1 CAT OMD DLAT MRPL15 RIOK3 RTN3 CHUK G3BP2 SDHC SAMM50 ARL4A SNCG PDCD4 COQ9 APLP2 SOD1 PTCD3 PHLDB1 ENPP2 HSPB8 AIFM1 CCNG2 PPP1R15B MDH2 ABCA1 COX7B MYLK COX8A DHRS7B FAM73B MGLL ITSN1 DHCR7 RREB1 CMBL UBC ATP5O PRDX3 DBT NDUFS3 NKIRAS1 CIDEA UQCRQ PEX14 BCL6 COX6A1 DNAJB9 MAP4K3 ANGPT1 UBQLN1 NDUFB7 SLC19A1 ABCB8 PQLC3 POR UCP2 UQCR11
kfs-all: 8 of 200 genes missing from data set analyzed in set HALLMARK_ADIPOGENESIS: DDT FAM82A2 ANKRD57 OBFC2A MOSC2 CD302 AGPAT6 RAB34
kfs-all: 197 of 200 genes from data set analyzed in set HALLMARK_ESTROGEN_RESPONSE_EARLY: GREB1 CA12 SLC9A3R1 MYB ANXA9 IGFBP4 SYBU NPY1R PDZK1 NRIP1 MLPH HSPB8 EGR3 KRT19 LRIG1 KDM4B PGR RHOBTB3 TPD52L1 ELOVL2 RET TPBG TFF1 MAPT SCNN1A ABAT FLNB XBP1 CELSR2 RAB31 MYBL1 MREG FAM102A MSMB STC2 FAM134B SIAH2 ZNF185 SLC19A2 SLC1A4 FHL2 BCL2 PMAIP1 AREG OVOL2 TSKU ADCY9 RASGRP1 MUC1 KAZN SLC27A2 FKBP4 CXCL12 TMPRSS3 RARA IL17RB CBFA2T3 TFF3 UGCG CCND1 SLC22A5 WFS1 PTGES WWC1 WISP2 MYC ITPK1 ARL3 MED13L SEMA3B KRT18 SLC16A1 TJP3 SLC26A2 SULT2B1 SNX24 TFAP2C TTC39A GJA1 PRSS23 OLFM1 RAPGEFL1 ASB13 TIPARP ABCA3 FRK DHRS2 AQP3 KCNK15 TGIF2 FOXC1 ELF3 REEP1 PEX11A PODXL KLF4 BAG1 CELSR1 PLA2G16 SLC7A5 MPPED2 TIAM1 CLDN7 MYOF RBBP8 OLFML3 GFRA1 FARP1 SVIL TGM2 DEPTOR CYP26B1 PAPSS2 SLC1A1 DLC1 JAK2 AFF1 KLK10 P2RY2 BLVRB CISH GLA ADD3 PDLIM3 FAM63A FOS KRT8 SLC37A1 B4GALT1 CALCR IGF1R NBL1 SFN OPN3 ABHD2 AR SLC39A6 SYT12 CD44 MED24 BCL11B CANT1 KRT13 KRT15 TOB1 SLC7A2 LAD1 TUBB2B TBC1D30 SEC14L2 ENDOD1 HR SCARB1 NCOR2 RHOD INPP5F PPIF DHRS3 FDFT1 GAB2 UNC119 KLF10 HES1 FKBP5 SLC2A1 AMFR NADSYN1 INHBB BHLHE40 CALB2 FASN CHPT1 MYBBP1A ELOVL5 DYNLT3 ABLIM1 SOX3 SLC24A3 RAB17 MAST4 KCNK5 ELF1 RPS6KA2 ISG20L2 IL6ST SYNGR1 SH3BP5 ALDH3B1 THSD4 CLIC3 NXT1 NAV2 RRP12 ADCY1 DHCR7 MICB AKAP1
kfs-all: 3 of 200 genes missing from data set analyzed in set HALLMARK_ESTROGEN_RESPONSE_EARLY: TMEM164 FAIM3 ESRP2
kfs-all: 199 of 200 genes from data set analyzed in set HALLMARK_ESTROGEN_RESPONSE_LATE: TFF1 SLC9A3R1 TPD52L1 PRSS23 CA12 PDZK1 ANXA9 CELSR2 TJP3 PGR RET MYB TPBG EGR3 ARL3 OLFM1 NPY1R SCNN1A XBP1 AREG IL17RB NRIP1 ASS1 TFF3 FKBP4 SLC27A2 SEMA3B LLGL2 AGR2 KRT19 WISP2 BLVRB FLNB PDCD4 CALCR IGFBP4 DNAJC12 TIAM1 TSPAN13 CXCL12 RAB31 PKP3 CYP26B1 FKBP5 SIAH2 ISG20 TMPRSS3 SERPINA3 WFS1 MAPT PDLIM3 RBBP8 GJB3 PRLR SLC1A4 FOS PLA2G16 SLC7A5 SERPINA5 IMPA2 DHCR7 MYOF CDH1 EMP2 OVOL2 DLG5 SOX3 CHPT1 KLK10 ELOVL5 RAPGEFL1 JAK2 SLC26A2 SLC22A5 ITPK1 PCP4 PAPSS2 NAB2 FAM102A BCL2 LSR CACNA2D2 CA2 ASCL1 ACOX2 CISH GLA PTGES PERP OPN3 KRT13 HSPB8 UGDH CLIC3 KLK11 PLAC1 ABHD2 SCARB1 DCXR CCND1 SFN ABCA3 SULT2B1 CCNA1 STIL MICB ZFP36 CAV1 NBL1 CD44 HR HOMER2 BTG3 GAL ETFB BAG1 FRK SLC16A1 AFF1 TFAP2C IGSF1 HPRT1 CDC6 FARP1 AMFR DHRS2 NXT1 S100A9 SLC29A1 SLC24A3 FOXC1 KIF20A TOB1 FDFT1 DNAJC1 TPSAB1 TSTA3 FGFR3 SGK1 ID2 GALE BATF MAPK13 FABP5 MEST JAK1 CYP4F11 KCNK5 CPE XRCC3 CXCL14 SCUBE2 CDC20 IL6ST GINS2 TRIM29 UNC13B LAMC2 LARGE SLC2A8 PLXNB1 PRKAR2B RPS6KA2 HSPA4L TFPI2 SERPINA1 TNNC1 HMGCS2 ALDH3A2 CD9 IDH2 SORD MDK ALDH3B1 PTGER3 RABEP1 KLF4 PPIF SNX10 METTL3 PLK4 COX6C ST14 NCOR2 MOCS2 NMU TH RNASEH2A CHST8 TST TOP2A CKB LTF DUSP2 PTPN6 ATP2B4 ST6GALNAC2 ADD3 DYNLT3
kfs-all: 1 of 200 genes missing from data set analyzed in set HALLMARK_ESTROGEN_RESPONSE_LATE: GPER
kfs-all: 97 of 101 genes from data set analyzed in set HALLMARK_ANDROGEN_RESPONSE: KLK3 KLK2 ACSL3 PIAS1 CAMKK2 NKX3-1 TMPRSS2 APPBP2 CENPN BMPR1B MAF ZBTB10 HMGCR SPCS3 INSIG1 NGLY1 UBE2J1 ELK4 ABCC4 ELOVL5 ALDH1A3 TARP AZGP1 ABHD2 SAT1 DBI DHCR24 SORD STK39 TPD52 IDI1 B2M MAP7 DNAJB9 FKBP5 PGM3 HOMER2 ELL2 UAP1 SEC24D LMAN1 PMEPA1 INPP4B RRP12 SEPP1 NDRG1 KRT19 ITGAV B4GALT1 MAK SPDEF GSR KRT8 LIFR STEAP4 GUCY1A3 SRP19 CCND3 IQGAP2 SLC26A2 SMS ZMIZ1 SGK1 MERTK HPGD ANKH GNAI3 SRF SLC38A2 HMGCS1 ARID5B CDC14B TNFAIP8 XRCC5 GPD1L ACTN1 RPS6KA3 TSC22D1 PDLIM5 TMEM50A ADAMTS1 NCOA4 AKAP12 SCD PTK2B CDK6 ADRM1 H1F0 HSD17B14 VAPA CCND1 XRCC6 MYL12A UBE2I PTPN21 AKT1 PA2G4
kfs-all: 4 of 101 genes missing from data set analyzed in set HALLMARK_ANDROGEN_RESPONSE: FADS1 HERC3 PPAP2A RAB4A
kfs-all: 198 of 200 genes from data set analyzed in set HALLMARK_MYOGENESIS: ACTA1 TNNI2 MYL1 TNNC1 TNNC2 MYH3 MYLPF TNNT3 TNNT2 CASQ2 ACTC1 MYOM1 MYL4 MYBPH MYH7 MYH8 ACTN2 TNNI1 CRYAB SGCG HRC TNNT1 DES MYOZ1 RYR1 CSRP3 ADAM12 ATP2A1 CKM SVIL MYOM2 MYL6B TPM2 MYL2 CKMT2 BIN1 MYH1 ENO3 FLII FXYD1 TPM3 DMD IGFBP3 CHRNB1 FHL1 ACTN3 TCAP MYLK MYL3 PYGM LDB3 COX6A2 FABP3 MYL7 ITGB5 CHRNA1 SSPN COL3A1 KCNH1 GJA5 MYF6 MYH2 MAPK12 PGAM2 MYOG MYH4 AEBP1 HBEGF MEF2C NOS1 CNN3 IGFBP7 CACNA1H GSN CACNG1 PPFIA4 MB SPHK1 MEF2D SMTN CDKN1A GAA TPD52L1 HSPB2 SGCA BDKRB2 COX7A1 COL4A2 PLXNB2 CTF1 COL15A1 KCNH2 AGRN MYO1C SIRT2 SGCD SORBS1 VIPR1 FGF2 FKBP1B TEAD4 CASQ1 KLF5 PDLIM7 AK1 TAGLN RIT1 MEF2A ANKRD2 AKT2 LAMA2 ST5 IFRD1 NCAM1 SYNGR2 PICK1 COL6A3 CRAT DMPK MYH11 MYH9 IGF1 CKB FST GPX3 PVALB PTP4A3 ITGB1 HSPB8 ACHE CHRNG PKIA NAV2 HDAC5 ATP6AP1 CLU ACSL1 COL1A1 MRAS PDE4DIP AGL ERBB3 GABARAPL2 CAV3 BHLHE40 PPP1R3C LARGE LPIN1 CDH13 NQO1 PRNP PSEN2 DAPK2 LSP1 SLC6A8 REEP1 EIF4A2 SH2B1 MYBPC3 ITGA7 SPTAN1 SORBS3 PC SCD GNAO1 STC2 CFD RB1 BAG1 ABLIM1 PTGIS MAPRE3 OCEL1 SH3BGR NOTCH1 TSC2 TGFB1 FDPS CAMK2B EPHB3 GADD45B APP APLNR ITGB4 SOD3 FOXO4 EFS PFKM COL6A2 DTNA KIFC3 SPARC SPDEF SLN WWTR1 CD36 ADCY9 APOD
kfs-all: 2 of 200 genes missing from data set analyzed in set HALLMARK_MYOGENESIS: SPEG SCHIP1
kfs-all: 96 of 96 genes from data set analyzed in set HALLMARK_PROTEIN_SECRETION: ARCN1 TMED10 COPB2 RAB14 ATP7A COPB1 LAMP2 EGFR IGF2R COPE PPT1 AP3S1 BET1 CLCN3 AP2S1 CLTC AP2M1 RER1 KIF1B ARF1 OCRL ICA1 MON2 ARFGEF2 TMED2 NAPG TMX1 PAM SCAMP1 SH3GL2 RAB2A COG2 VAMP3 ERGIC3 DOPEY1 VAMP4 VPS4B NAPA GNAS STX7 SEC22B VPS45 STX16 YKT6 SNX2 ARFGEF1 CLTA CLN5 M6PR SGMS1 USO1 TSG101 DNM1L LMAN1 YIPF6 ARFIP1 ANP32E TSPAN8 DST SCRN1 SEC31A VAMP7 SCAMP3 AP2B1 RAB22A AP3B1 TPD52 ATP6V1H GBF1 KRT18 CAV2 ATP1A1 BNIP3 ZW10 GALC ADAM10 RAB5A GOLGA4 SEC24D AP1G1 MAPK1 GOSR2 RPS6KA3 STAM ABCA1 SNAP23 SOD1 GLA ATP6V1B1 STX12 CD63 TOM1L1 SSPN ARFGAP3 RAB9A CTSC
kfs-all: 91 of 97 genes from data set analyzed in set HALLMARK_INTERFERON_ALPHA_RESPONSE: MX1 ISG15 OAS1 IFIT3 IFI44 IFI35 IRF7 RSAD2 IFI44L IFITM1 IFI27 IRF9 OASL EIF2AK2 IFIT2 CXCL10 TAP1 SP110 DDX60 UBE2L6 USP18 PSMB8 IFIH1 BST2 LGALS3BP ADAR ISG20 GBP2 IRF1 PLSCR1 PSMB9 HERC6 SAMD9 CMPK2 IFITM3 RTP4 STAT2 SAMD9L LY6E IFITM2 CXCL11 TRIM21 PARP14 TRIM26 PARP12 NMI RNF31 HLA-C CASP1 TRIM14 TDRD7 DHX58 PARP9 PNPT1 TRIM25 PSME1 WARS EPSTI1 B2M TRIM5 C1S LAP3 LAMP3 GBP4 NCOA7 TMEM140 CD74 GMPR PSMA3 PROCR IL7 IRF2 CSF1 IL15 CNP FAM46A IL4R CD47 LPAR6 MOV10 CASP8 TXNIP SLC25A28 SELL TRAFD1 BATF2 RIPK2 CCRL2 NUB1 OGFR ELF1
kfs-all: 6 of 97 genes missing from data set analyzed in set HALLMARK_INTERFERON_ALPHA_RESPONSE: PRIC285 UBA7 PSME2 IFI30 FTSJD2 FAM125A
kfs-all: 194 of 200 genes from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: STAT1 ISG15 IFIT1 MX1 IFIT3 IFI35 IRF7 IFIT2 OAS2 TAP1 EIF2AK2 RSAD2 MX2 IRF1 OAS3 TNFSF10 IRF9 CXCL10 IFI44 BST2 XAF1 SP110 OASL PSMB8 IFI44L IFITM3 DDX60 LGALS3BP GBP4 IRF8 PSMB9 PML IFIH1 UBE2L6 IFI27 ADAR LY6E STAT2 CXCL9 IL10RA PLA2G4A TRIM21 USP18 PTGS2 EPSTI1 C1S DDX58 IL15 NLRC5 NMI IDO1 PSMB10 CXCL11 ITGB7 SAMHD1 HERC6 CMPK2 SAMD9L RTP4 PTPN2 PARP14 TNFAIP2 IFITM2 PLSCR1 SOCS1 CASP1 ICAM1 WARS PSME1 ISG20 IRF2 TRIM14 FCGR1A MARCH1 SOCS3 JAK2 HLA-DMA PARP12 TNFAIP6 TRIM26 VCAM1 CD274 CIITA NAMPT SELP GPR18 FPR1 SERPING1 CCL5 RNF31 SOD2 TRIM25 LAP3 PSMA3 RNF213 PELI1 CFB CD86 TXNIP HLA-DQA1 GCH1 PNP CCL7 PTPN6 SPPL2A IL4R PNPT1 DHX58 BTG1 CASP8 CCL2 FGL2 CASP7 SECTM1 IL15RA CD40 TRAFD1 GBP6 LCP2 HLA-G MT2A RIPK1 UPP1 PSMB2 TDRD7 HIF1A EIF4E3 VAMP8 PFKP CD38 ZBP1 BANK1 TOR1B RBCK1 PDE4B MVP IL7 BPGM AUTS2 B2M RIPK2 CD69 MYD88 PSMA2 PIM1 NOD1 CFH TAPBP SLC25A28 PTPN1 TNFAIP3 SSPN NUP93 MTHFD2 CDKN1A IRF4 NFKB1 BATF2 HLA-B LATS2 IRF5 SLAMF7 ISOC1 P2RY14 STAT3 NCOA3 HLA-A IL6 GZMA IFNAR2 CD74 RAPGEF6 CASP4 FAS OGFR ARL4A SRI LYSMD2 CSF2RB ST3GAL5 C1R CASP3 CMKLR1 NFKBIA METTL7B ST8SIA4 XCL1 IL2RB VAMP5 IL18BP ZNFX1 ARID5B APOL6 STAT4
kfs-all: 6 of 200 genes missing from data set analyzed in set HALLMARK_INTERFERON_GAMMA_RESPONSE: PRIC285 PSME2 IFI30 HLA-DRB1 KLRK1 FTSJD2
kfs-all: 191 of 200 genes from data set analyzed in set HALLMARK_APICAL_JUNCTION: ACTN1 CLDN7 ACTN3 CLDN19 DLG1 TJP1 COL17A1 CLDN9 CDH3 CDH1 LIMA1 VCL SHROOM2 CLDN14 PTPRC THY1 VASP ITGB1 ZYX ACTN4 CLDN4 CADM3 ITGA3 NF2 B4GALT1 NEXN CDH6 ADAM15 PTK2 HADH LAMB3 CLDN11 CDH4 IRS1 SORBS3 CLDN8 EVL CLDN15 THBS3 JAM3 CDH11 ITGB4 RASA1 AKT2 TMEM8B LAMA3 RSU1 ICAM1 CLDN18 GTF2F1 TSC1 LAMC2 NRAP CTNNA1 CD99 FSCN1 COL16A1 GNAI2 TGFBI MPP5 JUP ACTN2 INSIG1 LAYN PFN1 CNN2 TAOK2 AMIGO2 MDK INPPL1 CLDN6 ARPC2 SRC PBX2 MAPK14 MAP4K2 PTEN CALB2 CNTN1 TSPAN4 VCAN CDH8 ATP1A3 EPB41L2 MYL9 ADRA1B SYK CADM2 ALOX15B CX3CL1 MYH10 DMP1 CDSN MAPK13 MYL12B RAC2 FBN1 DSC1 CD34 ICAM4 MSN MAPK11 ACTC1 TRAF1 CRB3 ITGA2 ITGA10 BAIAP2 ARHGEF6 MVD PDZD3 ADAM9 PCDH1 SLIT2 KRT31 SGCE GNAI1 PIK3CB NLGN2 YWHAH PARVA CRAT ADAMTS5 EGFR ICAM2 CD274 CDH15 SHC1 MPZL2 WNK4 NFASC PIK3R3 SDC3 SIRPA GRB7 FLNC PARD6G COL9A1 NRXN2 ZAK SLC30A3 RHOF BMP1 MMP2 ICAM5 VWF MYH9 CD209 VCAM1 DHX16 ACTG2 NEGR1 NF1 ADAM23 PLCG1 KCNH2 CERCAM NRTN IKBKG DSC3 ACTB TUBG1 PPP2R2C HRAS MMP9 TNFRSF11B CDK8 FYB AMIGO1 CD276 GAMT NLGN3 SKAP2 RRAS CAP1 EXOC4 ACTA1 TIAL1 LDLRAP1 VAV2 AKT3 SYMPK STX4 PECAM1 MADCAM1 ITGA9 CD86 TRO CLDN5 MPZL1 WASL
kfs-all: 9 of 200 genes missing from data set analyzed in set HALLMARK_APICAL_JUNCTION: PVRL1 CTNND1 PVRL3 PVRL2 PVRL4 SPEG ACTG1 AMH PKD1
kfs-all: 44 of 44 genes from data set analyzed in set HALLMARK_APICAL_SURFACE: B4GALT1 RHCG MAL LYPD3 PKHD1 ATP6V0A4 AIM1 SHROOM2 SRPX MDGA1 TMEM8B THY1 PCSK9 EPHB4 DCBLD2 GHRL LYN GAS1 FLOT2 PLAUR AKAP7 ATP8B1 EFNA5 SLC34A3 APP GSTM3 HSPB1 SLC2A4 IL2RB RTN4RL1 NCOA6 SULF2 ADAM10 BRCA1 GATA3 AFAP1L2 IL2RG CD160 ADIPOR2 SLC22A12 NTNG1 SCUBE1 CX3CL1 CROCC
kfs-all: 35 of 36 genes from data set analyzed in set HALLMARK_HEDGEHOG_SIGNALING: SHH PTCH1 NRCAM NRP1 SCG2 AMOT UNC5C HEY1 GLI1 THY1 SLIT1 CDK6 HEY2 NRP2 TLE3 TLE1 L1CAM PLG NKX6-1 NF1 RASA1 ETS2 RTN1 CRMP1 MYH9 VEGFA CELSR1 CNTFR ACHE PML CDK5R1 VLDLR OPHN1 LDB1 DPYSL2
kfs-all: 1 of 36 genes missing from data set analyzed in set HALLMARK_HEDGEHOG_SIGNALING: GPR56
kfs-all: 193 of 200 genes from data set analyzed in set HALLMARK_COMPLEMENT: C2 C1S CFB C1R SERPINE1 MMP14 SERPING1 F5 MMP13 F7 CTSS LGMN PLG C1QA CASP1 GZMA ADAM9 CALM3 C1QC TIMP1 DPP4 KLK1 KLKB1 CD59 CR2 MMP15 LAP3 SPOCK2 F10 CTSB SERPINA1 CTSO CD40LG CBLB PDP1 C4BPB PLEK GP9 PLAUR C3 F2 CASP4 STX4 CTSC CR1 DUSP6 SERPINB2 GPD2 CFH FN1 CD36 CA2 PSMB9 APOBEC3G FCN1 GZMK PDGFB CLU CASP10 LRP1 CTSD S100A9 WAS BRPF3 PLAT CDA MT3 CASP7 PRSS36 PFN1 GZMB RNF4 ZEB1 CASP5 IRF1 CDK5R1 ATOX1 PIK3CA TMPRSS6 CPM RCE1 CALM1 DOCK9 KYNU RASGRP1 USP14 LCP2 GP1BA KIF2A GNB4 LCK OLR1 PREP LTA4H ZFPM2 LYN ACTN2 SIRT6 APOC1 PRKCD ITGAM DGKH LTF MAFF KCNIP2 PCLO DOCK10 SH2B3 RABIF SRC HPCAL4 CD46 PRDM4 GNAI3 C9 PPP2CB IRF2 FYN JAK2 PLA2G4A PRCP USP8 RHOG L3MBTL4 LAMP2 PIM1 CXCL1 F3 GNAI2 CASP9 XPNPEP1 PLSCR1 IRF7 CD55 HSPA5 GNB2 DYRK2 PLA2G7 S100A12 GRB2 PHEX GNGT2 DOCK4 MMP12 KCNIP3 FDX1 TIMP2 MMP8 FCER1G ANXA5 GCA EHD1 PRSS3 COL4A2 CSRP1 PIK3R5 SERPINC1 ANG APOBEC3F GATA3 DUSP5 CASP3 USP16 CP PSEN1 LIPA PCSK9 DGKG GNG2 ME1 GMFB SCG3 PPP4C CCL5 CTSH F8 APOA4 IL6 AKAP10 ERAP2 VCPIP1 RAF1 NOTCH4 ADRA2B CEBPB HNF4A LGALS3 TNFAIP3 CDH13 ITIH1 TFPI2 PIK3CG S100A13
kfs-all: 7 of 200 genes missing from data set analyzed in set HALLMARK_COMPLEMENT: CTSL1 USP15 PGCP SEPX1 ZFYVE20 CTSL2 HSPA1A
kfs-all: 106 of 113 genes from data set analyzed in set HALLMARK_UNFOLDED_PROTEIN_RESPONSE: ATF4 HERPUD1 PARN EXOSC4 HSP90B1 XBP1 EXOSC9 HSPA5 ATF3 EXOSC1 EXOSC5 ASNS ARFGAP1 WFS1 SRPRB DNAJB9 TSPYL2 NFYA CALR KHSRP DNAJC3 EXOSC2 NOP14 ATF6 HYOU1 RRP9 CXXC1 IGFBP1 CNOT4 DCP2 PDIA6 ATP6V0D1 PREB SEC31A GOSR2 SERP1 NFYB NHP2 DCTN1 SLC7A5 SSR1 EDEM1 EDC4 EIF2AK3 MTHFD2 NOLC1 ERN1 FKBP14 ZBTB17 WIPI1 YIF1A CCL2 EIF4EBP1 EIF2S1 TATDN2 XPOT LSM4 CHAC1 STC2 LSM1 SDAD1 EIF4A2 EIF4E IARS DDX10 GEMIN4 TARS ALDH18A1 DDIT4 HSPA9 SEC11A EIF4A3 POP4 CEBPG BAG3 KDELR3 CEBPB CNOT2 SHC1 SPCS3 H2AFX SLC1A4 RPS14 NPM1 CNOT6 CKS1B PSAT1 EIF4G1 YWHAZ SLC30A5 SKIV2L2 KIF5B DCP1A IFIT1 IMP3 SPCS1 DNAJA4 VEGFA TTC37 TUBB2A FUS EXOSC10 EEF2 EXOC2 PAIP1 BANF1
kfs-all: 7 of 113 genes missing from data set analyzed in set HALLMARK_UNFOLDED_PROTEIN_RESPONSE: NOP56 SRPR DKC1 EIF4A1 PDIA5 OBFC2A ERO1L
kfs-all: 104 of 105 genes from data set analyzed in set HALLMARK_PI3K_AKT_MTOR_SIGNALING: MAPK8 PIK3R3 GRB2 NFKBIB MAP2K6 MAPK9 AKT1 MAPK1 PLCG1 TRIB3 GSK3B CDKN1A RAC1 RIPK1 AKT1S1 ACTR2 PRKAR2A YWHAB HRAS PDK1 PIKFYVE TBK1 ACTR3 E2F1 MYD88 ITPR2 SQSTM1 RPS6KA1 PTPN11 MAPKAP1 PLCB1 RAF1 CAMK4 RPTOR CFL1 CDK4 TRAF2 GNGT1 UBE2N ADCY2 CDKN1B VAV3 FGF6 ECSIT RALB ARF1 MKNK1 CDK1 PTEN ARHGDIA ADRBK1 FGF17 DDIT3 IRAK4 TIAM1 CDK2 SFN PRKCB GNA14 EIF4E CLTC TSC2 FGF22 PPP1CA DUSP3 HSP90B1 IL4 STAT2 SLA EGFR PLA2G12A MAPK10 CALR THEM4 RIT1 MKNK2 PPP2R1B CAB39L ARPC3 PITX2 NCK1 IL2RG PFN1 FASLG NOD1 DAPP1 UBE2D3 CAB39 AP2M1 MAP3K7 PRKAG1 CSNK2B PRKAA2 ATF1 SLC2A1 PIN1 TNFRSF1A LCK RPS6KA3 NGF CXCR4 ACACA SMAD2 PAK4
kfs-all: 1 of 105 genes missing from data set analyzed in set HALLMARK_PI3K_AKT_MTOR_SIGNALING: MAP2K3
kfs-all: 194 of 200 genes from data set analyzed in set HALLMARK_MTORC1_SIGNALING: DDIT4 CALR HK2 PGK1 SLC7A5 CTSC ACSL3 SLC1A5 M6PR TFRC DDIT3 TMEM97 IFRD1 PLOD2 TUBA4A PSAT1 CORO1A LDHA MTHFD2 FADS2 VLDLR WARS SCD P4HA1 ACTR2 IDH1 SLC2A1 GBE1 SERPINH1 NUPR1 PSMG1 PSPH NAMPT CDKN1A BHLHE40 HSPA9 HSPA5 EGLN3 LGMN PNP XBP1 SLA DDX39A HSPE1 ACLY SLC7A11 SSR1 GLA SQSTM1 PDK1 PSMC2 PRDX1 SERP1 TRIB3 NFIL3 HMGCS1 GOT1 TPI1 ELOVL6 ASNS PSMD14 PSMA4 PPA1 HPRT1 AURKA HMGCR GAPDH DHFR DHCR7 IMMT UCHL5 YKT6 INSIG1 SQLE IGFBP5 FGL2 ENO1 IDI1 CYB5B SHMT2 TXNRD1 G6PD SLC9A3R1 RAB1A EBP PNO1 PIK3R3 ACTR3 LDLR SLC2A3 UBE2D3 ELOVL5 CACYBP EDEM1 ATP6V1D TES TM7SF2 PSMA3 ITGB2 AK4 SLC1A4 TOMM40 SLC6A6 PPIA ADD3 ME1 CCNF SLC37A4 ALDOA BTG2 UFM1 CCNG1 STC1 NMT1 PSMC6 FDXR RRM2 DHCR24 PSMC4 CTH PSME3 CFP POLR3G ACACA QDPR MCM2 PSMD12 CANX RPN1 HSPA4 FAM129A TBK1 SEC11A BCAT1 PSMB5 PSMD13 PGM1 PLK1 GLRX COPS5 ETF1 GSK3B NUP205 SORD PHGDH GMPS RRP9 EEF1E1 LTA4H SDF2L1 FKBP2 RDH11 CXCR4 MLLT11 GCLC TCEA1 HSPD1 SYTL2 MCM4 PPP1R15A USO1 NFKBIB UNG GTF2H1 RPA1 HSP90B1 GSR PITPNB EPRS SRD5A1 TUBG1 MTHFD2L ADIPOR2 NUFIP1 CDC25A PDAP1 STARD4 BUB1 ARPC5L GPI EIF2S2 CD9 ATP2A2 GGA2 HMBS RIT1 SKAP2 STIP1 DAPP1 ABCF2 NFYC ATP5G1 PFKL CCT6A
kfs-all: 6 of 200 genes missing from data set analyzed in set HALLMARK_MTORC1_SIGNALING: FADS1 IFI30 CYP51A1 SC5DL MAP2K3 ERO1L
kfs-all: 194 of 200 genes from data set analyzed in set HALLMARK_E2F_TARGETS: AURKA BRCA2 CCP110 CENPE CKS2 DCLRE1B DNMT1 DONSON EED GINS1 GINS4 H2AFZ LIG1 MAD2L1 MCM2 MCM4 MCM5 MCM7 MELK NAA38 NASP NUDT21 NUP205 ORC6 PCNA PLK4 POLE PRIM2 RAD51AP1 RFC2 RPA2 RPA3 SUV39H1 TMPO UBE2T WDR90 CDK1 MCM3 TOP2A MCM6 BIRC5 CCNB2 RRM2 HMGB2 BUB1B RFC3 EZH2 CHEK1 SMC4 MKI67 CDC20 PLK1 KIF2C DLGAP5 AURKB CDC25A TRIP13 H2AFX HMMR E2F8 BRCA1 MYBL2 POLD1 RACGAP1 CKS1B KPNA2 MSH2 CDKN3 ATAD2 RPA1 STMN1 TIPIN TK1 CDCA8 ESPL1 NCAPD2 RANBP1 MRE11A KIF4A LMNB1 KIF22 UNG SMC1A CCNE1 CDCA3 ASF1B POLA2 TIMELESS HELLS UBE2S PRKDC RAN USP1 SPAG5 POLD3 DUT TACC3 KIF18B CDC25B SRSF1 GINS3 NOLC1 SLBP CHEK2 SPC25 BARD1 DCTPP1 SMC3 RNASEH2A DEK CENPM RAD51C CBX5 RFC1 POLD2 DSCC1 ILF3 DEPDC1 DCK CDKN2C MYC TCF19 RAD1 LBR NBN PTTG1 UBR7 POLE4 TUBG1 CTCF RQCD1 TUBB SMC6 ZW10 PA2G4 SSRP1 NAP1L1 ANP32E HMGB3 IPO7 RAD21 CDK4 CDKN1A BRMS1L RAD50 TRA2B CSE1L PAICS STAG1 LUC7L3 PPM1D NME1 XPO1 HNRNPD ASF1A EXOSC8 MLH1 NUP107 ORC2 TP53 TFRC HMGA1 PSIP1 DDX39A SNRPB CDKN1B MTHFD2 WEE1 PRDX4 PHF5A TBRG4 SHMT1 PRPS1 DIAPH3 NUP153 PSMC3IP XRCC6 PNN HUS1 RBBP7 PDS5B MXD3 PPP1R8 GSPT1 CDKN2A AK2 ING3 HN1 POP7 SYNCRIP EIF2S1 LYAR PAN2 SPC24
kfs-all: 6 of 200 genes missing from data set analyzed in set HALLMARK_E2F_TARGETS: MMS22L CTPS SRSF2 PMS2 NOP56 CIT
kfs-all: 191 of 200 genes from data set analyzed in set HALLMARK_MYC_TARGETS_V1: PCNA PSMD8 PSMD7 SET SNRPA1 RAN G3BP1 STARD7 NPM1 BUB3 EIF3D XPO1 FBL CANX NAP1L1 CBX3 CCT3 C1QBP U2AF1 UBE2L3 SSBP1 SRSF1 MCM2 EIF3B PSMD14 SNRPA PWP1 APEX1 TXNL4A HNRNPR PSMB2 HPRT1 MCM6 NME1 SNRPD1 HSPD1 CAD RPL18 PGK1 DDX18 RPS2 LDHA RUVBL2 RNPS1 EIF2S1 RANBP1 MCM5 IARS UBE2E1 MYC AP3S1 RFC4 DUT PSMA4 RPS3 SNRPG PHB2 SSB EIF4H SRSF3 CCT4 TFDP1 EIF2S2 CDK4 SNRPD3 PSMD1 GOT2 PABPC4 CCT5 PRPS2 ACP1 PRPF31 CCT2 KARS DEK EIF4G2 XPOT SRM UBA2 KPNB1 PSMA7 TRA2B COX5A PA2G4 PCBP1 HNRNPA1 CCNA2 PPIA EIF3J ORC2 PSMA2 SYNCRIP HDAC2 LSM2 VBP1 CNBP CDK2 TARDBP NOLC1 GSPT1 HNRNPA2B1 ETF1 RPL6 PTGES3 PSMA1 PSMC6 HSPE1 FAM120A PPM1G HNRNPD SERBP1 CSTF2 PRDX4 EIF4E ODC1 USP1 RPL22 HNRNPA3 NCBP1 RPLP0 ABCE1 EIF1AX YWHAE MCM7 YWHAQ VDAC1 SMARCC1 SNRPD2 HNRNPU HDDC2 PSMD3 RRM1 SF3A1 LSM7 ERH RPL14 PSMB3 IFRD1 NCBP2 GLO1 NDUFAB1 CUL1 NHP2 CLNS1A TRIM28 RSL1D1 HNRNPC COPS5 XRCC6 SLC25A3 MRPL9 POLE3 POLD2 H2AFZ AIMP2 PRDX3 MRPS18B EPRS KPNA2 HSP90AB1 RPL34 SRPK1 MAD2L1 DHX15 MCM4 RPS5 CCT7 HDGF RPS6 SNRPB2 PSMC4 CDC20 TUFM RRP9 CDC45 TYMS ILF2 VDAC3 IMPDH2 SF3B3 NOP16 SRSF7 GNL3 EXOSC7 MRPL23 RAD23B RPS10 PHB DDX21 CYC1 PABPC1
kfs-all: 9 of 200 genes missing from data set analyzed in set HALLMARK_MYC_TARGETS_V1: SRSF2 EIF4A1 TCP1 EEF1B2 GNB2L1 PSMA6 TOMM70A CTPS NOP56
kfs-all: 56 of 58 genes from data set analyzed in set HALLMARK_MYC_TARGETS_V2: SLC19A1 MRTO4 TMEM97 RRP9 PES1 TFB2M EXOSC5 IPO4 NDUFAF4 NOC4L MYC SRM PA2G4 GNL3 NOLC1 WDR43 RABEPK NOP16 TBRG4 DDX18 NIP7 WDR74 BYSL HSPD1 PLK4 NOP2 RCL1 NPM1 AIMP2 RRP12 PPRC1 TCOF1 MCM5 HK2 CBX3 PLK1 PHB MCM4 CDK4 DUSP2 MYBBP1A UTP20 PRMT3 FARSA MAP3K6 LAS1L PUS1 HSPE1 SLC29A2 DCTPP1 SUPV3L1 SORD IMP4 GRWD1 UNG MPHOSPH10
kfs-all: 2 of 58 genes missing from data set analyzed in set HALLMARK_MYC_TARGETS_V2: PPAN NOP56
kfs-all: 196 of 200 genes from data set analyzed in set HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION: COL3A1 COL5A2 COL5A1 FBN1 COL1A1 FN1 COL6A3 SERPINE1 COL1A2 COL4A1 COL4A2 VCAN IGFBP3 TGFBI SPARC LUM LAMC1 LOX LAMC2 CTGF TAGLN COL7A1 LOXL2 COL6A2 ITGAV THBS2 COL16A1 NNMT TPM1 CDH2 MMP2 COL11A1 THBS1 FAP BGN SERPINH1 FSTL1 POSTN THY1 SPP1 TNC TFPI2 NID2 ITGB5 MMP3 VIM LOXL1 FBLN5 COL12A1 ELN CDH11 COMP SPOCK1 BMP1 IL32 LAMA3 TIMP1 QSOX1 TIMP3 VCAM1 CYR61 EDIL3 CALD1 MAGEE1 FBLN1 SGCB ECM1 LAMA2 FSTL3 TPM2 INHBA DAB2 EMP3 BASP1 ITGA5 MGP VEGFA CXCL1 WNT5A SDC1 PLOD2 PCOLCE GREM1 ITGB1 COL5A3 RHOB HTRA1 FGF2 SNTB1 GADD45A MEST LRRC15 TNFRSF11B CD59 ACTA2 EFEMP2 MATN2 PCOLCE2 SERPINE2 GPC1 ABI3BP FUCA1 SLIT3 LAMA1 PMEPA1 COL8A2 FBN2 IGFBP2 PFN2 SDC4 CD44 GADD45B GLIPR1 ANPEP VEGFC MMP14 SGCD PLOD1 MATN3 MYL9 SLC6A8 CALU PRRX1 TNFRSF12A FMOD ID2 GEM PLAUR MYLK TGFB1 SFRP1 PLOD3 IL6 APLP1 FBLN2 MSX1 PTX3 JUN FERMT2 DKK1 SNAI2 DST TPM4 DCN GJA1 PMP22 IGFBP4 COPA LRP1 ITGA2 FLNA MFAP5 PTHLH TGFBR3 SFRP4 LGALS1 RGS4 CDH6 SAT1 NT5E DPYSL3 PPIB TGM2 SGCG ITGB3 PDLIM4 CTHRC1 ECM2 CRLF1 AREG IL15 MCM7 GAS1 PRSS2 CADM1 OXTR SCG2 CXCL6 MMP1 TNFAIP3 CAPG CAP2 MXRA5 FOXC2 NTM ENO2 FAS BDNF ADAM12 PVR CXCL12 PDGFRB SLIT2 NOTCH2 GPX7 WIPF1
kfs-all: 4 of 200 genes missing from data set analyzed in set HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION: IL8 LEPRE1 FZD8 GLT25D1
kfs-all: 197 of 200 genes from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: CXCL10 CCL2 CCL5 FPR1 CCL20 IL1A CCL7 CCL22 CXCL11 CCR7 EDN1 CD40 CXCL9 IL6 IL1B TLR2 IL1R1 CD69 ICAM1 CCRL2 AQP9 EREG C3AR1 GNA15 CMKLR1 PTGER4 LIF IL15 NAMPT OPRK1 ITGB8 PTAFR ADM PLAUR NFKB1 INHBA OSM TNFSF10 TNFSF15 IFNGR2 IL12B CSF1 CXCL6 TNFRSF9 LYN ACVR2A LDLR BDKRB1 HRH1 F3 BST2 PTGIR CD55 CALCRL CSF3 GPR132 IL4R NLRP3 IL15RA ADORA2B GCH1 OLR1 PTGER2 CSF3R MYC RELA TNFAIP6 IL7R IL18 GABBR1 CD82 TNFSF9 NMUR1 IL2RB TLR1 LPAR1 IRAK2 RIPK2 MMP14 P2RX7 SLC11A2 SELL P2RY2 ABCA1 FFAR2 PROK2 GNAI3 TACR1 SLC7A1 CDKN1A CYBB TIMP1 HBEGF SCARF1 EBI3 NFKBIA SRI SLC7A2 CCL17 TLR3 APLNR OSMR IL10RA PSEN1 GPR183 ATP2B1 TNFRSF1B BEST1 GPC3 SCN1B ACVR1B HPN SEMA4D KLF6 CD48 CXCR6 SLC1A2 GP1BA TAPBP RGS16 SLAMF1 LCK HIF1A AHR NMI RHOG TPBG NPFFR2 IFNAR1 ICOSLG RASGRP1 IFITM1 KCNJ2 LY6E IL18R1 IL10 KCNA3 HAS2 DCBLD2 LAMP3 VIP CD70 RGS1 SLC31A1 ADRM1 KCNMB2 SERPINE1 MXD1 AXL MEFV PVR CCL24 PDE4B LCP2 PDPN IRF7 MET ATP2A2 SLC31A2 FZD5 ITGA5 SGMS2 MARCO CD14 EIF2AK2 ROS1 ATP2C1 NDP BTG2 MSR1 PTPRE RNF144B PCDH7 SPHK1 IL18RAP RTP4 RAF1 CHST2 ITGB3 KIF1B SELE NOD2 C5AR1 EMP3 CLEC5A TACR3 SLC4A4 MEP1A LTA PIK3R5 STAB1 IRF1 ICAM4 P2RX4 ABI1 CX3CL1 SLC28A2
kfs-all: 3 of 200 genes missing from data set analyzed in set HALLMARK_INFLAMMATORY_RESPONSE: IL8 EMR1 SELS
kfs-all: 197 of 200 genes from data set analyzed in set HALLMARK_XENOBIOTIC_METABOLISM: CYP1A1 FAH DCXR CYP1A2 GSTA3 CYP2J2 CYP27A1 ADH1C UGDH ASL NQO1 ALAS1 GSTM4 CYP2C18 PTS CYB5A ACOX2 EPHX1 LCAT SLC35D1 GSS FMO3 IDH1 AKR1C3 SLC22A1 GSTO1 ARG1 CDO1 FMO1 ALDH9A1 POR NDRG2 UPB1 ECH1 PTGES PDK4 AHCY COMT AOX1 CFB DDAH2 HGFAC F11 CYP26A1 MCCC2 SERPINA6 GNMT BLVRB HACL1 MAOA KYNU DHPS SERPINE1 SLC6A12 GCH1 DHRS7 PAPSS2 ALDH2 HSD11B1 SLC35B1 KARS CA2 LPIN2 CAT CYP2S1 RAP1GAP FBP1 RBP4 GCKR CDA MTHFD1 ADH7 DHRS1 VNN1 CNDP2 SLC6A6 FETUB CROT GAD1 AKR1C2 IGF1 SSR3 GABARAPL1 TMBIM6 CD36 CES1 SHMT2 TMEM176B GSTT2 PLG HMOX1 SPINT2 ALDH3A1 GSR ABHD6 XDH PPARD ELOVL5 CYP4F2 RETSAT CYFIP2 PINK1 GCLC ESR1 PMM1 TDO2 MT2A ATP2A2 FABP1 ACP2 ABCD2 G6PC DDC ACOX3 SAR1B FBLN1 ADH5 CRP ABCC2 ETS2 NPC1 CASP6 BPHL IL1R1 ENTPD5 TNFRSF1A IGFBP4 PYCR1 CSAD ID2 ETFDH HRG TYR UPP1 BCAR1 CBR1 APOE SLC12A4 TMEM97 SLC46A3 PTGDS MPP2 PTGR1 AQP9 EPHA2 PSMB10 FAS ACOX1 GART HPRT1 PGD ABCC3 SMOX TTPA HES6 GCNT2 MAN1A1 IGFBP1 ITIH4 PROS1 TPST1 LEAP2 NFS1 PGRMC1 CYP17A1 ARPP19 SERTAD1 ARG2 HNF4A REG1A CCL25 PEMT ACO2 LONP1 NMT1 PTGES3 F10 TAT MARCH6 JUP ACP1 MBL2 TGFB2 ENPEP HSD17B2 ANGPTL3 PC PDLIM5 CYP2E1 BCAT1 ATOH8 SLC1A5 IRF8 NINJ1 AP4B1 ACSM1 ITIH1
kfs-all: 3 of 200 genes missing from data set analyzed in set HALLMARK_XENOBIOTIC_METABOLISM: DAK DDT VTN
kfs-all: 153 of 158 genes from data set analyzed in set HALLMARK_FATTY_ACID_METABOLISM: ACAA1 ACAA2 ACADL ACADM ACOT8 ACOX1 ACSL1 ALDH3A2 CCDC58 CPT2 CYP4A11 DECR1 ECH1 ECI1 ELOVL5 FABP1 FABP2 HADH HIBCH HMGCL HSD17B11 IDH1 ME1 MGLL MLYCD PCBD1 RETSAT S100A10 SUCLG1 VNN1 EHHADH ALDH9A1 HADHB ECHS1 ACADS CA2 HSD17B10 ALDH1A1 ACADVL HSD17B4 CA4 ADH1C ADH7 PTS MAOA HAO2 HSD17B7 MCEE ACAT2 AUH HPGD FH HMGCS2 ALAD GPD1 ACO2 CBR1 GRHPR G0S2 MDH2 HSP90AA1 BCKDHB UROS YWHAH LDHA CRYZ RDH16 INMT UGDH GSTZ1 IDH3B MDH1 CRAT ETFDH CD36 ECI2 SDHD ACSL5 HSDL2 HMGCS1 SDHC CD1D GCDH GPD2 ALDH3A1 SLC22A5 PDHB TDO2 FASN NBN PSME1 PPARA NCAPH2 BPHL ODC1 CA6 DLD HCCS EPHX1 FMO1 AOC3 UROD CPT1A UBE2L6 MIF SUCLG2 CPOX SMS CBR3 NTHL1 CIDEA IDI1 AADAT REEP6 HSPH1 APEX1 NSDHL ADIPOR2 ACSL4 ACSS1 ENO3 IDH3G LGALS1 METAP1 ALDOA ACSM3 LTC4S D2HGDH ADSL SUCLA2 SDHA XIST OSTC GLUL GABARAPL1 CYP1A1 PRDX6 ERP29 H2AFZ GAPDHS DHCR24 GAD2 PTPRG IL4I1 TP53INP2 PDHA1 RAP1GDS1 CEL BLVRA SERINC1 BMPR1B RDH11 ENO2
kfs-all: 5 of 158 genes missing from data set analyzed in set HALLMARK_FATTY_ACID_METABOLISM: ACOT2 DLST SETD8 CYP4A22 AQP7
kfs-all: 194 of 200 genes from data set analyzed in set HALLMARK_OXIDATIVE_PHOSPHORYLATION: NDUFS3 UQCRB NDUFS2 SDHA UQCRC1 NDUFA9 NDUFS4 NDUFS1 NDUFA2 SDHB NNT ATP5O ATP5G3 NDUFS7 ATP5A1 NDUFV1 COX5B NDUFA1 ATP5C1 ATP5B COX7B SDHD CYCS NDUFA6 NDUFAB1 COX8A ACO2 ATP5G1 CYC1 NDUFB6 ATP5E COX5A UQCRC2 COX6A1 ATP5D COX6C ATP5J NDUFB3 IDH3B OGDH NDUFB8 SURF1 COX6B1 NDUFB5 NDUFA4 NDUFB1 COX4I1 COX7C UQCRFS1 SDHC ATP6V1F COX7A2 SUCLG1 NDUFS6 NDUFA7 FH NDUFV2 OXA1L NDUFC1 UQCR11 NDUFA5 CS ATP6V1G1 ATP5F1 HCCS HADHB ATP5H PDHA1 NDUFA8 DLD OPA1 SLC25A11 ATP5I PDHB ATP5J2 NDUFB7 IDH2 MTX2 VDAC3 MDH1 ATP5G2 IMMT MDH2 SLC25A3 ATP6V1D VDAC2 ACADM COX7A2L TIMM17A ATP6V1E1 NDUFA3 SLC25A6 IDH3G ACADVL ETFA TIMM9 IDH3A TIMM8B ATP6AP1 TIMM13 UQCRQ ABCB7 VDAC1 ATP5L PHB2 DECR1 SUCLA2 GOT2 DLAT ATP6V1H NDUFB2 FDX1 HADHA ATP6V1C1 MAOB NDUFB4 UQCR10 ETFDH GPX4 PDHX MFN2 AIFM1 ACAA2 ETFB COX11 ECHS1 PMPCA ATP6V0B SLC25A5 COX15 CYB5A ALAS1 SLC25A4 CPT1A SLC25A20 MTRR COX17 CYB5R3 TOMM22 ACAT1 MRPS11 ATP6V0C PDK4 TIMM10 LDHA ECI1 MRPL11 FXN MRPS12 COX10 RHOT1 ACAA1 ACADSB LDHB MRPS30 ATP1B1 BDH2 SLC25A12 TIMM50 MRPL34 ISCA1 MRPL35 IDH1 HSPA9 MRPL15 MRPS15 TCIRG1 ISCU POLR2F NQO2 MRPS22 POR ATP6V0E1 PHYH GPI AFG3L2 HSD17B10 CASP7 PRDX3 MGST3 HTRA2 BCKDHA LRPPRC RETSAT ECH1 RHOT2 BAX MTRF1 GLUD1 SUPV3L1 GRPEL1 PDP1 ALDH6A1 OAT
kfs-all: 6 of 200 genes missing from data set analyzed in set HALLMARK_OXIDATIVE_PHOSPHORYLATION: NDUFS8 UQCRH DLST TOMM70A NDUFC2 BRP44L
kfs-all: 196 of 200 genes from data set analyzed in set HALLMARK_GLYCOLYSIS: PGK1 ALDOA ENO1 TPI1 PFKP ALDOB VEGFA MXI1 HK2 LDHA EXT1 SLC25A10 GUSB PFKFB1 PGAM1 PYGB AK4 P4HA1 PMM2 FAM162A SDC1 EGLN3 PC B4GALT7 FBP2 IGFBP3 CHPF B3GAT3 CHST12 HS2ST1 MPI GNPDA1 AKR1A1 PPFIA4 B3GAT1 CHPF2 G6PD MDH2 CHST6 PGLS PGAM2 CHST1 GPC1 TSTA3 ALG1 GFPT1 PRPS1 GOT1 MDH1 SLC35A3 GALK1 EGFR ANGPTL4 CITED2 PLOD2 QSOX1 ME2 SPAG4 P4HA2 GAPDHS ENO2 GOT2 EXT2 SLC25A13 HMMR PDK3 CXCR4 GPC4 ECD GNE B4GALT2 FUT8 MIOX VCAN GPC3 B3GALT6 HSPA5 ME1 ADORA2B UGP2 MIF NANP ZNF292 STC2 TPST1 PGM2 GYS1 TKTL1 TGFA CHST2 PHKA2 STMN1 GALE MET LCT IRS2 POLR3K B4GALT1 EFNA3 LHX9 KDELR3 TALDO1 DPYSL4 VLDLR CD44 AGL SOX9 DDIT4 IDUA CASP6 GLCE COPB2 DSC2 HS6ST2 CDK1 PLOD1 SDC2 PAXIP1 NSDHL RARS GLRX SRD5A3 SDC3 HDLBP COL5A1 CLDN9 TFF3 STC1 KIF20A GYS2 SLC37A4 LHPP SDHC NASP AURKA B3GNT3 ISG20 LDHC ARPP19 CENPA HOMER1 BIK CYB5A HAX1 COG2 IL13RA1 NOL3 CLDN3 AGRN CLN6 TXN PAM CAPN5 PKP2 ABCB6 DCN GMPPA BPNT1 ANG GPR87 GAL3ST1 ALDH7A1 NT5E IDH1 PYGL NDUFV3 NDST3 PPP2CB PSMC4 TPBG TGFBI GALK2 CTH KIF2A CACNA1H ANKZF1 SAP30 RBCK1 ELF3 RPE B4GALT4 DEPDC1 RRAGD IER3 ALDH9A1 DLD MERTK GCLC FKBP4 SOD1 MED24 AK3 XYLT2 ARTN PPIA CHST4
kfs-all: 4 of 200 genes missing from data set analyzed in set HALLMARK_GLYCOLYSIS: ERO1L PKM2 GMPPB SLC16A3
kfs-all: 47 of 49 genes from data set analyzed in set HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY: GSR PRDX2 TXNRD1 SOD1 GCLC CAT GPX4 MPO PRDX1 PRDX6 GCLM TXN SOD2 PRDX4 PDLIM1 TXNRD2 G6PD MSRA MBP SRXN1 NQO1 OXSR1 GLRX2 HMOX2 FES PFKP NDUFB4 GPX3 SCAF4 CDKN2D MGST1 ABCC1 FTL ATOX1 STK25 EGLN2 ERCC2 SBNO2 JUNB PPP2R4 LSP1 NDUFA6 HHEX GLRX NDUFS2 PRNP IPCEF1
kfs-all: 2 of 49 genes missing from data set analyzed in set HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY: SELS HBXIP
kfs-all: 194 of 200 genes from data set analyzed in set HALLMARK_P53_PATHWAY: CDKN1A BTG2 MDM2 CCNG1 FAS TOB1 GADD45A PHLDA3 TAP1 CDKN2B SFN ZMAT3 DDB2 EI24 PERP DDIT4 ATF3 BAX SESN1 FDXR SAT1 CDKN2A AEN PPM1D FOXO3 BTG1 TXNIP SLC19A2 IER3 TP53 NOTCH1 RRAD DCXR NINJ1 FOS S100A10 FBXW7 PLK3 XPC AK1 TRIAP1 BAK1 CCND2 APAF1 PDGFA NDRG1 RALGDS SERPINB5 DGKA CYFIP2 KLF4 IP6K2 ADA TNFSF9 KLK8 PRKAB1 STOM SOCS1 PLK2 CASP1 RCHY1 PCNA RPS27L RB1 PPP1R15A POLH RAB40C ERCC5 CDH13 DDIT3 TGFB1 FUCA1 HIST3H2A TP63 HSPA4L EPHX1 ABHD4 H2AFJ TRAF4 CTSF IER5 TSC22D1 RGS16 HRAS PVT1 ZFP36L1 SDC1 WRAP73 RAP2B ADCK3 PLXNB2 HEXIM1 PROCR SPHK1 NOL8 DEF6 SP1 JAG2 CCP110 DRAM1 RPL18 CEBPA KIF13B MXD1 TRAFD1 OSGIN1 ANKRA2 HBEGF RAD51C ITGB4 TRIB3 INHBB VAMP8 VWA5A ABAT CTSD PTPRE HINT1 ALOX15B VDR IKBKAP WWP1 NUPR1 TCN2 CDKN2AIP POM121 ZNF365 EPHA2 JUN MAPKAPK3 SLC7A11 SERTAD3 IRAK1 ABCC5 UPP1 CD81 LIF RPL36 FAM162A RNF19B CDK5R1 STEAP3 PITPNC1 SLC35D1 TPRKB RRP8 IL1A PMM1 TPD52L1 GM2A RPS12 EPS8L2 TM4SF1 BLCAP MKNK2 CD82 ST14 TCHH HDAC3 CCNK RHBDF2 NUDT15 TGFA ISCU LDHB TNNI1 FGF13 RXRA APP F2R CLCA2 CGRRF1 CSRNP2 ACVR1B BMP2 GPX2 TM7SF3 ZBTB16 PTPN14 TSPYL2 SLC3A2 S100A4 GLS2 CCND3 PRMT2 NHLH2 BAIAP2 RETSAT LRMP HIST1H1C DNTTIP2 SEC61A1 HMOX1 RAD9A
kfs-all: 6 of 200 genes missing from data set analyzed in set HALLMARK_P53_PATHWAY: PIDD TAX1BP3 IFI30 GNB2L1 KRT17 MXD4
kfs-all: 155 of 158 genes from data set analyzed in set HALLMARK_UV_RESPONSE_UP: NXF1 SLC6A8 BAK1 CDC5L HSPA2 POLR2H ALAS1 TUBA4A C4BPB CCNE1 EPHX1 GRPEL1 ICAM1 FEN1 ARRB2 JUNB DGAT1 ATF3 CASP3 RASGRP1 TMBIM6 FOS TAP1 E2F5 RAB27A CCND3 SLC25A4 SPR CDKN2B SHOX2 OLFM1 IGFBP2 LYN CLTB BCL2L11 LHX2 NFKBIA MSX1 H2AFX NR4A1 GLS CDC34 MMP14 STK25 PDAP1 ABCB1 BSG SEPW1 IRF1 RXRB TFRC PPIF CDKN1C HLA-F CREG1 APOM BMP2 TGFBRAP1 NAT1 CYB5R1 RRAD POLE3 IL6 YKT6 ACAA1 CLCN2 SOD2 PPP1R2 RHOB RET PDLIM3 EPCAM DNAJA1 SULT1A1 CHKA CYP1A1 ATP6V1F CDO1 ALDOA NPTXR EIF2S3 CNP GRINA BID POLG2 IL6ST HYAL2 FOSB MGAT1 NKX2-5 PPAT FURIN MRPL23 HTR7 CXCL2 KLHDC3 PRPF3 DNAJB1 AP2S1 PSMC3 TST SIGMAR1 GCH1 BTG2 CEBPG TARS UROD PARP2 BTG3 DLG4 CHRNA5 NPTX2 ATP6V1C1 AQP3 PLCL1 TYRO3 HMOX1 RPN1 BTG1 FMO1 ASNS DDX21 KCNH2 COL2A1 MAOA TCHH CYB5B HSPA13 GGH GAL NTRK3 PPT1 FGF18 FKBP4 STIP1 EIF5 ENO2 GPX3 PRKACA PRKCD STARD3 MARK2 SLC6A12 SQSTM1 PTPRD MAPK8IP2 CDK2 ONECUT1 RFC4 CA2 TACR3 AMD1 HNRNPU WIZ CCK
kfs-all: 3 of 158 genes missing from data set analyzed in set HALLMARK_UV_RESPONSE_UP: CTSL2 EIF2C2 NUPL1
kfs-all: 140 of 144 genes from data set analyzed in set HALLMARK_UV_RESPONSE_DN: TJP1 NFIB TGFBR3 TFPI MMP16 ABCC1 MAP2K5 AGGF1 PLCB4 MET IRS1 PTPRM AKT3 SIPA1L1 NR1D2 ATRN ANXA2 ADD3 CDKN1B ATXN1 CAP2 PRDM2 FAM179B SDC2 SMAD3 SLC7A1 GCNT1 RND3 NR3C1 YTHDC1 PPARG DLG1 ATP2B4 NIPBL PEX14 MYC RASA2 FZD2 BMPR1A LPAR1 PRKCA MGMT PRKCE RXRA LTBP1 LDLR RBPMS CACNA1A RGS4 COL5A2 PTPN21 PRKAR2B GJA1 BCKDHB ATP5S SERPINE1 AMPH MIOS CITED2 COL1A2 INSIG1 FYN WDR37 ZMIZ1 PMP22 CDON PIK3R3 NOTCH2 SYNJ2 SMAD7 MAP1B PAPD7 PTEN DYRK1A NEK7 SPOP F3 ERBB2 GRK5 DUSP1 VLDLR CAV1 COL11A1 CDC42BPA CDK13 SFMBT1 ADORA2B BHLHE40 COL3A1 KCNMA1 SYNE1 IGF1R CELF2 MTA1 EFEMP1 LAMC1 PHF3 SCAF8 VAV2 PIAS3 ACVR2A NRP1 MRPS31 CYR61 DAB2 MAGI2 ANXA4 COL1A1 DDAH1 PDGFRB ATRX KALRN TGFBR2 PTGFR ATP2C1 ARHGEF9 NFKB1 MGLL FBLN5 PDLIM5 MAPK14 SRI INPP4B IGFBP5 ITGB3 BDNF ID1 SNAI2 SCN8A ATP2B1 FHL2 KIT APBB2 PIK3CD DLC1 MT1E DBP HAS2 SLC22A18 ICA1
kfs-all: 4 of 144 genes missing from data set analyzed in set HALLMARK_UV_RESPONSE_DN: RUNX1 PPAP2B LPHN2 SCHIP1
kfs-all: 35 of 36 genes from data set analyzed in set HALLMARK_ANGIOGENESIS: VCAN POSTN FSTL1 LRPAP1 STC1 LPL VEGFA PF4 THBD FGFR1 TNFRSF21 CCND2 COL5A2 ITGAV SERPINA5 KCNJ8 APP JAG1 COL3A1 SPP1 NRP1 OLR1 PDGFA PTK2 SLCO2A1 PGLYRP1 VAV2 S100A4 MSX1 TIMP1 APOH PRG2 JAG2 LUM CXCL6
kfs-all: 1 of 36 genes missing from data set analyzed in set HALLMARK_ANGIOGENESIS: VTN
kfs-all: 192 of 200 genes from data set analyzed in set HALLMARK_HEME_METABOLISM: ALAS2 PPOX FECH HMBS GYPB ALAD RHD GYPA SELENBP1 BLVRB GYPE GYPC EPB42 SLC4A1 RHAG TAL1 MARCH8 SPTB UROD HBQ1 DCAF11 ERMAP EIF2AK1 CPOX MPP1 GLRX5 TSPAN5 OSBP2 ANK1 NFE2 AHSP SPTA1 BNIP3L SLC22A4 CLIC2 TRAK2 GCLC KEL RANBP10 TRIM10 TSPO2 UROS XK SNCA MARK3 UBAC1 CA1 CA2 BSG FOXO3 KLF1 CDC27 KAT2B NARF GCLM FBXO7 H1F0 HEBP1 HBD NUDT4 FBXO9 RAD23A CROCCP2 TMCC2 BLVRA GATA1 RBM38 PRDX2 RNF123 MINPP1 TNS1 CTSE HDGF XPO7 MKRN1 SMOX TFDP2 MXI1 HBB MOSPD1 SLC25A37 SLC30A1 ABCB6 SLC6A8 TFRC RCL1 TOP1 EPOR TNRC6B ACSL6 GAPVD1 MGST3 SLC30A10 CAT BCAM HBZ PSMD9 ISCA1 PDZK1IP1 ICAM4 MOCOS ADD1 FTCD ADD2 BMP2K BPGM CLCN3 E2F2 HAGH OPTN RAP1GAP CTNS NFE2L1 ELL2 SLC2A1 PIGQ KLF3 EPB41 LAMP2 TMEM9B EZH1 CTSB ATG4A MFHAS1 MYL4 RNF19A BTG2 SLC11A2 ADIPOR1 ASNS DCUN1D1 ALDH1L1 DCAF10 YPEL5 SEC14L1 RIOK3 SIDT2 FOXJ2 TCEA1 VEZF1 LPIN2 PC HBBP1 CCND3 SLC25A38 FAM46C FBXO34 BACH1 NR3C1 AQP3 TRIM58 LMO2 PICALM NCOA4 GDE1 SLC6A9 NNT ARHGEF12 PPP2R5B C3 MARCH2 UCP2 SYNJ1 FN3K ABCG2 DAAM1 AGPAT4 CCDC28A GMPS ACP5 SLC10A3 ALDH6A1 CIR1 RBM5 HTRA2 IGSF3 BTRC PGLS PQLC1 SDCBP LRP10 NEK7 ARL2BP ENDOD1 P4HA2 HTATIP2 SLC7A11 KHNYN MBOAT2 ATP6V0A1 CAST TYR
kfs-all: 8 of 200 genes missing from data set analyzed in set HALLMARK_HEME_METABOLISM: RHCE MAP2K3 EPB49 DARC HIST1H4C JHDM1D USP15 CDR2
kfs-all: 135 of 138 genes from data set analyzed in set HALLMARK_COAGULATION: F2 PROC C1S MMP14 F10 PLG C1R SERPINE1 SERPING1 C2 F12 CFI MMP2 C3 F9 CTSO TMPRSS6 MMP9 PROZ MMP1 CFB BMP1 VWF FGA F11 THBD FURIN MMP11 F8 LGMN HPN CTSB MBL2 F13B TIMP1 MMP8 A2M MMP10 MASP2 FGG C8A PLAU ADAM9 GSN CAPN2 PLAT FN1 CTSH OLR1 SPARC RGN C8B LAMP2 C9 PROS1 CLU F2RL2 CD9 CFH PREP LTA4H GP9 DUSP14 CTSK GDA CASP9 APOC1 CRIP2 KLK8 SERPINC1 ANXA1 ITIH1 PRSS23 FBN1 MST1 F3 KLF7 CTSE ITGB3 CAPN5 CSRP1 KLKB1 MSRB2 TFPI2 MMP3 MEP1A GP1BA APOA1 SERPINA1 TF PEF1 GNG12 SIRT2 COMP HTRA1 MAFF LRP1 PF4 MMP15 RABIF HRG C8G APOC2 SERPINB2 RAPGEF3 CPN1 ITGA2 RAC1 DPP4 WDR1 THBS1 FYN PDGFB SH2B2 PECAM1 MMP7 DUSP6 CPB2 S100A13 CFD DCT ANG C1QA HMGCS2 ISCU PLEK APOC3 P2RY1 USP11 TIMP3 ACOX2 HNF4A S100A1 GNB2 ARF4
kfs-all: 3 of 138 genes missing from data set analyzed in set HALLMARK_COAGULATION: CTSL2 PGCP LEFTY2
kfs-all: 194 of 200 genes from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: SOCS2 CISH PIM1 IL2RA TNFRSF4 SOCS1 TNFRSF9 XBP1 RRAGD HK2 PHLDA1 IL2RB CTLA4 NFIL3 CD83 IKZF2 IL10 TNFRSF18 DHRS3 ECM1 ADAM19 SLC2A3 HIPK2 BATF3 BHLHE40 PTGER2 DENND5A ITIH5 PHTF2 GADD45B NRP1 NCOA3 CD79B AHR TNFRSF1B NDRG1 BCL2L1 GABARAPL1 LIF TIAM1 BMPR2 MAP3K8 RHOB MYC S100A1 CAPG ST3GAL4 PENK IRF4 CST7 WLS TLR7 IKZF4 GBP4 RGS16 SPP1 IL13 SLC29A2 NFKBIZ IL4R MXD1 CSF2 FAH CTSZ ITGAE MUC1 MAPKAPK2 TNFRSF21 NT5E FLT3LG CCND2 TRAF1 LCLAT1 IL3RA CYFIP1 BCL2 FGL2 PRNP PUS1 ITGAV NCS1 DCPS AMACR FAM126B PTH1R ODC1 IGF1R PTCH1 ENO3 CD81 MAFF EMP1 CDKN1C CAPN3 IL1R2 SYT11 TTC39B ANXA4 BATF P4HA1 GPR65 SLC1A5 IGF2R CKAP4 CCR4 CD44 P2RX4 GATA1 KLF6 ARL4A HOPX GPR83 ITGA6 CD48 SELP GLIPR2 SMPDL3A PLSCR1 FURIN SERPINB6 TNFSF11 GPX4 LRRC8C CCNE1 CASP3 SH3BGRL2 SNX9 PLEC BMP2 ICOS ALCAM LTB ENPP1 IL1RL1 MYO1C IFNGR1 PLIN2 IL18R1 AHNAK PRKCH TNFRSF8 SYNGR2 GALM POU2F1 EOMES NOP2 PTRH2 RHOH CDC6 MYO1E CXCL10 SNX14 IRF6 IL10RA MAP6 TNFSF10 SPRED2 SELL SERPINC1 CDCP1 RORA COCH CSF1 F2RL2 CA2 IFITM3 UMPS HUWE1 COL6A1 ABCB1 RNH1 IRF8 GUCY1B3 AHCY PRAF2 GSTO1 TWSG1 CDC42SE2 PLAGL1 APLP1 SPRY4 SCN9A SHE PDCD2L CCND3 LRIG1 SWAP70 SLC39A8 RABGAP1L TGM2 PNP AGER ETV4 CD86
kfs-all: 6 of 200 genes missing from data set analyzed in set HALLMARK_IL2_STAT5_SIGNALING: METTL20 N6AMT2 CCDC164 UCK2 AKAP2 PPAP2A
kfs-all: 109 of 112 genes from data set analyzed in set HALLMARK_BILE_ACID_METABOLISM: SCP2 ABCD3 SLC27A2 HSD3B7 HSD17B4 AKR1D1 ABCD2 PEX1 CYP8B1 PNPLA8 PHYH SLC27A5 CYP7B1 CYP27A1 PEX26 AGXT PEX7 CROT CYP39A1 ABCA3 CYP7A1 HACL1 PIPOX PEX6 SOD1 GNPAT HSD3B1 ABCA2 HAO1 PEX16 ABCD1 ACSL1 MLYCD ABCG8 AQP9 ISOC1 NR1H4 PEX19 NPC1 HSD17B11 AMACR CYP46A1 PEX13 IDH1 PEX11A HSD17B6 EPHX2 PRDX5 PXMP2 BBOX1 FADS2 ALDH9A1 APOA1 OPTN GSTK1 ABCG4 ALDH8A1 NR3C2 ABCA6 RETSAT PECR PEX12 CAT GNMT ABCA9 ACSL5 DHCR24 ABCA8 PFKM DIO1 RXRA FDXR TTR KLF1 SLC29A1 BCAR3 LCK PEX11G SLCO1A2 ALDH1A1 SULT1B1 NR1I2 GC ABCA4 SLC23A1 NUDT12 ABCA1 PAOX SLC22A18 DIO2 RBP1 SLC23A2 ATXN1 GCLM NEDD4 RXRG AR BMP6 SERPINA6 LIPE EFHC1 IDH2 IDI1 CH25H ABCA5 SULT2B1 SOAT2 TFCP2L1 NR0B2
kfs-all: 3 of 112 genes missing from data set analyzed in set HALLMARK_BILE_ACID_METABOLISM: FADS1 LONP2 SLC35B2
kfs-all: 100 of 104 genes from data set analyzed in set HALLMARK_PEROXISOME: ABCD3 ACOT8 ACOX1 ACSL1 ECH1 ECI2 EHHADH GSTK1 HSD17B4 MLYCD PEX11A RETSAT SLC27A2 PEX13 PEX14 SCP2 HSD3B7 GNPAT ABCD2 SLC25A17 PEX2 ACAA1 HAO2 HSD17B11 CRAT PEX11B IDH1 FIS1 PEX6 ABCB4 SOD1 ABCB1 ISOC1 YWHAH EPHX2 ABCD1 HMGCL ACSL5 ALDH9A1 DHCR24 ELOVL5 NUDT19 PRDX5 IDE SLC23A2 PEX5 BCL10 NR1I2 TSPO CNBP MSH2 DHRS3 DIO1 SLC25A4 PRDX1 IDI1 HRAS MVP ABCC8 CLN6 CAT ACSL4 IDH2 ABCC5 SOD2 FDPS ALB STS SMARCC1 ITGB1BP1 SIAH1 SLC25A19 CDK7 RXRG ALDH1A1 UGT2B17 CADM1 SERPINA6 CLN8 RDH11 CTBP1 HSD11B2 TTR ERCC3 ATXN1 SULT2B1 CRABP2 CRABP1 TOP2A SCGB1A1 ERCC1 DLG4 PABPC1 FABP6 ABCB9 CACNA1B SEMA3C VPS4B CEL ESR2
kfs-all: 4 of 104 genes missing from data set analyzed in set HALLMARK_PEROXISOME: LONP2 CTPS SLC35B2 FADS1
kfs-all: 198 of 200 genes from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: PTPRC IL12B TGFB1 IL12A CD3E CD3D CD28 LYN HCLS1 IL18 CRTAM IFNG CD3G CD86 IL10 UBE2N BCL10 CD4 LCK NCK1 C2 HLA-A ITGB2 HLA-DQA1 CD1D CD80 HLA-DRA THY1 TLR1 HLA-G HLA-DMB IL7 IL4 TNF CD247 IL2 HLA-DMA STAT1 IRF4 SRGN INHBA TLR3 ZAP70 CD74 CD40 TRAF2 B2M LTB IFNGR1 CCR5 CD40LG HLA-DOA GLMN IL6 HLA-E CD2 CCL5 FAS FASLG TLR6 PF4 TGFB2 CD79A INHBB ELANE SPI1 MAP3K7 IL15 CTSS CD47 PRF1 IL12RB1 LCP2 SOCS1 CDKN2A STAT4 CD7 HLA-DOB CD8A ICAM1 CCL4 GZMB CSF1 IL11 STAB1 IL2RA NLRP3 CCND3 EIF3A SIT1 IFNAR2 HDAC9 CARTPT TRAT1 CCL22 APBB1 FYB IL1B TIMP1 RPS19 JAK2 KRT1 WARS IFNGR2 CCR2 EREG MMP9 EGFR IL16 CFP WAS ITGAL KLRD1 RARS TLR2 CCND2 IL2RG ETS1 ITK NCR1 MAP4K1 CCL19 PSMB10 RPL39 EIF3J ABCE1 CD8B F2 ELF4 LY86 FCGR2B GBP2 PRKCG RPS9 MTIF2 GZMA AARS CD96 CSK HIF1A CCL2 ICOSLG NPM1 IL4R CCL11 NME1 FLNA GPR65 ACHE EIF3D IGSF6 F2R IL13 TAP1 DARS IRF7 ACVR2A CXCR3 PRKCB CXCL9 PTPN6 NCF4 UBE2D1 LIF CCR1 MBL2 DEGS1 TPD52 AKT1 RIPK2 IKBKB GCNT1 SOCS5 IRF8 TAP2 EIF4G3 ABI1 CCL7 IL2RB BRCA1 FGR IL18RAP MRPL3 CXCL13 CAPG EIF5A GALNT1 ST8SIA4 CCL13 RPL3L LY75 TAPBP NOS2 RPL9 BCAT1 IL9 IL27RA DYRK3
kfs-all: 2 of 200 genes missing from data set analyzed in set HALLMARK_ALLOGRAFT_REJECTION: BCL3 RPS3A
kfs-all: 133 of 135 genes from data set analyzed in set HALLMARK_SPERMATOGENESIS: PDHA2 TSSK2 TNP1 ZPBP DPEP3 ADAM2 ACTL7B GAPDHS LDHC DDX25 PRM2 TCP11 PIAS2 PAPOLB OAZ3 PHF7 ODF1 ACRBP YBX2 CSNK2A2 NAA11 TULP2 ADAD1 SYCP1 DDX4 MLF1 TEKT2 SPATA6 PGK2 HSPA2 ACRV1 CLPB CRISP2 AKAP4 CCNA1 CCT6B PACRG GSG1 THEG HSPA4L CST8 DCC HSPA1L GSTM3 DNAJB8 IL13RA2 CAMK4 LPIN1 ZC3H14 COIL PHKG2 KIF2C RPL39L SLC2A5 PCSK4 AURKA MLLT10 NOS1 ART3 CCNB2 NPHP1 CLGN MAST2 MTOR CDKN3 ZNRF4 AGFG1 SNAP91 PSMG1 CHFR TNP2 EZH2 HBZ ARL4A SLC12A2 BRAF VDAC3 POMC IFT88 TKTL1 NEK2 STAM2 HIST1H1T GMCL1 MTNR1A RFC4 DBF4 PRKAR2A TTK DMC1 NCAPH PEBP1 CHRM4 TOPBP1 SCG5 NEFH MAP7 BUB1 SEPT4 PGS1 NPY5R TSN CDK1 SHE PARP2 TNNI3 PCSK1N IDE GPR182 RAD17 TLE4 ACE SIRT1 HTR5A TALDO1 NF2 CLVS1 CNIH2 GRM8 STRBP ADCYAP1 ALOX15 MEP1B SCG3 GFI1 ELOVL3 IL12RB2 DMRT1 GAD1 CFTR JAM3 IP6K1 HOXB1
kfs-all: 2 of 135 genes missing from data set analyzed in set HALLMARK_SPERMATOGENESIS: TUBA3C FAM164C
kfs-all: 193 of 200 genes from data set analyzed in set HALLMARK_KRAS_SIGNALING_UP: ANGPTL4 ITGA2 SPRY2 HBEGF RBP4 HSD11B1 ETV4 GLRX DUSP6 SCG5 ETV5 ITGB2 AKT2 PPBP G0S2 GABRA3 IRF8 BIRC3 FGF9 DCBLD2 INHBA TFPI TSPAN1 ADAM8 SLPI PRKG2 MMP11 MMP10 TMEM158 TNFAIP3 PRDM1 GALNT3 ETS1 MMP9 WNT7A IGFBP3 SPP1 ETV1 CLEC4A CCND2 TSPAN7 ITGBL1 EMP1 CDADC1 KIF5C TRIB2 SDCCAG8 PCP4 CFHR2 ALDH1A2 NR0B2 ALDH1A3 AMMECR1 SATB1 GUCY1A3 CSF2 APOD TOR1AIP2 CMKLR1 TMEM176B LAPTM5 CD37 CAB39L CIDEA ZNF639 IL1B GYPC LY96 FLT4 SPON1 BMP2 PLEK2 NR1H4 SNAP25 ACE PRRX1 C3AR1 TRAF1 TLR8 ID2 TMEM100 PLAUR GADD45G CBX8 SCN1B PTBP2 NAP1L2 AKAP12 PLAT SCG3 ANO1 IL1RL2 CXCL10 ATG10 YRDC HDAC9 PEG3 SEMA3B TNNT2 LIF CFB BTC PPP1R15A PTPRR CCL20 ARG1 RETN KLF4 MMD PDCD1LG2 HIST1H2BB HOXD11 TRIB1 F2RL1 ANXA10 TSPAN13 MTMR10 CFH LAT2 RELN KCNN4 TMEM176A MAP4K1 PTGS2 IL33 MAFB LCP1 NGF CA2 SERPINA3 RGS16 CTSS USP12 CPE SPARCL1 ABCB1 USH1C CSF2RA BTBD3 IL2RG DNMBP IL10RA EREG EPHB2 FBXO4 CROT MPZL2 ANKH CBR4 DOCK2 GPRC5B RABGAP1L MALL STRN ST6GAL1 PIGR VWA5A PSMB8 F13A1 NRP1 SOX9 JUP ZNF277 EPB41L3 PCSK1N FUCA1 PLVAP ADAM17 AVL9 ADAMDEC1 HKDC1 MAP7 IL7R RBM4 BPGM ENG GFPT2 PLAU GNG11 PTCD2 MAP3K1 CBL CXCR4 NIN IKZF1 MYCN FCER1G PECAM1 SNAP91 EVI5 TNFRSF1B GPNMB TPH1
kfs-all: 7 of 200 genes missing from data set analyzed in set HALLMARK_KRAS_SIGNALING_UP: GPR124 IGF2 ERO1L SLMO2 ELTD1 WDR33 FAM190B
kfs-all: 191 of 200 genes from data set analyzed in set HALLMARK_KRAS_SIGNALING_DN: CDH16 SPTBN2 FGFR3 NOS1 PDE6B SIDT1 NTF3 SCN10A TAS2R4 DTNB HTR1D MAST3 SLC6A3 CLDN8 TGM1 PCDHB1 THRB YPEL1 RYR2 GDNF CAMK1D AMBN LFNG SERPINA10 ALOX12B CALCB FGGY SPRR3 ATP6V1B1 EDN1 UPK3B GAMT RYR1 GPR19 SLC29A3 EDN2 GPRC5C C5 EDAR KCNMB1 FAM46C STAG3 KRT4 SLC25A23 INSL5 GP1BA ABCG4 MYH7 BRDT PTGFR KCNN1 SEPP1 IFI44L PROP1 BMPR1B PDK2 DCC SNCB COL2A1 UGT2B17 DLK2 WNT16 SLC6A14 ITGB1BP2 SLC12A3 YBX2 CKM CPB1 MAGIX ARHGDIG CALML5 KRT1 MTHFR ABCB11 MYOT CELSR2 KLK7 THNSL2 CHRNG NR4A2 CD40LG KRT13 GP2 CD207 CCR8 ZBTB16 PARK2 CPA2 MEFV CCNA1 SLC38A3 KLK8 CYP39A1 KCNQ2 SLC30A3 CHST2 ITIH3 EGF TEX15 CLPS ENTPD7 CLSTN3 CYP11B2 CLDN16 HSD11B2 ADCK3 HNF1A FGF22 TFCP2L1 OXT KCND1 H2AFY2 NRIP2 RGS11 CPEB3 TG PTPRJ NUDT11 FSHB IDUA TNNI3 GTF3C5 TFF2 SSTR4 COPZ2 PDCD1 SLC16A7 KCNE2 MFSD6 KLHDC8A CNTFR IL5 NPHS1 SCGB1A1 CCDC106 PAX3 VPREB1 TSHB CACNA1F AKR1B10 P2RX6 KRT15 PAX4 BTG2 GPR3 GRID2 TCL1A PLAG1 PKP1 IRS4 IL12B EPHA5 SOX10 SNN CACNG1 SPHK2 IGFBP2 CAPN9 TCF7L1 TGFB2 SMPX LYPD3 PNMT SYNPO MX1 IFNG NR6A1 ACTC1 RSAD2 ADRA2C BARD1 HTR1B FGF16 CDKAL1 SHOX2 SGK1 RIBC2 SKIL NGB ASB7 MYO15A SLC5A5 KRT5 TFAP2B CD80 ATP4A ARPP21 SERPINB2 TLX1 EFHD1 P2RY4
kfs-all: 9 of 200 genes missing from data set analyzed in set HALLMARK_KRAS_SIGNALING_DN: PRODH FAM164C MLL2 LGALS7 PPYR1 MSH5 ODZ2 ZFP112 CCDC132
kfs-all: 40 of 40 genes from data set analyzed in set HALLMARK_PANCREAS_BETA_CELLS: PAX6 NEUROD1 ISL1 NKX2-2 PCSK1 NKX6-1 SLC2A2 SEC11A DCX SPCS1 FOXA2 GCK MAFB INS PDX1 ABCC8 IAPP SRP9 NEUROG3 FOXO1 AKT3 GCG DPP4 PAX4 SYT13 SCGN HNF1A STXBP1 CHGA VDR PCSK2 INSM1 SST ELP4 SRPRB PAK3 G6PC2 PKLR LMO2 SRP14
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
Hallmark gene sets that are significant in TCGA:
[1] "HALLMARK_IL6_JAK_STAT3_SIGNALING"   "HALLMARK_INTERFERON_GAMMA_RESPONSE"
[3] "HALLMARK_COMPLEMENT"                "HALLMARK_INFLAMMATORY_RESPONSE"    
[5] "HALLMARK_IL2_STAT5_SIGNALING"       "HALLMARK_ALLOGRAFT_REJECTION"      
[[1]]
pdf 
  2 

[[2]]
pdf 
  2 

[[3]]
pdf 
  2 

[[4]]
pdf 
  2 

[[5]]
pdf 
  2 

[[6]]
pdf 
  2 

HALLMARK_IL6_JAK_STAT3_SIGNALING: A2M, ACVR1B, ACVRL1, BAK1, CBL, CCL7, CCR1, CD14, CD36, CD38, CD44, CD9, CNTFR, CRLF2, CSF1, CSF2, CSF2RA, CSF2RB, CSF3R, CXCL1, CXCL10, CXCL11, CXCL13, CXCL3, CXCL9, DNTT, EBI3, FAS, GRB2, HAX1, HMOX1, IFNAR1, IFNGR1, IFNGR2, IL10RB, IL12RB1, IL13RA1, IL15RA, IL17RA, IL17RB, IL18R1, IL1B, IL1R1, IL1R2, IL2RA, IL2RG, IL3RA, IL4R, IL6, IL6ST, IL7, IL9R, INHBE, IRF1, IRF9, ITGA4, ITGB3, JUN, LEPR, LTB, LTBR, MAP3K8, MYD88, OSMR, PDGFC, PF4, PIK3R5, PIM1, PLA2G2A, PTPN1, PTPN11, PTPN2, REG1A, SOCS1, SOCS3, STAM2, STAT1, STAT2, STAT3, TGFB1, TLR2, TNF, TNFRSF12A, TNFRSF1A, TNFRSF1B, TNFRSF21, TYK2

HALLMARK_INTERFERON_GAMMA_RESPONSE: ADAR, APOL6, ARID5B, ARL4A, AUTS2, B2M, BANK1, BATF2, BPGM, BST2, BTG1, C1R, C1S, CASP1, CASP3, CASP4, CASP7, CASP8, CCL2, CCL5, CCL7, CD274, CD38, CD40, CD69, CD74, CD86, CDKN1A, CFB, CFH, CIITA, CMKLR1, CMPK2, CSF2RB, CXCL10, CXCL11, CXCL9, DDX58, DDX60, DHX58, EIF2AK2, EIF4E3, EPSTI1, FAS, FCGR1A, FGL2, FPR1, FTSJD2, GBP4, GBP6, GCH1, GPR18, GZMA, HERC6, HIF1A, HLA-A, HLA-B, HLA-DMA, HLA-DQA1, HLA-DRB1, HLA-G, ICAM1, IDO1, IFI27, IFI30, IFI35, IFI44, IFI44L, IFIH1, IFIT1, IFIT2, IFIT3, IFITM2, IFITM3, IFNAR2, IL10RA, IL15, IL15RA, IL18BP, IL2RB, IL4R, IL6, IL7, IRF1, IRF2, IRF4, IRF5, IRF7, IRF8, IRF9, ISG15, ISG20, ISOC1, ITGB7, JAK2, KLRK1, LAP3, LATS2, LCP2, LGALS3BP, LY6E, LYSMD2, MARCH1, METTL7B, MT2A, MTHFD2, MVP, MX1, MX2, MYD88, NAMPT, NCOA3, NFKB1, NFKBIA, NLRC5, NMI, NOD1, NUP93, OAS2, OAS3, OASL, OGFR, P2RY14, PARP12, PARP14, PDE4B, PELI1, PFKP, PIM1, PLA2G4A, PLSCR1, PML, PNP, PNPT1, PRIC285, PSMA2, PSMA3, PSMB10, PSMB2, PSMB8, PSMB9, PSME1, PSME2, PTGS2, PTPN1, PTPN2, PTPN6, RAPGEF6, RBCK1, RIPK1, RIPK2, RNF213, RNF31, RSAD2, RTP4, SAMD9L, SAMHD1, SECTM1, SELP, SERPING1, SLAMF7, SLC25A28, SOCS1, SOCS3, SOD2, SP110, SPPL2A, SRI, SSPN, ST3GAL5, ST8SIA4, STAT1, STAT2, STAT3, STAT4, TAP1, TAPBP, TDRD7, TNFAIP2, TNFAIP3, TNFAIP6, TNFSF10, TOR1B, TRAFD1, TRIM14, TRIM21, TRIM25, TRIM26, TXNIP, UBE2L6, UPP1, USP18, VAMP5, VAMP8, VCAM1, WARS, XAF1, XCL1, ZBP1, ZNFX1

HALLMARK_COMPLEMENT: ACTN2, ADAM9, ADRA2B, AKAP10, ANG, ANXA5, APOA4, APOBEC3F, APOBEC3G, APOC1, ATOX1, BRPF3, C1QA, C1QC, C1R, C1S, C2, C3, C4BPB, C9, CA2, CALM1, CALM3, CASP1, CASP10, CASP3, CASP4, CASP5, CASP7, CASP9, CBLB, CCL5, CD36, CD40LG, CD46, CD55, CD59, CDA, CDH13, CDK5R1, CEBPB, CFB, CFH, CLU, COL4A2, CP, CPM, CR1, CR2, CSRP1, CTSB, CTSC, CTSD, CTSH, CTSL1, CTSL2, CTSO, CTSS, CXCL1, DGKG, DGKH, DOCK10, DOCK4, DOCK9, DPP4, DUSP5, DUSP6, DYRK2, EHD1, ERAP2, F10, F2, F3, F5, F7, F8, FCER1G, FCN1, FDX1, FN1, FYN, GATA3, GCA, GMFB, GNAI2, GNAI3, GNB2, GNB4, GNG2, GNGT2, GP1BA, GP9, GPD2, GRB2, GZMA, GZMB, GZMK, HNF4A, HPCAL4, HSPA1A, HSPA5, IL6, IRF1, IRF2, IRF7, ITGAM, ITIH1, JAK2, KCNIP2, KCNIP3, KIF2A, KLK1, KLKB1, KYNU, L3MBTL4, LAMP2, LAP3, LCK, LCP2, LGALS3, LGMN, LIPA, LRP1, LTA4H, LTF, LYN, MAFF, ME1, MMP12, MMP13, MMP14, MMP15, MMP8, MT3, NOTCH4, OLR1, PCLO, PCSK9, PDGFB, PDP1, PFN1, PGCP, PHEX, PIK3CA, PIK3CG, PIK3R5, PIM1, PLA2G4A, PLA2G7, PLAT, PLAUR, PLEK, PLG, PLSCR1, PPP2CB, PPP4C, PRCP, PRDM4, PREP, PRKCD, PRSS3, PRSS36, PSEN1, PSMB9, RABIF, RAF1, RASGRP1, RCE1, RHOG, RNF4, S100A12, S100A13, S100A9, SCG3, SEPX1, SERPINA1, SERPINB2, SERPINC1, SERPINE1, SERPING1, SH2B3, SIRT6, SPOCK2, SRC, STX4, TFPI2, TIMP1, TIMP2, TMPRSS6, TNFAIP3, USP14, USP15, USP16, USP8, VCPIP1, WAS, XPNPEP1, ZEB1, ZFPM2, ZFYVE20

HALLMARK_INFLAMMATORY_RESPONSE: ABCA1, ABI1, ACVR1B, ACVR2A, ADM, ADORA2B, ADRM1, AHR, APLNR, AQP9, ATP2A2, ATP2B1, ATP2C1, AXL, BDKRB1, BEST1, BST2, BTG2, C3AR1, C5AR1, CALCRL, CCL17, CCL2, CCL20, CCL22, CCL24, CCL5, CCL7, CCR7, CCRL2, CD14, CD40, CD48, CD55, CD69, CD70, CD82, CDKN1A, CHST2, CLEC5A, CMKLR1, CSF1, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL6, CXCL9, CXCR6, CYBB, DCBLD2, EBI3, EDN1, EIF2AK2, EMP3, EMR1, EREG, F3, FFAR2, FPR1, FZD5, GABBR1, GCH1, GNA15, GNAI3, GP1BA, GPC3, GPR132, GPR183, HAS2, HBEGF, HIF1A, HPN, HRH1, ICAM1, ICAM4, ICOSLG, IFITM1, IFNAR1, IFNGR2, IL10, IL10RA, IL12B, IL15, IL15RA, IL18, IL18R1, IL18RAP, IL1A, IL1B, IL1R1, IL2RB, IL4R, IL6, IL7R, IL8, INHBA, IRAK2, IRF1, IRF7, ITGA5, ITGB3, ITGB8, KCNA3, KCNJ2, KCNMB2, KIF1B, KLF6, LAMP3, LCK, LCP2, LDLR, LIF, LPAR1, LTA, LY6E, LYN, MARCO, MEFV, MEP1A, MET, MMP14, MSR1, MXD1, MYC, NAMPT, NDP, NFKB1, NFKBIA, NLRP3, NMI, NMUR1, NOD2, NPFFR2, OLR1, OPRK1, OSM, OSMR, P2RX4, P2RX7, P2RY2, PCDH7, PDE4B, PDPN, PIK3R5, PLAUR, PROK2, PSEN1, PTAFR, PTGER2, PTGER4, PTGIR, PTPRE, PVR, RAF1, RASGRP1, RELA, RGS1, RGS16, RHOG, RIPK2, RNF144B, ROS1, RTP4, SCARF1, SCN1B, SELE, SELL, SELS, SEMA4D, SERPINE1, SGMS2, SLAMF1, SLC11A2, SLC1A2, SLC28A2, SLC31A1, SLC31A2, SLC4A4, SLC7A1, SLC7A2, SPHK1, SRI, STAB1, TACR1, TACR3, TAPBP, TIMP1, TLR1, TLR2, TLR3, TNFAIP6, TNFRSF1B, TNFRSF9, TNFSF10, TNFSF15, TNFSF9, TPBG, VIP

HALLMARK_IL2_STAT5_SIGNALING: ABCB1, ADAM19, AGER, AHCY, AHNAK, AHR, AKAP2, ALCAM, AMACR, ANXA4, APLP1, ARL4A, BATF, BATF3, BCL2, BCL2L1, BHLHE40, BMP2, BMPR2, CA2, CAPG, CAPN3, CASP3, CCDC164, CCND2, CCND3, CCNE1, CCR4, CD44, CD48, CD79B, CD81, CD83, CD86, CDC42SE2, CDC6, CDCP1, CDKN1C, CISH, CKAP4, COCH, COL6A1, CSF1, CSF2, CST7, CTLA4, CTSZ, CXCL10, CYFIP1, DCPS, DENND5A, DHRS3, ECM1, EMP1, ENO3, ENPP1, EOMES, ETV4, F2RL2, FAH, FAM126B, FGL2, FLT3LG, FURIN, GABARAPL1, GADD45B, GALM, GATA1, GBP4, GLIPR2, GPR65, GPR83, GPX4, GSTO1, GUCY1B3, HIPK2, HK2, HOPX, HUWE1, ICOS, IFITM3, IFNGR1, IGF1R, IGF2R, IKZF2, IKZF4, IL10, IL10RA, IL13, IL18R1, IL1R2, IL1RL1, IL2RA, IL2RB, IL3RA, IL4R, IRF4, IRF6, IRF8, ITGA6, ITGAE, ITGAV, ITIH5, KLF6, LCLAT1, LIF, LRIG1, LRRC8C, LTB, MAFF, MAP3K8, MAP6, MAPKAPK2, METTL20, MUC1, MXD1, MYC, MYO1C, MYO1E, N6AMT2, NCOA3, NCS1, NDRG1, NFIL3, NFKBIZ, NOP2, NRP1, NT5E, ODC1, P2RX4, P4HA1, PDCD2L, PENK, PHLDA1, PHTF2, PIM1, PLAGL1, PLEC, PLIN2, PLSCR1, PNP, POU2F1, PPAP2A, PRAF2, PRKCH, PRNP, PTCH1, PTGER2, PTH1R, PTRH2, PUS1, RABGAP1L, RGS16, RHOB, RHOH, RNH1, RORA, RRAGD, S100A1, SCN9A, SELL, SELP, SERPINB6, SERPINC1, SH3BGRL2, SHE, SLC1A5, SLC29A2, SLC2A3, SLC39A8, SMPDL3A, SNX14, SNX9, SOCS1, SOCS2, SPP1, SPRED2, SPRY4, ST3GAL4, SWAP70, SYNGR2, SYT11, TGM2, TIAM1, TLR7, TNFRSF18, TNFRSF1B, TNFRSF21, TNFRSF4, TNFRSF8, TNFRSF9, TNFSF10, TNFSF11, TRAF1, TTC39B, TWSG1, UCK2, UMPS, WLS, XBP1

HALLMARK_ALLOGRAFT_REJECTION: AARS, ABCE1, ABI1, ACHE, ACVR2A, AKT1, APBB1, B2M, BCAT1, BCL10, BCL3, BRCA1, C2, CAPG, CARTPT, CCL11, CCL13, CCL19, CCL2, CCL22, CCL4, CCL5, CCL7, CCND2, CCND3, CCR1, CCR2, CCR5, CD1D, CD2, CD247, CD28, CD3D, CD3E, CD3G, CD4, CD40, CD40LG, CD47, CD7, CD74, CD79A, CD80, CD86, CD8A, CD8B, CD96, CDKN2A, CFP, CRTAM, CSF1, CSK, CTSS, CXCL13, CXCL9, CXCR3, DARS, DEGS1, DYRK3, EGFR, EIF3A, EIF3D, EIF3J, EIF4G3, EIF5A, ELANE, ELF4, EREG, ETS1, F2, F2R, FAS, FASLG, FCGR2B, FGR, FLNA, FYB, GALNT1, GBP2, GCNT1, GLMN, GPR65, GZMA, GZMB, HCLS1, HDAC9, HIF1A, HLA-A, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DRA, HLA-E, HLA-G, ICAM1, ICOSLG, IFNAR2, IFNG, IFNGR1, IFNGR2, IGSF6, IKBKB, IL10, IL11, IL12A, IL12B, IL12RB1, IL13, IL15, IL16, IL18, IL18RAP, IL1B, IL2, IL27RA, IL2RA, IL2RB, IL2RG, IL4, IL4R, IL6, IL7, IL9, INHBA, INHBB, IRF4, IRF7, IRF8, ITGAL, ITGB2, ITK, JAK2, KLRD1, KRT1, LCK, LCP2, LIF, LTB, LY75, LY86, LYN, MAP3K7, MAP4K1, MBL2, MMP9, MRPL3, MTIF2, NCF4, NCK1, NCR1, NLRP3, NME1, NOS2, NPM1, PF4, PRF1, PRKCB, PRKCG, PSMB10, PTPN6, PTPRC, RARS, RIPK2, RPL39, RPL3L, RPL9, RPS19, RPS3A, RPS9, SIT1, SOCS1, SOCS5, SPI1, SRGN, ST8SIA4, STAB1, STAT1, STAT4, TAP1, TAP2, TAPBP, TGFB1, TGFB2, THY1, TIMP1, TLR1, TLR2, TLR3, TLR6, TNF, TPD52, TRAF2, TRAT1, UBE2D1, UBE2N, WARS, WAS, ZAP70

Hallmark gene sets that are significant in KFS:
[1] "HALLMARK_IL6_JAK_STAT3_SIGNALING"   "HALLMARK_INTERFERON_GAMMA_RESPONSE"
[3] "HALLMARK_INFLAMMATORY_RESPONSE"     "HALLMARK_ALLOGRAFT_REJECTION"      
[[1]]
pdf 
  2 

[[2]]
pdf 
  2 

[[3]]
pdf 
  2 

[[4]]
pdf 
  2 

Immune gene sets that are significant in TCGA:
[1] "B cells"         "T cells"         "iDC"             "Cytotoxic cells"
[[1]]
pdf 
  2 

[[2]]
pdf 
  2 

[[3]]
pdf 
  2 

[[4]]
pdf 
  2 

Immune gene sets that are significant in KFS:
character(0)
[[1]]
pdf 
  2 

[[2]]
pdf 
  2 

[[3]]
pdf 
  2 

[[4]]
pdf 
  2 

Number of rows analyzed: 20294
Number of columns analyzed: 344
tcga-chemo-infg: 28 of 34 genes from data set analyzed in set B cells: MS4A1 TCL1A HLA-DOB PNOC KIAA0125 CD19 CR2 FCRL2 BLK COCH OSBPL10 TNFRSF17 ABCB4 BLNK GLDC MEF2C SPIB BCL11A GNG7 CD72 MICAL3 BACH2 CCR9 QRSL1 DTNB HLA-DQA1 SCN3A SLC15A2
tcga-chemo-infg: 6 of 34 genes missing from data set analyzed in set B cells: IGHG1 IGHA1 IGHM FAM30A IGKC IGL@
tcga-chemo-infg: 16 of 18 genes from data set analyzed in set T cells: PRKCQ CD3D CD3G CD28 LCK TRAT1 BCL11B CD2 ITM2A SH2D1A CD6 CD96 NCALD GIMAP5 CD3E SKAP1
tcga-chemo-infg: 2 of 18 genes missing from data set analyzed in set T cells: TRBC1 TRA@
tcga-chemo-infg: 16 of 17 genes from data set analyzed in set Cytotoxic cells: KLRD1 KLRF1 GNLY CTSW KLRB1 KLRK1 NKG7 GZMH SIGIRR ZBTB16 RUNX3 APOL3 RORA APBA2 DUSP2 GZMA
tcga-chemo-infg: 1 of 17 genes missing from data set analyzed in set Cytotoxic cells: WHDC1L1
tcga-chemo-infg: 30 of 31 genes from data set analyzed in set iDC: CD1B VASH1 F13A1 CD1E MMP12 FABP4 CLEC10A SYT17 MS4A6A CTNS GUCA1A CARD9 ABCG2 CD1A PPARG RAP1GAP SLC7A8 GSTT1 FZD2 CSF1R HS3ST2 CH25H LMAN2L SLC26A6 BLVRB NUDT9 PREP TM7SF4 TACSTD2 CD1C
tcga-chemo-infg: 1 of 31 genes missing from data set analyzed in set iDC: NM_021941
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
tcga-chemo-infg wnt vs CIRC: t = -7.66668942196379 df = 342 nrow = 344 cor = -0.3829621607261 pval = 1.84617074915233e-13
tcga-chemo-infg tak1 vs CIRC: t = -1.90764957903146 df = 342 nrow = 344 cor = -0.102609400758207 pval = 0.0572738736909823
tcga-chemo-infg wnt vs myc.sig: t = 29.5867669875905 df = 342 nrow = 344 cor = 0.847978818740452 pval = 2.60927229013165e-96

tcga-chemo-infg: Analyzing B cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 14142, n_WT = 219, n_MT = 125, p = 0.608824327411549
tcga-chemo-infg: Analyzing T cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 14788, n_WT = 219, n_MT = 125, p = 0.215001784047338
tcga-chemo-infg: Analyzing iDC vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15012, n_WT = 219, n_MT = 125, p = 0.135588232256003
tcga-chemo-infg: Analyzing Cytotoxic cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 15515, n_WT = 219, n_MT = 125, p = 0.0394550958525481

Computing B cells ~ KRAS
Computing T cells ~ KRAS
Computing iDC ~ KRAS
Computing Cytotoxic cells ~ KRAS
tcga-chemo-infg: Analyzing B cells CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 3646, n_CMS2 = 136, n_CMS1 = 51, p = 0.590257744594369
tcga-chemo-infg: Analyzing T cells CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 5510, n_CMS2 = 136, n_CMS1 = 51, p = 5.90005631157885e-10
tcga-chemo-infg: Analyzing iDC CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 5042, n_CMS2 = 136, n_CMS1 = 51, p = 1.81180338500876e-06
tcga-chemo-infg: Analyzing Cytotoxic cells CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 6170, n_CMS2 = 136, n_CMS1 = 51, p = 2.50075938898689e-16
tcga-chemo-infg: Analyzing B cells CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2119, n_CMS2 = 136, n_CMS3 = 42, p = 0.011630937374654
tcga-chemo-infg: Analyzing T cells CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1555, n_CMS2 = 136, n_CMS3 = 42, p = 8.37622958192056e-06
tcga-chemo-infg: Analyzing iDC CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1943, n_CMS2 = 136, n_CMS3 = 42, p = 0.00177141240326119
tcga-chemo-infg: Analyzing Cytotoxic cells CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1902, n_CMS2 = 136, n_CMS3 = 42, p = 0.00108862545600748
tcga-chemo-infg: Analyzing B cells CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 3337, n_CMS2 = 136, n_CMS4 = 87, p = 4.09703386644407e-08
tcga-chemo-infg: Analyzing T cells CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 3183, n_CMS2 = 136, n_CMS4 = 87, p = 6.08868291028078e-09
tcga-chemo-infg: Analyzing iDC CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1425, n_CMS2 = 136, n_CMS4 = 87, p = 1.23543418179019e-21
tcga-chemo-infg: Analyzing Cytotoxic cells CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 2497, n_CMS2 = 136, n_CMS4 = 87, p = 3.49003740650324e-13


tcga-chemo-infg: Analyzing B cells CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 316, n_CMS2 = 41, n_CMS1 = 12, p = 0.14117982071004
tcga-chemo-infg: Analyzing T cells CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 425, n_CMS2 = 41, n_CMS1 = 12, p = 4.97008627052545e-05
tcga-chemo-infg: Analyzing iDC CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 362, n_CMS2 = 41, n_CMS1 = 12, p = 0.0127125918622032
tcga-chemo-infg: Analyzing Cytotoxic cells CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 468, n_CMS2 = 41, n_CMS1 = 12, p = 5.03779969608335e-08
tcga-chemo-infg: Analyzing B cells CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 281, n_CMS2 = 41, n_CMS3 = 28, p = 0.000247522740949278
tcga-chemo-infg: Analyzing T cells CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 231, n_CMS2 = 41, n_CMS3 = 28, p = 1.35464709131168e-05
tcga-chemo-infg: Analyzing iDC CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 326, n_CMS2 = 41, n_CMS3 = 28, p = 0.00213458170523132
tcga-chemo-infg: Analyzing Cytotoxic cells CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 249, n_CMS2 = 41, n_CMS3 = 28, p = 4.1270926457969e-05
tcga-chemo-infg: Analyzing B cells CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 207, n_CMS2 = 41, n_CMS4 = 27, p = 5.83300583562136e-06
tcga-chemo-infg: Analyzing T cells CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 220, n_CMS2 = 41, n_CMS4 = 27, p = 1.40752849169632e-05
tcga-chemo-infg: Analyzing iDC CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 100, n_CMS2 = 41, n_CMS4 = 27, p = 3.91220507578672e-10
tcga-chemo-infg: Analyzing Cytotoxic cells CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 145, n_CMS2 = 41, n_CMS4 = 27, p = 4.0849562748099e-08

tcga-chemo-infg: Analyzing B cells CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1408, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.0105875016949902
tcga-chemo-infg: Analyzing T cells CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1472, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.0242889188167093
tcga-chemo-infg: Analyzing iDC CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1525, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.0453715531917853
tcga-chemo-infg: Analyzing Cytotoxic cells CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1197, n_CMS2-MT = 41, n_CMS2-WT = 95, p = 0.000375652180260398
tcga-chemo-infg: Analyzing B cells CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 176, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 0.14117982071004
tcga-chemo-infg: Analyzing T cells CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 67, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 4.97008627052545e-05
tcga-chemo-infg: Analyzing iDC CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 130, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 0.0127125918622032
tcga-chemo-infg: Analyzing Cytotoxic cells CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 24, n_CMS2-MT = 41, n_CMS1-MT = 12, p = 5.03779969608335e-08
tcga-chemo-infg: Analyzing B cells CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 619, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 0.0831673422112597
tcga-chemo-infg: Analyzing T cells CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 198, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 4.48399971362052e-10
tcga-chemo-infg: Analyzing iDC CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 286, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 2.19475132086228e-07
tcga-chemo-infg: Analyzing Cytotoxic cells CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 96, n_CMS2-MT = 41, n_CMS1-WT = 39, p = 1.8334861555091e-14
tcga-chemo-infg: Analyzing B cells CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 281, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.000247522740949278
tcga-chemo-infg: Analyzing T cells CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 231, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 1.35464709131168e-05
tcga-chemo-infg: Analyzing iDC CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 326, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 0.00213458170523132
tcga-chemo-infg: Analyzing Cytotoxic cells CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 249, n_CMS2-MT = 41, n_CMS3-MT = 28, p = 4.1270926457969e-05
tcga-chemo-infg: Analyzing B cells CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 186, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.0514162621640302
tcga-chemo-infg: Analyzing T cells CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 74, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 1.02420664791121e-05
tcga-chemo-infg: Analyzing iDC CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 125, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.00129532678767785
tcga-chemo-infg: Analyzing Cytotoxic cells CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 108, n_CMS2-MT = 41, n_CMS3-WT = 14, p = 0.000323079231856952
tcga-chemo-infg: Analyzing B cells CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 207, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 5.83300583562136e-06
tcga-chemo-infg: Analyzing T cells CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 220, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 1.40752849169632e-05
tcga-chemo-infg: Analyzing iDC CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 100, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 3.91220507578672e-10
tcga-chemo-infg: Analyzing Cytotoxic cells CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 145, n_CMS2-MT = 41, n_CMS4-MT = 27, p = 4.0849562748099e-08
tcga-chemo-infg: Analyzing B cells CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 492, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 3.39341057249629e-07
tcga-chemo-infg: Analyzing T cells CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 460, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 1.02932159398518e-07
tcga-chemo-infg: Analyzing iDC CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 130, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 2.880452428865e-14
tcga-chemo-infg: Analyzing Cytotoxic cells CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 273, n_CMS2-MT = 41, n_CMS4-WT = 60, p = 3.72390109821599e-11

Computing linear model with interaction for B cells
Computing linear model with interaction for T cells
Computing linear model with interaction for iDC
Computing linear model with interaction for Cytotoxic cells
Computing linear model for B cells
Computing linear model for T cells
Computing linear model for iDC
Computing linear model for Cytotoxic cells
tcga-chemo-infg: Analyzing B cells CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 766, n_MT = 27, n_WT = 60, p = 0.689819990251981
tcga-chemo-infg: Analyzing T cells CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 743, n_MT = 27, n_WT = 60, p = 0.541784028001671
tcga-chemo-infg: Analyzing iDC CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 805, n_MT = 27, n_WT = 60, p = 0.967067781377182
tcga-chemo-infg: Analyzing Cytotoxic cells CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 848, n_MT = 27, n_WT = 60, p = 0.730807799331991
tcga-chemo-infg: Analyzing B cells CMS1 MT vs WT using Wilcoxon rank sum test: W = 228, n_MT = 12, n_WT = 39, p = 0.90409718886891
tcga-chemo-infg: Analyzing T cells CMS1 MT vs WT using Wilcoxon rank sum test: W = 243, n_MT = 12, n_WT = 39, p = 0.852268856376717
tcga-chemo-infg: Analyzing iDC CMS1 MT vs WT using Wilcoxon rank sum test: W = 235, n_MT = 12, n_WT = 39, p = 0.991261191254726
tcga-chemo-infg: Analyzing Cytotoxic cells CMS1 MT vs WT using Wilcoxon rank sum test: W = 237, n_MT = 12, n_WT = 39, p = 0.95632638100914
tcga-chemo-infg: Analyzing B cells CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2487, n_MT = 41, n_WT = 95, p = 0.0105875016949902
tcga-chemo-infg: Analyzing T cells CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2423, n_MT = 41, n_WT = 95, p = 0.0242889188167093
tcga-chemo-infg: Analyzing iDC CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2370, n_MT = 41, n_WT = 95, p = 0.0453715531917853
tcga-chemo-infg: Analyzing Cytotoxic cells CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 2698, n_MT = 41, n_WT = 95, p = 0.000375652180260398
tcga-chemo-infg: Analyzing B cells CMS3 MT vs WT using Wilcoxon rank sum test: W = 166, n_MT = 28, n_WT = 14, p = 0.435894904638578
tcga-chemo-infg: Analyzing T cells CMS3 MT vs WT using Wilcoxon rank sum test: W = 250, n_MT = 28, n_WT = 14, p = 0.155172652157564
tcga-chemo-infg: Analyzing iDC CMS3 MT vs WT using Wilcoxon rank sum test: W = 208, n_MT = 28, n_WT = 14, p = 0.761829135682588
tcga-chemo-infg: Analyzing Cytotoxic cells CMS3 MT vs WT using Wilcoxon rank sum test: W = 217, n_MT = 28, n_WT = 14, p = 0.588696775886163

Computing linear model for B cells
Computing linear model for T cells
Computing linear model for iDC
Computing linear model for Cytotoxic cells
Computing rectum vs left
tcga-chemo-infg: Analyzing B cells site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 4066, n_rectum = 60, n_left = 133, p = 0.833510615444619
tcga-chemo-infg: Analyzing T cells site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3216, n_rectum = 60, n_left = 133, p = 0.0312779426199101
tcga-chemo-infg: Analyzing iDC site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 4093, n_rectum = 60, n_left = 133, p = 0.775358744641715
tcga-chemo-infg: Analyzing Cytotoxic cells site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 3424, n_rectum = 60, n_left = 133, p = 0.115390112018811
Computing right vs left
tcga-chemo-infg: Analyzing B cells site: right vs leftWilcoxon rank sum test with continuity correction: W = 9089, n_right = 148, n_left = 133, p = 0.268549316753168
tcga-chemo-infg: Analyzing T cells site: right vs leftWilcoxon rank sum test with continuity correction: W = 6974, n_right = 148, n_left = 133, p = 2.48543102236533e-05
tcga-chemo-infg: Analyzing iDC site: right vs leftWilcoxon rank sum test with continuity correction: W = 8504, n_right = 148, n_left = 133, p = 0.0492360591533541
tcga-chemo-infg: Analyzing Cytotoxic cells site: right vs leftWilcoxon rank sum test with continuity correction: W = 6998, n_right = 148, n_left = 133, p = 2.90445547761562e-05

Plotting B cells ~ site
Plotting T cells ~ site
Plotting iDC ~ site
Plotting Cytotoxic cells ~ site
Computing MSS vs MSI
tcga-chemo-infg: Analyzing B cells status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 7022, n_MSS = 289, n_MSI = 53, p = 0.336451549263752
tcga-chemo-infg: Analyzing T cells status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 10718, n_MSS = 289, n_MSI = 53, p = 3.77991150212955e-06
tcga-chemo-infg: Analyzing iDC status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 9344, n_MSS = 289, n_MSI = 53, p = 0.0108785574829102
tcga-chemo-infg: Analyzing Cytotoxic cells status: MSS vs MSIWilcoxon rank sum test with continuity correction: W = 12468, n_MSS = 289, n_MSI = 53, p = 3.65004032549294e-13

Plotting B cells ~ status
Plotting T cells ~ status
Plotting iDC ~ status
Plotting Cytotoxic cells ~ status
Number of rows analyzed: 20534
Number of columns analyzed: 290
kfs-chemo-infg: 31 of 34 genes from data set analyzed in set B cells: MS4A1 TCL1A HLA-DOB PNOC KIAA0125 CD19 CR2 IGHG1 FCRL2 BLK COCH OSBPL10 TNFRSF17 ABCB4 BLNK GLDC MEF2C IGHM SPIB BCL11A GNG7 IGKC CD72 MICAL3 BACH2 CCR9 QRSL1 DTNB HLA-DQA1 SCN3A SLC15A2
kfs-chemo-infg: 3 of 34 genes missing from data set analyzed in set B cells: IGHA1 FAM30A IGL@
kfs-chemo-infg: 16 of 18 genes from data set analyzed in set T cells: PRKCQ CD3D CD3G CD28 LCK TRAT1 BCL11B CD2 TRBC1 ITM2A SH2D1A CD6 CD96 NCALD CD3E SKAP1
kfs-chemo-infg: 2 of 18 genes missing from data set analyzed in set T cells: TRA@ GIMAP5
kfs-chemo-infg: 15 of 17 genes from data set analyzed in set Cytotoxic cells: KLRD1 KLRF1 GNLY CTSW KLRB1 NKG7 GZMH SIGIRR ZBTB16 RUNX3 APOL3 RORA APBA2 DUSP2 GZMA
kfs-chemo-infg: 2 of 17 genes missing from data set analyzed in set Cytotoxic cells: KLRK1 WHDC1L1
kfs-chemo-infg: 28 of 31 genes from data set analyzed in set iDC: CD1B VASH1 F13A1 CD1E MMP12 FABP4 CLEC10A SYT17 MS4A6A CTNS GUCA1A ABCG2 CD1A PPARG RAP1GAP SLC7A8 GSTT1 FZD2 CSF1R HS3ST2 CH25H LMAN2L SLC26A6 BLVRB NUDT9 PREP TACSTD2 CD1C
kfs-chemo-infg: 3 of 31 genes missing from data set analyzed in set iDC: CARD9 NM_021941 TM7SF4
Estimating GSVA scores for 1151 gene sets.
Computing observed enrichment scores
Estimating ECDFs in microarray data with Gaussian kernels
Using parallel with 1 cores
  |                                                                              |                                                                      |   0%  |                                                                              |                                                                      |   1%  |                                                                              |=                                                                     |   1%  |                                                                              |=                                                                     |   2%  |                                                                              |==                                                                    |   2%  |                                                                              |==                                                                    |   3%  |                                                                              |==                                                                    |   4%  |                                                                              |===                                                                   |   4%  |                                                                              |===                                                                   |   5%  |                                                                              |====                                                                  |   5%  |                                                                              |====                                                                  |   6%  |                                                                              |=====                                                                 |   6%  |                                                                              |=====                                                                 |   7%  |                                                                              |=====                                                                 |   8%  |                                                                              |======                                                                |   8%  |                                                                              |======                                                                |   9%  |                                                                              |=======                                                               |   9%  |                                                                              |=======                                                               |  10%  |                                                                              |=======                                                               |  11%  |                                                                              |========                                                              |  11%  |                                                                              |========                                                              |  12%  |                                                                              |=========                                                             |  12%  |                                                                              |=========                                                             |  13%  |                                                                              |=========                                                             |  14%  |                                                                              |==========                                                            |  14%  |                                                                              |==========                                                            |  15%  |                                                                              |===========                                                           |  15%  |                                                                              |===========                                                           |  16%  |                                                                              |============                                                          |  17%  |                                                                              |============                                                          |  18%  |                                                                              |=============                                                         |  18%  |                                                                              |=============                                                         |  19%  |                                                                              |==============                                                        |  19%  |                                                                              |==============                                                        |  20%  |                                                                              |==============                                                        |  21%  |                                                                              |===============                                                       |  21%  |                                                                              |===============                                                       |  22%  |                                                                              |================                                                      |  22%  |                                                                              |================                                                      |  23%  |                                                                              |================                                                      |  24%  |                                                                              |=================                                                     |  24%  |                                                                              |=================                                                     |  25%  |                                                                              |==================                                                    |  25%  |                                                                              |==================                                                    |  26%  |                                                                              |===================                                                   |  26%  |                                                                              |===================                                                   |  27%  |                                                                              |===================                                                   |  28%  |                                                                              |====================                                                  |  28%  |                                                                              |====================                                                  |  29%  |                                                                              |=====================                                                 |  29%  |                                                                              |=====================                                                 |  30%  |                                                                              |=====================                                                 |  31%  |                                                                              |======================                                                |  31%  |                                                                              |======================                                                |  32%  |                                                                              |=======================                                               |  32%  |                                                                              |=======================                                               |  33%  |                                                                              |=======================                                               |  34%  |                                                                              |========================                                              |  34%  |                                                                              |========================                                              |  35%  |                                                                              |=========================                                             |  35%  |                                                                              |=========================                                             |  36%  |                                                                              |==========================                                            |  36%  |                                                                              |==========================                                            |  37%  |                                                                              |==========================                                            |  38%  |                                                                              |===========================                                           |  38%  |                                                                              |===========================                                           |  39%  |                                                                              |============================                                          |  39%  |                                                                              |============================                                          |  40%  |                                                                              |============================                                          |  41%  |                                                                              |=============================                                         |  41%  |                                                                              |=============================                                         |  42%  |                                                                              |==============================                                        |  42%  |                                                                              |==============================                                        |  43%  |                                                                              |==============================                                        |  44%  |                                                                              |===============================                                       |  44%  |                                                                              |===============================                                       |  45%  |                                                                              |================================                                      |  45%  |                                                                              |================================                                      |  46%  |                                                                              |=================================                                     |  46%  |                                                                              |=================================                                     |  47%  |                                                                              |=================================                                     |  48%  |                                                                              |==================================                                    |  48%  |                                                                              |==================================                                    |  49%  |                                                                              |===================================                                   |  49%  |                                                                              |===================================                                   |  50%  |                                                                              |===================================                                   |  51%  |                                                                              |====================================                                  |  51%  |                                                                              |====================================                                  |  52%  |                                                                              |=====================================                                 |  52%  |                                                                              |=====================================                                 |  53%  |                                                                              |=====================================                                 |  54%  |                                                                              |======================================                                |  54%  |                                                                              |======================================                                |  55%  |                                                                              |=======================================                               |  55%  |                                                                              |=======================================                               |  56%  |                                                                              |========================================                              |  56%  |                                                                              |========================================                              |  57%  |                                                                              |========================================                              |  58%  |                                                                              |=========================================                             |  58%  |                                                                              |=========================================                             |  59%  |                                                                              |==========================================                            |  59%  |                                                                              |==========================================                            |  60%  |                                                                              |==========================================                            |  61%  |                                                                              |===========================================                           |  61%  |                                                                              |===========================================                           |  62%  |                                                                              |============================================                          |  62%  |                                                                              |============================================                          |  63%  |                                                                              |============================================                          |  64%  |                                                                              |=============================================                         |  64%  |                                                                              |=============================================                         |  65%  |                                                                              |==============================================                        |  65%  |                                                                              |==============================================                        |  66%  |                                                                              |===============================================                       |  66%  |                                                                              |===============================================                       |  67%  |                                                                              |===============================================                       |  68%  |                                                                              |================================================                      |  68%  |                                                                              |================================================                      |  69%  |                                                                              |=================================================                     |  69%  |                                                                              |=================================================                     |  70%  |                                                                              |=================================================                     |  71%  |                                                                              |==================================================                    |  71%  |                                                                              |==================================================                    |  72%  |                                                                              |===================================================                   |  72%  |                                                                              |===================================================                   |  73%  |                                                                              |===================================================                   |  74%  |                                                                              |====================================================                  |  74%  |                                                                              |====================================================                  |  75%  |                                                                              |=====================================================                 |  75%  |                                                                              |=====================================================                 |  76%  |                                                                              |======================================================                |  76%  |                                                                              |======================================================                |  77%  |                                                                              |======================================================                |  78%  |                                                                              |=======================================================               |  78%  |                                                                              |=======================================================               |  79%  |                                                                              |========================================================              |  79%  |                                                                              |========================================================              |  80%  |                                                                              |========================================================              |  81%  |                                                                              |=========================================================             |  81%  |                                                                              |=========================================================             |  82%  |                                                                              |==========================================================            |  82%  |                                                                              |==========================================================            |  83%  |                                                                              |===========================================================           |  84%  |                                                                              |===========================================================           |  85%  |                                                                              |============================================================          |  85%  |                                                                              |============================================================          |  86%  |                                                                              |=============================================================         |  86%  |                                                                              |=============================================================         |  87%  |                                                                              |=============================================================         |  88%  |                                                                              |==============================================================        |  88%  |                                                                              |==============================================================        |  89%  |                                                                              |===============================================================       |  89%  |                                                                              |===============================================================       |  90%  |                                                                              |===============================================================       |  91%  |                                                                              |================================================================      |  91%  |                                                                              |================================================================      |  92%  |                                                                              |=================================================================     |  92%  |                                                                              |=================================================================     |  93%  |                                                                              |=================================================================     |  94%  |                                                                              |==================================================================    |  94%  |                                                                              |==================================================================    |  95%  |                                                                              |===================================================================   |  95%  |                                                                              |===================================================================   |  96%  |                                                                              |====================================================================  |  96%  |                                                                              |====================================================================  |  97%  |                                                                              |====================================================================  |  98%  |                                                                              |===================================================================== |  98%  |                                                                              |===================================================================== |  99%  |                                                                              |======================================================================|  99%  |                                                                              |======================================================================| 100%
Done with gsva.
kfs-chemo-infg wnt vs CIRC: t = -4.09851997685246 df = 288 nrow = 290 cor = -0.234758375311116 pval = 5.41194167783526e-05
kfs-chemo-infg tak1 vs CIRC: t = -0.274339048635223 df = 288 nrow = 290 cor = -0.0161634716390661 pval = 0.784020752365827
kfs-chemo-infg wnt vs myc.sig: t = 36.8247724188401 df = 288 nrow = 290 cor = 0.908198394193576 pval = 5.93740129656503e-111

kfs-chemo-infg: Analyzing B cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11068, n_WT = 175, n_MT = 115, p = 0.150261830011206
kfs-chemo-infg: Analyzing T cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 9787, n_WT = 175, n_MT = 115, p = 0.693840383174566
kfs-chemo-infg: Analyzing iDC vs KRAS using Wilcoxon rank sum test with continuity correction: W = 9570, n_WT = 175, n_MT = 115, p = 0.481262527172169
kfs-chemo-infg: Analyzing Cytotoxic cells vs KRAS using Wilcoxon rank sum test with continuity correction: W = 11653, n_WT = 175, n_MT = 115, p = 0.0228456800761803

Computing B cells ~ KRAS
Computing T cells ~ KRAS
Computing iDC ~ KRAS
Computing Cytotoxic cells ~ KRAS
kfs-chemo-infg: Analyzing B cells CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 908, n_CMS2 = 106, n_CMS1 = 26, p = 0.00722397865879165
kfs-chemo-infg: Analyzing T cells CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1427, n_CMS2 = 106, n_CMS1 = 26, p = 0.781394269515124
kfs-chemo-infg: Analyzing iDC CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 1810, n_CMS2 = 106, n_CMS1 = 26, p = 0.0135523712028432
kfs-chemo-infg: Analyzing Cytotoxic cells CMS2 vs CMS1 using Wilcoxon rank sum test with continuity correction: W = 2040, n_CMS2 = 106, n_CMS1 = 26, p = 0.000153766976556723
kfs-chemo-infg: Analyzing B cells CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2340, n_CMS2 = 106, n_CMS3 = 48, p = 0.427307039305953
kfs-chemo-infg: Analyzing T cells CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2095, n_CMS2 = 106, n_CMS3 = 48, p = 0.0802048213905363
kfs-chemo-infg: Analyzing iDC CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 1597, n_CMS2 = 106, n_CMS3 = 48, p = 0.000222421981236132
kfs-chemo-infg: Analyzing Cytotoxic cells CMS2 vs CMS3 using Wilcoxon rank sum test with continuity correction: W = 2154, n_CMS2 = 106, n_CMS3 = 48, p = 0.128673668369111
kfs-chemo-infg: Analyzing B cells CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 3475, n_CMS2 = 106, n_CMS4 = 78, p = 0.0651216571551061
kfs-chemo-infg: Analyzing T cells CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 3149, n_CMS2 = 106, n_CMS4 = 78, p = 0.00582398696482567
kfs-chemo-infg: Analyzing iDC CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1356, n_CMS2 = 106, n_CMS4 = 78, p = 7.27405710199834e-15
kfs-chemo-infg: Analyzing Cytotoxic cells CMS2 vs CMS4 using Wilcoxon rank sum test with continuity correction: W = 1717, n_CMS2 = 106, n_CMS4 = 78, p = 1.30139930824631e-11


kfs-chemo-infg: Analyzing B cells CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 37, n_CMS2 = 36, n_CMS1 = 6, p = 0.0085501009762884
kfs-chemo-infg: Analyzing T cells CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 92, n_CMS2 = 36, n_CMS1 = 6, p = 0.586412407978518
kfs-chemo-infg: Analyzing iDC CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 116, n_CMS2 = 36, n_CMS1 = 6, p = 0.792732299792634
kfs-chemo-infg: Analyzing Cytotoxic cells CMS2 vs CMS1 (KRAS MT only) using Wilcoxon rank sum test: W = 158, n_CMS2 = 36, n_CMS1 = 6, p = 0.0747884111170375
kfs-chemo-infg: Analyzing B cells CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 523, n_CMS2 = 36, n_CMS3 = 30, p = 0.832864284091074
kfs-chemo-infg: Analyzing T cells CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 412, n_CMS2 = 36, n_CMS3 = 30, p = 0.100852652341942
kfs-chemo-infg: Analyzing iDC CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 325, n_CMS2 = 36, n_CMS3 = 30, p = 0.00520593149983288
kfs-chemo-infg: Analyzing Cytotoxic cells CMS2 vs CMS3 (KRAS MT only) using Wilcoxon rank sum test: W = 438, n_CMS2 = 36, n_CMS3 = 30, p = 0.192530672607381
kfs-chemo-infg: Analyzing B cells CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 449, n_CMS2 = 36, n_CMS4 = 28, p = 0.463451672054131
kfs-chemo-infg: Analyzing T cells CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 440, n_CMS2 = 36, n_CMS4 = 28, p = 0.392746803420663
kfs-chemo-infg: Analyzing iDC CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 149, n_CMS2 = 36, n_CMS4 = 28, p = 3.45755941046518e-07
kfs-chemo-infg: Analyzing Cytotoxic cells CMS2 vs CMS4 (KRAS MT only) using Wilcoxon rank sum test: W = 206, n_CMS2 = 36, n_CMS4 = 28, p = 2.94553861882198e-05

kfs-chemo-infg: Analyzing B cells CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1149, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.461026107477834
kfs-chemo-infg: Analyzing T cells CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1314, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.721163164110489
kfs-chemo-infg: Analyzing iDC CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1232, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.854440492416388
kfs-chemo-infg: Analyzing Cytotoxic cells CMS2-MT vs CMS2-WT using Wilcoxon rank sum test with continuity correction: W = 1094, n_CMS2-MT = 36, n_CMS2-WT = 70, p = 0.269562936247306
kfs-chemo-infg: Analyzing B cells CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 179, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.0085501009762884
kfs-chemo-infg: Analyzing T cells CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 124, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.586412407978518
kfs-chemo-infg: Analyzing iDC CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 100, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.792732299792634
kfs-chemo-infg: Analyzing Cytotoxic cells CMS2-MT vs CMS1-MT using Wilcoxon rank sum test: W = 58, n_CMS2-MT = 36, n_CMS1-MT = 6, p = 0.0747884111170375
kfs-chemo-infg: Analyzing B cells CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 418, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.328508270797163
kfs-chemo-infg: Analyzing T cells CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 334, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.665500679521308
kfs-chemo-infg: Analyzing iDC CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 231, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.0270955939058671
kfs-chemo-infg: Analyzing Cytotoxic cells CMS2-MT vs CMS1-WT using Wilcoxon rank sum test: W = 153, n_CMS2-MT = 36, n_CMS1-WT = 20, p = 0.000262759177537031
kfs-chemo-infg: Analyzing B cells CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 523, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.832864284091074
kfs-chemo-infg: Analyzing T cells CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 412, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.100852652341942
kfs-chemo-infg: Analyzing iDC CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 325, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.00520593149983288
kfs-chemo-infg: Analyzing Cytotoxic cells CMS2-MT vs CMS3-MT using Wilcoxon rank sum test: W = 438, n_CMS2-MT = 36, n_CMS3-MT = 30, p = 0.192530672607381
kfs-chemo-infg: Analyzing B cells CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 230, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.0862836593808099
kfs-chemo-infg: Analyzing T cells CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 308, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.778174222457639
kfs-chemo-infg: Analyzing iDC CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 216, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.0478626192908914
kfs-chemo-infg: Analyzing Cytotoxic cells CMS2-MT vs CMS3-WT using Wilcoxon rank sum test: W = 211, n_CMS2-MT = 36, n_CMS3-WT = 18, p = 0.0381461726283181
kfs-chemo-infg: Analyzing B cells CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 449, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 0.463451672054131
kfs-chemo-infg: Analyzing T cells CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 440, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 0.392746803420663
kfs-chemo-infg: Analyzing iDC CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 149, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 3.45755941046518e-07
kfs-chemo-infg: Analyzing Cytotoxic cells CMS2-MT vs CMS4-MT using Wilcoxon rank sum test: W = 206, n_CMS2-MT = 36, n_CMS4-MT = 28, p = 2.94553861882198e-05
kfs-chemo-infg: Analyzing B cells CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 693, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 0.0706606963612792
kfs-chemo-infg: Analyzing T cells CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 647, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 0.027082618031191
kfs-chemo-infg: Analyzing iDC CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 313, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 2.83525186241256e-07
kfs-chemo-infg: Analyzing Cytotoxic cells CMS2-MT vs CMS4-WT using Wilcoxon rank sum test with continuity correction: W = 270, n_CMS2-MT = 36, n_CMS4-WT = 50, p = 3.57829433893031e-08

Computing linear model with interaction for B cells
Computing linear model with interaction for T cells
Computing linear model with interaction for iDC
Computing linear model with interaction for Cytotoxic cells
Computing linear model for B cells
Computing linear model for T cells
Computing linear model for iDC
Computing linear model for Cytotoxic cells
kfs-chemo-infg: Analyzing B cells CMS1 MT vs WT using Wilcoxon rank sum test: W = 91, n_MT = 6, n_WT = 20, p = 0.0622421057203666
kfs-chemo-infg: Analyzing T cells CMS1 MT vs WT using Wilcoxon rank sum test: W = 68, n_MT = 6, n_WT = 20, p = 0.656456586891369
kfs-chemo-infg: Analyzing iDC CMS1 MT vs WT using Wilcoxon rank sum test: W = 78, n_MT = 6, n_WT = 20, p = 0.295426312817617
kfs-chemo-infg: Analyzing Cytotoxic cells CMS1 MT vs WT using Wilcoxon rank sum test: W = 82, n_MT = 6, n_WT = 20, p = 0.196273291925466
kfs-chemo-infg: Analyzing B cells CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1371, n_MT = 36, n_WT = 70, p = 0.461026107477834
kfs-chemo-infg: Analyzing T cells CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1206, n_MT = 36, n_WT = 70, p = 0.721163164110489
kfs-chemo-infg: Analyzing iDC CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1288, n_MT = 36, n_WT = 70, p = 0.854440492416388
kfs-chemo-infg: Analyzing Cytotoxic cells CMS2 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 1426, n_MT = 36, n_WT = 70, p = 0.269562936247306
kfs-chemo-infg: Analyzing B cells CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 763, n_MT = 28, n_WT = 50, p = 0.515034789770881
kfs-chemo-infg: Analyzing T cells CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 770, n_MT = 28, n_WT = 50, p = 0.469107391088378
kfs-chemo-infg: Analyzing iDC CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 581, n_MT = 28, n_WT = 50, p = 0.21707982865756
kfs-chemo-infg: Analyzing Cytotoxic cells CMS4 MT vs WT using Wilcoxon rank sum test with continuity correction: W = 834, n_MT = 28, n_WT = 50, p = 0.16435443113872
kfs-chemo-infg: Analyzing B cells CMS3 MT vs WT using Wilcoxon rank sum test: W = 334, n_MT = 30, n_WT = 18, p = 0.178071052462238
kfs-chemo-infg: Analyzing T cells CMS3 MT vs WT using Wilcoxon rank sum test: W = 214, n_MT = 30, n_WT = 18, p = 0.239876526869638
kfs-chemo-infg: Analyzing iDC CMS3 MT vs WT using Wilcoxon rank sum test: W = 250, n_MT = 30, n_WT = 18, p = 0.680905895056795
kfs-chemo-infg: Analyzing Cytotoxic cells CMS3 MT vs WT using Wilcoxon rank sum test: W = 328, n_MT = 30, n_WT = 18, p = 0.2231940194302

Computing linear model for B cells
Computing linear model for T cells
Computing linear model for iDC
Computing linear model for Cytotoxic cells
Computing rectum vs left
kfs-chemo-infg: Analyzing B cells site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2467, n_rectum = 188, n_left = 28, p = 0.593913345917893
kfs-chemo-infg: Analyzing T cells site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2527, n_rectum = 188, n_left = 28, p = 0.734833443487019
kfs-chemo-infg: Analyzing iDC site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2565, n_rectum = 188, n_left = 28, p = 0.829347651541514
kfs-chemo-infg: Analyzing Cytotoxic cells site: rectum vs leftWilcoxon rank sum test with continuity correction: W = 2579, n_rectum = 188, n_left = 28, p = 0.86488287786208
Computing right vs left
kfs-chemo-infg: Analyzing B cells site: right vs leftWilcoxon rank sum test with continuity correction: W = 1135, n_right = 74, n_left = 28, p = 0.460145727808952
kfs-chemo-infg: Analyzing T cells site: right vs leftWilcoxon rank sum test with continuity correction: W = 969, n_right = 74, n_left = 28, p = 0.618023582118717
kfs-chemo-infg: Analyzing iDC site: right vs leftWilcoxon rank sum test with continuity correction: W = 1012, n_right = 74, n_left = 28, p = 0.860124360110761
kfs-chemo-infg: Analyzing Cytotoxic cells site: right vs leftWilcoxon rank sum test with continuity correction: W = 866, n_right = 74, n_left = 28, p = 0.203727308545204

Plotting B cells ~ site
Plotting T cells ~ site
Plotting iDC ~ site
Plotting Cytotoxic cells ~ site
There were 42 warnings (use warnings() to see them)
[[1]]
pdf 
  2 

[[2]]
pdf 
  2 

[[3]]
pdf 
  2 

[[4]]
pdf 
  2 

[[5]]
pdf 
  2 

[[6]]
pdf 
  2 

[[7]]
pdf 
  2 

[[1]]
pdf 
  2 

[[2]]
pdf 
  2 

[[3]]
pdf 
  2 

[[4]]
pdf 
  2 

[[5]]
pdf 
  2 

[[6]]
pdf 
  2 

[[7]]
pdf 
  2 

R version 3.3.1 (2016-06-21)
Platform: x86_64-apple-darwin13.4.0 (64-bit)
Running under: OS X 10.11.6 (El Capitan)

locale:
[1] C

attached base packages:
 [1] grid      parallel  stats4    methods   stats     graphics  grDevices
 [8] utils     datasets  base     

other attached packages:
 [1] ggdendro_0.1-20      Matrix.utils_0.9.5   biomaRt_2.28.0      
 [4] doMC_1.3.4           iterators_1.0.8      gplots_3.0.1        
 [7] glmnet_2.0-5         foreach_1.4.3        GSA_1.03            
[10] forestmodel_0.4.1    plyr_1.8.4           gridExtra_2.2.1     
[13] ggbeeswarm_0.5.3     BayesFactor_0.9.12-2 Matrix_1.2-7.1      
[16] coda_0.19-1          caret_6.0-73         lattice_0.20-34     
[19] maxstat_0.7-24       data.table_1.10.0    corrplot_0.77       
[22] gtable_0.2.0         ggplot2_2.2.1        hgu133plus2.db_3.2.3
[25] org.Hs.eg.db_3.3.0   GSVA_1.20.0          synapseClient_1.13-4
[28] annotate_1.50.1      XML_3.98-1.5         AnnotationDbi_1.34.4
[31] IRanges_2.6.1        S4Vectors_0.10.3     Biobase_2.32.0      
[34] BiocGenerics_0.18.0 

loaded via a namespace (and not attached):
 [1] tidyr_0.6.1           splines_3.3.1         gtools_3.5.0         
 [4] assertthat_0.1        vipor_0.4.4           RSQLite_1.1-2        
 [7] quantreg_5.29         digest_0.6.11         minqa_1.2.4          
[10] colorspace_1.3-2      psych_1.6.12          GSEABase_1.34.1      
[13] broom_0.4.1           SparseM_1.74          xtable_1.8-2         
[16] mvtnorm_1.0-5         scales_0.4.1          gdata_2.17.0         
[19] lme4_1.1-12           MatrixModels_0.4-1    tibble_1.2           
[22] mgcv_1.8-16           grr_0.9.5             car_2.1-4            
[25] pbapply_1.3-1         nnet_7.3-12           lazyeval_0.2.0       
[28] mnormt_1.5-5          pbkrtest_0.4-6        magrittr_1.5         
[31] memoise_1.0.0         nlme_3.1-128          MASS_7.3-45          
[34] foreign_0.8-67        beeswarm_0.2.3        graph_1.50.0         
[37] tools_3.3.1           stringr_1.1.0         munsell_0.4.3        
[40] compiler_3.3.1        caTools_1.17.1        RCurl_1.95-4.8       
[43] nloptr_1.0.4          rjson_0.2.15          labeling_0.3         
[46] bitops_1.0-6          ModelMetrics_1.1.0    codetools_0.2-15     
[49] curl_2.3              DBI_0.5-1             reshape2_1.4.2       
[52] R6_2.2.0              dplyr_0.5.0           exactRankTests_0.8-28
[55] KernSmooth_2.23-15    stringi_1.1.2         Rcpp_0.12.9          
